<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD006496" GROUP_ID="HIV" ID="854506091212134259" MERGED_FROM="" MODIFIED="2008-05-15 00:10:54 +0200" MODIFIED_BY="Tara Horvath" NOTES="&lt;p&gt;Exported from Review Manager 4.2.10&lt;br&gt;Exported from Review Manager 4.3.1&lt;br&gt;Exported from Review Manager 4.2.9&lt;br&gt;Exported from Review Manager 4.3.1&lt;br&gt;Exported from Review Manager 4.2.9&lt;br&gt;Exported from Review Manager 4.3.1&lt;br&gt;Exported from Review Manager 4.2.9&lt;br&gt;Exported from Review Manager 4.3.1&lt;br&gt;Exported from Review Manager 4.2.9&lt;br&gt;Exported from Review Manager 4.3.1&lt;br&gt;Exported from Review Manager 4.2.9&lt;br&gt;Exported from Review Manager 4.3.1&lt;br&gt;Exported from Review Manager 4.2.9&lt;br&gt;Exported from Review Manager 4.3.1&lt;br&gt;Exported from Review Manager 4.2.9&lt;br&gt;Exported from Review Manager 4.3.1&lt;br&gt;Exported from Review Manager 4.2.9&lt;br&gt;Exported from Review Manager 4.3.1&lt;br&gt;Exported from Review Manager 4.2.9&lt;br&gt;Exported from Review Manager 4.3.1&lt;br&gt;Exported from Review Manager 4.2.9&lt;br&gt;Exported from Review Manager 4.3.1&lt;br&gt;Exported from Review Manager 4.2.9&lt;br&gt;Exported from Review Manager 4.3.1&lt;br&gt;Exported from Review Manager 4.2.8&lt;br&gt;&lt;/p&gt;" NOTES_MODIFIED="2008-05-14 15:09:17 -0700" NOTES_MODIFIED_BY="Tara Horvath" REVIEW_NO="" REVMAN_SUB_VERSION="5.0.5" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="2.2">
<COVER_SHEET MODIFIED="2008-05-14 15:09:17 -0700" MODIFIED_BY="Tara Horvath">
<TITLE>Adjunctive therapies for AIDS dementia complex</TITLE>
<CONTACT>
<PERSON ID="DC84C05982E26AA201BA4B543B94C67E" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Olalekan</FIRST_NAME>
<MIDDLE_INITIALS>A</MIDDLE_INITIALS>
<LAST_NAME>Uthman</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1>uthlekan@yahoo.com</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT/>
<ORGANISATION>Save the Youth Initiative</ORGANISATION>
<ADDRESS_1>P. O. Box 5146</ADDRESS_1>
<ADDRESS_2/>
<CITY>Ilorin</CITY>
<ZIP>240-001</ZIP>
<REGION>Kwara State</REGION>
<COUNTRY CODE="NG">Nigeria</COUNTRY>
<PHONE_1>+ 234 803 727 7991</PHONE_1>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CONTACT>
<CREATORS MODIFIED="2008-05-14 14:29:08 -0700" MODIFIED_BY="Tara Horvath">
<PERSON ID="DC84C05982E26AA201BA4B543B94C67E" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Olalekan</FIRST_NAME>
<MIDDLE_INITIALS>A</MIDDLE_INITIALS>
<LAST_NAME>Uthman</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1>uthlekan@yahoo.com</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT/>
<ORGANISATION>Save the Youth Initiative</ORGANISATION>
<ADDRESS_1>P. O. Box 5146</ADDRESS_1>
<ADDRESS_2/>
<CITY>Ilorin</CITY>
<ZIP>240-001</ZIP>
<REGION>Kwara State</REGION>
<COUNTRY CODE="NG">Nigeria</COUNTRY>
<PHONE_1>+ 234 803 727 7991</PHONE_1>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="E8ADF86A82E26AA200FD2E1F1818CA69" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Jubril</FIRST_NAME>
<MIDDLE_INITIALS>O</MIDDLE_INITIALS>
<LAST_NAME>Abdulmalik</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1/>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT/>
<ORGANISATION>Federal Neuropsychiatric Hospital</ORGANISATION>
<ADDRESS_1/>
<ADDRESS_2/>
<CITY>Maiduguri</CITY>
<ZIP/>
<REGION/>
<COUNTRY CODE="NG">Nigeria</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CREATORS>
<DATES MODIFIED="2008-05-14 14:34:22 -0700" MODIFIED_BY="Tara Horvath">
<UP_TO_DATE>
<DATE DAY="12" MONTH="2" YEAR="2007"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="12" MONTH="2" YEAR="2007"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="14" MONTH="5" YEAR="2010"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="2" YEAR="2007"/>
<REVIEW_PUBLISHED ISSUE="" YEAR=""/>
<LAST_CITATION_ISSUE ISSUE="2" YEAR="2007"/>
</DATES>
<WHATS_NEW MODIFIED="2008-05-14 14:30:55 -0700" MODIFIED_BY="Tara Horvath" NOTES="&lt;p&gt;Protocol deviation. &lt;br&gt;We proposed to discard studies if over 30% of participants were lost during follow up. We graded completeness of follow up: A = &amp;gt;80%; B = &amp;lt;80%, C = unclear. &lt;br&gt;&lt;/p&gt;" NOTES_MODIFIED="2008-05-14 14:30:55 -0700" NOTES_MODIFIED_BY="Tara Horvath">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2008-05-14 14:30:55 -0700" MODIFIED_BY="Tara Horvath">
<DATE DAY="14" MONTH="5" YEAR="2008"/>
<DESCRIPTION>
<P>Finished; converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2008-05-14 15:09:17 -0700" MODIFIED_BY="Tara Horvath">
<WHATS_NEW_ENTRY EVENT="FEEDBACK" MODIFIED="2008-05-14 15:09:17 -0700" MODIFIED_BY="Tara Horvath">
<DATE DAY="12" MONTH="9" YEAR="2006"/>
<DESCRIPTION>
<P>Substantive amendment</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES>
<SOURCE>
<NAME>Save the Youth Initiative</NAME>
<COUNTRY CODE="NG">Nigeria</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES>
<SOURCE>
<NAME>Reviews for Africa Programme Fellowship</NAME>
<COUNTRY CODE="ZA">South Africa</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE>
<NAME>South African Cochrane Centre (SACC) HIV/AIDS Mentoring Program</NAME>
<COUNTRY CODE="ZA">South Africa</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2008-05-14 13:57:45 -0700" MODIFIED_BY="Tara Horvath">
<SUMMARY MODIFIED="2008-05-14 12:54:56 -0700" MODIFIED_BY="Tara Horvath">
<TITLE MODIFIED="2008-05-14 12:40:56 -0700" MODIFIED_BY="Tara Horvath">There is no evidence that adjunctive therapies for AIDS dementia are effective, though they are well-tolerated and safe.</TITLE>
<SUMMARY_BODY MODIFIED="2008-05-14 12:54:56 -0700" MODIFIED_BY="Tara Horvath">
<P>The authors did a systematic review of ten studies, to see if adjunctive therapies (supplemental to the main treatment) for AIDS dementia were effective and safe. They found no evidence that adjunctive therapies had any effect on the patients They did find adjunctive therapies to be safe, and without any harmful effect on the patients.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2008-05-14 12:34:34 -0700" MODIFIED_BY="Tara Horvath">
<ABS_BACKGROUND>
<P>AIDS dementia complex is a common complication of human immunodeficiency virus type 1 (HIV-1) that continues to exist despite the current use of potent antiretroviral therapy. It is a source of great morbidity and, when severe, is associated with limited survival.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES>
<P>To determine efficacy and safety of adjunctive therapies for AIDS dementia complex</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2008-05-14 12:34:34 -0700" MODIFIED_BY="Tara Horvath">
<P>We searched the Cochrane HIV/AIDS group trials Specialized Register (December 2006), the Cochrane Central Register of Controlled Trials (The Cochrane Library Issue 1, 2007), MEDLINE (January 1980 to February 2007), EMBASE (January 1980 to February 2007), AIDSearch (January 1980 to February 2007), PsycINFO (January 1980 to February 2007), PSYCHLIT (January 1980 to February 2007), LILACS (January 1980 to February 2007), conference proceedings, trial registers, theses databases, and reference lists of the articles. We also contacted manufacturers and researchers in the field.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA>
<P>Randomized controlled trials, either published or published, that compared one type of adjunctive therapy to no therapy or placebo in adults with AIDS dementia complex</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION>
<P>Two authors independently assessed trials quality, extracted data and entered data into RevMan 4.2 software. Where possible intention-to-treat data were used and we contacted study authors for additional information. We collected neurocognitive performance, adverse effects, tolerability and all-cause mortality information from the trials.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS>
<P>Ten trials involving 711 people were included. All the studies were phase 2 trials. Six studies used adequate methods for allocation of sequence generation and unclear in the remaining four trials. Allocation concealment was adequate in five trials and unclear in the remaining trials. The trials were heterogeneous in terms of types, dosages, routes and frequencies of administration of the adjunctive therapies. There were no significant differences between the treated and placebo groups on neuropsychological test scores, number of those that complete the assign dosage of experimental medication, adverse effects, and all-cause mortality.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS>
<P>This review confirms the absence of evidence that any of the adjunctive therapies improves cognitive performance or quality of life, or both for patients with ADC, though they were well tolerated and safe. </P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2008-05-14 13:57:45 -0700" MODIFIED_BY="Tara Horvath">
<BACKGROUND MODIFIED="2008-05-14 12:47:26 -0700" MODIFIED_BY="Tara Horvath">
<P>AIDS Dementia Complex (ADC) is a common complication of human immunodeficiency virus type 1 (HIV-1) that continues to exist despite the current use of potent antiretroviral therapy (<LINK REF="STD-Schifitto-2001" TYPE="STUDY">Schifitto 2001</LINK>). ADC (also known as AIDS-related dementia, HIV encephalopathy, and HIV-associated dementia) is a condition in people with AIDS that results in the loss of mental awareness, judgment, and inability to function in a social or occupational setting. It is a source of great morbidity and, when severe, is associated with limited survival (<LINK REF="REF-Parnes-2006" TYPE="REFERENCE">Parnes 2006</LINK>). ADC is common in HIV-1 patients with high plasma HIV-1 RNA levels, low CD4 cell count (<LINK REF="REF-Childs-1999" TYPE="REFERENCE">Childs 1999</LINK>), anemia, low body mass index, older age, injection drug use (<LINK REF="REF-Stern-2001" TYPE="REFERENCE">Stern 2001</LINK>) and female sex (<LINK REF="REF-Chiesi-1996" TYPE="REFERENCE">Chiesi 1996</LINK>).<BR/>
<B>
<BR/>
</B>There is variation in the reported incidence of ADC worldwide (see <LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>). <LINK REF="REF-Gonzalez-2006" TYPE="REFERENCE">Gonzalez 2006</LINK> reported annual incidence of ADC among HIV-positive individuals was 7%, with an estimated 20% risk of ADC after developing full-blown AIDS in United State of America and 5% to 7% in Europe (<LINK REF="REF-Mollace-2001" TYPE="REFERENCE">Mollace 2001</LINK>). Whether people living with AIDS in other regions suffer from similar rates of ADC is unknown. Some have claimed that competing causes of early death could translate into lower rates of ADC; however studies of ADC in Africa have failed to resolve this question by reporting different rates from 3% to 68% (<LINK REF="REF-Birbeck-2005" TYPE="REFERENCE">Birbeck 2005</LINK>).<BR/>
<B>
<BR/>
</B>ADC produces a highly variable clinical course ranging from subtle cognitive (Stage 0) and motor impairments to profound dementia (stage 4) (see <LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>) (<LINK REF="REF-McArthur-2005" TYPE="REFERENCE">McArthur 2005</LINK>). Early symptoms include word-finding difficulty, forgetfulness, psychomotor slowing, and diminished writing or visual/motor skills. Simple strategies, such as written reminders, can be used to compensate for early deficits. Common psychiatric symptoms include depressed mood and hypomania. Some patients experience a gradual mental decline, whereas others deteriorate rapidly over a relatively short period of time (<LINK REF="TBL-02" TYPE="TABLE">Table 2</LINK>). Seizures, global cognitive deterioration, mutism, incontinence, and severe confusion are common clinical features of late-stage ADC (<LINK REF="REF-AIDS-institutes-2006" TYPE="REFERENCE">AIDS institutes 2006</LINK>).<BR/>
<B>
<BR/>
</B>The main direct targets of HIV infection are cells of the immune system (<LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>: <LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>); the nervous system is often damaged in the course of infection (<LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>: <LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK>), not only by disease processes that are secondary to immune dysfunction and its systemic manifestations but also by more fundamental effects of the retrovirus (<LINK REF="REF-Price-1996" TYPE="REFERENCE">Price 1996</LINK>; <LINK REF="REF-Ghafouri-2006" TYPE="REFERENCE">Ghafouri 2006</LINK>). Structural similarities between HIV and a protein (neuroleukin) that stimulates nerve cells may contribute to ADC, and thus may provide a way to reverse that dementia. This similarity creates a competition between virus and protein for binding sites on neurons leading to inhibition of nerve function by the viruses, and in turn causing symptoms associated with dementia (<LINK REF="REF-Edward-1987" TYPE="REFERENCE">Edward 1987</LINK>; <LINK REF="REF-Gonzalez-2006" TYPE="REFERENCE">Gonzalez 2006</LINK>).</P>
<P>Generally, three tests are used to diagnose ADC. Mental status examination (neuropsychological testing) is the primary method to diagnose and evaluate ADC and is designed to reveal problems like memory loss, disorientation, concentration, abstract thinking and mood swings. Standard scan like magnetic resonance imaging (MRI) and computerized tomography (CT) scans are used to rule out other causes of symptoms of ADC (<LINK REF="TBL-03" TYPE="TABLE">Table 3</LINK>). Examination of cerebrospinal fluid can be use to assess the virus load and other chemicals in the brain.<BR/>
<B>
<BR/>
</B>Just as there is no cure for AIDS, there is no cure for ADC. Treatment of ADC is multidisciplinary and involves different therapeutic modalities (antiretroviral therapy, treatment of symptoms and adjunctive therapies). The efficacy of antiretroviral agents remains uncertain because most do not achieve effective levels in the brain and can cause neurologic complications as well (<LINK REF="REF-Mollace-2001" TYPE="REFERENCE">Mollace 2001</LINK>; <LINK REF="REF-Zink-2005" TYPE="REFERENCE">Zink 2005</LINK>). Hence, this concern provides an additional impetus for the development of effective adjunctive therapy for ADC.</P>
<P>Attention has focused on adjunctive therapies targeted at reducing or counteracting the effects HIV-1 on the central nervous system (<LINK REF="TBL-04" TYPE="TABLE">Table 4</LINK>). These have included the calcium blocker channel antagonist nimodipine (<LINK REF="REF-McArthur-2005" TYPE="REFERENCE">McArthur 2005</LINK>), peptide T (<LINK REF="STD-Heseltine-1998" TYPE="STUDY">Heseltine 1998</LINK>), and minocycline (<LINK REF="REF-Zink-2005" TYPE="REFERENCE">Zink 2005</LINK>).<BR/>
<B>
<BR/>
</B>Although there are general reviews on neurological complications of HIV infection (<LINK REF="REF-McArthur-2005" TYPE="REFERENCE">McArthur 2005</LINK>) and neuroprotective therapy for ADC (<LINK REF="REF-Turchan-2003" TYPE="REFERENCE">Turchan 2003</LINK>), to the best of our knowledge there is no systematic review on adjunctive therapies for ADC. There is a need for a systematic review of well designed treatment studies to produce an up-to-date synthesis of research evidence on effectiveness of adjunctive therapies for treatment of ADC, add to the body of knowledge related to treatment of ADC, and help policy makers, medical practitioners, and HIV infected individuals identify interventions for treating ADC which are supported by reliable evidence of effectiveness.</P>
</BACKGROUND>
<OBJECTIVES>
<P>To determine the efficacy and safety of adjunctive therapies in the management AIDS dementia complex and effects on symptom severity and all-cause mortality. </P>
</OBJECTIVES>
<METHODS>
<SELECTION_CRITERIA>
<CRIT_STUDIES>
<P>Only randomized controlled trials, either published or unpublished, that compared one type of ADC therapy to no therapy or placebo, in any language were eligible for inclusion in this review.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS>
<P>All HIV infected patients on antiretroviral therapy (either sex, aged 18 to 60 years) with dementia and randomly assigned to treatment were eligible for inclusion. Any clinically useful subgroup of ADC was acceptable, for example minor cognitive-motor disorder, as long as it is defined in the study's inclusion criteria. There were no exclusions based on country of study. </P>
<P>Studies that include patients with history of a neurologic disease unrelated to HIV infection, chronic seizures or head injuries, any psychiatric illness were excluded unless subgroup analysis is presented that allows exclusion of just these patients. </P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS>
<P>
<B>Intervention<BR/>
</B>Any intervention other than antiretroviral therapy used for the treatment of ADC. Interventions may be combined with antiretroviral therapy as long as intervention and control group both received antiretrovirals and the only difference between groups is a non-antiretroviral intervention. No limits were placed on the frequency of use, dose, and the duration of treatment. <BR/>
<B>
<BR/>Control <BR/>
</B>Placebo or no therapy.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES>
<P>The following outcomes were considered in this review:<B>
<BR/>Primary outcomes<BR/>
</B>1. Change in cognitive function (as measured by neuropsychological tests) <BR/>2. Change in mean Karnofsky performance score<BR/>3. Global impression of change</P>
<P>
<B>Secondary outcomes</B>
<BR/>1. All cause mortality<BR/>2. Activities of daily living<BR/>3. Center for Epidemiologic Studies - Depression Scale (CES-D)<BR/>4. Any adverse effects</P>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS>
<P>See: HIV/AIDS Collaborative Review Group search strategy</P>
<P>We attempted to identify all relevant trials regardless of language or publication status (published, unpublished, in press, and in progress).</P>
<P>
<B>Databases<BR/>
</B>We searched the following databases using the search terms and strategy described in (<LINK REF="TBL-05" TYPE="TABLE">Table 5</LINK>): <BR/>
</P>
<UL>
<LI>Cochrane HIV/AIDS Group Specialized Register (December 2006)</LI>
<LI>Cochrane Central Register of Controlled Trials (CENTRAL), published in The Cochrane Library (2007 Issue 1)</LI>
<LI>MEDLINE (1980 to February 2007)</LI>
<LI>EMBASE (1980 to February 2007)</LI>
<LI>AIDSearch (1980 to February 2007)</LI>
<LI>PsycINFO (1980 to February 2007)</LI>
<LI>PSYCHLIT (1980 to February 2007)</LI>
<LI>LILACS (1980 to February 2007)</LI>
</UL>
<P>
<BR/>
<B>Conference proceedings</B>
<BR/>We searched the following conference proceedings for relevant abstract:<BR/>
</P>
<UL>
<LI>Annual Conference of the British HIV Association (2001 to 2006)</LI>
<LI>Conference on Retroviruses and Opportunistic Infections (1996 to 2006)</LI>
<LI>International AIDS Society (IAS) Pathogenesis and Treatment (2001 to 2005)</LI>
<LI>International AIDS Conferences (1985 to 2004)</LI>
<LI>International Congress on Drug Therapy in HIV Infection (1992 to 2004)</LI>
<LI>International HIV Drug Resistance Workshop (2002 to 2006)</LI>
<LI>National HIV/AIDS Update Conference (2000 to 2005)</LI>
<LI>National HIV Prevention Conference (1999 to 2005)</LI>
<LI>Eleventh International Conference on AIDS and STDs in Africa (ICASA): Lusaka, Zambia (www.africa.upenn.edu/Urgent_Action/apic_91599.html)</LI>
<LI>National Cancer Institute's AIDS-related Malignancy conferences; and </LI>
<LI>International Congress on Drug Therapy in HIV Infection</LI>
</UL>
<P>
<BR/>
<B>Ongoing trials:</B>
<BR/>
</P>
<UL>
<LI>Australian Clinical Trials Registry (www.actr.org.au/)</LI>
<LI>ClinicalTrials.gov (http://clinicaltrials.gov/)</LI>
<LI>CenterWatch Clinical Trials Listing Service (www.centerwatch.com/)</LI>
<LI>Current Controlled Trials (www.controlled-trials.com/)</LI>
<LI>PsiTri Database (mental health treatments) (http://psitri.stakes.fi/EN/psitri.htm)</LI>
<LI>GlaxoSmithKline Clinical Trial Register (http://ctr.gsk.co.uk/)</LI>
<LI>NovartisClinicalTrials.com (www.novartisclinicaltrials.com)</LI>
<LI>Johns Hopkins HIV Neurology Group Clinical Trials and Cohort Studies (/www.neuro.jhmi.edu/HIV/clinical_trials.htm)</LI>
<LI>National Institutes of Health (NIH) (www.nih.gov/)</LI>
</UL>
<P>
<BR/>
<B>Theses</B>
<BR/>
</P>
<UL>
<LI>Networked Digital Library of Theses (www.ndltd.org/)</LI>
<LI>Australian Digital Theses Program (http://adt.caul.edu.au/)</LI>
<LI>Canadian Theses and Dissertations (www.collectionscanada.ca/thesescanada/index-e.html)</LI>
<LI>DATAD - Database of African Theses and Dissertations (www.aau.org/datad/backgrd.htm)</LI>
<LI>Dissertation Abstract Online (USA) (/wwwlib.umi.com/dissertations/gateway) </LI>
</UL>
<P>
<BR/>
<B>Researchers, organization, and pharmaceutical companies<BR/>
</B>For unpublished and ongoing trials, we contacted individual researchers working in the field and the following organizations: National Institutes of Health (NIH), World Health Organization (WHO) and the US Centers for Disease Control and Prevention (CDC); and pharmaceutical companies such as Centaur pharmaceuticals, Miles Pharmaceuticalsand Roche, Somerset Pharmaceuticals, and Otsuka America Pharmaceuticals.</P>
<P>
<B>Reference lists<BR/>
</B>Reference lists of all studies and reviews identified by the above methods were checked for further trials. </P>
</SEARCH_METHODS>
<DATA_COLLECTION>
<P>
<B>Selection of Studies</B>
<BR/>Both authors (AO and JO) independently applied the inclusion criteria to all identified trials. We used the titles and abstracts of the identified citations to exclude trials that clearly did not meet the inclusion criteria (see <LINK REF="FIG-04" TYPE="FIGURE">Figure 4</LINK>). If either author judged that the trial might be eligible for inclusion, we obtained the full paper. We independently screened the full articles of selected trials and resolved any disagreements by discussion. We gave reasons for excluding potentially relevant trials in the "Characteristics of Excluded Studies." We attempted to contact the authors for clarification when necessary. </P>
<P>
<B>Assessment</B>
<B> of methodological quality and risk of bias</B>
<BR/>Two authors assessed the methodological quality of each trial in terms of sequence generation, allocation concealment (<LINK REF="REF-J_x00fc_ni-2001" TYPE="REFERENCE">Jüni 2001</LINK>), blinding (of participants, personnels, and outcomes), completeness of follow up, incomplete outcome data, selective outcome reporting, and topic specific or design specific or potential threats to validity. </P>
<P>Generation of allocation sequence<BR/>
</P>
<UL>
<LI>Adequate (using a computer random number generator, coin tossing , shuffling cards or envelopes, throwing dice, drawing of lots, minimization)</LI>
<LI>Inadequate (non-random approach, allocation by alternate allocation, and allocation by judgment of the clinician)</LI>
<LI>Unclear (Insufficient information about the sequence generation process) </LI>
</UL>
<P>
<BR/>Allocation concealment <BR/>
</P>
<UL>
<LI>Adequate (participants and the investigators enrolling participants cannot foresee assignment)</LI>
<LI>Inadequate (participants and investigators enrolling participants can foresee upcoming assignment) </LI>
<LI>Unclear (method not described)</LI>
</UL>
<P>
<BR/>Blinding<BR/>We recorded who was blinded in each trial, such as the participants, care provider, or outcome assessor. </P>
<P>Completeness of follow up<BR/>A = &gt;80%; B = &lt;80%, C = unclear<BR/>(This is a change from the protocol; we proposed to discard studies if over 30% of participants were lost during follow up)</P>
<P>Incomplete outcome data adequately addressed?<BR/>
</P>
<UL>
<LI>Yes (no missing outcome data; reasons for missing outcome data unlikely to be related to true outcome; missing outcome data balanced in number across groups) </LI>
<LI>No (reason for missing outcome data likely to be related to true outcome, with either imbalance in number across groups or reasons for missing data having different profiles across groups)</LI>
<LI>Unclear (insufficient reporting of attrition/exclusions) </LI>
</UL>
<P>
<BR/>Free of selective outcome reporting?<BR/>
</P>
<UL>
<LI>Yes (all pre-specified (primary and secondary) outcomes have been reported or it is clear that the published report includes all of the study's pre-specified outcomes and all expected outcomes)</LI>
<LI>No (not all pre-specified outcomes have been reported; one or more reported outcomes were not pre-specified; one or more outcomes are reported incompletely in a way related to the actual results; or the study report fails to include results for an outcome that would be expected to have been reported for such a study)</LI>
<LI>Unclear (insufficient information) </LI>
</UL>
<P>
<BR/>Free of topic specific, design specific or other potential threats to validity?<BR/>
</P>
<UL>
<LI>Yes (the study appears to be free of other sources of bias)</LI>
<LI>No (there is at least one important risk of bias)</LI>
<LI>Unclear (there may be a risk of bias, but there is either insufficient information or insufficient rationale or evidence that an identified problem will introduce bias)</LI>
</UL>
<P>
<BR/>
<B>Data extraction</B>
<BR/>Two authors independently extracted the data using a pre-designed data collection forms. For each of the studies, we extracted data the following: citation, study design, methodological criteria, inclusion and exclusion criteria, comparison group intervention, participant characteristics, trial setting, elements of intervention, all relevant outcomes measures, and results. Where reports were uncertain or include summary measures, authors were contacted for clarification. We also took note of any data that is consistently underreported, and highlighted this deficit along with future research needs.</P>
<P>We checked whether authors had conducted an intention-to-treat analysis (all randomized participants should be analysed in the groups to which they were originally randomized). We calculated the percentage lost to follow-up and reported this information. For dichotomous outcome measures, we recorded the number of participants experiencing the event and the number analysed in each group. For continuous outcome measures, we extracted the mean change from baseline, the standard deviation of the mean change, and the number of patients for each treatment group at each assessment. Where standard errors were presented (eg <LINK REF="STD-Heseltine-1998" TYPE="STUDY">Heseltine 1998</LINK>), standard transformation (<LINK REF="REF-Higgins-2006" TYPE="REFERENCE">Higgins 2006</LINK>) was applied to estimate the standard deviation by multiplying standard errors of means by the square root of the sample size. Trialists were contacted to supply missing information and to clarify issues. We resolved discrepancies through discussion.</P>
<P>
<B>Data analysis<BR/>
</B>All eligible studies were summarized and analyzed in <LINK REF="REF-Review-Manager-4.2" TYPE="REFERENCE">Review Manager 4.2</LINK>. The two authors extracted the data, the first author entered all data into RevMan and second author rechecked all entries. Disagreements were resolved by discussion. </P>
<P>The outcomes measured in clinical trials of dementia and cognitive impairment often arise from ordinal rating scales, such as neuropsychological test scores, clinical global impression scales, and quality of life scales. Where the rating scales used in the trials have a reasonably large number of categories (more than 10) the data we treated as continuous variables arising from a normal distribution. We used weighted mean difference (WMD) when the pooled trials use the same rating scale or test, and the standardized mean difference (SMD). Study results for dichotomous data were expressed as relative risk (RR) and 95% confidence interval (CI). </P>
<P>
<B>Stratification of results</B>
<BR/>Due to the variety of combinations of different treatments and different comparators, it was not be possible to combine all included trials in a single meta-analysis. We thus decided to use a narrative synthesis; to present details for each study and discuss them in turn. For trials with more than two arms, we considered each pair wise comparison as if it were separate two-arm trials (<LINK REF="REF-Ramsay-2007" TYPE="REFERENCE">Ramsay 2007</LINK>). For example, if a trial with two experimental groups, high dose nimodipine and low dose nimodipine, and a placebo group; we included the high dose nimodipine versus placebo arm and low dose nimodipine versus placebo as separate trials. We did not include the two comparisons in one meta-analysis to avoid 'unit analysis error' (counting placebo patients twice). We proposed to prepare separate meta-analyses if there are more than one trial comparing similar interventions and comparison groups: (1) adjunctive therapy versus another adjunctive therapy belonging to the same or different drug class; and (2) adjunctive therapy grouped by drug class versus other adjunctive therapy belonging to a different drug class (<LINK REF="TBL-04" TYPE="TABLE">Table 4</LINK>). </P>
<P>
<B>Not included in this review:</B>
<BR/>Due to insufficient data, we were unable to carry out the following analyses:</P>
<P>
<U>Heterogeneity</U>
<BR/>We planned to assess the presence of statistical heterogeneity in the meta-analyses by looking at the forest plot and chi-squared test for heterogeneity using a P value of 0.10 to determine statistical significance; and to quantify inconsistent across studies using a simplified categorization of I<SUP>2</SUP>: low (I<SUP>2</SUP> value of 25%), moderate (I<SUP>2</SUP> value of 50%), and high (I<SUP>2</SUP> value of 75%) (<LINK REF="REF-Higgins-2003" TYPE="REFERENCE">Higgins 2003</LINK>).</P>
<P>
<U>Sensitivity test</U>
<BR/>We planned sensitivity analyses to assess the robustness of the meta-analysis by comparing the results using all trials and then excluding trials of a lower methodological quality. </P>
<P>
<U>Sub-Group Analyses</U>
<BR/>We proposed to stratify our analysis by intervention setting (dosage, route of administration, antiretroviral therapy naive or not) and CD4 count given sufficient data.</P>
<P>
<U>Publication bias</U>
<BR/>We planned to look for asymmetry in a funnel plot of the standard error plotted against the risk ratio measured on a logarithmic scale as an indication of publication bias (<LINK REF="REF-Egger-1997" TYPE="REFERENCE">Egger 1997</LINK>). <BR/>
</P>
</DATA_COLLECTION>
</METHODS>
<RESULTS>
<STUDY_DESCRIPTION>
<P>
<B>Trial selection<BR/>
</B>We prepared a QUOROM (<LINK REF="REF-Moher-1999" TYPE="REFERENCE">Moher 1999</LINK>) statement flowchart to describe how we processed the references identified through the search results (see <LINK REF="FIG-05" TYPE="FIGURE">Figure 5</LINK>).</P>
<P>The literature searches yielded 969 titles of potentially relevant articles. After scanning titles and abstracts, a total of 33 potentially relevant articles were identified and full-text copies were assessed independently against the inclusion criteria by the two authors. The reference lists of these studies were scanned, which resulted in another two papers for inclusion. Twenty papers were excluded (see 'Characteristics of excluded studies') and 12 papers (ten RCTs) met the inclusion criteria (see 'Characteristics of included studies'). All trials were identified from published literature. <BR/>
<B> <BR/>Included studies</B>
<BR/>All trials had randomized double-blind controlled design (see 'Characteristics of Included Studies' for detailed information about the individual trials). The trials were published between 1997 and 2007 in Neurology (<LINK REF="STD-Clifford-2002" TYPE="STUDY">Clifford 2002</LINK>; <LINK REF="STD-Dana-1997" TYPE="STUDY">Dana 1997</LINK>; <LINK REF="STD-Dana-1998" TYPE="STUDY">Dana 1998</LINK>; <LINK REF="STD-Navia-1998" TYPE="STUDY">Navia 1998</LINK>; <LINK REF="STD-Sacktor-2000" TYPE="STUDY">Sacktor 2000</LINK>; <LINK REF="STD-Schiffito-1999" TYPE="STUDY">Schiffito 1999</LINK>; <LINK REF="STD-Schiffito-2006a" TYPE="STUDY">Schiffito 2006a</LINK>; <LINK REF="STD-Schiffito-2007b" TYPE="STUDY">Schiffito 2007b</LINK>), Archives of neurology, Journal of neurovirology (<LINK REF="STD-Heseltine-1998" TYPE="STUDY">Heseltine 1998</LINK>), and AIDS (<LINK REF="STD-Schiffito-2007a" TYPE="STUDY">Schiffito 2007a</LINK>). </P>
<P>
<B>Trial location</B>
<BR/>All the studies reviewed were conducted in USA. Multicenter studies were organized by the Charles A. Dana Foundation Consortium on the Therapy of HIV Dementia and Related Cognitive Disorders (University of Rochester, Columbia University, Johns Hopkins University); other sites included the University of Southern California Los Angeles (USC), the University of Miami, Miami, Fla (UM), and the University of California, San diego (USCD).<BR/>
<B>
<BR/>Participants</B>
<BR/>This review was based on data from 711 participants. The breakdown, with respect to individual studies, was as follows:<BR/>
</P>
<UL>
<LI>
<LINK REF="STD-Schiffito-1999" TYPE="STUDY">Schiffito 1999</LINK>: 30 participants</LI>
<LI>
<LINK REF="STD-Dana-1998" TYPE="STUDY">Dana 1998</LINK>: 36 participants</LI>
<LI>
<LINK REF="STD-Schiffito-2006a" TYPE="STUDY">Schiffito 2006a</LINK>: 16 participants</LI>
<LI>
<LINK REF="STD-Clifford-2002" TYPE="STUDY">Clifford 2002</LINK>: 64 participants</LI>
<LI>
<LINK REF="STD-Navia-1998" TYPE="STUDY">Navia 1998</LINK>: 38 participants</LI>
<LI>
<LINK REF="STD-Sacktor-2000" TYPE="STUDY">Sacktor 2000</LINK>: 14 participants</LI>
<LI>
<LINK REF="STD-Heseltine-1998" TYPE="STUDY">Heseltine 1998</LINK>: 215 participants</LI>
<LI>
<LINK REF="STD-Dana-1997" TYPE="STUDY">Dana 1997</LINK>: 30 participants</LI>
<LI>
<LINK REF="STD-Schiffito-2007a" TYPE="STUDY">Schiffito 2007a</LINK>: 140 participants</LI>
<LI>
<LINK REF="STD-Schiffito-2007b" TYPE="STUDY">Schiffito 2007b</LINK>: 128 participants</LI>
</UL>
<P>
<BR/>The trials were homogenous in terms of the age groups studied [mean age of 38.50 years (<LINK REF="STD-Navia-1998" TYPE="STUDY">Navia 1998</LINK>) to 62.00 years (<LINK REF="STD-Heseltine-1998" TYPE="STUDY">Heseltine 1998</LINK>)]. Most of the studies included more male participants [60.00% (<LINK REF="STD-Sacktor-2000" TYPE="STUDY">Sacktor 2000</LINK>) to 95.40% (<LINK REF="STD-Heseltine-1998" TYPE="STUDY">Heseltine 1998</LINK>)]. The proportion of white participants [27.70% (<LINK REF="STD-Schiffito-2006a" TYPE="STUDY">Schiffito 2006a</LINK>) to 86.00%(<LINK REF="STD-Heseltine-1998" TYPE="STUDY">Heseltine 1998</LINK>)] and mean duration of known HIV infection [mean year = 4.60 (<LINK REF="STD-Dana-1998" TYPE="STUDY">Dana 1998</LINK>) to 10.40 (<LINK REF="STD-Schiffito-2006a" TYPE="STUDY">Schiffito 2006a</LINK>)] differed across studies. </P>
<P>The following inclusion criteria were used in the studies reviewed:<BR/>
</P>
<UL>
<LI>Patients who had HIV infection (confirmed by enzyme-linked immunosorbent assay (<LINK REF="STD-Dana-1997" TYPE="STUDY">Dana 1997</LINK>; <LINK REF="STD-Dana-1998" TYPE="STUDY">Dana 1998</LINK>; <LINK REF="STD-Heseltine-1998" TYPE="STUDY">Heseltine 1998</LINK>), Western blot (<LINK REF="STD-Clifford-2002" TYPE="STUDY">Clifford 2002</LINK>; <LINK REF="STD-Dana-1997" TYPE="STUDY">Dana 1997</LINK>; <LINK REF="STD-Dana-1998" TYPE="STUDY">Dana 1998</LINK>; <LINK REF="STD-Heseltine-1998" TYPE="STUDY">Heseltine 1998</LINK>), or polymerase chain reaction(<LINK REF="STD-Heseltine-1998" TYPE="STUDY">Heseltine 1998</LINK>)), </LI>
<LI>Evidence of cognitive impairment</LI>
<LI>Stable antiretroviral regimen for 6 weeks before randomization</LI>
</UL>
<P> Cognitive impairment was defined as performing at or below 1 SD from the mean on at least two neuropsychological tests, or 2 SDs below the mean on at least one test. </P>
<P>Most of the studies excluded patients with:<BR/>
</P>
<UL>
<LI>Active opportunistic central nervous system infection (within 12 weeks of initial treatment of toxoplasmosis or cryptococcal meningitis), </LI>
<LI>Severe premorbid psychiatric illness likely to interfere with protocol compliance, </LI>
<LI>History of a chronic neurologic disorder unrelated to HIV infection, </LI>
</UL>
<P>
<BR/>
<LINK REF="STD-Heseltine-1998" TYPE="STUDY">Heseltine 1998</LINK> excluded participants with previous use of Peptide T. In <LINK REF="STD-Schiffito-2006a" TYPE="STUDY">Schiffito 2006a</LINK> no information was provided for exclusion of the participants.</P>
<P>
<B>Interventions</B>
<BR/>Most of the trials had one form experimental treatment of adjunctive therapy (See <LINK REF="TBL-07" TYPE="TABLE">Table 7</LINK>) and control group (<LINK REF="STD-Dana-1997" TYPE="STUDY">Dana 1997</LINK>; <LINK REF="STD-Heseltine-1998" TYPE="STUDY">Heseltine 1998</LINK>; <LINK REF="STD-Sacktor-2000" TYPE="STUDY">Sacktor 2000</LINK>; <LINK REF="STD-Schiffito-1999" TYPE="STUDY">Schiffito 1999</LINK>; <LINK REF="STD-Schiffito-2006a" TYPE="STUDY">Schiffito 2006a</LINK>). Three studies (<LINK REF="STD-Clifford-2002" TYPE="STUDY">Clifford 2002</LINK>; <LINK REF="STD-Navia-1998" TYPE="STUDY">Navia 1998</LINK>;<LINK REF="STD-Schiffito-2007b" TYPE="STUDY">Schiffito 2007b</LINK>) had three arms with two different doses and placebo. <LINK REF="STD-Dana-1998" TYPE="STUDY">Dana 1998</LINK> had four arms: thioctic acid alone, thioctic acid and deprenyl, deprenyl alone, and control group.</P>
<P>See <LINK REF="TBL-07" TYPE="TABLE">Table 7</LINK> for details of drugs, route of administration, and treatment regimen. </P>
<P>
<B>Outcome measures</B>
<BR/>Primary outcome of most of the trials was tolerability, defined by whether the subject completed the study at the originally assigned dosage of experimental medications, regardless of whether dosage halving or suspension occurred during the study. A secondary measure of tolerability was whether the subject completed the study. Measures of safety included frequencies of adverse experiences and abnormal results on laboratory tests, and changes over time in laboratory tests and vital signs. Measures of efficacy included changes from baseline in neuropsychological test results (see <LINK REF="TBL-08" TYPE="TABLE">Table 8</LINK>), global impression, and measures of function and mood. In <LINK REF="STD-Heseltine-1998" TYPE="STUDY">Heseltine 1998</LINK> the primary efficacy end point was change in cognitive function. </P>
<P>All studies used validated neuropsychological test scores.</P>
<P>
<B>Sources of support</B>
<BR/>Of the eight trials, seven listed the study sponsors (<LINK REF="TBL-09" TYPE="TABLE">Table 9</LINK>) and sources of support (<LINK REF="TBL-10" TYPE="TABLE">Table 10</LINK>). <LINK REF="STD-Heseltine-1998" TYPE="STUDY">Heseltine 1998</LINK> provided no information about the trial sponsor(s). </P>
<P>
<B>Excluded studies</B>
<BR/>Twenty papers identified by the search strategy were not relevant and were excluded after reading the full-text. The reasons for exclusion for each individual study are listed in the 'Characteristics of excluded studies' section, and can be summarized as follows: -<BR/>
</P>
<UL>
<LI>Seven studies used antiretroviral interventions not adjunctive therapies (<LINK REF="STD-Brew-2007" TYPE="STUDY">Brew 2007</LINK>; <LINK REF="STD-Day-1992" TYPE="STUDY">Day 1992</LINK>; <LINK REF="STD-Galgani-1997" TYPE="STUDY">Galgani 1997</LINK>; <LINK REF="STD-Sacktor-2002" TYPE="STUDY">Sacktor 2002</LINK>; <LINK REF="STD-Schmitt-1988" TYPE="STUDY">Schmitt 1988</LINK>; <LINK REF="STD-Sidtis-1993" TYPE="STUDY">Sidtis 1993</LINK>; <LINK REF="STD-Tozzi-1993" TYPE="STUDY">Tozzi 1993</LINK>)</LI>
<LI>Five were not a randomized study (<LINK REF="STD-Bridge-1989" TYPE="STUDY">Bridge 1989</LINK>; <LINK REF="STD-Bridge-1991" TYPE="STUDY">Bridge 1991</LINK>; <LINK REF="STD-Cysique-2006" TYPE="STUDY">Cysique 2006</LINK>; <LINK REF="STD-Kosten-1997" TYPE="STUDY">Kosten 1997</LINK>; <LINK REF="STD-Villemagne-1996" TYPE="STUDY">Villemagne 1996</LINK>)</LI>
<LI>One was a comment / Letter (<LINK REF="STD-Anonymous-1996" TYPE="STUDY">Anonymous 1996</LINK>)</LI>
<LI>One was drug interaction study (<LINK REF="STD-DiCenzo-2004" TYPE="STUDY">DiCenzo 2004</LINK>)</LI>
<LI>Three were validation studies (<LINK REF="STD-Chang-2004" TYPE="STUDY">Chang 2004</LINK>; <LINK REF="STD-Lee-2003" TYPE="STUDY">Lee 2003</LINK>; <LINK REF="STD-Schifitto-2001" TYPE="STUDY">Schifitto 2001</LINK>), and </LI>
<LI>Three were carried out on patient with no evidence of cognitive impairment (<LINK REF="STD-Polianova--2003" TYPE="STUDY">Polianova 2003</LINK>; <LINK REF="STD-Schifitto-2006b" TYPE="STUDY">Schifitto 2006b</LINK>; <LINK REF="STD-Simpson-1996" TYPE="STUDY">Simpson 1996</LINK>).</LI>
</UL>
<P>
<BR/>
<B>Studies awaiting assessment</B>
<BR/>A randomized, placebo-controlled study (<LINK REF="STD-Vitiello-1998" TYPE="STUDY">Vitiello 1998</LINK>) of two doses of nimodipine (90mg per day and 300mg per day) for 16 weeks in 49 patients with HIV-associated dementia has been completed, but was only presented during International Conference on AIDS, 1998. <BR/>
<B>
<BR/>Ongoing studies</B>
<BR/>We identified two relevant trials (<LINK REF="STD-Nimodipine-1999" TYPE="STUDY">Nimodipine 1999</LINK>; <LINK REF="STD-Minocycline-2006" TYPE="STUDY">Minocycline 2006</LINK>) from clinical trials registers (see 'Characteristics of Ongoing Studies' for detailed information about the individual trials).</P>
</STUDY_DESCRIPTION>
<STUDY_QUALITY>
<P>See <LINK REF="TBL-06" TYPE="TABLE">Table 6</LINK> for details.</P>
<P>
<B>Generation of allocation sequence</B>
<BR/>All trials were reported as randomized. Six trials used adequate methods - computer-generated random sequences (<LINK REF="STD-Clifford-2002" TYPE="STUDY">Clifford 2002</LINK>; <LINK REF="STD-Dana-1997" TYPE="STUDY">Dana 1997</LINK>; <LINK REF="STD-Dana-1998" TYPE="STUDY">Dana 1998</LINK>; <LINK REF="STD-Sacktor-2000" TYPE="STUDY">Sacktor 2000</LINK>; <LINK REF="STD-Schiffito-1999" TYPE="STUDY">Schiffito 1999</LINK>) and minimization method as described by the author (<LINK REF="STD-Heseltine-1998" TYPE="STUDY">Heseltine 1998</LINK>). The remaining trials reports did not describe their methods of allocation sequence (<LINK REF="STD-Navia-1998" TYPE="STUDY">Navia 1998</LINK>; <LINK REF="STD-Schiffito-2006a" TYPE="STUDY">Schiffito 2006a</LINK>; <LINK REF="STD-Schiffito-2007a" TYPE="STUDY">Schiffito 2007a</LINK>; <LINK REF="STD-Schiffito-2007b" TYPE="STUDY">Schiffito 2007b</LINK>)</P>
<P>
<B>Allocation concealment </B>
<BR/>Five trials employed adequate methods for concealing allocation using call-in computer enrolment modules (<LINK REF="STD-Clifford-2002" TYPE="STUDY">Clifford 2002</LINK>; <LINK REF="STD-Dana-1997" TYPE="STUDY">Dana 1997</LINK>; <LINK REF="STD-Dana-1998" TYPE="STUDY">Dana 1998</LINK>; <LINK REF="STD-Sacktor-2000" TYPE="STUDY">Sacktor 2000</LINK>; <LINK REF="STD-Schiffito-1999" TYPE="STUDY">Schiffito 1999</LINK>). Allocation concealed was unclear in the remaining trials (<LINK REF="STD-Heseltine-1998" TYPE="STUDY">Heseltine 1998</LINK>; <LINK REF="STD-Navia-1998" TYPE="STUDY">Navia 1998</LINK>; <LINK REF="STD-Schiffito-2006a" TYPE="STUDY">Schiffito 2006a</LINK>; <LINK REF="STD-Schiffito-2007a" TYPE="STUDY">Schiffito 2007a</LINK>; <LINK REF="STD-Schiffito-2007b" TYPE="STUDY">Schiffito 2007b</LINK>).</P>
<P>
<B>Blinding</B>
<BR/>All trials were reported as double-blind. Five trials reported that both participants and providers were blinded to treatment assignment (<LINK REF="STD-Clifford-2002" TYPE="STUDY">Clifford 2002</LINK>; <LINK REF="STD-Dana-1997" TYPE="STUDY">Dana 1997</LINK>; <LINK REF="STD-Dana-1998" TYPE="STUDY">Dana 1998</LINK>; <LINK REF="STD-Sacktor-2000" TYPE="STUDY">Sacktor 2000</LINK>; <LINK REF="STD-Schiffito-1999" TYPE="STUDY">Schiffito 1999</LINK>); and assessor (personal communication <LINK REF="STD-Sacktor-2000" TYPE="STUDY">Sacktor 2000</LINK>). Blinding methods were unclear in the other five trials (<LINK REF="STD-Heseltine-1998" TYPE="STUDY">Heseltine 1998</LINK>; <LINK REF="STD-Navia-1998" TYPE="STUDY">Navia 1998</LINK>; <LINK REF="STD-Schiffito-2006a" TYPE="STUDY">Schiffito 2006a</LINK>; <LINK REF="STD-Schiffito-2007a" TYPE="STUDY">Schiffito 2007a</LINK>; <LINK REF="STD-Schiffito-2007b" TYPE="STUDY">Schiffito 2007b</LINK>).</P>
<P>
<B>Completeness of follow up</B>
<BR/>All trials reported the number of participants lost to follow up and all randomized participants were included in analysis. The inclusion of randomized participants was adequate in six trials (<LINK REF="STD-Clifford-2002" TYPE="STUDY">Clifford 2002</LINK>; <LINK REF="STD-Dana-1998" TYPE="STUDY">Dana 1998</LINK>; <LINK REF="STD-Sacktor-2000" TYPE="STUDY">Sacktor 2000</LINK>; <LINK REF="STD-Schiffito-1999" TYPE="STUDY">Schiffito 1999</LINK>; <LINK REF="STD-Schiffito-2006a" TYPE="STUDY">Schiffito 2006a</LINK>; <LINK REF="STD-Schiffito-2007b" TYPE="STUDY">Schiffito 2007b</LINK>) and inadequate in four trials (<LINK REF="STD-Heseltine-1998" TYPE="STUDY">Heseltine 1998</LINK>; <LINK REF="STD-Navia-1998" TYPE="STUDY">Navia 1998</LINK>; <LINK REF="STD-Dana-1997" TYPE="STUDY">Dana 1997</LINK>; <LINK REF="STD-Schiffito-2007a" TYPE="STUDY">Schiffito 2007a</LINK>). Participant loss to follow-up ranged from 6 to 40% (mean 20% across all studies). See <LINK REF="TBL-06" TYPE="TABLE">Table 6</LINK> for details of individual studies.</P>
<P>
<B>Incomplete outcome</B>
<BR/>Incomplete outcome data were adequately addressed in eight trials (<LINK REF="STD-Clifford-2002" TYPE="STUDY">Clifford 2002</LINK>; <LINK REF="STD-Dana-1997" TYPE="STUDY">Dana 1997</LINK>; <LINK REF="STD-Dana-1998" TYPE="STUDY">Dana 1998</LINK>; <LINK REF="STD-Sacktor-2000" TYPE="STUDY">Sacktor 2000</LINK>; <LINK REF="STD-Schiffito-1999" TYPE="STUDY">Schiffito 1999</LINK>; <LINK REF="STD-Schiffito-2006a" TYPE="STUDY">Schiffito 2006a</LINK>; <LINK REF="STD-Schiffito-2007a" TYPE="STUDY">Schiffito 2007a</LINK>; <LINK REF="STD-Schiffito-2007b" TYPE="STUDY">Schiffito 2007b</LINK>). Reasons for discontinuing treatment in the remaining studies were considered inadequate, because they were related to true outcomes:<BR/>
</P>
<UL>
<LI>
<LINK REF="STD-Navia-1998" TYPE="STUDY">Navia 1998</LINK>: 11 patients out of 38 randomized were loss to follow up due to neurologic and toxicity endpoint</LI>
<LI>
<LINK REF="STD-Heseltine-1998" TYPE="STUDY">Heseltine 1998</LINK>: number of deaths (eight in Peptide T group vs three in placebo group) and entry into salvage protocol (eight in Peptide T group vs six in placebo group). </LI>
</UL>
<P>
<BR/>
<B>Selective outcome reporting</B>
<BR/>All trials were free of suggestive outcome reporting.</P>
<P>
<B>T</B>
<B>opic specific, design specific or other potential threats to validity</B>
<BR/>All trials were apparently free of design specific or other potential threat to validity. </P>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2008-05-14 13:57:26 -0700" MODIFIED_BY="Tara Horvath">
<P>The studies could not be combined for meta-analysis due to heterogeneity in interventions tested (<LINK REF="TBL-07" TYPE="TABLE">Table 7</LINK>). Results for individual comparisons are, therefore presented by outcome. For more details on individual studies, please refer to the 'Characteristics of Included Studies' and 'Analyses'</P>
<P>
<B>01. Lexipafant vs placebo (</B>
<LINK REF="STD-Schiffito-1999" TYPE="STUDY">Schiffito 1999</LINK>
<B>)</B>
<BR/>
<U>01.01 Neuropsychological test scores </U>(see '<LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>')<BR/>Several tests were used to assess neuropsychological function. There was trend toward improvement in the Rey auditory verbal learning (RAVL) - recall after interference (WMD 2.20; 95% CI 0.68 to 3.72), favouring the lexipafant group. There were no significant treatment effects for other measures of neuropsychological function:<BR/>
</P>
<UL>
<LI>Rey auditory verbal learning - Total number correct (WMD 4.10; 95% CI -0.53 to 8.73)</LI>
<LI>Rey auditory verbal learning - Number correct Trial 5 (WMD 0.80; 95% CI -0.39 to 1.99)</LI>
<LI>Rey auditory verbal learning - Delayed Recall (WMD 1.40; 95% CI -0.40 to 3.20)</LI>
<LI>Rey auditory verbal learning - Correct Recognition (WMD -0.20; 95% CI -1.63 to 1.23)</LI>
<LI>Mean reaction time - Choice (WMD -5.10; 95% CI -102.44 to 92.24)</LI>
<LI>Mean reaction time - Sequential (WMD 11.70; 95% CI -71.48 to 94.88)</LI>
<LI>Digit Symbol (WMD 1.30; 95% CI -2.87 to 5.47)</LI>
<LI>Groove pegboard - Dominant Hand (WMD 3.50; 95% CI -8.39 to 15.39)</LI>
<LI>Groove pegboard - Nondominant Hand (WMD 1.80; 95% CI -9.32 to 12.92)</LI>
<LI>Timed Gait (WMD 0.00; 95% CI -1.58 to 1.58)</LI>
</UL>
<P>
<BR/>
<U>01.02 Tolerability </U>(see '<LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK>')<BR/>The analysis of tolerability (treatment completers) (RR 0.94; CI 0.74 to 1.19) showed no significant difference between intervention and control groups.</P>
<P>
<U>01.03 All cause mortality</U>
<BR/>No deaths were reported in both arms.</P>
<P>
<U>01.04 Adverse effects</U> (see '<LINK REF="CMP-001.04" TYPE="ANALYSIS">Analysis 1.4</LINK>')<BR/>Various adverse effects were recorded, none of the events showed statistical difference between the intervention and control groups:<BR/>
</P>
<UL>
<LI>Number of patient experiencing any adverse effects (RR 0.58; 95% CI 0.34 to 1.00)</LI>
<LI>Diarrhoea (RR 0.29; 95% CI 0.01 to 6.69)</LI>
<LI>Herpes zoster (RR 0.29; 95% CI 0.01 to 6.69)</LI>
<LI>Blepharitis (RR 2.65; 95% CI 0.12 to 60.21)</LI>
<LI>Headache (RR 0.58; 95% CI 0.11 to 3.00)</LI>
<LI>Gastroesophageal reflux (RR 0.58; 95% CI 0.11 to 3.00)</LI>
<LI>Vomiting (RR 0.18; 95% CI 0.01 to 3.39)</LI>
<LI>Nephrolithiasis (RR 0.88; 95% CI 0.06 to 12.73)</LI>
<LI>Bacteria pneumonia (RR 0.88; 95% CI 0.06 to 12.73)</LI>
</UL>
<P>
<BR/>
<B>02. Peptide T vs placebo (</B>
<LINK REF="STD-Heseltine-1998" TYPE="STUDY">Heseltine 1998</LINK>
<B>)<BR/>
</B>
<U>02.01 Neurocognitive performance scores </U>(see '<LINK REF="CMP-002.01" TYPE="ANALYSIS">Analysis 2.1</LINK>')<BR/>No difference was found between the two treatment groups on the score changes of the global and seven cognitive domains using 'available case analysis' (all patients for whom complete outcome data were available 66/106 in peptide T arm and 77/109 in placebo arm):<BR/>
</P>
<UL>
<LI>Global (WMD 0.08; 95% CI -0.03 to 0.19)</LI>
<LI>Verbal fluency (WMD -0.01; 95% CI -0.25 to 0.23)</LI>
<LI>Visuospatial ability (WMD -0.08; 95% CI -0.24 to 0.08)</LI>
<LI>Abstract thinking (WMD 0.11; 95% CI -0.05 to 0.27)</LI>
<LI>Speed of information processing (WMD 0.09; 95% CI -0.08 to 0.26)</LI>
<LI>Working memory (WMD 0.15; 95% CI -0.07 to 0.37)</LI>
<LI>Learning and retention (WMD 0.08; 95% CI -0.10 to 0.26)</LI>
<LI>Motor performance (WMD 0.01; 95% CI -0.16 to 0.18)</LI>
</UL>
<P>
<BR/>
<U>02.02 Tolerability </U>(see '<LINK REF="CMP-002.02" TYPE="ANALYSIS">Analysis 2.2</LINK>')<BR/>There was no significant difference between intervention and control group in the number of those that completed the assign dosage of experimental medication (RR 0.88; 95% CI 0.73 to 1.07).</P>
<P>
<U>02.03 All cause mortality </U>(see '<LINK REF="CMP-002.03" TYPE="ANALYSIS">Analysis 2.3</LINK>')<BR/>There were more death in peptide T group compared to placebo, but the difference did not reach statistical significance (RR 2.88; 95% CI 0.74 to 11.18).</P>
<P>
<U>02.04 Adverse effects </U>(see '<LINK REF="CMP-002.04" TYPE="ANALYSIS">Analysis 2.4</LINK>')<BR/>Various adverse effects were recorded, peripheral neuropathy event show a significant difference in favour of peptide compared to placebo (RR 0.37; 95% CI 0.17 to 0.80). There were no significant differences in all other adverse events:<BR/>
</P>
<UL>
<LI>Number of patient experiencing any adverse effects (RR 1.03; 95% CI 0.88 to 1.21)</LI>
<LI>Worsening of mood disorder (RR 7.20; 95% CI 0.90 to 57.51)</LI>
<LI>Rash (RR 0.83; 95% CI 0.58 to 1.20)</LI>
<LI>Nasal congestion (RR 2.47; 95% CI 0.90 to 6.77)</LI>
<LI>Proteinuria (RR 2.06; 95% CI 0.97 to 4.37)</LI>
</UL>
<P>
<BR/>
<B>03. OPC-1147 vs placebo (</B>
<LINK REF="STD-Dana-1997" TYPE="STUDY">Dana 1997</LINK>
<B>)<U>
<BR/>
</U>
</B>
<U>03.01 Neuropsychological test scores </U>(see '<LINK REF="CMP-003.01" TYPE="ANALYSIS">Analysis 3.1</LINK>')<BR/>OPC-1147 compared placebo showed no statistical significant benefit on neurocognitive functions as measured by the neuropsychological test scores:<BR/>
</P>
<UL>
<LI>Rey auditory verbal learning - Total number correct (WMD 2.30; 95% CI -4.68 to 9.28)</LI>
<LI>Rey auditory verbal learning - Recall after Interference (WMD 1.70; 95% CI -0.34 to 3.74)</LI>
<LI>Rey auditory verbal learning - Delayed Recall (WMD 1.50; 95% CI -0.50 to 3.50)</LI>
<LI>Digit Symbol (WMD 0.40; 95% CI -3.45 to 4.25)</LI>
<LI>Groove pegboard - Dominant Hand (WMD -7.30; 95% CI -24.27 to 9.67)</LI>
<LI>Groove pegboard - Nondominant Hand (WMD -4.20; 95% CI -14.81 to 6.41)</LI>
<LI>Timed Gait (WMD 1.10; 95% CI -0.59 to 2.79)</LI>
</UL>
<P>
<BR/>
<U>03.02 Tolerability </U>(see '<LINK REF="CMP-003.02" TYPE="ANALYSIS">Analysis 3.2</LINK>')<BR/>There was no significant difference between intervention and control group in the number of those that complete the assign dosage of experimental medication (RR 0.78; 95% CI 0.39 to 1.54)</P>
<P>
<U>03.03 All cause mortality</U>
<BR/>No deaths were reported in both arms.</P>
<P>
<U>03.04 Adverse effects </U>(see '<LINK REF="CMP-003.04" TYPE="ANALYSIS">Analysis 3.4</LINK>')<BR/>Fewer subjects experienced any adverse effects in OPC-1147 compared to placebo group (RR 0.54; 95% CI; 0.30 to 0.96). Although, there were no significant differences in any of the individual adverse events:<BR/>
</P>
<UL>
<LI>Fatigue (RR 0.60; 95% CI; 0.17 to 2.07)</LI>
<LI>Diarrhoea (RR 1.50; 95% CI; 0.29 to 7.73)</LI>
<LI>Nausea (RR 0.33; 95% CI; 0.04 to 2.85)</LI>
<LI>Cough (RR 0.14; 95% CI; 0.01 to 2.55)</LI>
</UL>
<P>
<BR/>
<B>04. Valproic acid vs placebo (</B>
<LINK REF="STD-Schiffito-2006a" TYPE="STUDY">Schiffito 2006a</LINK>
<B>)</B>
<BR/>
<U>04.01 Neuropsychological test scores </U>(see '<LINK REF="CMP-004.01" TYPE="ANALYSIS">Analysis 4.1</LINK>')<BR/>For neuropsychological test scores there was no significant difference between valproic acid and placebo groups on:<BR/>
</P>
<UL>
<LI>Rey auditory verbal learning - Total number correct (WMD 2.22; 95% CI -5.16 to 9.60)</LI>
<LI>Rey auditory verbal learning - Number correct Trial 5 (WMD -0.39; 95% CI -2.37 to 1.59)</LI>
<LI>Rey auditory verbal learning - Recall after Interference (WMD 4.78; 95% CI -3.73 to 13.29)</LI>
<LI>Rey auditory verbal learning - Delayed Recall (WMD 1.78; 95% CI -0.35 to 3.91)</LI>
<LI>Rey auditory verbal learning - Correct Recognition (WMD -0.72; 95% CI -5.60 to 4.16)</LI>
<LI>Mean reaction time - Choice (WMD -19.38; 95% CI -148.91 to 110.15)</LI>
<LI>Mean reaction time - Sequential (WMD 56.04; 95% CI -54.18 to 166.26)</LI>
<LI>Digit Symbol (WMD 4.56; 95% CI -2.43 to 11.55)</LI>
<LI>Groove pegboard - Dominant Hand (WMD -10.33; 95% CI -27.31 to 6.65)</LI>
<LI>Groove pegboard - Nondominant Hand (WMD -3.94; 95% CI -21.02 to 13.14)</LI>
<LI>Timed Gait (WMD -0.39; 95% CI -1.34 to 0.56)</LI>
<LI>Composite neuropsychological Z score (WMD 2.55; 95% CI -2.57 to 7.67)</LI>
</UL>
<P>
<BR/>
<U>04.02 Tolerability</U> (see '<LINK REF="CMP-004.02" TYPE="ANALYSIS">Analysis 4.2</LINK>')<BR/>There was no significant difference between intervention and control group in the number of those that complete the assign dosage of experimental medication (RR 1.07; 95% CI 0.70 to 1.63)</P>
<P>
<U>04.03 All cause mortality</U>
<BR/>No deaths were reported in both arms.</P>
<P>
<U>04.04 Adverse effects </U>(see '<LINK REF="CMP-004.04" TYPE="ANALYSIS">Analysis 4.4</LINK>')<BR/>Various adverse effects were recorded, none of the events showed statistical difference between the intervention and control groups:<BR/>
</P>
<UL>
<LI>Number of patient experiencing any adverse effects (RR 3.50; 95% CI 0.20 to 62.27)</LI>
<LI>Abnormal liver function (RR 2.10; 95% CI 0.10 to 44.40)</LI>
<LI>Gastroesophageal reflux (RR 2.10; 95% CI 0.10 to 44.40)</LI>
</UL>
<P>
<BR/>
<B>05. Memantine vs placebo (</B>
<LINK REF="STD-Schiffito-2007a" TYPE="STUDY">Schiffito 2007a</LINK>
<B>)</B>
<BR/>
<U>05.01 Neuropsychological test scores</U> (see '<LINK REF="CMP-005.01" TYPE="ANALYSIS">Analysis 5.1</LINK>')<BR/>There was no statistically significance difference between memantine and placebo on composite NPZ test score (WMD 43; 95% CI 10.16 to 96.16).</P>
<P>
<U>05.02 Tolerability</U> (see '<LINK REF="CMP-005.02" TYPE="ANALYSIS">Analysis 5.2</LINK>')<BR/>There was no significant difference between intervention and control group in the number of those that complete the assign dosage of experimental medication (RR 0.96; 95% CI 0.81 to 1.85)</P>
<P>
<U>05.03 All cause mortality</U>
<BR/>There were two deaths during the first 16 weeks, both in the placebo arm (RR 0.20; 95% CI 0.01 to 4.09).</P>
<P>
<U>05.04 Adverse effects</U> (see '<LINK REF="CMP-005.04" TYPE="ANALYSIS">Analysis 5.4</LINK>')<BR/>There were nine subjects in the memantine arm who experienced Grade 1 toxicity and none in the placebo arm (RR 19; 95% CI 1.13 to 320.27). There was no statistically difference between number of subjects who experienced grade 2 or more toxicities in both arms (RR 1.20; 95% CI 0.73 to 1.96).</P>
<P>
<B>06. Thioctic acid vs placebo (</B>
<LINK REF="STD-Dana-_x0028_thioctic_x0029_-1998" TYPE="STUDY">Dana (thioctic) 1998</LINK>
<B>)<U>
<BR/>
</U>
</B>
<U>06.01 Neuropsychological test scores </U>(see '<LINK REF="CMP-006.01" TYPE="ANALYSIS">Analysis 6.1</LINK>')<BR/>Several tests were used to assess neuropsychological function. Subjects on thioctic acid performed worse on Rey auditory verbal learning (RAVL) - total number of correct (RR -11.00; 95% CI -15.95 to -6.05) and better on mean reaction time sequential (RR 70.70; 95% CI 12.15 to 129.25) than subjects did not receive thioctic acid. There were no significant treatment effects for other measures of neuropsychological function:<BR/>
</P>
<UL>
<LI>Rey auditory verbal learning - Number correct Trial 5 (WMD -0.60; 95% CI -2.54 to 1.34)</LI>
<LI>Rey auditory verbal learning - Recall after Interference (WMD -1.60; 95% CI -3.59 to 0.39)</LI>
<LI>Rey auditory verbal learning - Delayed Recall (WMD -1.20; 95% CI -2.78 to 0.38)</LI>
<LI>Rey auditory verbal learning - Correct Recognition (WMD -0.60; 95% CI -1.92 to 0.72)</LI>
<LI>Mean reaction time - Choice (WMD -0.50; 95% CI -53.58 to 52.58)</LI>
<LI>Digit Symbol (WMD -0.30; 95% CI -7.64 to 7.04)</LI>
<LI>Groove pegboard - Dominant Hand (WMD 0.70; 95% CI -14.26 to 15.66)</LI>
<LI>Groove pegboard - Nondominant Hand (WMD 13.30; 95% CI -1.43 to 28.03)</LI>
</UL>
<P>
<BR/>
<U>06.02 Tolerability </U>(see '<LINK REF="CMP-006.02" TYPE="ANALYSIS">Analysis 6.2</LINK>')<BR/>There was no significant difference between intervention and control group in the number of those that complete the assign dosage of experimental medication (RR 4.00; 95% CI 0.33 to 48.66)</P>
<P>
<U>06.03 All cause mortality</U>
<BR/>No deaths were reported in both arms.</P>
<P>
<U>06.04 Adverse effects </U>(see '<LINK REF="CMP-006.04" TYPE="ANALYSIS">Analysis 6.4</LINK>')<BR/>One case of headache was reported in each arm (RR 1.00; 95% CI 0.07 to 13.64)</P>
<P>
<B>07. Oral deprenyl (selegiline) vs placebo (</B>
<LINK REF="STD-Dana-1998" TYPE="STUDY">Dana 1998</LINK>
<B>)<U>
<BR/>
</U>
</B>
<U>07.01 Neuropsychological test scores </U>(see '<LINK REF="CMP-007.01" TYPE="ANALYSIS">Analysis 7.1</LINK>')<BR/>Deprenyl arm performed significantly better on the Rey auditory verbal learning (RAVL) - number of correct trial 5 (RR 1.80; 95% CI 0.24 to 3.36) and RAVL-recall after interference (RR 1.90; 95% CI 0.07 to 3.73) compared to placebo arm. There were no significant treatment effects for other measures of neuropsychological function:<BR/>
</P>
<UL>
<LI>Rey auditory verbal learning - Total number correct (WMD 2.80; 95% CI-2.10 to 7.70)</LI>
<LI>Rey auditory verbal learning - Delayed Recall (WMD 0.70; 95% CI-1.11 to 2.51)</LI>
<LI>Rey auditory verbal learning - Correct Recognition (WMD 1.30; 95% CI-0.41 to 3.01)</LI>
<LI>Digit Symbol (WMD 5.90; 95% CI-0.05 to 11.85)</LI>
<LI>Groove pegboard - Dominant Hand (WMD -10.00; 95% CI-22.37 to 2.37)</LI>
<LI>Groove pegboard - Nondominant Hand (WMD 3.10; 95% CI-12.79 to 18.99)</LI>
<LI>Mean reaction time - Choice (WMD 24.40; 95% CI-28.86 to 77.66)</LI>
<LI>Mean reaction time - Sequential (WMD 20.00; 95% CI-33.12 to 73.12)</LI>
</UL>
<P>
<BR/>
<U>07.02 Tolerability </U>(see '<LINK REF="CMP-007.02" TYPE="ANALYSIS">Analysis 7.2</LINK>')<BR/>There was no significant difference between intervention and control group in the number of those that complete the assign dosage of experimental medication (RR 1.33; 95% CI 0.80 to 2.23).</P>
<P>
<U>07.03 All cause mortality</U>
<BR/>No deaths were reported in both arms.</P>
<P>
<U>07.04 Adverse effects</U> (see '<LINK REF="CMP-007.04" TYPE="ANALYSIS">Analysis 7.4</LINK>')<BR/>The total number of subjects that experienced any adverse effects were more in experimental arm compared to placebo group (RR 8.00; 95% CI 1.24 to 51.51). Although, there were no significant differences in any of the individual adverse events:<BR/>
</P>
<UL>
<LI>Headache (RR 2.00; 95% CI 0.22 to 18.33)</LI>
<LI>Nausea (RR 5.00; 95% CI 0.27 to 91.52)</LI>
<LI>Acute lymphocytic leukemia (RR 5.00; 95% CI 0.27 to 91.52)</LI>
<LI>Bacteria pneumonia (RR 3.00; 95% CI 0.14 to 65.16)</LI>
<LI>Flu (RR 3.00; 95% CI 0.14 to 65.16)</LI>
</UL>
<P>
<BR/>
<B>08. Thioctic acid and deprenyl (selegiline) vs placebo (</B>
<LINK REF="STD-Dana-_x0028_both_x0029_-1998" TYPE="STUDY">Dana (both) 1998</LINK>
<B>)<U>
<BR/>
</U>
</B>
<U>08.01. Neuropsychological test scores </U>(see '<LINK REF="CMP-008.01" TYPE="ANALYSIS">Analysis 8.1</LINK>')<BR/>No statistical significant differences between thioctic acid and deprenyl (selegiline) and placebo group emerged in any of the neuropsychological test scores:<BR/>
</P>
<UL>
<LI>Rey auditory verbal learning - Total number correct (WMD -2.60; 95% CI -7.95 to 2.75)</LI>
<LI>Rey auditory verbal learning - Number correct Trial 5 (WMD 1.00; 95% CI -0.56 to 2.56)</LI>
<LI>Rey auditory verbal learning - Recall after Interference (WMD -1.00; 95% CI -3.68 to 1.68)</LI>
<LI>Rey auditory verbal learning - Delayed Recall (WMD 0.10; 95% CI -1.37 to 1.57)</LI>
<LI>Rey auditory verbal learning - Correct Recognition (WMD -0.10; 95% CI -1.77 to 1.57)</LI>
<LI>Mean reaction time - Choice (WMD -4.30; 95% CI -58.71 to 50.11)</LI>
<LI>Mean reaction time - Sequential (WMD -5.20; 95% CI -49.57 to 39.17)</LI>
<LI>Groove pegboard - Dominant Hand (WMD -10.80; 95% CI -26.85 to 5.25)</LI>
<LI>Groove pegboard - Nondominant Hand (WMD 4.70; 95% CI -12.53 to 21.93)</LI>
<LI>Digit Symbol (WMD 0.60; 95% CI -4.78 to 5.98)</LI>
</UL>
<P>
<BR/>
<U>08.02 Tolerability </U>(see '<LINK REF="CMP-008.02" TYPE="ANALYSIS">Analysis 8.2</LINK>')<BR/>There was no significant difference between intervention and control group in the number of those that complete the assign dosage of experimental medication (RR 1.46; 95% CI 0.91 to 2.35)</P>
<P>
<U>08.03 All cause mortality </U>(see '<LINK REF="CMP-008.03" TYPE="ANALYSIS">Analysis 8.3</LINK>')<BR/>No deaths were reported in both arms.<BR/>
<U>
<BR/>08.04 Adverse effects</U> (see '<LINK REF="CMP-008.04" TYPE="ANALYSIS">Analysis 8.4</LINK>')<BR/>Various adverse effects were recorded, none of the events showed statistical difference between the intervention and control groups:<BR/>
</P>
<UL>
<LI>Number of patient experiencing any adverse effects (RR 6.00; 95% CI 0.89 to 40.31)</LI>
<LI>Headache (RR 2.00; 95% CI 0.22 to 18.33)</LI>
<LI>Nausea (RR 5.00; 95% CI 0.27 to 91.52)</LI>
<LI>Acute lymphocytic leukemia (RR 3.00; 95% CI 0.14 to 65.16)</LI>
<LI>Neutropenia (RR 3.00; 95% CI 0.14 to 65.16)</LI>
</UL>
<P>
<B>09. Low dose transdermal deprenyl (selegiline) vs placebo (</B>
<LINK REF="STD-Sacktor-2000" TYPE="STUDY">Sacktor 2000</LINK>
<B>; </B>
<LINK REF="STD-Schiffito-2007b" TYPE="STUDY">Schiffito 2007b</LINK>
<B>)</B>
<BR/>
<U>09.01 Neuropsychological test scores</U> (see '<LINK REF="CMP-009.01" TYPE="ANALYSIS">Analysis 9.1</LINK>')<BR/>Two trials (<LINK REF="STD-Sacktor-2000" TYPE="STUDY">Sacktor 2000</LINK>; <LINK REF="STD-Schiffito-2007b" TYPE="STUDY">Schiffito 2007b</LINK>) compared low dose transdermal selegiline with placebo. Changes from baseline on the neuropsychological test scores results illustrate varieties of findings in <LINK REF="STD-Sacktor-2000" TYPE="STUDY">Sacktor 2000</LINK>. The selegiline group performed better than the placebo group on Rey Auditory Verbal Learning - Delayed Recall (WMD 2.90; 95% CI 0.13 to 5.67) and Groove pegboard - Nondominant Hand (WMD 23.50; 95% CI 4.11 to 42.89). While placebo group showed improved on mean reaction time -choice test score (WMD -98.50; 95% CI -153.98 to -43.02). There were no differences between the groups on other tests. Individual neuropsychological performance tests scores were not reported in <LINK REF="STD-Schiffito-2007b" TYPE="STUDY">Schiffito 2007b</LINK>. However, no statistically significant evidence in favour of low dose transdermal selegiline emerged in all the reported three neuropsychological composite test scores (NPZ): NPZ- 6 (WMD -0.03; 95% CI -0.30 to 0.24), NPZ-8 (WMD -0.01; 95% CI -0.22 to 0.20), and NPZ total (WD 0.06; 95% CI -0.17 to 0.29).</P>
<P>
<U>09.02 Tolerability</U> (see '<LINK REF="CMP-009.02" TYPE="ANALYSIS">Analysis 9.2</LINK>')<BR/>There was no significant difference between intervention and control group in the number of those that complete the assign dosage of experimental medication, with combined RR 0.99; 95% CI 0.83 to 1.17, with no significant heterogeneity (I<SUP>2</SUP> =0%; Chi<SUP>2</SUP> =0.26; P=0.61)</P>
<P>
<U>09.03 All cause mortality</U>
<BR/>No deaths were reported in both arms in <LINK REF="STD-Sacktor-2000" TYPE="STUDY">Sacktor 2000</LINK> and <LINK REF="STD-Schiffito-2007b" TYPE="STUDY">Schiffito 2007b</LINK> reported one death in each arm (RR 1.02; 95% CI 0.07 to 15.84).</P>
<P>
<U>09. 04 Adverse effects</U> (see '<LINK REF="CMP-009.04" TYPE="ANALYSIS">Analysis 9.4</LINK>')<BR/>Various adverse effects were recorded, none of the events showed statistical difference between the intervention and control groups.<BR/>
<BR/>
<B>10. High dose transdermal deprenyl (selegiline) vs placebo</B> (<LINK REF="STD-Schifitto-_x0028_high_x0029_2007" TYPE="STUDY">Schifitto (high)2007</LINK>)<BR/>
<U>10.01 Neuropsychological test scores</U> (see '<LINK REF="CMP-010.01" TYPE="ANALYSIS">Analysis 10.1</LINK>')<BR/>Individual neuropsychological performance tests scores were not reported. No statistically significant evidence in favour of high dose transdermal selegiline emerged in all the reported three neuropsychological composite test scores (NPZ): NPZ- 6 (WD 0.04; 95% CI -0.26 to 0.34), NPZ-8 (WD -0.21; 95% CI -0.48 to 0.1), and NPZ total (WD 0.02; 95% CI -0.26 to 0.30).</P>
<P>
<U>10.02 Tolerability</U> (see '<LINK REF="CMP-010.02" TYPE="ANALYSIS">Analysis 10.2</LINK>')<BR/>There was no significant difference between intervention and control group in the number of those that complete the assign dosage of experimental medication (RR 0.97; 95% CI 0.81 to 1.16)</P>
<P>
<U>10.03 All cause mortality</U>
<BR/>One death was reported in each arm (RR 1.00; 95% CI 0.06 to 15.48)</P>
<P>
<U>10. 04 Adverse effects</U> (see '<LINK REF="CMP-010.04" TYPE="ANALYSIS">Analysis 10.4</LINK>')<BR/>Various adverse effects were recorded, none of the events showed statistical difference between the intervention and control groups:<BR/>
</P>
<UL>
<LI>Rash (RR 3.00; 95% CI 0.13 to 71.65)</LI>
<LI>Back pain (RR .033; 95% CI 0.01 to 7.96)</LI>
<LI>Parasthesia (RR 3.00; 95% CI 0.13 to 71.65)</LI>
<LI>Headache (RR 0.20; 95% CI 0.01 to 4.05)</LI>
<LI>Shortness of breath (RR .033; 95% CI 0.01 to 7.96)</LI>
</UL>
<P>
<B>11. Low dose (50mg) CPI-1189 vs placebo (</B>
<LINK REF="STD-Clifford-2002" TYPE="STUDY">Clifford 2002</LINK>
<B>)<BR/>
</B>
<U>11.01 Neuropsychological test scores </U>(see '<LINK REF="CMP-011.01" TYPE="ANALYSIS">Analysis 11.1</LINK>')<BR/>No statistically significant evidence in favour of low dose (50mg) CPI-1189 emerged in all the neuropsychological test scores:<BR/>
</P>
<UL>
<LI>Rey Auditory Verbal Learning - Total Number Correct (WMD -2.60; 95% CI -7.99 to 2.79)</LI>
<LI>Rey Auditory Verbal Learning - Number Correct - Trial 5 (WMD -1.40; 95% CI -2.79 to -0.01)</LI>
<LI>Rey Auditory Verbal Learning - Recall after Interference (WMD -1.50; 95% CI -3.30 to 0.30)</LI>
<LI>Rey Auditory Verbal Learning - Delayed Recall (WMD -0.80; 95% CI -2.92 to 1.32)</LI>
<LI>Mean Reaction Time - Choice (WMD 22.00; 95% CI -24.22 to 68.22)</LI>
<LI>Mean Reaction Time - Sequential (WMD -2.40; 95% CI -52.47 to 47.67)</LI>
<LI>Trail Making - Part A (WMD 0.00; 95% CI -0.10 to 0.10)</LI>
<LI>Trail Making - Part B (WMD 0.00; 95% CI -0.10 to 0.10)</LI>
<LI>Digit Symbol (WMD -2.60; 95% CI -8.47 to 3.27)</LI>
<LI>Grooved Pegboard - Dominant Hand (WMD -2.40; 95% CI -13.86 to 9.06)</LI>
<LI>Grooved Pegboard - Nondominant Hand (WMD 5.40; 95% CI -4.57 to 15.37)</LI>
<LI>Finger Tapping - Dominant Hand (WMD -1.80; 95% CI -6.30 to 2.70)</LI>
<LI>Finger Tapping - Nondominant Hand (WMD -1.60; 95% CI -5.46 to 2.26)</LI>
<LI>Timed Gait (WMD 0.40; 95% CI -0.54 to 1.34)</LI>
<LI>Composite neuropsychological Z score (WMD 0.30; 95% CI -0.16 to 0.76)</LI>
</UL>
<P>
<BR/>
<U>11.02 Tolerability </U>(see '<LINK REF="CMP-011.02" TYPE="ANALYSIS">Analysis 11.2</LINK>')<BR/>More subjects were able to tolerate experimental medication compared to placebo, but the difference did not reach statistical significant (RR 1.19; 95% CI 0.90 to 1.57).<BR/>
<BR/>
<U>11.03 All cause mortality</U> (see '<LINK REF="CMP-011.03" TYPE="ANALYSIS">Analysis 11.3</LINK>')<BR/>There was one death in placebo group (RR 0.33; 95% CI 0.01 to 7.74).</P>
<P>
<U>11.04 Adverse effects </U>(see '<LINK REF="CMP-011.04" TYPE="ANALYSIS">Analysis 11.4</LINK>)<BR/>The total number of subjects that experienced any adverse effects were more in experimental arm compared to placebo group (RR 0.60; 95% CI 0.41 to 0.88). Although, there were no significant differences in any of the individual adverse events:<BR/>
</P>
<UL>
<LI>Abdominal pain (RR 0.50; 95% CI 0.05 to 5.10)</LI>
<LI>Diarrhoea (RR 0.67; 95% CI 0.12 to 3.59)</LI>
<LI>Fatigue (RR 0.33; 95% CI 0.01 to 7.74)</LI>
<LI>Fever (RR 1.00; 95% CI 0.07 to 14.95)</LI>
<LI>Headache (RR 1.00; 95% CI 0.16 to 6.45)</LI>
<LI>Rash (RR 0.60; 95% CI 0.16 to 2.20)</LI>
<LI>Upper respiratory tract infection (RR 0.50; 95% CI 0.05 to 5.10)</LI>
<LI>Weight decrease (RR 0.20; 95% CI 0.01 to 3.93)</LI>
<LI>Nausea (RR 1.00; 95% CI 0.16 to 6.45)</LI>
</UL>
<P>
<BR/>
<B>12. High dose (100mg) CPI-1189 vs placebo (</B>
<LINK REF="STD-Clifford-_x0028_high_x0029_-2002" TYPE="STUDY">Clifford (high) 2002</LINK>
<B>)<U>
<BR/>
</U>
</B>
<U>12.01 Neuropsychological test scores </U>(see '<LINK REF="CMP-012.01" TYPE="ANALYSIS">Analysis 12.1</LINK>')<BR/>The composite neuropsychological Z score (WMD 0.50; 95% CI 0.08 to 0.92) and Grooved Pegboard - Nondominant Hand (WMD 11.50; 95% CI 0.98 to 22.02) were improved in the 100mg/day CPI-1189 arm compared with placebo. There were no significant treatment effects on other test:<BR/>
</P>
<UL>
<LI>Rey Auditory Verbal Learning - Total Number Correct (WMD 0.60; 95% CI -4.82 to 6.02)</LI>
<LI>Rey Auditory Verbal Learning - Number Correct - Trial 5 (WMD 0.00; 95% CI -1.08 to 1.08)</LI>
<LI>Rey Auditory Verbal Learning - Recall after Interference (WMD 0.10; 95% CI -1.89 to 2.11)</LI>
<LI>Rey Auditory Verbal Learning - Delayed Recall (WMD 0.50; 95% CI -1.43 to 2.43)</LI>
<LI>Mean Reaction Time - Choice (WMD 24.20; 95% CI -21.38 to 69.78)</LI>
<LI>Mean Reaction Time - Sequential (WMD -25.10; 95% CI -82.04 to 31.84)</LI>
<LI>Trail Making - Part A (WMD 0.00; 95% CI -0.10 to 0.10)</LI>
<LI>Trail Making - Part B (WMD 0.00; 95% CI -0.11 to 0.11)</LI>
<LI>Digit Symbol (WMD -1.00; 95% CI -6.75 to 4.75)</LI>
<LI>Grooved Pegboard - Dominant Hand (WMD 2.60; 95% CI -7.08 to 12.28)</LI>
<LI>Finger Tapping - Dominant Hand (WMD -2.80; 95% CI -7.59 to 1.99)</LI>
<LI>Finger Tapping - Nondominant Hand (WMD -2.10; 95% CI -6.00 to 1.80)</LI>
<LI>Timed Gait (WMD 0.60; 95% CI -0.61 to 1.81</LI>
</UL>
<P>
<BR/>
<U>12.02 Tolerability </U>(see '<LINK REF="CMP-012.02" TYPE="ANALYSIS">Analysis 12.2</LINK>')<BR/>More subjects were able to tolerate experimental medication compared to placebo, but the difference did not reach statistical significant (RR 1.19; 95% CI 0.91 to 1.57).</P>
<P>
<U>12.03 All cause mortality </U>(see '<LINK REF="CMP-012.03" TYPE="ANALYSIS">Analysis 12.3</LINK>')<BR/>There was one death in placebo group (RR 0.32; 95% CI 0.01 to 7.42])</P>
<P>
<U>12.04 Adverse effects </U>(see '<LINK REF="CMP-012.04" TYPE="ANALYSIS">Analysis 12.4</LINK>')<BR/>Various adverse effects were recorded, none of the events showed statistical difference between the intervention and control groups:<BR/>
</P>
<UL>
<LI>Number of patient experiencing any adverse effects (RR 0.95; 95% CI 0.81 to 1.12)</LI>
<LI>Abdominal pain (RR 0.19; 95% CI 0.01 to 3.76)</LI>
<LI>Diarrhoea (RR 0.95; 95% CI 0.22 to 4.21)</LI>
<LI>Fatigue (RR 1.91; 95% CI 0.19 to 19.52)</LI>
<LI>Fever (RR 0.95; 95% CI 0.06 to 14.30)</LI>
<LI>Headache (RR 1.91; 95% CI 0.39 to 9.35)</LI>
<LI>Rash (RR 0.57; 95% CI 0.16 to 2.10)</LI>
<LI>Upper respiratory tract infections (RR 1.43; 95% CI 0.27 to 7.73)</LI>
<LI>Weight decrease (RR 0.48; 95% CI 0.05 to 4.88)</LI>
<LI>Nausea (RR 1.43; 95% CI 0.27 to 7.73)</LI>
</UL>
<P>
<BR/>
<B>13. Low dose nimodipine vs placebo (</B>
<LINK REF="STD-Navia-1998" TYPE="STUDY">Navia 1998</LINK>
<B>)<U>
<BR/>
</U>
</B>
<U>13.01 Neuropsychological test scores</U>
<BR/>Individual neuropsychological performance tests scores were not reported. A summary measure, neuropsychological percent change (NPC) was presented graphically. The authors reported an increase in NPC in placebo group whereas the nimodipine group displayed a marginal decrease.<BR/>
<BR/>
<U>13.02 Tolerability </U>(see '<LINK REF="CMP-013.02" TYPE="ANALYSIS">Analysis 13.2</LINK>')<BR/>There was no significant difference between intervention and control group in the number of those that complete the assign dosage of experimental medication (RR 1.57; 95% CI 0.88 to 2.81)</P>
<P>
<U>13.03 All cause mortality </U>(see '<LINK REF="CMP-013.03" TYPE="ANALYSIS">Analysis 13.3</LINK>')<BR/>One death was reported in each arm (RR 0.79; 95% CI 0.06 to 11.20)</P>
<P>
<U>13.04 Adverse effects</U> (see '<LINK REF="CMP-013.04" TYPE="ANALYSIS">Analysis 13.4</LINK>')<BR/>Various adverse effects were recorded, none of the events showed statistical difference between the intervention and control groups:<BR/>
</P>
<UL>
<LI>Number of patient experiencing any adverse effects (RR 0.52; 95% CI 0.19 to 1.41)</LI>
<LI>Haematological toxicity (RR 0.52; 95% CI 0.11 to 2.61)</LI>
<LI>Cardiac toxicity (RR 0.79; 95% CI 0.06 to 11.20)</LI>
<LI>Psychiatrics toxicity (RR 0.79; 95% CI 0.06 to 11.20)</LI>
<LI>Hypotension (RR 0.27; 95% CI 0.01 to 5.97)</LI>
</UL>
<P>
<BR/>
<B>14. High dose nimodipine vs placebo (</B>
<LINK REF="STD-Navia-_x0028_high_x0029_-1998" TYPE="STUDY">Navia (high) 1998</LINK>
<B>)<U>
<BR/>
</U>
</B>
<U>14.01 Neuropsychological test scores</U>
<BR/>Individual neuropsychological performance tests scores were not reported. A summary measure, neuropsychological percent change (NPC) was presented graphically. The authors reported an increase in NPC in placebo group whereas the nimodipine group displayed a marginal decrease.<BR/>
<U>
<BR/>14.02 Tolerability </U>(see '<LINK REF="CMP-014.02" TYPE="ANALYSIS">Analysis 14.2</LINK>')<BR/>There was no significant difference between intervention and control group in the number of those that complete the assign dosage of experimental medication (RR 1.88; 95% CI 0.35 to 9.98)</P>
<P>
<U>14.03 All cause mortality </U>(see '<LINK REF="CMP-014.03" TYPE="ANALYSIS">Analysis 14.3</LINK>')<BR/>One death was reported in each arm (RR 0.85; 95% CI 0.06 to 12.01)</P>
<P>
<U>14.04 Adverse effects </U>(see '<LINK REF="CMP-014.09" TYPE="ANALYSIS">Analysis 14.9</LINK>')<BR/>Various adverse effects were recorded, none of the events showed statistical difference between the intervention and control groups:<BR/>
</P>
<UL>
<LI>Number of patient experiencing any adverse effects (RR 0.71; 95% CI 0.29 to 1.69)</LI>
<LI>Haematological toxicity (RR 1.13; 95% CI 0.32 to 3.99)</LI>
<LI>Cardiac toxicity (RR 0.29; 95% CI 0.01 to 6.38)</LI>
<LI>Psychiatrics toxicity (RR 0.85; 95% CI 0.06 to 12.01)</LI>
<LI>Hypotension (RR 0.29; 95% CI 0.01 to 6.38)</LI>
</UL>
<P>
<BR/>
<B>15. Any adjunctive therapy vs placebo<BR/>
</B>For numerical details see 'comparisons and data tables':<BR/>
</P>
<UL>
<LI>Tolerability - <LINK REF="CMP-015.01" TYPE="ANALYSIS">Analysis 15.1</LINK>
</LI>
<LI>All cause mortality- <LINK REF="CMP-015.02" TYPE="ANALYSIS">Analysis 15.2</LINK>
</LI>
<LI>Number of patient experiencing any adverse effects - <LINK REF="CMP-015.03" TYPE="ANALYSIS">Analysis 15.3</LINK>.</LI>
</UL>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2008-05-14 13:57:45 -0700" MODIFIED_BY="Tara Horvath">
<P>This review of adjunctive therapies for AIDS dementia complex (ADC) has brought together evidence from ten randomized, placebo controlled, double blind trials of peptide T, selegiline (deprenyl), CPI-1189, OPC-14117, valproic acid, nimodipine, memantine, and lexipafant primarily from the last ten years incorporating 711 subjects.</P>
<P>
<B>Main findings</B>
<BR/>A goal of systematic reviews and meta-analyses is to provide the clinician or researcher with a balanced appraisal of the totality of the evidence in an area, ideally by reading one review, as opposed to a multitude of individual studies. This allows for a more objective appraisal of the evidence, which may lead to resolution of uncertainty and disagreement. This process should be free of bias, such as multiple publications of an individual study, and should synthesize the findings using clinically meaningful endpoints. In reviewing the evidence presented here, we hoped to identify effective intervention strategies for the treatment of ADC. Unfortunately, the results of the trials in this review did not allow for pooling of some key endpoints, so we have provided a predominantly narrative review of the evidence. The trials were heterogeneous in terms of types, dosages, routes and frequencies of administration of the adjunctive therapies. Although we identified a number of studies for inclusion in the review, we found no clear evidence of benefit (or harm) for using these adjunctive therapies to improve clinical outcomes in patients with ADC.</P>
<P>However, there was some evidence of a beneficial effect in terms of improvement and better performance in some of the neuropsychological test scores in some of the drugs (deprenyl, 100mg/day CPI-1189, and valproic acid) compared to placebo. All the adjunctive therapies were well tolerated, safe, and no clinically significant toxic effects emerged in participants with ADC. Though there were no significant differences among treatment groups regarding the primary and secondary measures of tolerability; and incidences of both common and severe adverse events. We found like <LINK REF="REF-Turchan-2003" TYPE="REFERENCE">Turchan 2003</LINK> that methods of analysis and reporting the batteries of neuropsychological test scores vary between the studies making them difficult to compare.</P>
<P>
<B>Strengths and limitations of the review </B>
<BR/>Our review had several strengths. We performed a comprehensive search of several databases and sources to identify studies. We contacted authors for original study articles. We evaluated the quality of included studies using established quality criteria. Screening for study eligibility and data abstraction were performed by two authors. We tried to minimize publication bias by including both published and unpublished data. Our review had noteworthy limitation. This review was designed to access both the efficacy and safety of adjunctive therapies for ADC, all the studies reviewed were phase 2 trials. The primary end points were safety and tolerability, and were not designed primarily designed to detect clinical improvement. To date not a single phase 3 trial of these agents has been conducted.</P>
<P>
<B>Strengths and limitations of the available evidence</B>
<BR/>Most of the studies reviewed are of good quality. Generation of allocation sequence, allocation concealment, sample size calculation, and blinding were adequate in most. All the trials reported the number of participants lost to follow up and all randomized participants were included in the analysis in most. All the trials were free of suggestive outcome reporting and used validated batteries of neuropsychological test.</P>
<P>We identified eight randomized trials, but they had important limitation in term of sample size, most were small. The small size of these trials lack statistical power and make it difficult to draw a reliable conclusion. The numbers of participants lost to follow up were very high in some (<LINK REF="STD-Heseltine-1998" TYPE="STUDY">Heseltine 1998</LINK> [33.49%]; <LINK REF="STD-Dana-1997" TYPE="STUDY">Dana 1997</LINK> [40.00%]) and this may lead to imbalances in the comparison groups. Almost all of the trials included are not independent of the drug manufacturing or marketing companies. Care should be taken in transposing these results to other settings because the data are mainly from USA involving multicenter AIDS cohort study (<LINK REF="REF-Selnes-1991" TYPE="REFERENCE">Selnes 1991</LINK>) subjects (which have inherent referral and selection biases(<LINK REF="REF-Sacktor-1997" TYPE="REFERENCE">Sacktor 1997</LINK>)) and subjects were recruited based on clinical confirmation of the American Academy of Neurology algorithm for ADC (<LINK REF="REF-Dana-1996" TYPE="REFERENCE">Dana 1996</LINK>). In addition, data provided in one trial (<LINK REF="STD-Navia-1998" TYPE="STUDY">Navia 1998</LINK>) were not complete to allow us to statistically re-evaluate the evidence on neuropsychological test scores, and available case analysis was used to analysis neurocognitive performance test (<LINK REF="STD-Heseltine-1998" TYPE="STUDY">Heseltine 1998</LINK>).</P>
</DISCUSSION>
<CONCLUSIONS>
<IMPLICATIONS_PRACTICE>
<P>There is a lack of evidence that any of the adjunctive therapies improves cognitive performance or quality of life, or both for patients with ADC. The evidence of safety and tolerability of these drugs does not justify recommending its routine clinical use.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH>
<P>There is a need for well designed, adequately powered, phase III trials on adjunctive therapies for ADC, with main objective on cognitive performance and/or quality of life. In addition there is a need for more research in transitional and developing countries with high burden of HIV and ADC. </P>
<P>Future trials should address the following: <BR/>
</P>
<UL>
<LI>Review, and refine, the methodology for trials of neuropsychological endpoints, in people with ADC;</LI>
<LI>Recruit an adequate number of participants and provide treatment for a sufficient duration and follow up;</LI>
<LI>Interventions need to be carefully specified and monitored; include careful assessment and complete reporting of adverse events; and</LI>
<LI>Define a priori an unambiguous, measurable, primary endpoint; and report results for all outcomes using CONSORT statement.</LI>
</UL>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2008-05-14 13:28:53 -0700" MODIFIED_BY="Tara Horvath">
<P>Uthman AO was awarded a Reviews for Africa Programme Fellowship (www.mrc.ac.za/cochrane/rap.htm), funded from the Nuffield Commonwealth Programme, through The Nuffield Foundation. We would like to acknowledge the support provided by the staff at the South African Cochrane Centre and the Cochrane HIV/AIDS Review group mentoring programme. Martie Muller (Uthman AO's mentor).</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2008-05-14 13:29:26 -0700" MODIFIED_BY="Tara Horvath">
<P>We declare that we have no affiliation with or involvement in any organization or entity with a financial interest in the subject matter of the review; for example, employment, consultancy, stock ownership, honoria or expert testimony.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS>
<P>Olalekan Uthman contributed to the protocol design, conducted the literature search, selected studies for inclusion, located copies of study reports, extracted data, and did the data entry and analysis; and has overall responsibility for maintaining the review.</P>
<P>Abdulmalik Jibril selected studies for inclusion, extracted data and assisted with data entry and analysis.</P>
<P>All authors contributed to the writing of the report.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF/>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES>
<STUDIES>
<INCLUDED_STUDIES>
<STUDY DATA_SOURCE="PUB" ID="STD-Clifford-_x0028_high_x0029_-2002" NAME="Clifford (high) 2002" YEAR="2002">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Clifford DB, McArthur JC, Schifitto G, Kieburtz K, McDermott MP, Letendre S, et al</AU>
<TI>A randomized clinical trial of CPI-1189 for HIV-associated cognitive-motor impairment</TI>
<SO>Neurology</SO>
<YR>2002</YR>
<VL>59</VL>
<NO>10</NO>
<PG>1568-73</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Clifford-2002" NAME="Clifford 2002" YEAR="2002">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Clifford DB, McArthur JC, Schifitto G, Kieburtz K, McDermott MP, Letendre S, et al</AU>
<TI>A randomized clinical trial of CPI-1189 for HIV-associated cognitive-motor impairment</TI>
<SO>Neurology</SO>
<YR>2002</YR>
<VL>59</VL>
<NO>10</NO>
<PG>1568-73</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dana-_x0028_both_x0029_-1998" NAME="Dana (both) 1998" YEAR="1998">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<TI>A randomized, double-blind, placebo-controlled trial of deprenyl and thioctic acid in human immunodeficiency virus-associated cognitive impairment. Dana Consortium on the Therapy of HIV Dementia and Related Cognitive Disorders</TI>
<SO>Neurology</SO>
<YR>1998</YR>
<VL>50</VL>
<NO>3</NO>
<PG>645-51</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dana-_x0028_thioctic_x0029_-1998" NAME="Dana (thioctic) 1998" YEAR="1998">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<TI>A randomized, double-blind, placebo-controlled trial of deprenyl and thioctic acid in human immunodeficiency virus-associated cognitive impairment. Dana Consortium on the Therapy of HIV Dementia and Related Cognitive Disorders</TI>
<SO>Neurology</SO>
<YR>1998</YR>
<VL>50</VL>
<NO>3</NO>
<PG>645-51</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dana-1997" NAME="Dana 1997" YEAR="1997">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<TI>Safety and tolerability of the antioxidant OPC-14117 in HIV-associated cognitive impairment. The Dana Consortium on the Therapy of HIV Dementia and Related Cognitive Disorders</TI>
<SO>Neurology</SO>
<YR>1997</YR>
<VL>49</VL>
<NO>1</NO>
<PG>142-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dana-1998" NAME="Dana 1998" YEAR="1998">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<TI>A randomized, double-blind, placebo-controlled trial of deprenyl and thioctic acid in human immunodeficiency virus-associated cognitive impairment. Dana Consortium on the Therapy of HIV Dementia and Related Cognitive Disorders</TI>
<SO>Neurology</SO>
<YR>1998</YR>
<VL>50</VL>
<NO>3</NO>
<PG>645-51</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Heseltine-1998" NAME="Heseltine 1998" YEAR="1998">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Goodkin K, Vitiello B, Lyman WD, Asthana D, Atkinson JH, Heseltine PN, et al</AU>
<TI>Cerebrospinal and peripheral human immunodeficiency virus type 1 load in a multisite, randomized, double-blind, placebo-controlled trial of D-Ala1-peptide T-amide for HIV-1-associated cognitive-motor impairment</TI>
<SO>Journal of Neurovirology</SO>
<YR>2006</YR>
<VL>12</VL>
<NO>3</NO>
<PG>178-89</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;Heseltine PN, Goodkin K, Atkinson JH et al. Randomized double-blind placebo-controlled trial of peptide T for HIV-associated cognitive impairment. Arch Neurol 1998; 55(1):41-51.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Heseltine PN, Goodkin K, Atkinson JH, Vitiello B, Rochon J, Heaton RK, et al</AU>
<TI>Randomized double-blind placebo-controlled trial of peptide T for HIV-associated cognitive impairment</TI>
<SO>Archives of Neurology</SO>
<YR>1998</YR>
<VL>55</VL>
<NO>1</NO>
<PG>41-51</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Navia-_x0028_high_x0029_-1998" NAME="Navia (high) 1998" YEAR="1998">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Navia BA, Dafni U, Simpson D, Tucker T, Singer E, McArthur JC, et al</AU>
<TI>A phase I/II trial of nimodipine for HIV-related neurologic complications</TI>
<SO>Neurology</SO>
<YR>1998</YR>
<VL>51</VL>
<NO>1</NO>
<PG>221-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Navia-1998" NAME="Navia 1998" YEAR="1998">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Navia BA, Dafni U, Simpson D, Tucker T, Singer E, McArthur JC, et al</AU>
<TI>A phase I/II trial of nimodipine for HIV-related neurologic complications</TI>
<SO>Neurology</SO>
<YR>1998</YR>
<VL>51</VL>
<NO>1</NO>
<PG>221-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sacktor-2000" NAME="Sacktor 2000" YEAR="2000">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Sacktor N, Schifitto G, McDermott MP, Marder K, McArthur JC, Kieburtz K</AU>
<TI>Transdermal selegiline in HIV-associated cognitive impairment: pilot, placebo-controlled study</TI>
<SO>Neurology</SO>
<YR>2000</YR>
<VL>54</VL>
<NO>1</NO>
<PG>233-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schiffito-1999" NAME="Schiffito 1999" YEAR="1999">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schifitto G, Sacktor N, Marder K, McDermott MP, McArthur JC, Kieburtz K, et al</AU>
<TI>Randomized trial of the platelet-activating factor antagonist lexipafant in HIV-associated cognitive impairment. Neurological AIDS Research Consortium</TI>
<SO>Neurology</SO>
<YR>1999</YR>
<VL>53</VL>
<NO>2</NO>
<PG>391-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schiffito-2006a" NAME="Schiffito 2006a" YEAR="2006">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schifitto G, Peterson DR, Zhong J, Ni H, Cruttenden K, Gaugh M, et al</AU>
<TI>Valproic acid adjunctive therapy for HIV-associated cognitive impairment: a first report</TI>
<SO>Neurology</SO>
<YR>2006</YR>
<VL>66</VL>
<NO>6</NO>
<PG>919-21</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schiffito-2007a" NAME="Schiffito 2007a" YEAR="2007">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schifitto G, Navia BA, Yiannoutsos CT, Marra CM, Chang L, Ernst T, et al</AU>
<TI>Memantine and HIV-associated cognitive impairment: a neuropsychological and proton magnetic resonance spectroscopy study</TI>
<SO>AIDS</SO>
<YR>2007</YR>
<VL>21</VL>
<NO>4</NO>
<PG>1877-86</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schiffito-2007b" NAME="Schiffito 2007b" YEAR="2007">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schifitto G, Zhang J, Evans SR, Sacktor N, Simpson D, Millar LL, et al</AU>
<TI>A multicenter trial of selegiline transdermal system for HIV-associated cognitive impairment</TI>
<SO>Neurology</SO>
<YR>2007</YR>
<VL>69</VL>
<NO>13</NO>
<PG>1314 - 21</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schifitto-_x0028_high_x0029_2007" NAME="Schifitto (high)2007" YEAR="2007">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schifitto G, Zhang J, Evans SR, Sacktor N, Simpson D, Millar LL, et al</AU>
<TI>A multicenter trial of selegiline transdermal system for HIV-associated cognitive impairment</TI>
<SO>Neurology</SO>
<YR>2007</YR>
<VL>69</VL>
<NO>13</NO>
<PG>1314 - 21</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES>
<STUDY DATA_SOURCE="PUB" ID="STD-Anonymous-1996" NAME="Anonymous 1996" YEAR="1996">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<TI>Analyses of peptide T efficacy on neuropsychological performance</TI>
<SO>AIDS Patient Care STDS</SO>
<YR>1996</YR>
<VL>10</VL>
<NO>1</NO>
<PG>52</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Brew-2007" NAME="Brew 2007" YEAR="2007">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Brew BJ, Halman M, Catalan J, Sacktor N, Price RW, Brown S, et al</AU>
<TI>Factors in AIDS dementia complex trial design: results and lessons from the abacavir trial</TI>
<SO>PLoS Clinical Trials</SO>
<YR>2007</YR>
<VL>2</VL>
<NO>3</NO>
<PG>e13</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bridge-1989" NAME="Bridge 1989" YEAR="1989">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Bridge TP, Heseltine PN, Parker ES, Eaton E, Ingraham LJ, Gill M, et al</AU>
<TI>Improvement in AIDS patients on peptide T</TI>
<SO>Lancet</SO>
<YR>1989</YR>
<VL>2</VL>
<PG>226-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bridge-1991" NAME="Bridge 1991" YEAR="1991">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Bridge TP, Heseltine PN, Parker ES, Eaton EM, Ingraham LJ, McGrail ML, et al</AU>
<TI>Results of extended peptide T administration in AIDS and ARC patients</TI>
<SO>Psychopharmacology bulletin</SO>
<YR>1991</YR>
<VL>27</VL>
<PG>237-45</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chang-2004" NAME="Chang 2004" YEAR="2004">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Chang L, Lee PL, Yiannoutsos CT, Ernst T, Marra CM, Richards T, et al</AU>
<TI>A multicenter in vivo proton-MRS study of HIV-associated dementia and its relationship to age</TI>
<SO>NeuroImage</SO>
<YR>2004</YR>
<VL>23</VL>
<NO>4</NO>
<PG>1336-47</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cysique-2006" NAME="Cysique 2006" YEAR="2006">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Cysique LA, Maruff P, Brew BJ</AU>
<TI>Valproic acid is associated with cognitive decline in HIV-infected individuals: a clinical observational study</TI>
<SO>BMC neurology</SO>
<YR>2006</YR>
<VL>6</VL>
<PG>42</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Day-1992" NAME="Day 1992" YEAR="1992">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Day JJ, Grant I, Atkinson JH, Brysk LT, McCutchan JA, Hesselink JR, et al</AU>
<TI>Incidence of AIDS dementia in a two-year follow-up of AIDS and ARC patients on an initial phase II AZT placebo-controlled study: San Diego cohort</TI>
<SO>The Journal of Neuropsychiatry and Clinical Neurosciences</SO>
<YR>1992</YR>
<VL>4</VL>
<NO>1</NO>
<PG>15-20</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-DiCenzo-2004" NAME="DiCenzo 2004" YEAR="2004">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>DiCenzo R, Peterson D, Cruttenden K, Morse G, Riggs G, Gelbard H. et al</AU>
<TI>Effects of valproic acid coadministration on plasma efavirenz and lopinavir concentrations in human immunodeficiency virus-infected adults</TI>
<SO>Antimicrobial Agents and Chemotherapy</SO>
<YR>2004</YR>
<VL>48</VL>
<NO>11</NO>
<PG>4328-31</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Galgani-1997" NAME="Galgani 1997" YEAR="1997">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Galgani S, Balestra P, Narciso P, Tozzi V, Sette P, Pau F, et al</AU>
<TI>Nimodipine plus zidovudine versus zidovudine alone in the treatment of HIV-1-associated cognitive deficits</TI>
<SO>AIDS</SO>
<YR>1997</YR>
<VL>11</VL>
<PG>1520-1</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kosten-1997" NAME="Kosten 1997" YEAR="1997">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Kosten TR, Rosen MI, McMahon TL, Bridge TP, O'Malley SS, Pearsall R</AU>
<TI>Treatment of early AIDS dementia in intravenous drug users: high versus low dose peptide T</TI>
<SO>The American Journal of Drug and Alcohol Abuse</SO>
<YR>1997</YR>
<VL>23</VL>
<NO>4</NO>
<PG>543-53</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lee-2003" NAME="Lee 2003" YEAR="2003">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Lee PL, Yiannoutsos CT, Ernst T, Chang L, Marra CM, Jarvik JG, et al</AU>
<TI>A multi-center 1H MRS study of the AIDS dementia complex: validation and preliminary analysis</TI>
<SO>Journal of Magnetic Resonance Imaging</SO>
<YR>2003</YR>
<VL>17</VL>
<NO>6</NO>
<PG>625-33</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Polianova--2003" NAME="Polianova  2003" YEAR="2003">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Polianova MT, Ruscetti FW, Pert CB, Tractenberg RE, Leoung G, et al</AU>
<TI>Antiviral and immunological benefits in HIV patients receiving intranasal peptide T (DAPTA)</TI>
<SO>Peptides</SO>
<YR>2003</YR>
<VL>24</VL>
<PG>1093-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sacktor-2002" NAME="Sacktor 2002" YEAR="2002">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Sacktor N, McDermott MP, Marder K, Schifitto G, Selnes OA, McArthur JC, et al</AU>
<TI>HIV-associated cognitive impairment before and after the advent of combination therapy</TI>
<SO>Journal of Neurovirology</SO>
<YR>2002</YR>
<VL>8</VL>
<NO>2</NO>
<PG>136-42</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schifitto-2001" NAME="Schifitto 2001" YEAR="2001">
<REFERENCE NOTES="&lt;p&gt;Schifitto G, Kieburtz K, McDermott MP et al. Clinical trials in HIV-associated cognitive impairment: cognitive and functional outcomes. Neurology 2001; 56(3):415-8.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schifitto G, Kieburtz K, McDermott MP, McArthur J, Marder K, Sacktor N, et al</AU>
<TI>Clinical trials in HIV-associated cognitive impairment: cognitive and functional outcomes</TI>
<SO>Neurology</SO>
<YR>2001</YR>
<VL>56</VL>
<NO>3</NO>
<PG>415-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schifitto-2006b" NAME="Schifitto 2006b" YEAR="2006">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Schifitto G, Yiannoutsos CT, Simpson DM, Marra CM, Singer EJ, Kolson DL, et al</AU>
<TI>A placebo-controlled study of memantine for the treatment of human immunodeficiency virus-associated sensory neuropathy</TI>
<SO>Journal of Neurovirology</SO>
<YR>2006</YR>
<VL>12</VL>
<NO>4</NO>
<PG>328-31</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schmitt-1988" NAME="Schmitt 1988" YEAR="1988">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Schmitt FA, Bigley JW, McKinnis R, Logue PE, Evans RW, Drucker JL</AU>
<TI>Neuropsychological outcome of zidovudine (AZT) treatment of patients with AIDS and AIDS-related complex</TI>
<SO>The New England Journal of Medicine</SO>
<YR>1988</YR>
<VL>319</VL>
<NO>24</NO>
<PG>1573-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sidtis-1993" NAME="Sidtis 1993" YEAR="1993">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Sidtis JJ, Gatsonis C, Price RW, Singer EJ, Collier AC, Richman DD, et al</AU>
<TI>Zidovudine treatment of the AIDS dementia complex: results of a placebo-controlled trial. AIDS Clinical Trials Group</TI>
<SO>Annals of Neurology</SO>
<YR>1993</YR>
<VL>33</VL>
<NO>4</NO>
<PG>343-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Simpson-1996" NAME="Simpson 1996" YEAR="196">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Simpson DM, Dorfman D, Olney RK, McKinley G, Dobkin J, So Y, et al</AU>
<TI>Peptide T in the treatment of painful distal neuropathy associated with AIDS: results of a placebo-controlled trial. The Peptide T Neuropathy Study Group</TI>
<SO>Neurology</SO>
<YR>1996</YR>
<VL>47</VL>
<NO>5</NO>
<PG>1254-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tozzi-1993" NAME="Tozzi 1993" YEAR="1993">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Tozzi V, Narciso P, Galgani S, Sette P, Balestra P, Gerace C, et al</AU>
<TI>Effects of zidovudine in 30 patients with mild to end-stage AIDS dementia complex</TI>
<SO>AIDS</SO>
<YR>1993</YR>
<VL>7</VL>
<NO>5</NO>
<PG>683-92</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Villemagne-1996" NAME="Villemagne 1996" YEAR="1996">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Villemagne VL, Phillips RL, Liu X, Gilson SF, Dannals RF, Wong DF, et al</AU>
<TI>Peptide T and glucose metabolism in AIDS dementia complex</TI>
<SO>Journal of Nuclear Medicine</SO>
<YR>1996</YR>
<VL>37</VL>
<NO>7</NO>
<PG>1177-80</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES>
<STUDY DATA_SOURCE="UNPUB" ID="STD-Vitiello-1998" NAME="Vitiello 1998" YEAR="1998">
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Vitiello B</AU>
<TI>Research on possible treatments of HIV-associated cognitive impairment</TI>
<SO>The XII International AIDS Conference; 1998 June 28 - July 3; Geneva, Switzerland</SO>
<YR>1998</YR>
<PG>1148 (abstract no. 60804)</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</AWAITING_STUDIES>
<ONGOING_STUDIES>
<STUDY DATA_SOURCE="UNPUB" ID="STD-Minocycline-2006" NAME="Minocycline 2006" YEAR="2006">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<TI>Minocycline for the Treatment of Decreased Mental Function in HIV Infected Adults</TI>
<SO>www.clinicaltrials.gov/ct/show/NCT00361257?order=1</SO>
<YR>(accessed 28 May 2007)</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-Nimodipine-1999" NAME="Nimodipine 1999" YEAR="1999">
<REFERENCE PRIMARY="NO" TYPE="OTHER">
<TI>Randomized, Double-Blind, Placebo-Controlled Trial of Nimodipine for the Neurological Manifestations of HIV-1</TI>
<SO>www.clinicaltrials.gov/ct/show/NCT00000738?order=1</SO>
<YR>(accessed 28 May 2007)</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</ONGOING_STUDIES>
</STUDIES>
<OTHER_REFERENCES>
<ADDITIONAL_REFERENCES>
<REFERENCE ID="REF-AIDS-institutes-2006" NAME="AIDS institutes 2006" TYPE="OTHER">
<AU>AIDS institutes</AU>
<TI>Cognitive disorders and HIV/AIDS: HIV - associated dementia and delirium</TI>
<SO>www.hivguidelines.org/GuideLine.aspx?pageID=261&amp;guideLineID=44&amp;vType=txt</SO>
<YR>(accessed 28 August 2006)</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Birbeck-2005" NAME="Birbeck 2005" NOTES="&lt;p&gt;Birbeck GL. Human immunodeficiency virus dementia patients in Africa: How many? Who cares? And where to from here? J Neurovirol 2005; 11 Suppl 3:30-3.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Birbeck GL</AU>
<TI>Human immunodeficiency virus dementia patients in Africa: How many? Who cares? And where to from here?</TI>
<SO>Journal of Neurovirolology</SO>
<YR>2005</YR>
<VL>11 Suppl 3</VL>
<PG>30-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Chiesi-1996" NAME="Chiesi 1996" NOTES="&lt;p&gt;Chiesi A, Vella S, Dally LG et al. Epidemiology of AIDS dementia complex in Europe. AIDS in Europe Study Group. J Acquir Immune Defic Syndr Hum Retrovirol 1996; 11(1):39-44.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Chiesi A, Vella S, Dally LG, Pedersen C, Danner S, Johnson AM, et al</AU>
<TI>Epidemiology of AIDS dementia complex in Europe. AIDS in Europe Study Group</TI>
<SO>Journal of Acquired Immune Deficiency Syndrome and Human Retrovirology</SO>
<YR>1996</YR>
<VL>11</VL>
<NO>1</NO>
<PG>39-44</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Childs-1999" NAME="Childs 1999" NOTES="&lt;p&gt;Childs EA, Lyles RH, Selnes OA et al. Plasma viral load and CD4 lymphocytes predict HIV-associated dementia and sensory neuropathy. Neurology 1999; 52(3):607-13.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Childs EA, Lyles RH, Selnes OA, Chen B, Miller EN, Cohen BA, et al</AU>
<TI>Plasma viral load and CD4 lymphocytes predict HIV-associated dementia and sensory neuropathy</TI>
<SO>Neurology</SO>
<YR>1999</YR>
<VL>52</VL>
<NO>3</NO>
<PG>607-13</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Dana-1996" NAME="Dana 1996" TYPE="JOURNAL_ARTICLE">
<TI>Clinical confirmation of the American Academy of Neurology algorithm for HIV-1-associated cognitive/motor disorder. The Dana Consortium on Therapy for HIV Dementia and Related Cognitive Disorders</TI>
<SO>Neurology</SO>
<YR>1996</YR>
<VL>47</VL>
<NO>5</NO>
<PG>1247-53</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Edward-1987" NAME="Edward 1987" TYPE="OTHER">
<AU>Edward DD</AU>
<TI>Competition' cause of AIDS dementia? Science News Sept 1987</TI>
<SO>www.findarticles.com/p/articles/mi_m1200/is_v132/ai_5197123</SO>
<YR>(accessed 23 July 2006)</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Egger-1997" NAME="Egger 1997" TYPE="JOURNAL_ARTICLE">
<AU>Egger M, Davey Smith G, Schneider M, Minder C</AU>
<TI>Bias in meta-analysis detected by a simple, graphical test</TI>
<SO>British Medical Journal</SO>
<YR>1997</YR>
<VL>315</VL>
<NO>7109</NO>
<PG>629-34</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ghafouri-2006" NAME="Ghafouri 2006" NOTES="&lt;p&gt;Ghafouri M, Amini S, Khalili K, Sawaya BE. HIV-1 associated dementia: symptoms and causes. Retrovirology 2006; 3:28.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Ghafouri M, Amini S, Khalili K, Sawaya BE</AU>
<TI>HIV-1 associated dementia: symptoms and causes</TI>
<SO>Retrovirology</SO>
<YR>2006</YR>
<VL>3</VL>
<PG>28</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gonzalez-2006" NAME="Gonzalez 2006" NOTES="&lt;p&gt;Gonzalez-Scarano F, Martin-Garcia J. The neuropathogenesis of AIDS. Nat Rev Immunol 2005; 5(1):69-81.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Gonzalez-Scarano F, Martin-Garcia J</AU>
<TI>The neuropathogenesis of AIDS</TI>
<SO>Nature Reviews Immunology</SO>
<YR>2005</YR>
<VL>5</VL>
<NO>1</NO>
<PG>69-81</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2003" NAME="Higgins 2003" TYPE="JOURNAL_ARTICLE">
<AU>Higgins JP, Thompson SG, Deeks JJ, Altman DG.</AU>
<TI>Measuring inconsistency in meta-analyses</TI>
<SO>British Medical Journal</SO>
<YR>2003</YR>
<VL>327</VL>
<NO>7414</NO>
<PG>557-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2006" NAME="Higgins 2006" TYPE="OTHER">
<AU>Higgins JPT, Green S, editors</AU>
<TI>Analysis and presenting results. Cochrane Handbook for Systematic Reviews of Interventions 4.2.6 [updated September 2006]; Section 8</TI>
<SO>www.cochrane.org/resources/handbook/hbook.htm</SO>
<YR>(accessed 6th October 2006)</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-J_x00fc_ni-2001" NAME="Jüni 2001" TYPE="JOURNAL_ARTICLE">
<AU>Jüni P, Altman DG, Egger M</AU>
<TI>Systematic reviews in health care: Assessing the quality of controlled clinical trials</TI>
<SO>British Medical Journal</SO>
<YR>2001</YR>
<VL>323</VL>
<NO>7303</NO>
<PG>42-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-McArthur-2005" NAME="McArthur 2005" NOTES="&lt;p&gt;McArthur JC, Brew BJ, Nath A. Neurological complications of HIV infection. Lancet Neurol 2005; 4(9):543-55.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>McArthur JC, Brew BJ, Nath A</AU>
<TI>Neurological complications of HIV infection</TI>
<SO>Lancet Neurology</SO>
<YR>2005</YR>
<VL>4</VL>
<NO>9</NO>
<PG>543-55</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Moher-1999" NAME="Moher 1999" TYPE="JOURNAL_ARTICLE">
<AU>Moher D, Cook DJ, Eastwood S, Olkin I, Rennie D, Stroup DF</AU>
<TI>Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Quality of Reporting of Meta-analyses</TI>
<SO>Lancet</SO>
<YR>1999</YR>
<VL>354</VL>
<NO>9193</NO>
<PG>1896-900</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mollace-2001" NAME="Mollace 2001" NOTES="&lt;p&gt;Mollace V, Nottet HS, Clayette P et al. Oxidative stress and neuroAIDS: triggers, modulators and novel antioxidants. Trends Neurosci 2001; 24(7):411-6.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Mollace V, Nottet HS, Clayette P, Turco MC, Muscoli C, Salvemini D, et al</AU>
<TI>Oxidative stress and neuroAIDS: triggers, modulators and novel antioxidants</TI>
<SO>Trends in Neuroscience</SO>
<YR>2001</YR>
<VL>24</VL>
<NO>7</NO>
<PG>411-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Parnes-2006" NAME="Parnes 2006" TYPE="OTHER">
<AU>Parnes RB</AU>
<TI>AIDS Dementia Complex</TI>
<SO>www.thirdage.com/healthgate/files/43788.html</SO>
<YR>(accessed 12 July 2006)</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Price-1996" NAME="Price 1996" NOTES="&lt;p&gt;Price RW. Neurological complications of HIV infection. Lancet 1996; 348(9025):445-52.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Price RW</AU>
<TI>Neurological complications of HIV infection</TI>
<SO>Lancet</SO>
<YR>1996</YR>
<VL>348</VL>
<NO>9025</NO>
<PG>445-52</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ramsay-2007" NAME="Ramsay 2007" TYPE="OTHER">
<AU>Ramsay C</AU>
<TI>How do you include trials with more than two groups into a single meta-analysis?</TI>
<SO>www.epoc.uottawa.ca/FAQmultiplegroups2003.pdf</SO>
<YR>(accessed 06 June 2007)</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Review-Manager-4.2" NAME="Review Manager 4.2" TYPE="COMPUTER_PROGRAM">
<TI>Review Manager (RevMan)</TI>
<YR>2003</YR>
<EN>4.2 for Windows</EN>
<PB>The Nordic Cochrane Centre, The Cochrane Collaboration</PB>
<CY>Copenhagen</CY>
<MD>CD-ROM and Internet</MD>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sacktor-1997" NAME="Sacktor 1997" TYPE="JOURNAL_ARTICLE">
<AU>Sacktor N, McArthur J</AU>
<TI>Prospects for therapy of HIV-associated neurologic diseases</TI>
<SO>Journal of Neurovirology</SO>
<YR>1997</YR>
<VL>3</VL>
<NO>2</NO>
<PG>89-101</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Selnes-1991" NAME="Selnes 1991" TYPE="JOURNAL_ARTICLE">
<AU>Selnes OA, Jacobson L, Machado AM, Becker JT, Wesch J, Miller EN</AU>
<TI>Normative data for a brief neuropsychological screening battery. Multicenter AIDS Cohort Study</TI>
<SO>Perceptual and Motor Skills</SO>
<YR>1991</YR>
<VL>73</VL>
<NO>2</NO>
<PG>539-50</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Stern-2001" NAME="Stern 2001" NOTES="&lt;p&gt;Stern Y, McDermott MP, Albert S et al. Factors associated with incident human immunodeficiency virus-dementia. Arch Neurol 2001; 58(3):473-9.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Stern Y, McDermott MP, Albert S, Palumbo D, Selnes OA, McArthur J, et al</AU>
<TI>Factors associated with incident human immunodeficiency virus-dementia</TI>
<SO>Archives of Neurology</SO>
<YR>2001</YR>
<VL>58</VL>
<NO>3</NO>
<PG>473-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Turchan-2003" NAME="Turchan 2003" TYPE="JOURNAL_ARTICLE">
<AU>Turchan J, Sacktor N, Wojna V, Conant K, Nath A</AU>
<TI>Neuroprotective therapy for HIV dementia</TI>
<SO>Current HIV Research</SO>
<YR>2003</YR>
<VL>1</VL>
<PG>373-83</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Zink-2005" NAME="Zink 2005" NOTES="&lt;p&gt;Zink MC, Uhrlaub J, DeWitt J et al. Neuroprotective and anti-human immunodeficiency virus activity of minocycline. JAMA 2005; 293(16):2003-11.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Zink MC, Uhrlaub J, DeWitt J, Voelker T, Bullock B, Mankowski J, et al</AU>
<TI>Neuroprotective and anti-human immunodeficiency virus activity of minocycline</TI>
<SO>Journal of the American Medical Association</SO>
<YR>2005</YR>
<VL>293</VL>
<NO>16</NO>
<PG>2003-11</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES/>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES>
<CHARACTERISTICS_OF_INCLUDED_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR STUDY_ID="STD-Clifford-_x0028_high_x0029_-2002">
<CHAR_METHODS>
<P>[Refer to Clifford 2002 for details; author described high dose of CPI-1189 versus placebo]</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Clifford-2002">
<CHAR_METHODS>
<P>Design: RCT<BR/>Technique of randomization: Stratified and blocked<BR/>Allocation sequence: Computer generated (Adequate)<BR/>Allocation concealment: Adequate<BR/>Method of concealment: Call-in computer enrolment module<BR/>Binding: Double, participants and investigators<BR/>Inclusion of all randomized participants: Grade A<BR/>Loss to follow up: Overall (14.06%), placebo arm (23.81%), CPI-1189 (50mg) arm ( 9.52%), and CPI-1189 (100mg) arm ( 9.09%)<BR/>Sample size calculation done a priori: Yes<BR/>Follow-up: 2, 6, 10 weeks<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Number: randomized (n=64), completed (n=55)<BR/>Inclusion criteria: HIV infection(confirmed by Western blot), evidence of cognitive impairment, and stable antiretroviral regimen for six weeks<BR/>Exclusion criteria: Active opportunist CNS infection, severe pre-morbid psychiatric illness, history of a chronic neurologic disorder unrelated to HIV infection<BR/>Age: Placebo (mean age = 42.2), CPI-1189 - 50mg (mean age = 44.7), CPI-1189 - 100mg (mean age = 43.3)<BR/>Male: Placebo (76.2%), CPI-1189 - 50mg (95.2%), CPI-1189 - 100mg (81.8%)<BR/>White: Placebo (42.9%), CPI-1189 - 50mg (66.7%), CPI-1189 - 100mg (45.5%)<BR/>Years of HIV: Placebo (mean = 7.7), CPI-1189 - 50mg (mean = 7.8), CPI-1189 - 100mg (mean = 8.3)<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>(1) CPI-1189 50mg orally once daily<BR/>(2) CPI-1189 100mg orally once daily<BR/>(3) Placebo<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>(1) Tolerability of the drug - treatment completers<BR/>(2) Measures of safety - Adverse effects and abnormal laboratory results and eye examinations<BR/>(3) Measures of efficacy - change in neuropsychological test scores, neurologic exam results, measures of function and mood</P>
<P>Outcome not included in this review<BR/>(4) HIV markers<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Study location: USA<BR/>Multi-center study: Yes<BR/>Study date: November 1998 - March 2000<BR/>Study sponsors: National Institute of Neurologic Diseases and Stroke grant, GCRC at Columbia, GCTC at Rochester, and Centaur pharmaceuticals<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Dana-_x0028_both_x0029_-1998">
<CHAR_METHODS>
<P>[Refer to Dana 1998 for details; author described both deprenyl and thioctic acid versus placebo]</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Dana-_x0028_thioctic_x0029_-1998">
<CHAR_METHODS>
<P>[Refer to Dana 1998 for details; author described both thioctic acid versus placebo]</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Dana-1997">
<CHAR_METHODS>
<P>Design: RCT<BR/>Technique of randomization: Stratified and blocked<BR/>Allocation sequence: Computer generated (Adequate)<BR/>Allocation concealment: Adequate<BR/>Method of concealment: Call-in computer enrolment module<BR/>Binding: Double, participants and investigators<BR/>Inclusion of all randomized participants: Grade B<BR/>Loss to follow up: Overall (40.00%), placebo arm (33.33%), and OPC-14117 arm (46.67%)<BR/>Sample size calculation done a priori: Yes<BR/>Follow-up: 2, 4, 8, 12 weeks</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Number: randomized (n=30), completed (n=18)<BR/>Inclusion criteria: HIV infection (confirmed by ELISA or Western blot), evidence of cognitive impairment, and stable antiretroviral regimen for six weeks<BR/>Exclusion criteria: Active opportunist CNS infection, severe pre-morbid psychiatric illness, history of a chronic neurologic disorder unrelated to HIV infection<BR/>Age: Placebo (mean age = 42.9), OPC-14117 (mean age = 40.5)<BR/>Male: Placebo (80%), OPC-14117 (87%)<BR/>White: Placebo (53%), OPC-14117 (60%)<BR/>Years of HIV: Placebo (4.9), OPC-14117 (5.6)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>DRUGS<BR/>(1) OPC-14117<BR/>(4) Placebo</P>
<P>REGIMEN: <BR/>60mg tablet of OPC-14117 orally, twice daily for the first six weeks then maintenance dosage of 120mg twice daily</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>(1) Tolerability of the drug - treatment completers<BR/>(2) Measures of safety - Adverse effects and abnormal laboratory results<BR/>(3) Measures of efficacy - change in neuropsychological test scores<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Study location: USA <BR/>Multi-center study: Yes<BR/>Study sponsors: The Charles A. Dana Foundation, and National Institutes of Health (NIH), and Otsuka America Pharmaceuticals, Inc., Rockville, MD</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Dana-1998">
<CHAR_METHODS>
<P>Design: RCT<BR/>Technique of randomization: Stratified and blocked<BR/>Allocation sequence: Computer generated (Adequate)<BR/>Allocation concealment: Adequate<BR/>Method of concealment: Call-in computer enrolment module<BR/>Binding: Double, participants and investigators<BR/>Inclusion of all randomized participants: Grade A<BR/>Loss to follow up: Overall (13.39%), placebo arm (33.33%), deprenyl arm (11.11%), thioctic acid arm (11.11%), and thioctic acid+deprenyl (none)<BR/>Sample size calculation done a priori: Yes<BR/>Follow-up: 2, 4, 10 weeks<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Number: randomized (n=36), completed (n=31)<BR/>Inclusion criteria: HIV infection (confirmed by ELISA or Western blot), evidence of cognitive impairment, and stable antiretroviral regimen for six weeks<BR/>Exclusion criteria: Active opportunist CNS infection, severe pre-morbid psychiatric illness, history of a chronic neurologic disorder unrelated to HIV infection<BR/>Age: Placebo (mean age = 38.5), Deprenyl (mean age = 40.6), Thiotic acid (mean age = 43.7), and Both (mean age = 42.1)<BR/>Male: Placebo (77.8%), Deprenyl (66.7%), Thiotic acid (66.7%), and Both (77.8%)<BR/>White: Placebo (44%), Deprenyl (55%), Thiotic acid (44%), and Both (78%)<BR/>Years of HIV: Placebo (4.6), Deprenyl (5.3), Thiotic acid (6.6), and Both (6.3)<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>DRUGS<BR/>(1) Deprenyl alone 2.5mg orally<BR/>(2) Deprenyl (2.5mg) and Thiotic acid (600mg) orally<BR/>(3) Thiotic acid alone 600mg orally<BR/>(4) Placebo</P>
<P>REGIMEN<BR/>Deprenyl - three times a week<BR/>Thiotic acid twice daily<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>(1) Tolerability of the drug - treatment completers<BR/>(2) Measures of safety - Adverse effects and abnormal laboratory results<BR/>(3) Measures of efficacy - change in neuropsychological test scores<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Study location: USA<BR/>Multi-center study: Yes<BR/>Study sponsors: Neurological AIDS Research Consortium, the Charles A. Dana Foundation, and National Institutes of Health (NIH), and National Institute of Mental Health<BR/>Sources of support: ASTA Medica provided Thiotic acid and matching placebo<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Heseltine-1998">
<CHAR_METHODS>
<P>Design: RCT<BR/>Technique of randomization: Stratified<BR/>Allocation sequence: Minimization (Adequate)<BR/>Allocation concealment: NR<BR/>Method of concealment: NR<BR/>Binding: Double (not described)<BR/>Inclusion of all randomized participants: Grade B<BR/>Loss to follow up: Overall (33.49%), placebo arm (37.74%), and peptide T arm (29.36%)<BR/>Sample size calculation done a priori: Yes<BR/>Follow-up: Monthly for six months</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Number: randomized (n=215), completed (n=143)</P>
<P>INCLUSION CRITERIA: <BR/>(1) HIV infection (confirmed with ELISA, Western blot, or polymerase chain reaction), <BR/>(2) Cognitive dysfunction as measured by the neuropsychiatry screening battery and judged as likely due to HIV<BR/>(3) Agreement to use barrier methods of contraception (for men) or a reliable method of contraception (for women)<BR/>(4) Negative results on a pregnancy test within one month study entry<BR/>(5) CD4+ lymphocyte count of 0.500x109/L or less (for UM and UCSD sites only); <BR/>(6) expected survival of at least 6 months; <BR/>(7) screening laboratory results meeting the following values: total granulocyte count, 0.750x109/L or more; hemoglobin, more than 80 g/L; platelet count, 75x109 or more; prothrombin time, more than 70% of the control; creatinine, 130 µmol/L or less (1.5 mg/dL); aspartate aminotransferase, less than 5 times normal; bilirubin, 51 µmol/L (3.0 mg/dL); and (8) a normal baseline electrocardiogram or urinalysis or abnormalities for which the patient's condition would still be judged medically stable.</P>
<P>EXCLUSION CRITERIA<BR/>(1) the presence of active AIDS-defining opportunistic infections or malignant neoplasm that required treatment at study entry or Kaposi sarcoma or another malignant neoplasm likely to require chemotherapy during the first 6 months of the study; <BR/>(2) a requirement of more than 2 transfusions per month to achieve a hemoglobin level of more than 80 g/L; <BR/>(3) alcohol or substance dependence or abuse during the last 3 months, judged by the investigators as likely to interfere with the study; <BR/>(4) underlying serious medical problems that could complicate the interpretation of the treatment results, including unstable diabetes mellitus, clinical ischemic disease, uncontrolled hypertension, and hepatic or renal failure; <BR/>(5) current or recent (within the past 6 months) DSM III-R Axis I psychiatric disorder (from the Diagnostic and Statistical Manual of Mental Disorders, Third Edition, Revised)21 or history of psychotic disorder or bipolar mania; <BR/>(6) a history of mental retardation or learning disability; <BR/>(7) treatment with psychoactive agents within 4 weeks, or within 8 weeks for long-acting agents (eg, fluoxetine); <BR/>(8) previous use of peptide T; and <BR/>(9) Inability to participate in NP testing or to comply with the instructions for medication administration.<BR/>Age: Placebo (mean age = 60), Peptide T (mean age = 62)<BR/>Male: Placebo (95%), Peptide T (95.4%)<BR/>White: Placebo (78%), Peptide T (86%)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>DRUGS<BR/>(1) Peptide T<BR/>(2) Placebo</P>
<P>REGIMEN<BR/>Intranasally three times a day for 6 months</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>(1) Change in Cognitive function <BR/>(2) Adverse medical events</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Study location: USA<BR/>Multi-center study: Yes<BR/>Study date: April 1993 to March 1994 <BR/>Study sponsors: NR<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Navia-_x0028_high_x0029_-1998">
<CHAR_METHODS>
<P>[Refer to Navia 1998 for details; author described high dose nimodipine versus placebo]</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Navia-1998">
<CHAR_METHODS>
<P>Design: RCT<BR/>Technique of randomization: NR<BR/>Allocation sequence: NR<BR/>Allocation concealment: NR<BR/>Method of concealment: NR<BR/>Binding: Double blind<BR/>Inclusion of all randomized participants: Grade B<BR/>Loss to follow up: Overall (28.95%), placebo arm (30.77%), low dose nimodipine arm (14.29%), and high dose nimodipine arm (45.45%)<BR/>Sample size calculation done a priori: Yes<BR/>Follow-up: 4, 8, 16, 20 weeks<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Number: randomized (n=38), completed (n= 27)<BR/>Inclusion criteria: HIV infection and evidence of cognitive impairment<BR/>Exclusion criteria: NR <BR/>Age: Nimodipine - high dose (mean age = 40.38), Nimodipine - low dose (mean age = 41.64), Placebo (mean age = 38.64)<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>(1) Nimodipine 60mg orally, five times daily<BR/>(2) Nimodipine 30mg orally, three times daily (plus two doses of placebo)<BR/>(3) Placebo orally, five times daily <BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>(1) Neuropsychological test scores<BR/>(2) Measures of safety - Adverse effects and abnormal laboratory results </P>
<P>Not included in this review<BR/>(3) Change in painful neuropathy<BR/>(4) HIV markers in cerebrospinal fluid and serum samples<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Study location: USA<BR/>Study date: May 1992 to September 1993<BR/>Multi-center study: Yes<BR/>Study sponsors: National Institutes of Allergy and Infectious Diseases, Miles Pharmaceuticals, inc., and American Foundation for AIDS Research. <BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Sacktor-2000">
<CHAR_METHODS>
<P>Design: RCT<BR/>Technique of randomization: NR<BR/>Allocation sequence: Computer generated (Adequate)<BR/>Allocation concealment: Adequate<BR/>Method of concealment: Call-in computer enrolment module<BR/>Binding: Double, participants, investigators, and assesors<BR/>Inclusion of all randomized participants: Grade A<BR/>Loss to follow up: Overall (14.29%), placebo arm (20.00%), and selegiline arm (11.11%)<BR/>Sample size calculation done a priori: NR<BR/>Follow-up: 4, 10 weeks<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Number: randomized (n=14), completed (n=12)<BR/>Inclusion criteria: HIV infection and evidence of cognitive impairment<BR/>Exclusion criteria: NR <BR/>Age: Placebo (mean age = 43.3), Selegiline (mean age = 41.3)<BR/>Male: Placebo (60%), Selegiline (78%)<BR/>White: Placebo (80%), Selegiline (33%)<BR/>Years of HIV: Placebo (mean = 5.1), Selegiline (mean = 6.0)<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>DRUGS<BR/>(1) Selegiline <BR/>(2) Placebo</P>
<P>REGIMEN<BR/>Transdermal patch form of Selegiline (1.0mg/cm X 15 cm2) delivering approximately 3.1 mg per 24 hours.<BR/>One patch was applied every 24 hours (rotated at different sites)<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>(1) Tolerability of the drug - Treatment completers<BR/>(2) Measures of safety - Adverse effects and abnormal laboratory results<BR/>(3) Measures of efficacy - change in neuropsychological test scores, neurologic exam results, measures of function and mood <BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Study location: USA<BR/>Multi-center study: Yes<BR/>Study sponsors: National Institutes of Health (NIH) and Somerset Pharmaceuticals<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Schiffito-1999">
<CHAR_METHODS>
<P>Design: RCT<BR/>Technique of randomization: Stratified and blocked<BR/>Allocation sequence: Computer generated (Adequate)<BR/>Allocation concealment: Adequate<BR/>Method of concealment: Call-in computer enrolment module<BR/>Binding: Double, participants and investigators<BR/>Inclusion of all randomized participants: Grade A<BR/>Loss to follow up: Overall (10.00%), placebo arm (7.14%), and lexipafant arm (12.50%)<BR/>Sample size calculation done a priori: Yes<BR/>Follow-up: 2, 6, 10 weeks<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Number: randomized (n=30), completed (n=27)<BR/>Inclusion criteria: HIV infection, evidence of cognitive impairment, and stable antiretroviral regimen for six weeks<BR/>Exclusion criteria: Active opportunist CNS infection, severe pre-morbid psychiatric illness, history of a chronic neurologic disorder unrelated to HIV infection<BR/>Age: Lexipafant mean age = 43.2, placebo mean age = 42.1<BR/>Male: Lexipafant (64.3%), Placebo (81.2%)<BR/>White: Lexipafant (42.9%), Placebo (43.8%)<BR/>Years of HIV: Lexipafant (mean = 6.4), Placebo (mean = 6.5)<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Tablet Lexipafant - 250mg twice daily<BR/>Matching placebo<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>(1) Tolerability of the drug - treatment completers<BR/>(2) Measures of safety - Adverse effects and abnormal laboratory results<BR/>(3) Measures of efficacy - change in neuropsychological test scores<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Study location: USA<BR/>Multi-center study: Yes<BR/>Study sponsors: Neurological AIDS Research Consortium, the Charles A. Dana Foundation, and NIH<BR/>Sources of support: Lexipafant and placebo donated by British Biotech, Inc., Annapolis, MD<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Schiffito-2006a">
<CHAR_METHODS>
<P>Design: RCT<BR/>Technique of randomization: Blocked and stratified<BR/>Allocation sequence: NR<BR/>Allocation concealment: NR<BR/>Method of concealment: NR<BR/>Binding: Double<BR/>Inclusion of all randomized participants: Grade A<BR/>Loss to follow up: Overall (6.25%). placebo arm (14.29%), and valproic acid arm (none)<BR/>Sample size calculation done a priori: Yes<BR/>Follow-up: 2, 6, 10 weeks<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Number: randomized (n=16), completed (n=15)<BR/>Inclusion criteria: HIV infection and evidence of cognitive impairment<BR/>Exclusion criteria: NR <BR/>Age: Placebo (mean age = 46.6), Valproic acid (mean age = 43.7)<BR/>Male: Placebo (72.7%), Valproic acid (81.8%)<BR/>White: Placebo (27.7%), Valproic acid (63.6%)<BR/>Years of HIV: Placebo (10.4), Valproic acid (8.3)<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>(1) Valproic acid 250mg twice daily<BR/>(2) Placebo<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>(1) Tolerability of the drug - treatment completers<BR/>(2) Measures of safety - Adverse effects and abnormal laboratory results<BR/>(3) Measures of efficacy - change in neuropsychological test scores, investigator Clinical Global Impression<BR/>Not included in this review<BR/>(4) MRI indices<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Study location: USA<BR/>Multi-center study: NR<BR/>Study sponsors: National Institutes of Health (NIH)<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Schiffito-2007a">
<CHAR_METHODS>
<P>Design: RCT<BR/>Technique of randomization: Stratified <BR/>Allocation sequence: NR<BR/>Allocation concealment: NR<BR/>Method of concealment: NR <BR/>Binding: Double<BR/>Inclusion of all randomized participants: Grade B<BR/>Loss to follow up: Overall (16.00%), placebo arm (22.8%), and memantine arm (20.00%)<BR/>Sample size calculation done a priori: Yes<BR/>Follow-up: 4, 8, 12, 16, 20 weeks</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Number: randomized (n=140), completed (n=110)<BR/>Inclusion criteria: HIV infection, evidence of cognitive impairment, and stable antiretroviral regimen for six weeks<BR/>Exclusion criteria: Active opportunist CNS infection, severe pre-morbid psychiatric illness, history of a chronic neurologic disorder unrelated to HIV infection<BR/>Age: Memantine median age = 42, placebo median age = 44<BR/>Male: Memantine (93.0%), Placebo (87.0%)<BR/>White: Memantine (72.0%), Placebo (83.0%)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Tablet Memantine - 10mg daily during the first week and escalated by 10mg weekly<BR/>Matching placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>(1) Tolerability of the drug - treatment completers<BR/>(2) Measures of safety - Adverse effects and abnormal laboratory results<BR/>(3) Measures of efficacy - change in neuropsychological test scores</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Study location: USA<BR/>Study date: February 1997 to December 1999 <BR/>Multi-center study: Yes</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Schiffito-2007b">
<CHAR_METHODS>
<P>Design: RCT<BR/>Technique of randomization: Stratified <BR/>Allocation sequence: NR<BR/>Allocation concealment: NR<BR/>Method of concealment: NR <BR/>Binding: Double<BR/>Inclusion of all randomized participants: Grade A<BR/>Loss to follow up: Overall (15.6%), placebo arm (14.0%), low dose transdermal selegilie arm (16.7%), and high dose transdermal selegiline (16.3%)<BR/>Sample size calculation done a priori: NR<BR/>Follow-up: 8, 12, 16, 24 weeks</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Number: randomized (n=128), completed (n=108)<BR/>Inclusion criteria: HIV infection, evidence of cognitive impairment, and stable antiretroviral regimen for six weeks<BR/>Exclusion criteria: Active opportunist CNS infection, severe pre-morbid psychiatric illness, history of a chronic neurologic disorder unrelated to HIV infection<BR/>Age: Low dose selegiline (median age = 45), high dose selegiline (median age=43), and placebo (median age =47)<BR/>Male: Low dose selegiline (85.7%), high dose selegiline (88.4%), and placebo (88.4%)<BR/>White: Low dose selegiline (59.5%), high dose selegiline (48.8%), and placebo (44.1%)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Selegiline transdermal system (STS) 3mg/24 hour<BR/>Selegiline transdermal system (STS) 6mg/24 hour <BR/>Matching placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>(1) Tolerability of the drug - treatment completers<BR/>(2) Measures of safety - Adverse effects and abnormal laboratory results<BR/>(3) Measures of efficacy - change in neuropsychological test scores</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Study location: USA<BR/>Study date: November 2001 to December 2004 <BR/>Multi-center study: Yes<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Schifitto-_x0028_high_x0029_2007">
<CHAR_METHODS>
<P>[Refer to Schiffito 2007b for details; author described high dose transdermal selegiline versus placebo]</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>*Cognitive impairment was defined as performing at or below 1 SD from the mean on at least two neuropsychological tests, or 2 SDs below the mean on at least one test.<BR/>*Neuropsychiatry test: Rey Auditory Verbal Learning Test, Digit Symbol Test, Grooved Pegboard (dominant and non-dominant hands), timed gait, and the California Computerized Assessment package (Cal Cap) reaction time test<BR/>* RCT - Randomized controlled trial<BR/>* NR - Not reported<BR/>* Inclusion of all randomized participants: A = &gt;80%; B = &lt;80%, C = unclear<BR/>
</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES SORT_BY="STUDY">
<EXCLUDED_CHAR STUDY_ID="STD-Anonymous-1996">
<CHAR_REASON_FOR_EXCLUSION>
<P>Letter / Commentary</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Brew-2007">
<CHAR_REASON_FOR_EXCLUSION>
<P>Efficacy study of antiretroviral intervention not adjunctive therapy</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Bridge-1989">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomized study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Bridge-1991">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomized study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Chang-2004">
<CHAR_REASON_FOR_EXCLUSION>
<P>Validation study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Cysique-2006">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomized study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Day-1992">
<CHAR_REASON_FOR_EXCLUSION>
<P>Efficacy study of antiretroviral intervention not adjunctive therapy</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-DiCenzo-2004">
<CHAR_REASON_FOR_EXCLUSION>
<P>Drug interaction study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Galgani-1997">
<CHAR_REASON_FOR_EXCLUSION>
<P>Efficacy study of antiretroviral intervention not adjunctive therapy</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Kosten-1997">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomized study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Lee-2003">
<CHAR_REASON_FOR_EXCLUSION>
<P>Validation study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Polianova--2003">
<CHAR_REASON_FOR_EXCLUSION>
<P>Aim of the study was not to treat participants with AIDS dementia complex</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Sacktor-2002">
<CHAR_REASON_FOR_EXCLUSION>
<P>Efficacy study of antiretroviral intervention not adjunctive therapy</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Schifitto-2001">
<CHAR_REASON_FOR_EXCLUSION>
<P>Validation study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Schifitto-2006b">
<CHAR_REASON_FOR_EXCLUSION>
<P>Aim of the study was to treat participants with HIV-associated sensory neuropathy</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Schmitt-1988">
<CHAR_REASON_FOR_EXCLUSION>
<P>Efficacy study of antiretroviral intervention not adjunctive therapy</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Sidtis-1993">
<CHAR_REASON_FOR_EXCLUSION>
<P>Efficacy study of antiretroviral intervention not adjunctive therapy</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Simpson-1996">
<CHAR_REASON_FOR_EXCLUSION>
<P>Aim of the study was to treat participants with HIV-associated distal neuropathy</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Tozzi-1993">
<CHAR_REASON_FOR_EXCLUSION>
<P>Efficacy study of antiretroviral intervention not adjunctive therapy</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Villemagne-1996">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomized study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<ONGOING_CHAR STUDY_ID="STD-Minocycline-2006">
<CHAR_STUDY_NAME>
<P>Minocycline for the Treatment of Decreased Mental Function in HIV Infected Adults</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS/>
<CHAR_PARTICIPANTS>
<P>Ages Eligible for Study: 18 Years - 65 Years, Genders Eligible for Study: Both<BR/>Inclusion Criteria: HIV infected, AIDS Dementia Scale (ADC) Stage greater than 0, Cognitive impairment, and willing to use acceptable methods of contraception <BR/>Exclusion Criteria: current cancers, severe premorbid psychiatric illness, including schizophrenia and major depression, which, in the opinion of the investigator, may interfere with the study, inability to undergo lumbar punctures and breastfeeding.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Minocycline<BR/>Matching placebo<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Primary Outcome Measures: <BR/>"Change in cognitive performance from study entry to Week 24 <BR/>Secondary Outcome Measures: <BR/>"24 week change in Global Deficit Score (summary measure of neuropsychological test defects) <BR/>"24 week change of clinical global impression by the investigator <BR/>"24 week change of cognitive domain scores <BR/>"24 week change of Karnofsky performance score <BR/>"toxicity and/or signs and symptoms of Grade 2 or higher <BR/>"time from treatment initiation to the development of a Grade 2 or higher toxicity and/or signs and symptoms <BR/>"24 week changes in Instrumental Activities of Daily Living Questionnaire</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE>
<P>August 2006</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION>
<P>Sofia Solis ssolis@mednet.ucla.edu</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES>
<P>Study location: USA<BR/>Multi-center study: Yes<BR/>Study sponsors: National Institute of Allergy and Infectious Diseases (NIAID) <BR/>Neurologic AIDS Research Consortium (NARC)<BR/>Study ID Numbers: ACTG A5235<BR/>ClinicalTrials.gov identifier NCT00361257<BR/>
</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR STUDY_ID="STD-Nimodipine-1999">
<CHAR_STUDY_NAME>
<P>Randomized, Double-Blind, Placebo-Controlled Trial of Nimodipine for the Neurological Manifestations of HIV-1</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS/>
<CHAR_PARTICIPANTS>
<P>Ages Eligible for Study: 18 Years and above, Genders Eligible for Study: Both <BR/>Criteria<BR/>Inclusion Criteria: documented HIV infection, HIV-Associated Motor / Cognitive Complex, acceptable neurological and neuropsychological impairment scores, and ability to provide written informed consent. <BR/>Exclusion Criteria: Active symptomatic AIDS-defining opportunistic infection, neoplasms other than basal cell carcinoma, in situ carcinoma of the cervix, or Kaposi's sarcoma without evidence of visceral involvement or that do not require systemic chemotherapy, and confounding neurological disorders, including the following.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Nimodipine<BR/>Matching placebo<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES/>
<CHAR_STARTING_DATE>
<P>November 1999</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION/>
<CHAR_NOTES>
<P>Study location: USA<BR/>Multi-center study: Yes<BR/>Study sponsors: National Institute of Allergy and Infectious Diseases (NIAID), Miles, and Glaxo Wellcome<BR/>Study ID Numbers: ACTG 162<BR/>Last Updated: June 23, 2005<BR/>Record first received: November 2, 1999<BR/>ClinicalTrials.gov Identifier: NCT00000738<BR/>
</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" NO="1">
<NAME>Adequate sequence generation?</NAME>
<DESCRIPTION>
<P>Was the allocation sequence adequately generated?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" NO="2">
<NAME>Allocation concealment?</NAME>
<DESCRIPTION>
<P>Was allocation adequately concealed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Clifford-_x0028_high_x0029_-2002">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Clifford-2002">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Dana-_x0028_both_x0029_-1998">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Dana-_x0028_thioctic_x0029_-1998">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Dana-1997">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Dana-1998">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Heseltine-1998">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Navia-_x0028_high_x0029_-1998">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Navia-1998">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Sacktor-2000">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Schiffito-1999">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Schiffito-2006a">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Schiffito-2007a">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Schiffito-2007b">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Schifitto-_x0028_high_x0029_2007">
<DESCRIPTION>
<P>D - Not used</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" NO="3">
<NAME>Blinding?</NAME>
<DESCRIPTION>
<P>Was knowledge of the allocated interventions adequately prevented during the study?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" NO="4">
<NAME>Incomplete outcome data addressed?</NAME>
<DESCRIPTION>
<P>Were incomplete outcome data adequately addressed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" NO="5">
<NAME>Free of selective reporting?</NAME>
<DESCRIPTION>
<P>Are reports of the study free of suggestion of selective outcome reporting?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" NO="6">
<NAME>Free of other bias?</NAME>
<DESCRIPTION>
<P>Was the study apparently free of other problems that could put it at a high risk of bias?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES>
<ADDITIONAL_TABLE ID="TBL-01" NO="1">
<TITLE>Staging of AIDS dementia complex</TITLE>
<TABLE COLS="3" ROWS="7">
<TR>
<TH>
<P>Stage</P>
</TH>
<TH>
<P>Grading</P>
</TH>
<TH>
<P>Presentation</P>
</TH>
</TR>
<TR>
<TD>
<P>0</P>
</TD>
<TD>
<P>Normal</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>0.5</P>
</TD>
<TD>
<P>Subclinical or Equivocal</P>
</TD>
<TD>
<P>- Minimal or equivocal symptoms <BR/>- Mild (soft) neurological signs <BR/>- No impairment of work or activities of daily living (ADL)<BR/>
</P>
</TD>
</TR>
<TR>
<TD>
<P>1</P>
</TD>
<TD>
<P>Mild</P>
</TD>
<TD>
<P>- Unequivocal intellectual or motor impairment <BR/>- Able to do all but the most demanding work or <BR/>
</P>
</TD>
</TR>
<TR>
<TD>
<P>2</P>
</TD>
<TD>
<P>Moderate</P>
</TD>
<TD>
<P>- Cannot work or perform demanding ADL <BR/>- Capable of self-care <BR/>- Ambulatory, but may need a single prop<BR/>- Major intellectual disability or <BR/>- Cannot walk unassisted<BR/>
</P>
</TD>
</TR>
<TR>
<TD>
<P>3</P>
</TD>
<TD>
<P>Severe</P>
</TD>
<TD>
<P>- Major intellectual disability or <BR/>- Cannot walk unassisted<BR/>
</P>
</TD>
</TR>
<TR>
<TD>
<P>4</P>
</TD>
<TD>
<P>End-stage</P>
</TD>
<TD>
<P>- Nearly vegetative <BR/>- Rudimentary cognition <BR/>- Para- or quadriplegic<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-02" NO="2">
<TITLE>Clinical manifestations of ADC</TITLE>
<TABLE COLS="2" ROWS="5">
<TR>
<TH>
<P>Type of impairment</P>
</TH>
<TH>
<P>Manifestations</P>
</TH>
</TR>
<TR>
<TD>
<P>Affective</P>
</TD>
<TD>
<P>- Apathy (depression-like feature)<BR/>- Irritability<BR/>- Mania, new-onset psychosis<BR/>
</P>
</TD>
</TR>
<TR>
<TD>
<P>Behavioral</P>
</TD>
<TD>
<P>- Psychomotor retardation (Slowed speech or response time)<BR/>- Personality change<BR/>- Social withdrawal<BR/>
</P>
</TD>
</TR>
<TR>
<TD>
<P>Cognitive</P>
</TD>
<TD>
<P>- Lack of visuospatial memory (misplacing things)<BR/>- Lack of visuomotor coordination (eye movement abnormalities)<BR/>- Difficulty with complex sequencing <BR/>- Impaired concentration and attention<BR/>- Impaired verbal memory (word-finding ability)<BR/>- Mental slowing<BR/>
</P>
</TD>
</TR>
<TR>
<TD>
<P>Motor</P>
</TD>
<TD>
<P>- Unsteady gait, loss of balance<BR/>- Dropping things<BR/>- Tremors, poor handwriting<BR/>- Decline in fine motor skills<BR/>
<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-03" NO="3">
<TITLE>Differential diagnosis of symptoms presenting as possible ADC</TITLE>
<TABLE COLS="2" ROWS="6">
<TR>
<TH>
<P>CNS disease</P>
</TH>
<TH>
<P>Manifestations</P>
</TH>
</TR>
<TR>
<TD>
<P>Central nervous system disease</P>
</TD>
<TD>
<P>Infectious<BR/>- CMV encephalitis<BR/>- Neurosyphilis<BR/>- Cryptococcal meningitis<BR/>- Tuberculous meningitis<BR/>- CNS toxoplasmosis<BR/>- Progressive multifocal leukoencephalopathy*<BR/>- HIV minor cognitive motor disorder<BR/>
<BR/>Tumors<BR/>- CNS lymphoma<BR/>- Metastatic disease<BR/>
<BR/>Vasculitis</P>
</TD>
</TR>
<TR>
<TD>
<P>Systemic/metabolic/endocrine disease</P>
</TD>
<TD>
<P>- B12 deficiency<BR/>- Anemia<BR/>- Thyroid disease<BR/>- Addison's disease<BR/>
</P>
</TD>
</TR>
<TR>
<TD>
<P>Primary psychiatric illness</P>
</TD>
<TD>
<P>- Mood disorders (major depression, hypomania, dysthymia)<BR/>- Delirium<BR/>
</P>
</TD>
</TR>
<TR>
<TD>
<P>Substance withdrawal or intoxification</P>
</TD>
<TD>
<P>- Alcohol<BR/>- Opioids<BR/>- Chronic cannabis</P>
</TD>
</TR>
<TR>
<TD>
<P>Medications</P>
</TD>
<TD>
<P>Medication reactions<BR/>- Psychotropics <BR/>- Antiretroviral medications</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-04" NO="4">
<TITLE>Adjunctive therapies for ADC</TITLE>
<TABLE COLS="2" ROWS="14">
<TR>
<TH>
<P>Agent</P>
</TH>
<TH>
<P>Action</P>
</TH>
</TR>
<TR>
<TD>
<P>CPI-1189</P>
</TD>
<TD>
<P>TNF-alpha antagonist</P>
</TD>
</TR>
<TR>
<TD>
<P>Lexipafant</P>
</TD>
<TD>
<P>Platelet activating factor antagonist</P>
</TD>
</TR>
<TR>
<TD>
<P>Memantine</P>
</TD>
<TD>
<P>N-methyl-D-aspartate antagonist</P>
</TD>
</TR>
<TR>
<TD>
<P>Minocycline</P>
</TD>
<TD>
<P>Anti-inflammatory and p38 MAP kinase inhibitor</P>
</TD>
</TR>
<TR>
<TD>
<P>Nimodipine</P>
</TD>
<TD>
<P>Calcium Channel blocker</P>
</TD>
</TR>
<TR>
<TD>
<P>Nitroglycerin</P>
</TD>
<TD>
<P>Vasodilator</P>
</TD>
</TR>
<TR>
<TD>
<P>OPC 14117</P>
</TD>
<TD>
<P>Antioxidant</P>
</TD>
</TR>
<TR>
<TD>
<P>Pentoxifylline</P>
</TD>
<TD>
<P>Platelet activating factor antagonist</P>
</TD>
</TR>
<TR>
<TD>
<P>Peptide T</P>
</TD>
<TD>
<P>Possibly Chemokine receptor blockade</P>
</TD>
</TR>
<TR>
<TD>
<P>Prednisone</P>
</TD>
<TD>
<P>Macrophage suppression</P>
</TD>
</TR>
<TR>
<TD>
<P>Selegiline (deprenyl)</P>
</TD>
<TD>
<P>Monoamine oxidase-B inhibitor</P>
</TD>
</TR>
<TR>
<TD>
<P>Thioctic acid</P>
</TD>
<TD>
<P>Antioxidant</P>
</TD>
</TR>
<TR>
<TD>
<P>Valproic acid</P>
</TD>
<TD>
<P>Unknown</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-05" NO="5">
<TITLE>Search Strategy</TITLE>
<TABLE COLS="2" ROWS="8">
<TR>
<TH>
<P>Search</P>
</TH>
<TH>
<P>Query</P>
</TH>
</TR>
<TR>
<TD>
<P>#1</P>
</TD>
<TD>
<P>HIV Infections[MeSH] OR HIV[MeSH] OR hiv[tw] OR hiv-1*[tw] OR hiv-2*[tw] OR hiv1[tw] OR hiv2[tw] OR hiv infect*[tw] OR human immunodeficiency virus[tw] OR human immunedeficiency virus[tw] OR human immuno-deficiency virus[tw] OR human immune-deficiency virus[tw] OR ((human immun*) AND (deficiency virus[tw])) OR acquired immunodeficiency syndrome[tw] OR acquired immunedeficiency syndrome[tw] OR acquired immuno-deficiency syndrome[tw] OR acquired immune-deficiency syndrome[tw] OR ((acquired immun*) AND (deficiency syndrome[tw])) OR "Sexually Transmitted Diseases, Viral"[MeSH:NoExp]</P>
</TD>
</TR>
<TR>
<TD>
<P>#2</P>
</TD>
<TD>
<P>"AIDS DEMENTIA COMPLEX"[MeSH ] OR AIDS DEMENTIA COMPLEX[tw]</P>
</TD>
</TR>
<TR>
<TD>
<P>#3</P>
</TD>
<TD>
<P>#1 OR #2</P>
</TD>
</TR>
<TR>
<TD>
<P>#4</P>
</TD>
<TD>
<P>randomized controlled trial [pt] OR controlled clinical trial [pt] OR randomized controlled trials [mh] OR random allocation [mh] OR double-blind method [mh] OR single-blind method [mh] OR clinical trial [pt] OR clinical trials [mh] OR ("clinical trial" [tw]) OR ((singl* [tw] OR doubl* [tw] OR trebl* [tw] OR tripl* [tw]) AND (mask* [tw] OR blind* [tw])) OR ( placebos [mh] OR placebo* [tw] OR random* [tw] OR research design [mh:noexp] OR comparative study [mh] OR evaluation studies [mh] OR follow-up studies [mh] OR prospective studies [mh] OR control* [tw] OR prospectiv* [tw] OR volunteer* [tw]) NOT (animals [mh] NOT human [mh])</P>
</TD>
</TR>
<TR>
<TD>
<P>#5</P>
</TD>
<TD>
<P>ADJUNCTIVE THERAPY OR ADJUNCTIVE THERAPIES OR CPI-1189 OR LEXIPAFANT OR MEMANTINE OR MINOCYCLINE OR NIMODIPINE OR NITROGLYCERIN OPC 14117 OR PENTOXIFYLLINE OR PEPTIDE T OR PREDNISONE OR SELEGILINE OR THIOCTIC ACID OR VALPROIC ACID</P>
</TD>
</TR>
<TR>
<TD>
<P>#6</P>
</TD>
<TD>
<P>#3 AND #4 AND #5</P>
</TD>
</TR>
<TR>
<TD>
<P>#7</P>
</TD>
<TD>
<P>#6 Field: All Fields, Limits: from 1980 to 2006, HUMAN</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-06" NO="6">
<TITLE>Risk-of-bias assessment tool</TITLE>
<TABLE COLS="8" ROWS="12">
<TR>
<TH>
<P>Trial</P>
</TH>
<TH>
<P>*Sequence</P>
</TH>
<TH>
<P>*Concealment</P>
</TH>
<TH>
<P>*Blinding</P>
</TH>
<TH>
<P>*Follow-up</P>
</TH>
<TH>
<P>*Outcome Data</P>
</TH>
<TH>
<P>*Outcome Reporting</P>
</TH>
<TH>
<P>*Others</P>
</TH>
</TR>
<TR>
<TD>
<P>Schiffito 1999</P>
</TD>
<TD>
<P>ADEQUATE</P>
</TD>
<TD>
<P>ADEQUATE</P>
</TD>
<TD>
<P>Participants = YES<BR/>Provider = YES<BR/>Assessor = UNCLEAR</P>
</TD>
<TD>
<P>90.00%<BR/>27/30<BR/>GRADE A</P>
</TD>
<TD>
<P>YES</P>
</TD>
<TD>
<P>YES</P>
</TD>
<TD>
<P>YES</P>
</TD>
</TR>
<TR>
<TD>
<P>Dana 1998</P>
</TD>
<TD>
<P>ADEQUATE</P>
</TD>
<TD>
<P>ADEQUATE</P>
</TD>
<TD>
<P>Participants = YES<BR/>Provider = YES<BR/>Assessor = UNCLEAR</P>
</TD>
<TD>
<P>86.11%<BR/>31/36<BR/>GRADE A<BR/>
</P>
</TD>
<TD>
<P>YES</P>
</TD>
<TD>
<P>YES</P>
</TD>
<TD>
<P>YES</P>
</TD>
</TR>
<TR>
<TD>
<P>Schiffito 2006</P>
</TD>
<TD>
<P>UNCLEAR</P>
</TD>
<TD>
<P>UNCLEAR</P>
</TD>
<TD>
<P>Participants = UNCLEAR<BR/>Provider = UNCLEAR<BR/>Assessor = UNCLEAR<BR/>
</P>
</TD>
<TD>
<P>93.75%<BR/>15/16<BR/>GRADE A</P>
</TD>
<TD>
<P>YES</P>
</TD>
<TD>
<P>YES</P>
</TD>
<TD>
<P>YES</P>
</TD>
</TR>
<TR>
<TD>
<P>Clifford 2002</P>
</TD>
<TD>
<P>ADEQUATE</P>
</TD>
<TD>
<P>ADEQUATE</P>
</TD>
<TD>
<P>Participants = YES<BR/>Provider = YES<BR/>Assessor = UNCLEAR</P>
</TD>
<TD>
<P>85.94%<BR/>55/64<BR/>GRADE A</P>
</TD>
<TD>
<P>YES</P>
</TD>
<TD>
<P>YES</P>
</TD>
<TD>
<P>YES</P>
</TD>
</TR>
<TR>
<TD>
<P>Navia 1998</P>
</TD>
<TD>
<P>UNCLEAR</P>
</TD>
<TD>
<P>UNCLEAR</P>
</TD>
<TD>
<P>Participants = UNCLEAR<BR/>Provider = UNCLEAR<BR/>Assessor = UNCLEAR<BR/>
</P>
</TD>
<TD>
<P>71.05%<BR/>27/38<BR/>GRADE B</P>
</TD>
<TD>
<P>NO</P>
</TD>
<TD>
<P>YES</P>
</TD>
<TD>
<P>YES</P>
</TD>
</TR>
<TR>
<TD>
<P>Sacktor 2000</P>
</TD>
<TD>
<P>ADEQUATE</P>
</TD>
<TD>
<P>ADEQUATE</P>
</TD>
<TD>
<P>Participants = YES<BR/>Provider = YES <BR/>Assessor = YES<BR/>
</P>
</TD>
<TD>
<P>85.71%<BR/>12/14<BR/>GRADE A</P>
</TD>
<TD>
<P>YES</P>
</TD>
<TD>
<P>YES</P>
</TD>
<TD>
<P>YES</P>
</TD>
</TR>
<TR>
<TD>
<P>Helsetine 1998</P>
</TD>
<TD>
<P>ADEQUATE</P>
</TD>
<TD>
<P>UNCLEAR</P>
</TD>
<TD>
<P>Participants = UNCLEAR<BR/>Provider = UNCLEAR<BR/>Assessor = UNCLEAR<BR/>
</P>
</TD>
<TD>
<P>66.51%<BR/>143/215<BR/>GRADE B</P>
</TD>
<TD>
<P>NO</P>
</TD>
<TD>
<P>YES</P>
</TD>
<TD>
<P>YES</P>
</TD>
</TR>
<TR>
<TD>
<P>Dana 1997</P>
</TD>
<TD>
<P>ADEQUATE</P>
</TD>
<TD>
<P>ADEQUATE</P>
</TD>
<TD>
<P>Participants = YES<BR/>Provider = YES<BR/>Assessor = UNCLEAR<BR/>
</P>
</TD>
<TD>
<P>60.00%<BR/>18/30<BR/>GRADE B</P>
</TD>
<TD>
<P>YES</P>
</TD>
<TD>
<P>YES</P>
</TD>
<TD>
<P>YES</P>
</TD>
</TR>
<TR>
<TD>
<P>Schiffito 2007a</P>
</TD>
<TD>
<P>UNCLEAR</P>
</TD>
<TD>
<P>UNCLEAR</P>
</TD>
<TD>
<P>Participants = UNCLEAR<BR/>Provider = UNCLEAR<BR/>Assessor = UNCLEAR<BR/>
</P>
</TD>
<TD>
<P>79%<BR/>110/140<BR/>GRADE B<BR/>
</P>
</TD>
<TD>
<P>YES</P>
</TD>
<TD>
<P>YES</P>
</TD>
<TD>
<P>YES</P>
</TD>
</TR>
<TR>
<TD>
<P>Schiffito 2007b</P>
</TD>
<TD>
<P>UNCLEAR</P>
</TD>
<TD>
<P>UNCLEAR</P>
</TD>
<TD>
<P>Participants = UNCLEAR<BR/>Provider = UNCLEAR<BR/>Assessor = UNCLEAR<BR/>
</P>
</TD>
<TD>
<P>84%<BR/>108/128<BR/>Grade A<BR/>
</P>
</TD>
<TD>
<P>YES</P>
</TD>
<TD>
<P>YES</P>
</TD>
<TD>
<P>YES</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>*Generation of allocation sequence</P>
</TD>
<TD>
<P>*Allocation concealment</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>*Completeness of follow up: A = &gt;80%; B = &lt;80%, C = unclear</P>
</TD>
<TD>
<P>*Incomplete outcome data adequately addressed?</P>
</TD>
<TD>
<P>*Free of selective outcome reporting?</P>
</TD>
<TD>
<P>*Free of topic specific, design specific or other potential threats to validity?</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-07" NO="7">
<TITLE>Drugs - Routes and regimen</TITLE>
<TABLE COLS="3" ROWS="13">
<TR>
<TH>
<P>Drug</P>
</TH>
<TH>
<P>Route</P>
</TH>
<TH>
<P>Dosage</P>
</TH>
</TR>
<TR>
<TD>
<P>Lexipafant</P>
</TD>
<TD>
<P>Oral</P>
</TD>
<TD>
<P>250mg twice daily</P>
</TD>
</TR>
<TR>
<TD>
<P>Deprenyl (Selegiline)</P>
</TD>
<TD>
<P>Oral</P>
</TD>
<TD>
<P>2.5mg three times a week</P>
</TD>
</TR>
<TR>
<TD>
<P>Thioctic acid</P>
</TD>
<TD>
<P>Oral</P>
</TD>
<TD>
<P>600mg twice daily</P>
</TD>
</TR>
<TR>
<TD>
<P>Valproic acid</P>
</TD>
<TD>
<P>Oral</P>
</TD>
<TD>
<P>250mg twice daily</P>
</TD>
</TR>
<TR>
<TD>
<P>CPI-1189</P>
</TD>
<TD>
<P>Oral</P>
</TD>
<TD>
<P>50mg once daily</P>
</TD>
</TR>
<TR>
<TD>
<P>CPI-1189</P>
</TD>
<TD>
<P>Oral</P>
</TD>
<TD>
<P>100mg once daily</P>
</TD>
</TR>
<TR>
<TD>
<P>Nimodipine</P>
</TD>
<TD>
<P>Oral</P>
</TD>
<TD>
<P>30mg three times daily</P>
</TD>
</TR>
<TR>
<TD>
<P>Nimodipine</P>
</TD>
<TD>
<P>Oral</P>
</TD>
<TD>
<P>60mg five times daily</P>
</TD>
</TR>
<TR>
<TD>
<P>Deprenyl (Selegiline)</P>
</TD>
<TD>
<P>Transdermal</P>
</TD>
<TD>
<P>1.0mg/cm X 15 cm2 delivering approximately 3.1 mg per 24 hours</P>
</TD>
</TR>
<TR>
<TD>
<P>Peptide T</P>
</TD>
<TD>
<P>Intranasal</P>
</TD>
<TD>
<P>Three times a day</P>
</TD>
</TR>
<TR>
<TD>
<P>OPC-14117</P>
</TD>
<TD>
<P>Oral</P>
</TD>
<TD>
<P>60mg twice daily for the first six weeks then maintenance dosage of 120mg twice daily</P>
</TD>
</TR>
<TR>
<TD>
<P>Memantine</P>
</TD>
<TD>
<P>Oral</P>
</TD>
<TD>
<P>10mg daily</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-08" NO="8">
<TITLE>Neuropsychological test scores</TITLE>
<TABLE COLS="2" ROWS="9">
<TR>
<TH>
<P>Domain</P>
</TH>
<TH>
<P>Test</P>
</TH>
</TR>
<TR>
<TD>
<P>Rey Auditory Verbal Learning</P>
</TD>
<TD>
<P>- Total Number Correct<BR/>- Number Correct - Trial 5<BR/>- Recall after Interference<BR/>- Delayed Recall<BR/>
</P>
</TD>
</TR>
<TR>
<TD>
<P>Mean Reaction Time</P>
</TD>
<TD>
<P>- Choice<BR/>- Sequential<BR/>
</P>
</TD>
</TR>
<TR>
<TD>
<P>Trail Making</P>
</TD>
<TD>
<P>- Part A<BR/>- Part B<BR/>
</P>
</TD>
</TR>
<TR>
<TD>
<P>Digit Symbol</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Grooved Pegboard</P>
</TD>
<TD>
<P>- Dominant Hand<BR/>- Non-dominant Hand<BR/>
</P>
</TD>
</TR>
<TR>
<TD>
<P>Finger Tapping</P>
</TD>
<TD>
<P>- Dominant Hand<BR/>- Non-dominant Hand<BR/>
</P>
</TD>
</TR>
<TR>
<TD>
<P>Timed Gait</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Composite neurological Z score (NPZ)</P>
</TD>
<TD>
<P/>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-09" NO="9">
<TITLE>Trials sponsors</TITLE>
<TABLE COLS="2" ROWS="14">
<TR>
<TH>
<P>Sponsor</P>
</TH>
<TH>
<P>Study ID</P>
</TH>
</TR>
<TR>
<TD>
<P>The Charles A. Dana Foundation</P>
</TD>
<TD>
<P>Schiffito 1999; Dana 1998; Dana 1997</P>
</TD>
</TR>
<TR>
<TD>
<P>National Institutes of Health (NIH)</P>
</TD>
<TD>
<P>Schiffito 1999; Dana 1998; Schiffto 2006; Sacktor 2000; Dana 1997</P>
</TD>
</TR>
<TR>
<TD>
<P>Neurological AIDS Research Consortium</P>
</TD>
<TD>
<P>Schiffito 1999; Dana 1998</P>
</TD>
</TR>
<TR>
<TD>
<P>National Institute of Mental Health</P>
</TD>
<TD>
<P>Dana 1998</P>
</TD>
</TR>
<TR>
<TD>
<P>National Institute of Neurologic Diseases and Stroke grant</P>
</TD>
<TD>
<P>Clifford 2002</P>
</TD>
</TR>
<TR>
<TD>
<P>General Clinical Research Centers (GCRC) at Columbia</P>
</TD>
<TD>
<P>Clifford 2002</P>
</TD>
</TR>
<TR>
<TD>
<P>GCTC at Rochester</P>
</TD>
<TD>
<P>Clifford 2002</P>
</TD>
</TR>
<TR>
<TD>
<P>Centaur pharmaceuticals</P>
</TD>
<TD>
<P>Clifford 2002</P>
</TD>
</TR>
<TR>
<TD>
<P>National Institutes of Allergy and Infectious Diseases</P>
</TD>
<TD>
<P>Navia 1998</P>
</TD>
</TR>
<TR>
<TD>
<P>Miles Pharmaceuticals</P>
</TD>
<TD>
<P>Navia 1998</P>
</TD>
</TR>
<TR>
<TD>
<P>American Foundation for AIDS Research</P>
</TD>
<TD>
<P>Navia 1998</P>
</TD>
</TR>
<TR>
<TD>
<P>Somerset Pharmaceuticals</P>
</TD>
<TD>
<P>Sacktor 2000</P>
</TD>
</TR>
<TR>
<TD>
<P>Otsuka America Pharmaceuticals</P>
</TD>
<TD>
<P>Dana 1997</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-10" NO="10">
<TITLE>Sources of support</TITLE>
<TABLE COLS="3" ROWS="3">
<TR>
<TH>
<P>Company</P>
</TH>
<TH>
<P>Support</P>
</TH>
<TH>
<P>Study ID</P>
</TH>
</TR>
<TR>
<TD>
<P>British Biotech</P>
</TD>
<TD>
<P>Donated Lexipafant and placebo</P>
</TD>
<TD>
<P>Schiffito 1999</P>
</TD>
</TR>
<TR>
<TD>
<P>ASTA Medica</P>
</TD>
<TD>
<P>Provided Thiotic acid and matching placebo</P>
</TD>
<TD>
<P>Dana 1998</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
</ADDITIONAL_TABLES>
<ANALYSES_AND_DATA CALCULATED_DATA="YES">
<COMPARISON ID="CMP-001" NO="1">
<NAME>Lexipafant vs Placebo</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-001.01" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="NO" TOTAL_1="192" TOTAL_2="168" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Neuropsychological test scores</NAME>
<GROUP_LABEL_1>Lexipafant</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours lexipafant</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.01.01" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="16" TOTAL_2="14" WEIGHT="0.0" Z="0.0">
<NAME>Rey Auditory Verbal Learning - Total Number Correct</NAME>
<CONT_DATA CI_END="8.728312623007476" CI_START="-0.5283126230074746" EFFECT_SIZE="4.1000000000000005" ESTIMABLE="YES" MEAN_1="4.9" MEAN_2="0.8" ORDER="25647" SD_1="5.9" SD_2="6.9" SE="2.361427383112656" STUDY_ID="STD-Schiffito-1999" TOTAL_1="16" TOTAL_2="14" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.01.02" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="16" TOTAL_2="14" WEIGHT="0.0" Z="0.0">
<NAME>Rey Auditory Verbal Learning - Number Correct &#8211; Trial 5</NAME>
<CONT_DATA CI_END="1.9864317375511469" CI_START="-0.3864317375511469" EFFECT_SIZE="0.7999999999999999" ESTIMABLE="YES" MEAN_1="1.2" MEAN_2="0.4" ORDER="25648" SD_1="1.6" SD_2="1.7" SE="0.6053334382210943" STUDY_ID="STD-Schiffito-1999" TOTAL_1="16" TOTAL_2="14" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.01.03" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="16" TOTAL_2="14" WEIGHT="0.0" Z="0.0">
<NAME>Rey Auditory Verbal Learning - Recall after Interference</NAME>
<CONT_DATA CI_END="3.7225806385245948" CI_START="0.6774193614754047" EFFECT_SIZE="2.1999999999999997" ESTIMABLE="YES" MEAN_1="1.9" MEAN_2="-0.3" ORDER="25649" SD_1="1.9" SD_2="2.3" SE="0.7768411310281805" STUDY_ID="STD-Schiffito-1999" TOTAL_1="16" TOTAL_2="14" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.01.04" NO="4" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="16" TOTAL_2="14" WEIGHT="0.0" Z="0.0">
<NAME>Rey Auditory Verbal Learning - Delayed Recall</NAME>
<CONT_DATA CI_END="3.202055674241325" CI_START="-0.4020556742413248" EFFECT_SIZE="1.4000000000000001" ESTIMABLE="YES" MEAN_1="1.6" MEAN_2="0.2" ORDER="25650" SD_1="1.8" SD_2="3.0" SE="0.9194330551253543" STUDY_ID="STD-Schiffito-1999" TOTAL_1="16" TOTAL_2="14" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.01.05" NO="5" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="16" TOTAL_2="14" WEIGHT="0.0" Z="0.0">
<NAME>Rey Auditory Verbal Learning - Correct Recognition</NAME>
<CONT_DATA CI_END="1.2321538396188099" CI_START="-1.6321538396188098" EFFECT_SIZE="-0.2" ESTIMABLE="YES" MEAN_1="-0.1" MEAN_2="0.1" ORDER="25651" SD_1="1.4" SD_2="2.4" SE="0.7307041613598293" STUDY_ID="STD-Schiffito-1999" TOTAL_1="16" TOTAL_2="14" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.01.06" NO="6" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="16" TOTAL_2="14" WEIGHT="0.0" Z="0.0">
<NAME>Mean Reaction Time - Choice</NAME>
<CONT_DATA CI_END="92.23788169095637" CI_START="-102.43788169095636" EFFECT_SIZE="-5.1" ESTIMABLE="YES" MEAN_1="-6.5" MEAN_2="-1.4" ORDER="25652" SD_1="117.4" SD_2="149.9" SE="49.66309710726582" STUDY_ID="STD-Schiffito-1999" TOTAL_1="16" TOTAL_2="14" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.01.07" NO="7" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="16" TOTAL_2="14" WEIGHT="0.0" Z="0.0">
<NAME>Mean Reaction Time - Sequential</NAME>
<CONT_DATA CI_END="94.87982968096706" CI_START="-71.47982968096706" EFFECT_SIZE="11.7" ESTIMABLE="YES" MEAN_1="30.8" MEAN_2="19.1" ORDER="25653" SD_1="85.1" SD_2="137.4" SE="42.43946844793013" STUDY_ID="STD-Schiffito-1999" TOTAL_1="16" TOTAL_2="14" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.01.08" NO="8" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="16" TOTAL_2="14" WEIGHT="0.0" Z="0.0">
<NAME>Digit Symbol</NAME>
<CONT_DATA CI_END="5.469244675434739" CI_START="-2.869244675434738" EFFECT_SIZE="1.3000000000000003" ESTIMABLE="YES" MEAN_1="4.2" MEAN_2="2.9" ORDER="25654" SD_1="5.2" SD_2="6.3" SE="2.1272047386182646" STUDY_ID="STD-Schiffito-1999" TOTAL_1="16" TOTAL_2="14" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.01.09" NO="9" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="16" TOTAL_2="14" WEIGHT="0.0" Z="0.0">
<NAME>Grooved Pegboard - Dominant Hand</NAME>
<CONT_DATA CI_END="15.390249456918607" CI_START="-8.390249456918607" EFFECT_SIZE="3.5" ESTIMABLE="YES" MEAN_1="8.6" MEAN_2="5.1" ORDER="25655" SD_1="16.2" SD_2="16.9" SE="6.066565279110931" STUDY_ID="STD-Schiffito-1999" TOTAL_1="16" TOTAL_2="14" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.01.10" NO="10" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="16" TOTAL_2="14" WEIGHT="0.0" Z="0.0">
<NAME>Grooved Pegboard - Nondominant Hand</NAME>
<CONT_DATA CI_END="12.924522318752578" CI_START="-9.324522318752576" EFFECT_SIZE="1.8" ESTIMABLE="YES" MEAN_1="3.5" MEAN_2="1.7" ORDER="25656" SD_1="11.7" SD_2="18.2" SE="5.6758809888862185" STUDY_ID="STD-Schiffito-1999" TOTAL_1="16" TOTAL_2="14" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.01.11" NO="11" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="16" TOTAL_2="14" WEIGHT="0.0" Z="0.0">
<NAME>Timed Gait</NAME>
<CONT_DATA CI_END="1.578001421278538" CI_START="-1.578001421278538" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="0.5" MEAN_2="0.5" ORDER="25657" SD_1="2.2" SD_2="2.2" SE="0.80511756018254" STUDY_ID="STD-Schiffito-1999" TOTAL_1="16" TOTAL_2="14" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.01.12" NO="12" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="16" TOTAL_2="14" WEIGHT="0.0" Z="0.0">
<NAME>Composite neuropsychological Z score</NAME>
<CONT_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" MEAN_1="0.0" MEAN_2="0.0" ORDER="25658" SD_1="0.0" SD_2="0.0" SE="0.0" STUDY_ID="STD-Schiffito-1999" TOTAL_1="16" TOTAL_2="14" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="14" EVENTS_2="13" I2="0.0" I2_Q="0.0" ID="CMP-001.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="2.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="16" TOTAL_2="14" WEIGHT="0.0" Z="0.0">
<NAME>Tolerability</NAME>
<GROUP_LABEL_1>Lexipafant</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours lexipafant</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.192391125577024" CI_START="0.7446749375567123" EFFECT_SIZE="0.9423076923076923" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="13" LOG_CI_END="0.07641873511699145" LOG_CI_START="-0.12803326232956255" LOG_EFFECT_SIZE="-0.025807263606285505" ORDER="25659" O_E="0.0" SE="0.12009611535381537" STUDY_ID="STD-Schiffito-1999" TOTAL_1="16" TOTAL_2="14" VAR="0.014423076923076927" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-001.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="16" TOTAL_2="14" WEIGHT="0.0" Z="0.0">
<NAME>All cause mortality</NAME>
<GROUP_LABEL_1>Lexipafant</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours lexipafant</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="25660" O_E="0.0" SE="0.0" STUDY_ID="STD-Schiffito-1999" TOTAL_1="16" TOTAL_2="14" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="15" EVENTS_2="24" I2="0.0" I2_Q="0.0" ID="CMP-001.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="4" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="144" TOTAL_2="126" WEIGHT="0.0" Z="0.0">
<NAME>Adverse effects</NAME>
<GROUP_LABEL_1>Lexipafant</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours lexipafant</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="8" EVENTS_2="12" I2="0.0" ID="CMP-001.04.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="16" TOTAL_2="14" WEIGHT="0.0" Z="0.0">
<NAME>Number of patient experiencing any adverse effects</NAME>
<DICH_DATA CI_END="0.9956370517563475" CI_START="0.3417688977901263" EFFECT_SIZE="0.5833333333333334" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="12" LOG_CI_END="-0.0018989498759095357" LOG_CI_START="-0.4662674621908264" LOG_EFFECT_SIZE="-0.23408320603336794" ORDER="25661" O_E="0.0" SE="0.27277236279499045" STUDY_ID="STD-Schiffito-1999" TOTAL_1="16" TOTAL_2="14" VAR="0.07440476190476189" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="1" I2="0.0" ID="CMP-001.04.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="16" TOTAL_2="14" WEIGHT="0.0" Z="0.0">
<NAME>Diarrhea</NAME>
<DICH_DATA CI_END="6.690017380199802" CI_START="0.012930488128094391" EFFECT_SIZE="0.29411764705882354" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8254272460361436" LOG_CI_START="-1.8883850801206539" LOG_EFFECT_SIZE="-0.5314789170422551" ORDER="25662" O_E="0.0" SE="1.5941067939721714" STUDY_ID="STD-Schiffito-1999" TOTAL_1="16" TOTAL_2="14" VAR="2.541176470588235" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="1" I2="0.0" ID="CMP-001.04.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="16" TOTAL_2="14" WEIGHT="0.0" Z="0.0">
<NAME>Herpes zoster</NAME>
<DICH_DATA CI_END="6.690017380199802" CI_START="0.012930488128094391" EFFECT_SIZE="0.29411764705882354" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8254272460361436" LOG_CI_START="-1.8883850801206539" LOG_EFFECT_SIZE="-0.5314789170422551" ORDER="25663" O_E="0.0" SE="1.5941067939721714" STUDY_ID="STD-Schiffito-1999" TOTAL_1="16" TOTAL_2="14" VAR="2.541176470588235" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="1" EVENTS_2="0" I2="0.0" ID="CMP-001.04.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="4" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="16" TOTAL_2="14" WEIGHT="0.0" Z="0.0">
<NAME>Blepharitis</NAME>
<DICH_DATA CI_END="60.21015642179821" CI_START="0.11637439315284949" EFFECT_SIZE="2.6470588235294117" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.7796697554754684" LOG_CI_START="-0.934142570681329" LOG_EFFECT_SIZE="0.42276359239706973" ORDER="25664" O_E="0.0" SE="1.5941067939721714" STUDY_ID="STD-Schiffito-1999" TOTAL_1="16" TOTAL_2="14" VAR="2.541176470588235" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="2" EVENTS_2="3" I2="0.0" ID="CMP-001.04.05" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="5" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="16" TOTAL_2="14" WEIGHT="0.0" Z="0.0">
<NAME>Headache</NAME>
<DICH_DATA CI_END="3.004555588665069" CI_START="0.1132539464610019" EFFECT_SIZE="0.5833333333333334" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.4777802435055779" LOG_CI_START="-0.9459466555723139" LOG_EFFECT_SIZE="-0.23408320603336794" ORDER="25665" O_E="0.0" SE="0.8363042280801657" STUDY_ID="STD-Schiffito-1999" TOTAL_1="16" TOTAL_2="14" VAR="0.6994047619047619" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="2" EVENTS_2="3" I2="0.0" ID="CMP-001.04.06" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="6" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="16" TOTAL_2="14" WEIGHT="0.0" Z="0.0">
<NAME>Gastroesophageal reflux</NAME>
<DICH_DATA CI_END="3.004555588665069" CI_START="0.1132539464610019" EFFECT_SIZE="0.5833333333333334" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.4777802435055779" LOG_CI_START="-0.9459466555723139" LOG_EFFECT_SIZE="-0.23408320603336794" ORDER="25666" O_E="0.0" SE="0.8363042280801657" STUDY_ID="STD-Schiffito-1999" TOTAL_1="16" TOTAL_2="14" VAR="0.6994047619047619" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="2" I2="0.0" ID="CMP-001.04.07" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="7" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="16" TOTAL_2="14" WEIGHT="0.0" Z="0.0">
<NAME>Vomiting</NAME>
<DICH_DATA CI_END="3.3916425334872047" CI_START="0.009181943027495709" EFFECT_SIZE="0.17647058823529413" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.530410072972988" LOG_CI_START="-2.037065406290211" LOG_EFFECT_SIZE="-0.7533276666586115" ORDER="25667" O_E="0.0" SE="1.5081478057277968" STUDY_ID="STD-Schiffito-1999" TOTAL_1="16" TOTAL_2="14" VAR="2.2745098039215685" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="1" EVENTS_2="1" I2="0.0" ID="CMP-001.04.08" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="8" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="16" TOTAL_2="14" WEIGHT="0.0" Z="0.0">
<NAME>Nephroliatisis</NAME>
<DICH_DATA CI_END="12.728737323171048" CI_START="0.06014932829246754" EFFECT_SIZE="0.875" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.104785324252448" LOG_CI_START="-1.2207692182078216" LOG_EFFECT_SIZE="-0.057991946977686754" ORDER="25668" O_E="0.0" SE="1.3660422499218055" STUDY_ID="STD-Schiffito-1999" TOTAL_1="16" TOTAL_2="14" VAR="1.8660714285714286" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="1" EVENTS_2="1" I2="0.0" ID="CMP-001.04.09" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="9" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="16" TOTAL_2="14" WEIGHT="0.0" Z="0.0">
<NAME>Bacteria pneumonia</NAME>
<DICH_DATA CI_END="12.728737323171048" CI_START="0.06014932829246754" EFFECT_SIZE="0.875" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.104785324252448" LOG_CI_START="-1.2207692182078216" LOG_EFFECT_SIZE="-0.057991946977686754" ORDER="25669" O_E="0.0" SE="1.3660422499218055" STUDY_ID="STD-Schiffito-1999" TOTAL_1="16" TOTAL_2="14" VAR="1.8660714285714286" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" NO="2">
<NAME>Peptide T vs placebo</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-002.01" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="0.5" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="NO" TOTAL_1="528" TOTAL_2="616" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Neurocognitive performance test</NAME>
<GROUP_LABEL_1>Peptide T</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours peptide T</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-002.01.01" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="66" TOTAL_2="77" WEIGHT="0.0" Z="0.0">
<NAME>Global</NAME>
<CONT_DATA CI_END="0.19470213911946352" CI_START="-0.03470213911946354" EFFECT_SIZE="0.07999999999999999" ESTIMABLE="YES" MEAN_1="0.24" MEAN_2="0.16" ORDER="25670" SD_1="0.41" SD_2="0.26" SE="0.058522574916794065" STUDY_ID="STD-Heseltine-1998" TOTAL_1="66" TOTAL_2="77" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-002.01.02" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="66" TOTAL_2="77" WEIGHT="0.0" Z="0.0">
<NAME>Verbal fluency</NAME>
<CONT_DATA CI_END="0.22550481273598125" CI_START="-0.2455048127359812" EFFECT_SIZE="-0.009999999999999981" ESTIMABLE="YES" MEAN_1="0.14" MEAN_2="0.15" ORDER="25671" SD_1="0.73" SD_2="0.7" SE="0.12015772462841824" STUDY_ID="STD-Heseltine-1998" TOTAL_1="66" TOTAL_2="77" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-002.01.03" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="66" TOTAL_2="77" WEIGHT="0.0" Z="0.0">
<NAME>Visuospatial ability</NAME>
<CONT_DATA CI_END="0.08401277255133996" CI_START="-0.24401277255133993" EFFECT_SIZE="-0.07999999999999999" ESTIMABLE="YES" MEAN_1="0.17" MEAN_2="0.25" ORDER="25672" SD_1="0.48" SD_2="0.52" SE="0.08368152366321614" STUDY_ID="STD-Heseltine-1998" TOTAL_1="66" TOTAL_2="77" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-002.01.04" NO="4" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="66" TOTAL_2="77" WEIGHT="0.0" Z="0.0">
<NAME>Abstract thinking</NAME>
<CONT_DATA CI_END="0.26609023528281606" CI_START="-0.04609023528281603" EFFECT_SIZE="0.11000000000000001" ESTIMABLE="YES" MEAN_1="0.34" MEAN_2="0.23" ORDER="25673" SD_1="0.56" SD_2="0.35" SE="0.07963933853582815" STUDY_ID="STD-Heseltine-1998" TOTAL_1="66" TOTAL_2="77" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-002.01.05" NO="5" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="66" TOTAL_2="77" WEIGHT="0.0" Z="0.0">
<NAME>Speed of information processing</NAME>
<CONT_DATA CI_END="0.25902360527032253" CI_START="-0.07902360527032254" EFFECT_SIZE="0.09" ESTIMABLE="YES" MEAN_1="0.23" MEAN_2="0.14" ORDER="25674" SD_1="0.57" SD_2="0.44" SE="0.08623811794683942" STUDY_ID="STD-Heseltine-1998" TOTAL_1="66" TOTAL_2="77" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-002.01.06" NO="6" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="66" TOTAL_2="77" WEIGHT="0.0" Z="0.0">
<NAME>working memory</NAME>
<CONT_DATA CI_END="0.3726670043121436" CI_START="-0.07266700431214354" EFFECT_SIZE="0.15000000000000002" ESTIMABLE="YES" MEAN_1="0.23" MEAN_2="0.08" ORDER="25675" SD_1="0.73" SD_2="0.61" SE="0.11360770201315558" STUDY_ID="STD-Heseltine-1998" TOTAL_1="66" TOTAL_2="77" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-002.01.07" NO="7" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="66" TOTAL_2="77" WEIGHT="0.0" Z="0.0">
<NAME>Learning and retention</NAME>
<CONT_DATA CI_END="0.2614505316550058" CI_START="-0.1014505316550058" EFFECT_SIZE="0.08" ESTIMABLE="YES" MEAN_1="0.19" MEAN_2="0.11" ORDER="25676" SD_1="0.57" SD_2="0.53" SE="0.09257850301651685" STUDY_ID="STD-Heseltine-1998" TOTAL_1="66" TOTAL_2="77" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-002.01.08" NO="8" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="66" TOTAL_2="77" WEIGHT="0.0" Z="0.0">
<NAME>Motor performance</NAME>
<CONT_DATA CI_END="0.17729794646829225" CI_START="-0.15729794646829223" EFFECT_SIZE="0.010000000000000009" ESTIMABLE="YES" MEAN_1="0.19" MEAN_2="0.18" ORDER="25677" SD_1="0.49" SD_2="0.53" SE="0.08535766360398307" STUDY_ID="STD-Heseltine-1998" TOTAL_1="66" TOTAL_2="77" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="66" EVENTS_2="77" I2="0.0" I2_Q="0.0" ID="CMP-002.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="2.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="106" TOTAL_2="109" WEIGHT="0.0" Z="0.0">
<NAME>Tolerability</NAME>
<GROUP_LABEL_1>Peptide T</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours peptide T</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.067261167795642" CI_START="0.7279088140128578" EFFECT_SIZE="0.8814016172506739" ESTIMABLE="YES" EVENTS_1="66" EVENTS_2="77" LOG_CI_END="0.028270707946957963" LOG_CI_START="-0.13792302185647753" LOG_EFFECT_SIZE="-0.05482615695475978" ORDER="25678" O_E="0.0" SE="0.09762301955876847" STUDY_ID="STD-Heseltine-1998" TOTAL_1="106" TOTAL_2="109" VAR="0.00953025394777169" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="8" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-002.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="106" TOTAL_2="109" WEIGHT="0.0" Z="0.0">
<NAME>All cause mortality</NAME>
<GROUP_LABEL_1>Peptide T</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours peptide T</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="11.18228981654792" CI_START="0.7439886322543672" EFFECT_SIZE="2.8843537414965987" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="3" LOG_CI_END="1.0485307438783376" LOG_CI_START="-0.1284337001892245" LOG_EFFECT_SIZE="0.4600485218445566" ORDER="25679" O_E="0.0" SE="0.6913547405132457" STUDY_ID="STD-Heseltine-1998" TOTAL_1="106" TOTAL_2="109" VAR="0.47797137723013733" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="158" EVENTS_2="158" I2="0.0" I2_Q="0.0" ID="CMP-002.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="4" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="636" TOTAL_2="654" WEIGHT="0.0" Z="0.0">
<NAME>Adverse effects</NAME>
<GROUP_LABEL_1>Peptide T</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours peptide T</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="79" EVENTS_2="79" I2="0.0" ID="CMP-002.04.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="106" TOTAL_2="109" WEIGHT="0.0" Z="0.0">
<NAME>Number of patient experiencing any adverse effects</NAME>
<DICH_DATA CI_END="1.2073606265143444" CI_START="0.8757986198652603" EFFECT_SIZE="1.028301886792453" ESTIMABLE="YES" EVENTS_1="79" EVENTS_2="79" LOG_CI_END="0.08183700888173175" LOG_CI_START="-0.057595743530024814" LOG_EFFECT_SIZE="0.012120632675853438" ORDER="25680" O_E="0.0" SE="0.08190348896992168" STUDY_ID="STD-Heseltine-1998" TOTAL_1="106" TOTAL_2="109" VAR="0.006708181505446081" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="7" EVENTS_2="1" I2="0.0" ID="CMP-002.04.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="106" TOTAL_2="109" WEIGHT="0.0" Z="0.0">
<NAME>Worsening of mood disorder</NAME>
<DICH_DATA CI_END="57.511248837457266" CI_START="0.9009165127869581" EFFECT_SIZE="7.19811320754717" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="1" LOG_CI_END="1.7597527982589636" LOG_CI_START="-0.04531545287874314" LOG_EFFECT_SIZE="0.8572186726901102" ORDER="25681" O_E="0.0" SE="1.0603060259502377" STUDY_ID="STD-Heseltine-1998" TOTAL_1="106" TOTAL_2="109" VAR="1.1242488686663863" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="34" EVENTS_2="42" I2="0.0" ID="CMP-002.04.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="106" TOTAL_2="109" WEIGHT="0.0" Z="0.0">
<NAME>Rash</NAME>
<DICH_DATA CI_END="1.1987059839775855" CI_START="0.5780798683180391" EFFECT_SIZE="0.8324348607367476" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="42" LOG_CI_END="0.07871267334526003" LOG_CI_START="-0.23801215470484394" LOG_EFFECT_SIZE="-0.07964974067979194" ORDER="25682" O_E="0.0" SE="0.1860457318098153" STUDY_ID="STD-Heseltine-1998" TOTAL_1="106" TOTAL_2="109" VAR="0.034613014324649714" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="12" EVENTS_2="5" I2="0.0" ID="CMP-002.04.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="4" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="106" TOTAL_2="109" WEIGHT="0.0" Z="0.0">
<NAME>Nasal congestion</NAME>
<DICH_DATA CI_END="6.765304031829922" CI_START="0.9002775704888242" EFFECT_SIZE="2.4679245283018867" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="5" LOG_CI_END="0.8302873185063098" LOG_CI_START="-0.045623569731390985" LOG_EFFECT_SIZE="0.3923318743874594" ORDER="25683" O_E="0.0" SE="0.5145143915796495" STUDY_ID="STD-Heseltine-1998" TOTAL_1="106" TOTAL_2="109" VAR="0.2647250591425769" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="18" EVENTS_2="9" I2="0.0" ID="CMP-002.04.05" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="5" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="106" TOTAL_2="109" WEIGHT="0.0" Z="0.0">
<NAME>Proteinuria</NAME>
<DICH_DATA CI_END="4.371988322785754" CI_START="0.9674360426536173" EFFECT_SIZE="2.056603773584906" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="9" LOG_CI_END="0.640678993315066" LOG_CI_START="-0.01437773663539668" LOG_EFFECT_SIZE="0.31315062833983465" ORDER="25684" O_E="0.0" SE="0.3847835657560107" STUDY_ID="STD-Heseltine-1998" TOTAL_1="106" TOTAL_2="109" VAR="0.1480583924759102" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="8" EVENTS_2="22" I2="0.0" ID="CMP-002.04.06" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="6" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="106" TOTAL_2="109" WEIGHT="0.0" Z="0.0">
<NAME>Peripheral neuropathy</NAME>
<DICH_DATA CI_END="0.8025637412677368" CI_START="0.17421933138495962" EFFECT_SIZE="0.37392795883361923" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="22" LOG_CI_END="-0.09552046498973377" LOG_CI_START="-0.7589036573190847" LOG_EFFECT_SIZE="-0.42721206115440924" ORDER="25685" O_E="0.0" SE="0.3896745709740232" STUDY_ID="STD-Heseltine-1998" TOTAL_1="106" TOTAL_2="109" VAR="0.15184627126378902" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-003" NO="3">
<NAME>OPC-1147 vs placebo</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-003.01" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="NO" TOTAL_1="120" TOTAL_2="120" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Neuropsychological test scores</NAME>
<GROUP_LABEL_1>OPC-1147</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours OPC-1147</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-003.01.01" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="15" TOTAL_2="15" WEIGHT="0.0" Z="0.0">
<NAME>Rey Auditory Verbal Learning - Total Number Correct</NAME>
<CONT_DATA CI_END="9.278682893552345" CI_START="-4.678682893552345" EFFECT_SIZE="2.3" ESTIMABLE="YES" MEAN_1="0.3" MEAN_2="-2.0" ORDER="25686" SD_1="9.6" SD_2="9.9" SE="3.5606179239002884" STUDY_ID="STD-Dana-1997" TOTAL_1="15" TOTAL_2="15" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-003.01.03" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="15" TOTAL_2="15" WEIGHT="0.0" Z="0.0">
<NAME>Rey Auditory Verbal Learning - Recall after Interference</NAME>
<CONT_DATA CI_END="3.739995193397598" CI_START="-0.33999519339759754" EFFECT_SIZE="1.7000000000000002" ESTIMABLE="YES" MEAN_1="0.8" MEAN_2="-0.9" ORDER="25687" SD_1="3.5" SD_2="2.0" SE="1.0408329997330663" STUDY_ID="STD-Dana-1997" TOTAL_1="15" TOTAL_2="15" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-003.01.04" NO="4" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="15" TOTAL_2="15" WEIGHT="0.0" Z="0.0">
<NAME>Rey Auditory Verbal Learning - Delayed Recall</NAME>
<CONT_DATA CI_END="3.4962147387827223" CI_START="-0.49621473878272226" EFFECT_SIZE="1.5" ESTIMABLE="YES" MEAN_1="0.6" MEAN_2="-0.9" ORDER="25688" SD_1="3.4" SD_2="2.0" SE="1.0184956226382778" STUDY_ID="STD-Dana-1997" TOTAL_1="15" TOTAL_2="15" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-003.01.09" NO="9" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="15" TOTAL_2="15" WEIGHT="0.0" Z="0.0">
<NAME>Digit Symbol</NAME>
<CONT_DATA CI_END="4.246392908266997" CI_START="-3.446392908266997" EFFECT_SIZE="0.4" ESTIMABLE="YES" MEAN_1="0.1" MEAN_2="-0.3" ORDER="25689" SD_1="4.1" SD_2="6.4" SE="1.9624814224173777" STUDY_ID="STD-Dana-1997" TOTAL_1="15" TOTAL_2="15" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-003.01.10" NO="10" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="15" TOTAL_2="15" WEIGHT="0.0" Z="0.0">
<NAME>Grooved Pegboard - Dominant Hand</NAME>
<CONT_DATA CI_END="9.666617787882242" CI_START="-24.266617787882243" EFFECT_SIZE="-7.3" ESTIMABLE="YES" MEAN_1="-3.3" MEAN_2="4.0" ORDER="25690" SD_1="13.7" SD_2="30.6" SE="8.656596713874723" STUDY_ID="STD-Dana-1997" TOTAL_1="15" TOTAL_2="15" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-003.01.11" NO="11" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="15" TOTAL_2="15" WEIGHT="0.0" Z="0.0">
<NAME>Grooved Pegboard - Nondominant Hand</NAME>
<CONT_DATA CI_END="6.40797500566751" CI_START="-14.807975005667512" EFFECT_SIZE="-4.2" ESTIMABLE="YES" MEAN_1="-5.0" MEAN_2="-0.8" ORDER="25691" SD_1="20.8" SD_2="2.6" SE="5.412331598611946" STUDY_ID="STD-Dana-1997" TOTAL_1="15" TOTAL_2="15" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-003.01.14" NO="14" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="15" TOTAL_2="15" WEIGHT="0.0" Z="0.0">
<NAME>Timed Gait</NAME>
<CONT_DATA CI_END="2.791332709771664" CI_START="-0.5913327097716636" EFFECT_SIZE="1.1" ESTIMABLE="YES" MEAN_1="0.3" MEAN_2="-0.8" ORDER="25692" SD_1="2.1" SD_2="2.6" SE="0.862940708662343" STUDY_ID="STD-Dana-1997" TOTAL_1="15" TOTAL_2="15" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-003.01.15" NO="15" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="15" TOTAL_2="15" WEIGHT="0.0" Z="0.0">
<NAME>Composite neuropsychological Z score</NAME>
<CONT_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" MEAN_1="0.0" MEAN_2="0.0" ORDER="25693" SD_1="0.0" SD_2="0.0" SE="0.0" STUDY_ID="STD-Dana-1997" TOTAL_1="15" TOTAL_2="15" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="7" EVENTS_2="9" I2="0.0" I2_Q="0.0" ID="CMP-003.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="15" TOTAL_2="15" WEIGHT="0.0" Z="0.0">
<NAME>Tolerability</NAME>
<GROUP_LABEL_1>OPC-1147</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours OPC-1147</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.5363827814901816" CI_START="0.3937418974574756" EFFECT_SIZE="0.7777777777777778" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="9" LOG_CI_END="0.18649943130640095" LOG_CI_START="-0.40478837015653707" LOG_EFFECT_SIZE="-0.10914446942506803" ORDER="25694" O_E="0.0" SE="0.3473253815011518" STUDY_ID="STD-Dana-1997" TOTAL_1="15" TOTAL_2="15" VAR="0.12063492063492064" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-003.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="15" TOTAL_2="15" WEIGHT="0.0" Z="0.0">
<NAME>All cause mortality</NAME>
<GROUP_LABEL_1>OPC-1147</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours OPC-1147</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="25695" O_E="0.0" SE="0.0" STUDY_ID="STD-Dana-1997" TOTAL_1="15" TOTAL_2="15" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="14" EVENTS_2="26" I2="0.0" I2_Q="0.0" ID="CMP-003.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="4" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="75" TOTAL_2="75" WEIGHT="0.0" Z="0.0">
<NAME>Adverse effects</NAME>
<GROUP_LABEL_1>OPC-1147</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours OPC-1147</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="7" EVENTS_2="13" I2="0.0" ID="CMP-003.04.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="15" TOTAL_2="15" WEIGHT="0.0" Z="0.0">
<NAME>Number of patient experiencing any adverse effects</NAME>
<DICH_DATA CI_END="0.958128371409792" CI_START="0.3026116719367649" EFFECT_SIZE="0.5384615384615384" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="13" LOG_CI_END="-0.018576299627153937" LOG_CI_START="-0.519114324958006" LOG_EFFECT_SIZE="-0.26884531229257996" ORDER="25696" O_E="0.0" SE="0.29401851378252775" STUDY_ID="STD-Dana-1997" TOTAL_1="15" TOTAL_2="15" VAR="0.08644688644688646" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="3" EVENTS_2="5" I2="0.0" ID="CMP-003.04.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="15" TOTAL_2="15" WEIGHT="0.0" Z="0.0">
<NAME>Fatigue</NAME>
<DICH_DATA CI_END="2.0725183060916335" CI_START="0.17370172265396777" EFFECT_SIZE="0.6" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="5" LOG_CI_END="0.31649837526548136" LOG_CI_START="-0.760195874498194" LOG_EFFECT_SIZE="-0.22184874961635637" ORDER="25697" O_E="0.0" SE="0.6324555320336759" STUDY_ID="STD-Dana-1997" TOTAL_1="15" TOTAL_2="15" VAR="0.4" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="3" EVENTS_2="2" I2="0.0" ID="CMP-003.04.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="15" TOTAL_2="15" WEIGHT="0.0" Z="0.0">
<NAME>Diarrhea</NAME>
<DICH_DATA CI_END="7.731389706964666" CI_START="0.29102141856503916" EFFECT_SIZE="1.5" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.8882575647876687" LOG_CI_START="-0.5360750466763062" LOG_EFFECT_SIZE="0.17609125905568124" ORDER="25698" O_E="0.0" SE="0.8366600265340756" STUDY_ID="STD-Dana-1997" TOTAL_1="15" TOTAL_2="15" VAR="0.7" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="1" EVENTS_2="3" I2="0.0" ID="CMP-003.04.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="4" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="15" TOTAL_2="15" WEIGHT="0.0" Z="0.0">
<NAME>Nausea</NAME>
<DICH_DATA CI_END="2.8531415452949767" CI_START="0.03894342756823292" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.45532331768430767" LOG_CI_START="-1.4095658271236327" LOG_EFFECT_SIZE="-0.4771212547196625" ORDER="25699" O_E="0.0" SE="1.0954451150103321" STUDY_ID="STD-Dana-1997" TOTAL_1="15" TOTAL_2="15" VAR="1.2" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="3" I2="0.0" ID="CMP-003.04.05" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="5" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="15" TOTAL_2="15" WEIGHT="0.0" Z="0.0">
<NAME>Cough</NAME>
<DICH_DATA CI_END="2.5475015595668227" CI_START="0.008011050351928473" EFFECT_SIZE="0.14285714285714285" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.40611445855130324" LOG_CI_START="-2.0963105385798166" LOG_EFFECT_SIZE="-0.8450980400142569" ORDER="25700" O_E="0.0" SE="1.469936830518334" STUDY_ID="STD-Dana-1997" TOTAL_1="15" TOTAL_2="15" VAR="2.1607142857142856" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-004" NO="4">
<NAME>Valproic acid vs Placebo</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-004.01" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="NO" TOTAL_1="108" TOTAL_2="72" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Neuropsychological test scores</NAME>
<GROUP_LABEL_1>Valproic acid</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Valproic acid</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-004.01.01" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="9" TOTAL_2="6" WEIGHT="0.0" Z="0.0">
<NAME>Rey Auditory Verbal Learning - Total Number Correct</NAME>
<CONT_DATA CI_END="9.595945714437505" CI_START="-5.155945714437504" EFFECT_SIZE="2.22" ESTIMABLE="YES" MEAN_1="2.89" MEAN_2="0.67" ORDER="25701" SD_1="6.83" SD_2="7.34" SE="3.763306761051745" STUDY_ID="STD-Schiffito-2006a" TOTAL_1="9" TOTAL_2="6" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-004.01.02" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="9" TOTAL_2="6" WEIGHT="0.0" Z="0.0">
<NAME>Rey Auditory Verbal Learning - Number Correct &#8211; Trial 5</NAME>
<CONT_DATA CI_END="1.5944037128708604" CI_START="-2.37440371287086" EFFECT_SIZE="-0.3899999999999999" ESTIMABLE="YES" MEAN_1="0.78" MEAN_2="1.17" ORDER="25702" SD_1="2.05" SD_2="1.83" SE="1.01246947827796" STUDY_ID="STD-Schiffito-2006a" TOTAL_1="9" TOTAL_2="6" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-004.01.03" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="9" TOTAL_2="6" WEIGHT="0.0" Z="0.0">
<NAME>Rey Auditory Verbal Learning - Recall after Interference</NAME>
<CONT_DATA CI_END="13.292590133457704" CI_START="-3.7325901334577027" EFFECT_SIZE="4.78" ESTIMABLE="YES" MEAN_1="-0.22" MEAN_2="-5.0" ORDER="25703" SD_1="2.91" SD_2="10.37" SE="4.343238039374156" STUDY_ID="STD-Schiffito-2006a" TOTAL_1="9" TOTAL_2="6" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-004.01.04" NO="4" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="9" TOTAL_2="6" WEIGHT="0.0" Z="0.0">
<NAME>Rey Auditory Verbal Learning - Delayed Recall</NAME>
<CONT_DATA CI_END="3.906357691442573" CI_START="-0.34635769144257234" EFFECT_SIZE="1.7800000000000002" ESTIMABLE="YES" MEAN_1="1.11" MEAN_2="-0.67" ORDER="25704" SD_1="0.78" SD_2="2.58" SE="1.0848963084092416" STUDY_ID="STD-Schiffito-2006a" TOTAL_1="9" TOTAL_2="6" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-004.01.05" NO="5" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="9" TOTAL_2="6" WEIGHT="0.0" Z="0.0">
<NAME>Rey Auditory Verbal Learning - Correct Recognition</NAME>
<CONT_DATA CI_END="4.16242200789629" CI_START="-5.60242200789629" EFFECT_SIZE="-0.72" ESTIMABLE="YES" MEAN_1="0.11" MEAN_2="0.83" ORDER="25705" SD_1="4.14" SD_2="5.08" SE="2.491077410813776" STUDY_ID="STD-Schiffito-2006a" TOTAL_1="9" TOTAL_2="6" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-004.01.06" NO="6" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="9" TOTAL_2="6" WEIGHT="0.0" Z="0.0">
<NAME>Mean Reaction Time - Choice</NAME>
<CONT_DATA CI_END="110.14768078131769" CI_START="-148.90768078131768" EFFECT_SIZE="-19.380000000000003" ESTIMABLE="YES" MEAN_1="-43.38" MEAN_2="-24.0" ORDER="25706" SD_1="107.57" SD_2="135.98" SE="66.08676577886915" STUDY_ID="STD-Schiffito-2006a" TOTAL_1="9" TOTAL_2="6" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-004.01.07" NO="7" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="9" TOTAL_2="6" WEIGHT="0.0" Z="0.0">
<NAME>Mean Reaction Time - Sequential</NAME>
<CONT_DATA CI_END="166.25746793396024" CI_START="-54.17746793396024" EFFECT_SIZE="56.04" ESTIMABLE="YES" MEAN_1="-8.63" MEAN_2="-64.67" ORDER="25707" SD_1="74.79" SD_2="123.47" SE="56.234435328068045" STUDY_ID="STD-Schiffito-2006a" TOTAL_1="9" TOTAL_2="6" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-004.01.08" NO="8" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="9" TOTAL_2="6" WEIGHT="0.0" Z="0.0">
<NAME>Digit Symbol</NAME>
<CONT_DATA CI_END="11.546644675391853" CI_START="-2.426644675391854" EFFECT_SIZE="4.56" ESTIMABLE="YES" MEAN_1="6.56" MEAN_2="2.0" ORDER="25708" SD_1="5.83" SD_2="7.32" SE="3.564680132135904" STUDY_ID="STD-Schiffito-2006a" TOTAL_1="9" TOTAL_2="6" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-004.01.09" NO="9" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="9" TOTAL_2="6" WEIGHT="0.0" Z="0.0">
<NAME>Grooved Pegboard - Dominant Hand</NAME>
<CONT_DATA CI_END="6.648676900168132" CI_START="-27.30867690016813" EFFECT_SIZE="-10.33" ESTIMABLE="YES" MEAN_1="-9.33" MEAN_2="1.0" ORDER="25709" SD_1="17.63" SD_2="15.59" SE="8.66274943524155" STUDY_ID="STD-Schiffito-2006a" TOTAL_1="9" TOTAL_2="6" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-004.01.10" NO="10" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="9" TOTAL_2="6" WEIGHT="0.0" Z="0.0">
<NAME>Grooved Pegboard - Nondominant Hand</NAME>
<CONT_DATA CI_END="13.142060956822679" CI_START="-21.02206095682268" EFFECT_SIZE="-3.9400000000000004" ESTIMABLE="YES" MEAN_1="-6.44" MEAN_2="-2.5" ORDER="25710" SD_1="17.57" SD_2="15.81" SE="8.715497372178161" STUDY_ID="STD-Schiffito-2006a" TOTAL_1="9" TOTAL_2="6" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-004.01.11" NO="11" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="9" TOTAL_2="6" WEIGHT="0.0" Z="0.0">
<NAME>Timed Gait</NAME>
<CONT_DATA CI_END="0.5622032287664633" CI_START="-1.3422032287664634" EFFECT_SIZE="-0.39" ESTIMABLE="YES" MEAN_1="-0.65" MEAN_2="-0.26" ORDER="25711" SD_1="1.09" SD_2="0.79" SE="0.4858269010437543" STUDY_ID="STD-Schiffito-2006a" TOTAL_1="9" TOTAL_2="6" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-004.01.12" NO="12" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="9" TOTAL_2="6" WEIGHT="0.0" Z="0.0">
<NAME>Composite neuropsychological Z score</NAME>
<CONT_DATA CI_END="7.673613941921584" CI_START="-2.573613941921584" EFFECT_SIZE="2.55" ESTIMABLE="YES" MEAN_1="4.56" MEAN_2="2.01" ORDER="25712" SD_1="6.22" SD_2="3.9" SE="2.6141367812551644" STUDY_ID="STD-Schiffito-2006a" TOTAL_1="9" TOTAL_2="6" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="8" EVENTS_2="5" I2="0.0" I2_Q="0.0" ID="CMP-004.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="9" TOTAL_2="6" WEIGHT="0.0" Z="0.0">
<NAME>Tolerability</NAME>
<GROUP_LABEL_1>Valproic acid</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Valproic acid</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.6330540606304904" CI_START="0.6967177665499352" EFFECT_SIZE="1.0666666666666667" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="5" LOG_CI_END="0.2130005618615268" LOG_CI_START="-0.1569431146610397" LOG_EFFECT_SIZE="0.028028723600243534" ORDER="25713" O_E="0.0" SE="0.21730674684008836" STUDY_ID="STD-Schiffito-2006a" TOTAL_1="9" TOTAL_2="6" VAR="0.04722222222222225" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-004.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="9" TOTAL_2="6" WEIGHT="0.0" Z="0.0">
<NAME>All cause mortality</NAME>
<GROUP_LABEL_1>Valproic acid</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Valproic acid</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="25714" O_E="0.0" SE="0.0" STUDY_ID="STD-Schiffito-2006a" TOTAL_1="9" TOTAL_2="6" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="4" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-004.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="4" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="27" TOTAL_2="18" WEIGHT="0.0" Z="0.0">
<NAME>Adverse effects</NAME>
<GROUP_LABEL_1>Valproic acid</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Valproic acid</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="2" EVENTS_2="0" I2="0.0" ID="CMP-004.04.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="9" TOTAL_2="6" WEIGHT="0.0" Z="0.0">
<NAME>Number of patient experiencing any adverse effects</NAME>
<DICH_DATA CI_END="62.265295761701466" CI_START="0.19673880690910994" EFFECT_SIZE="3.5" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.7942460553486765" LOG_CI_START="-0.7061099666481251" LOG_EFFECT_SIZE="0.5440680443502757" ORDER="25715" O_E="0.0" SE="1.468721504282843" STUDY_ID="STD-Schiffito-2006a" TOTAL_1="9" TOTAL_2="6" VAR="2.157142857142857" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="1" EVENTS_2="0" I2="0.0" ID="CMP-004.04.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="9" TOTAL_2="6" WEIGHT="0.0" Z="0.0">
<NAME>Abnormal liver function</NAME>
<DICH_DATA CI_END="44.40378209183373" CI_START="0.09931586437568438" EFFECT_SIZE="2.1" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.6474199627195685" LOG_CI_START="-1.0029813732517299" LOG_EFFECT_SIZE="0.3222192947339193" ORDER="25716" O_E="0.0" SE="1.5568588644477455" STUDY_ID="STD-Schiffito-2006a" TOTAL_1="9" TOTAL_2="6" VAR="2.4238095238095236" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="1" EVENTS_2="0" I2="0.0" ID="CMP-004.04.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="9" TOTAL_2="6" WEIGHT="0.0" Z="0.0">
<NAME>Gastroesophageal reflux</NAME>
<DICH_DATA CI_END="44.40378209183373" CI_START="0.09931586437568438" EFFECT_SIZE="2.1" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.6474199627195685" LOG_CI_START="-1.0029813732517299" LOG_EFFECT_SIZE="0.3222192947339193" ORDER="25717" O_E="0.0" SE="1.5568588644477455" STUDY_ID="STD-Schiffito-2006a" TOTAL_1="9" TOTAL_2="6" VAR="2.4238095238095236" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-005" NO="5">
<NAME>Memantine versus placebo</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-005.01" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="NO" TOTAL_1="70" TOTAL_2="70" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Neuropsychological test scores</NAME>
<GROUP_LABEL_1>Memantine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours memantine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-005.01.01" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="70" TOTAL_2="70" WEIGHT="0.0" Z="0.0">
<NAME>NPZ-8 score</NAME>
<CONT_DATA CI_END="96.16010365335276" CI_START="-10.160103653352763" EFFECT_SIZE="43.0" ESTIMABLE="YES" MEAN_1="60.0" MEAN_2="17.0" ORDER="25718" SD_1="210.0" SD_2="86.0" SE="27.123000255450037" STUDY_ID="STD-Schiffito-2007a" TOTAL_1="70" TOTAL_2="70" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="54" EVENTS_2="56" I2="0.0" I2_Q="0.0" ID="CMP-005.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="2.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="70" TOTAL_2="70" WEIGHT="0.0" Z="0.0">
<NAME>Tolerability</NAME>
<GROUP_LABEL_1>Memantine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours memantine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.1465743254061285" CI_START="0.81097833622443" EFFECT_SIZE="0.9642857142857143" ESTIMABLE="YES" EVENTS_1="54" EVENTS_2="56" LOG_CI_END="0.05940221263551315" LOG_CI_START="-0.0909907470019769" LOG_EFFECT_SIZE="-0.015794267183231903" ORDER="25719" O_E="0.0" SE="0.08834156894821828" STUDY_ID="STD-Schiffito-2007a" TOTAL_1="70" TOTAL_2="70" VAR="0.007804232804232805" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-005.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="70" TOTAL_2="70" WEIGHT="0.0" Z="0.0">
<NAME>All cause mortality</NAME>
<GROUP_LABEL_1>Memantine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours memantine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="4.092080860459946" CI_START="0.009774977905862802" EFFECT_SIZE="0.2" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.611944206883865" LOG_CI_START="-2.0098842155559025" LOG_EFFECT_SIZE="-0.6989700043360187" ORDER="25720" O_E="0.0" SE="1.540074993601121" STUDY_ID="STD-Schiffito-2007a" TOTAL_1="70" TOTAL_2="70" VAR="2.371830985915493" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="33" EVENTS_2="20" I2="0.0" I2_Q="0.0" ID="CMP-005.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="4" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="140" TOTAL_2="140" WEIGHT="0.0" Z="0.0">
<NAME>Adverse effects</NAME>
<GROUP_LABEL_1>Memantine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours memantine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="9" EVENTS_2="0" I2="0.0" ID="CMP-005.04.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="70" TOTAL_2="70" WEIGHT="0.0" Z="0.0">
<NAME>Grade 1 toxicity</NAME>
<DICH_DATA CI_END="320.26988510742825" CI_START="1.1271743513409302" EFFECT_SIZE="19.0" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="0" LOG_CI_END="2.505516103988384" LOG_CI_START="0.051991097917273146" LOG_EFFECT_SIZE="1.2787536009528289" ORDER="25721" O_E="0.0" SE="1.4412127337108251" STUDY_ID="STD-Schiffito-2007a" TOTAL_1="70" TOTAL_2="70" VAR="2.0770941438102297" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="24" EVENTS_2="20" I2="0.0" ID="CMP-005.04.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="70" TOTAL_2="70" WEIGHT="0.0" Z="0.0">
<NAME>Grade 2+ toxicity</NAME>
<DICH_DATA CI_END="1.9633266682913513" CI_START="0.7334490094066755" EFFECT_SIZE="1.2" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="20" LOG_CI_END="0.29299256574017213" LOG_CI_START="-0.13463007364492244" LOG_EFFECT_SIZE="0.07918124604762482" ORDER="25722" O_E="0.0" SE="0.25118765514100827" STUDY_ID="STD-Schiffito-2007a" TOTAL_1="70" TOTAL_2="70" VAR="0.0630952380952381" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-006" NO="6">
<NAME>Thioctic acid vs Placebo</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-006.01" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="NO" TOTAL_1="99" TOTAL_2="99" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Neuropsychological test scores</NAME>
<GROUP_LABEL_1>Thioctic acid</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Thioctic acid</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-006.01.01" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="9" TOTAL_2="9" WEIGHT="0.0" Z="0.0">
<NAME>Rey Auditory Verbal Learning - Total Number Correct</NAME>
<CONT_DATA CI_END="-6.051549147648754" CI_START="-15.948450852351247" EFFECT_SIZE="-11.0" ESTIMABLE="YES" MEAN_1="-6.0" MEAN_2="5.0" ORDER="25723" SD_1="5.6" SD_2="5.1" SE="2.5247662157998794" STUDY_ID="STD-Dana-_x0028_thioctic_x0029_-1998" TOTAL_1="9" TOTAL_2="9" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-006.01.02" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="9" TOTAL_2="9" WEIGHT="0.0" Z="0.0">
<NAME>Rey Auditory Verbal Learning - Number Correct &#8211; Trial 5</NAME>
<CONT_DATA CI_END="1.342463955762717" CI_START="-2.5424639557627167" EFFECT_SIZE="-0.6" ESTIMABLE="YES" MEAN_1="-0.7" MEAN_2="-0.1" ORDER="25724" SD_1="2.2" SD_2="2.0" SE="0.9910712498212337" STUDY_ID="STD-Dana-_x0028_thioctic_x0029_-1998" TOTAL_1="9" TOTAL_2="9" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-006.01.03" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="9" TOTAL_2="9" WEIGHT="0.0" Z="0.0">
<NAME>Rey Auditory Verbal Learning - Recall after Interference</NAME>
<CONT_DATA CI_END="0.39129082769746315" CI_START="-3.5912908276974633" EFFECT_SIZE="-1.6" ESTIMABLE="YES" MEAN_1="-1.2" MEAN_2="0.4" ORDER="25725" SD_1="2.0" SD_2="2.3" SE="1.015983376941878" STUDY_ID="STD-Dana-_x0028_thioctic_x0029_-1998" TOTAL_1="9" TOTAL_2="9" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-006.01.04" NO="4" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="9" TOTAL_2="9" WEIGHT="0.0" Z="0.0">
<NAME>Rey Auditory Verbal Learning - Delayed Recall</NAME>
<CONT_DATA CI_END="0.38017348207441537" CI_START="-2.7801734820744155" EFFECT_SIZE="-1.2" ESTIMABLE="YES" MEAN_1="-1.2" MEAN_2="0.0" ORDER="25726" SD_1="2.1" SD_2="1.2" SE="0.806225774829855" STUDY_ID="STD-Dana-_x0028_thioctic_x0029_-1998" TOTAL_1="9" TOTAL_2="9" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-006.01.05" NO="5" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="9" TOTAL_2="9" WEIGHT="0.0" Z="0.0">
<NAME>Rey Auditory Verbal Learning - Correct Recognition</NAME>
<CONT_DATA CI_END="0.722874864529938" CI_START="-1.922874864529938" EFFECT_SIZE="-0.6" ESTIMABLE="YES" MEAN_1="-0.6" MEAN_2="0.0" ORDER="25727" SD_1="0.7" SD_2="1.9" SE="0.6749485577105528" STUDY_ID="STD-Dana-_x0028_thioctic_x0029_-1998" TOTAL_1="9" TOTAL_2="9" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-006.01.06" NO="6" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="9" TOTAL_2="9" WEIGHT="0.0" Z="0.0">
<NAME>Mean Reaction Time - Choice</NAME>
<CONT_DATA CI_END="52.57937265476864" CI_START="-53.57937265476864" EFFECT_SIZE="-0.5" ESTIMABLE="YES" MEAN_1="-9.1" MEAN_2="-8.6" ORDER="25728" SD_1="46.1" SD_2="66.9" SE="27.081810213581452" STUDY_ID="STD-Dana-_x0028_thioctic_x0029_-1998" TOTAL_1="9" TOTAL_2="9" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-006.01.07" NO="7" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="9" TOTAL_2="9" WEIGHT="0.0" Z="0.0">
<NAME>Mean Reaction Time - Sequential</NAME>
<CONT_DATA CI_END="129.25118813420627" CI_START="12.14881186579374" EFFECT_SIZE="70.7" ESTIMABLE="YES" MEAN_1="63.6" MEAN_2="-7.1" ORDER="25729" SD_1="61.7" SD_2="65.0" SE="29.873604104999153" STUDY_ID="STD-Dana-_x0028_thioctic_x0029_-1998" TOTAL_1="9" TOTAL_2="9" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-006.01.08" NO="8" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="9" TOTAL_2="9" WEIGHT="0.0" Z="0.0">
<NAME>Digit Symbol</NAME>
<CONT_DATA CI_END="7.036423267880831" CI_START="-7.636423267880831" EFFECT_SIZE="-0.2999999999999998" ESTIMABLE="YES" MEAN_1="2.0" MEAN_2="2.3" ORDER="25730" SD_1="9.9" SD_2="5.3" SE="3.743141876967945" STUDY_ID="STD-Dana-_x0028_thioctic_x0029_-1998" TOTAL_1="9" TOTAL_2="9" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-006.01.09" NO="9" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="9" TOTAL_2="9" WEIGHT="0.0" Z="0.0">
<NAME>Grooved Pegboard - Dominant Hand</NAME>
<CONT_DATA CI_END="15.658062537225206" CI_START="-14.258062537225204" EFFECT_SIZE="0.7000000000000002" ESTIMABLE="YES" MEAN_1="5.4" MEAN_2="4.7" ORDER="25731" SD_1="17.8" SD_2="14.4" SE="7.6318047960128315" STUDY_ID="STD-Dana-_x0028_thioctic_x0029_-1998" TOTAL_1="9" TOTAL_2="9" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-006.01.10" NO="10" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="9" TOTAL_2="9" WEIGHT="0.0" Z="0.0">
<NAME>Grooved Pegboard - Nondominant Hand</NAME>
<CONT_DATA CI_END="28.034677328346046" CI_START="-1.4346773283460443" EFFECT_SIZE="13.3" ESTIMABLE="YES" MEAN_1="2.8" MEAN_2="-10.5" ORDER="25732" SD_1="12.9" SD_2="18.5" SE="7.517830656364759" STUDY_ID="STD-Dana-_x0028_thioctic_x0029_-1998" TOTAL_1="9" TOTAL_2="9" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-006.01.11" NO="11" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="9" TOTAL_2="9" WEIGHT="0.0" Z="0.0">
<NAME>Composite neuropsychological Z score</NAME>
<CONT_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" MEAN_1="0.0" MEAN_2="0.0" ORDER="25733" SD_1="0.0" SD_2="0.0" SE="0.0" STUDY_ID="STD-Dana-_x0028_thioctic_x0029_-1998" TOTAL_1="9" TOTAL_2="9" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="8" EVENTS_2="6" I2="0.0" I2_Q="0.0" ID="CMP-006.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="9" TOTAL_2="9" WEIGHT="0.0" Z="0.0">
<NAME>Tolerability</NAME>
<GROUP_LABEL_1>Thioctic acid</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Thioctic acid</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="48.655653617324056" CI_START="0.32884153865940735" EFFECT_SIZE="4.0" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="6" LOG_CI_END="1.687133311041173" LOG_CI_START="-0.4830133283852482" LOG_EFFECT_SIZE="0.6020599913279624" ORDER="25734" O_E="0.0" SE="1.2747548783981961" STUDY_ID="STD-Dana-_x0028_thioctic_x0029_-1998" TOTAL_1="9" TOTAL_2="9" VAR="1.625" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-006.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="9" TOTAL_2="9" WEIGHT="0.0" Z="0.0">
<NAME>All cause mortality</NAME>
<GROUP_LABEL_1>Thioctic acid</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Thioctic acid</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="25735" O_E="0.0" SE="0.0" STUDY_ID="STD-Dana-_x0028_thioctic_x0029_-1998" TOTAL_1="9" TOTAL_2="9" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="1" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-006.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="4" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="9" TOTAL_2="9" WEIGHT="0.0" Z="0.0">
<NAME>Adverse effects</NAME>
<GROUP_LABEL_1>Thioctic acid</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Thioctic acid</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="1" EVENTS_2="1" I2="0.0" ID="CMP-006.04.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="9" TOTAL_2="9" WEIGHT="0.0" Z="0.0">
<NAME>Headache</NAME>
<DICH_DATA CI_END="13.643801456189747" CI_START="0.0732933561962918" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1349353909531412" LOG_CI_START="-1.1349353909531412" LOG_EFFECT_SIZE="0.0" ORDER="25736" O_E="0.0" SE="1.3333333333333333" STUDY_ID="STD-Dana-_x0028_thioctic_x0029_-1998" TOTAL_1="9" TOTAL_2="9" VAR="1.7777777777777777" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-007" NO="7">
<NAME>Oral selegiline (deprenly) vs Placebo</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-007.01" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="NO" TOTAL_1="99" TOTAL_2="99" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Neuropsychological test scores</NAME>
<GROUP_LABEL_1>Deprenyl</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours deprenyl</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-007.01.01" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="9" TOTAL_2="9" WEIGHT="0.0" Z="0.0">
<NAME>Rey Auditory Verbal Learning - Total Number Correct</NAME>
<CONT_DATA CI_END="7.700345489546307" CI_START="-2.1003454895463074" EFFECT_SIZE="2.8" ESTIMABLE="YES" MEAN_1="7.8" MEAN_2="5.0" ORDER="25737" SD_1="5.5" SD_2="5.1" SE="2.5002222123465567" STUDY_ID="STD-Dana-1998" TOTAL_1="9" TOTAL_2="9" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-007.01.02" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="9" TOTAL_2="9" WEIGHT="0.0" Z="0.0">
<NAME>Rey Auditory Verbal Learning - Number Correct &#8211; Trial 5</NAME>
<CONT_DATA CI_END="3.358414460980903" CI_START="0.2415855390190973" EFFECT_SIZE="1.8" ESTIMABLE="YES" MEAN_1="1.7" MEAN_2="-0.1" ORDER="25738" SD_1="1.3" SD_2="2.0" SE="0.7951240294584375" STUDY_ID="STD-Dana-1998" TOTAL_1="9" TOTAL_2="9" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-007.01.03" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="9" TOTAL_2="9" WEIGHT="0.0" Z="0.0">
<NAME>Rey Auditory Verbal Learning - Recall after Interference</NAME>
<CONT_DATA CI_END="3.7304659923530368" CI_START="0.06953400764696305" EFFECT_SIZE="1.9" ESTIMABLE="YES" MEAN_1="2.3" MEAN_2="0.4" ORDER="25739" SD_1="1.6" SD_2="2.3" SE="0.93392838174146" STUDY_ID="STD-Dana-1998" TOTAL_1="9" TOTAL_2="9" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-007.01.04" NO="4" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="9" TOTAL_2="9" WEIGHT="0.0" Z="0.0">
<NAME>Rey Auditory Verbal Learning - Delayed Recall</NAME>
<CONT_DATA CI_END="2.511715526208296" CI_START="-1.111715526208296" EFFECT_SIZE="0.7" ESTIMABLE="YES" MEAN_1="0.7" MEAN_2="0.0" ORDER="25740" SD_1="2.5" SD_2="1.2" SE="0.9243616415908031" STUDY_ID="STD-Dana-1998" TOTAL_1="9" TOTAL_2="9" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-007.01.05" NO="5" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="9" TOTAL_2="9" WEIGHT="0.0" Z="0.0">
<NAME>Rey Auditory Verbal Learning - Correct Recognition</NAME>
<CONT_DATA CI_END="3.009905550405076" CI_START="-0.4099055504050757" EFFECT_SIZE="1.3" ESTIMABLE="YES" MEAN_1="1.3" MEAN_2="0.0" ORDER="25741" SD_1="1.8" SD_2="1.9" SE="0.8724168218868267" STUDY_ID="STD-Dana-1998" TOTAL_1="9" TOTAL_2="9" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-007.01.06" NO="6" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="9" TOTAL_2="9" WEIGHT="0.0" Z="0.0">
<NAME>Digit Symbol</NAME>
<CONT_DATA CI_END="11.846659784137536" CI_START="-0.04665978413753802" EFFECT_SIZE="5.8999999999999995" ESTIMABLE="YES" MEAN_1="8.2" MEAN_2="2.3" ORDER="25742" SD_1="7.4" SD_2="5.3" SE="3.034065845619629" STUDY_ID="STD-Dana-1998" TOTAL_1="9" TOTAL_2="9" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-007.01.07" NO="7" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="9" TOTAL_2="9" WEIGHT="0.0" Z="0.0">
<NAME>Grooved Pegboard - Dominant Hand</NAME>
<CONT_DATA CI_END="2.3726365017590716" CI_START="-22.37263650175907" EFFECT_SIZE="-10.0" ESTIMABLE="YES" MEAN_1="-5.3" MEAN_2="4.7" ORDER="25743" SD_1="12.3" SD_2="14.4" SE="6.312685640834653" STUDY_ID="STD-Dana-1998" TOTAL_1="9" TOTAL_2="9" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-007.01.08" NO="8" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="9" TOTAL_2="9" WEIGHT="0.0" Z="0.0">
<NAME>Grooved Pegboard - Nondominant Hand</NAME>
<CONT_DATA CI_END="18.99451708881835" CI_START="-12.794517088818347" EFFECT_SIZE="3.0999999999999996" ESTIMABLE="YES" MEAN_1="-7.4" MEAN_2="-10.5" ORDER="25744" SD_1="15.8" SD_2="18.5" SE="8.109596510033995" STUDY_ID="STD-Dana-1998" TOTAL_1="9" TOTAL_2="9" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-007.01.09" NO="9" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="9" TOTAL_2="9" WEIGHT="0.0" Z="0.0">
<NAME>Mean Reaction Time - Sequential</NAME>
<CONT_DATA CI_END="77.65927399383938" CI_START="-28.859273993839388" EFFECT_SIZE="24.4" ESTIMABLE="YES" MEAN_1="17.3" MEAN_2="-7.1" ORDER="25745" SD_1="49.2" SD_2="65.0" SE="27.173598297694113" STUDY_ID="STD-Dana-1998" TOTAL_1="9" TOTAL_2="9" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-007.01.10" NO="10" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="9" TOTAL_2="9" WEIGHT="0.0" Z="0.0">
<NAME>Mean Reaction Time - Choice</NAME>
<CONT_DATA CI_END="73.11647042922563" CI_START="-33.11647042922563" EFFECT_SIZE="20.0" ESTIMABLE="YES" MEAN_1="11.4" MEAN_2="-8.6" ORDER="25746" SD_1="46.2" SD_2="66.9" SE="27.100737997331365" STUDY_ID="STD-Dana-1998" TOTAL_1="9" TOTAL_2="9" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-007.01.11" NO="11" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="9" TOTAL_2="9" WEIGHT="0.0" Z="0.0">
<NAME>Composite neuropsychological Z score</NAME>
<CONT_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" MEAN_1="0.0" MEAN_2="0.0" ORDER="25747" SD_1="0.0" SD_2="0.0" SE="0.0" STUDY_ID="STD-Dana-1998" TOTAL_1="9" TOTAL_2="9" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="8" EVENTS_2="6" I2="0.0" I2_Q="0.0" ID="CMP-007.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="5.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="9" TOTAL_2="9" WEIGHT="0.0" Z="0.0">
<NAME>Tolerability</NAME>
<GROUP_LABEL_1>Deprenyl</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours deprenyl</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.2348585393474605" CI_START="0.7954766471692912" EFFECT_SIZE="1.3333333333333333" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="6" LOG_CI_END="0.3492500386423989" LOG_CI_START="-0.09937256542579911" LOG_EFFECT_SIZE="0.12493873660829992" ORDER="25748" O_E="0.0" SE="0.2635231383473649" STUDY_ID="STD-Dana-1998" TOTAL_1="9" TOTAL_2="9" VAR="0.06944444444444442" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-007.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="9" TOTAL_2="9" WEIGHT="0.0" Z="0.0">
<NAME>All cause mortality</NAME>
<GROUP_LABEL_1>Deprenyl</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours deprenyl</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="25749" O_E="0.0" SE="0.0" STUDY_ID="STD-Dana-1998" TOTAL_1="9" TOTAL_2="9" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="16" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-007.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="4" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="54" TOTAL_2="54" WEIGHT="0.0" Z="0.0">
<NAME>Adverse effects</NAME>
<GROUP_LABEL_1>Deprenyl</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours deprenyl</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="8" EVENTS_2="1" I2="0.0" ID="CMP-007.04.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="9" TOTAL_2="9" WEIGHT="0.0" Z="0.0">
<NAME>Number of patient experiencing any adverse effects</NAME>
<DICH_DATA CI_END="51.50577047184636" CI_START="1.2425792180894195" EFFECT_SIZE="8.0" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="1" LOG_CI_END="1.7118558881419772" LOG_CI_START="0.09432408584190972" LOG_EFFECT_SIZE="0.9030899869919435" ORDER="25750" O_E="0.0" SE="0.9501461875826149" STUDY_ID="STD-Dana-1998" TOTAL_1="9" TOTAL_2="9" VAR="0.9027777777777777" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="2" EVENTS_2="1" I2="0.0" ID="CMP-007.04.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="9" TOTAL_2="9" WEIGHT="0.0" Z="0.0">
<NAME>Headache</NAME>
<DICH_DATA CI_END="18.332356199323183" CI_START="0.21819344750390995" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.2632182870354172" LOG_CI_START="-0.6611582957074547" LOG_EFFECT_SIZE="0.3010299956639812" ORDER="25751" O_E="0.0" SE="1.130388330520878" STUDY_ID="STD-Dana-1998" TOTAL_1="9" TOTAL_2="9" VAR="1.2777777777777777" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="2" EVENTS_2="0" I2="0.0" ID="CMP-007.04.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="9" TOTAL_2="9" WEIGHT="0.0" Z="0.0">
<NAME>Nausea</NAME>
<DICH_DATA CI_END="91.51787421498676" CI_START="0.2731706807488985" EFFECT_SIZE="5.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.9615059237367205" LOG_CI_START="-0.5635659150646828" LOG_EFFECT_SIZE="0.6989700043360189" ORDER="25752" O_E="0.0" SE="1.4832396974191324" STUDY_ID="STD-Dana-1998" TOTAL_1="9" TOTAL_2="9" VAR="2.1999999999999997" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="2" EVENTS_2="0" I2="0.0" ID="CMP-007.04.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="4" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="9" TOTAL_2="9" WEIGHT="0.0" Z="0.0">
<NAME>Acute lymphocytic leukemia</NAME>
<DICH_DATA CI_END="91.51787421498676" CI_START="0.2731706807488985" EFFECT_SIZE="5.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.9615059237367205" LOG_CI_START="-0.5635659150646828" LOG_EFFECT_SIZE="0.6989700043360189" ORDER="25753" O_E="0.0" SE="1.4832396974191324" STUDY_ID="STD-Dana-1998" TOTAL_1="9" TOTAL_2="9" VAR="2.1999999999999997" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="1" EVENTS_2="0" I2="0.0" ID="CMP-007.04.05" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="5" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="9" TOTAL_2="9" WEIGHT="0.0" Z="0.0">
<NAME>Bacteria pneumonia</NAME>
<DICH_DATA CI_END="65.16081469815073" CI_START="0.13811982004355478" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8139865056042341" LOG_CI_START="-0.8597439961649094" LOG_EFFECT_SIZE="0.47712125471966244" ORDER="25754" O_E="0.0" SE="1.5705625319186327" STUDY_ID="STD-Dana-1998" TOTAL_1="9" TOTAL_2="9" VAR="2.4666666666666663" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="1" EVENTS_2="0" I2="0.0" ID="CMP-007.04.06" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="6" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="9" TOTAL_2="9" WEIGHT="0.0" Z="0.0">
<NAME>Flu</NAME>
<DICH_DATA CI_END="65.16081469815073" CI_START="0.13811982004355478" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8139865056042341" LOG_CI_START="-0.8597439961649094" LOG_EFFECT_SIZE="0.47712125471966244" ORDER="25755" O_E="0.0" SE="1.5705625319186327" STUDY_ID="STD-Dana-1998" TOTAL_1="9" TOTAL_2="9" VAR="2.4666666666666663" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-008" NO="8">
<NAME>Thiotic acid and oral selegiline (deprenyl) vs Placebo</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-008.01" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="NO" TOTAL_1="99" TOTAL_2="99" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Neuropsychological test scores</NAME>
<GROUP_LABEL_1>Thioctic+deprenyl</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Thioctic+deprenyl</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-008.01.01" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="9" TOTAL_2="9" WEIGHT="0.0" Z="0.0">
<NAME>Rey Auditory Verbal Learning - Total Number Correct</NAME>
<CONT_DATA CI_END="2.7464681719376993" CI_START="-7.946468171937699" EFFECT_SIZE="-2.6" ESTIMABLE="YES" MEAN_1="2.4" MEAN_2="5.0" ORDER="25756" SD_1="6.4" SD_2="5.1" SE="2.7278400083419685" STUDY_ID="STD-Dana-_x0028_both_x0029_-1998" TOTAL_1="9" TOTAL_2="9" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-008.01.02" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="9" TOTAL_2="9" WEIGHT="0.0" Z="0.0">
<NAME>Rey Auditory Verbal Learning - Number Correct &#8211; Trial 5</NAME>
<CONT_DATA CI_END="2.5584144609809027" CI_START="-0.5584144609809027" EFFECT_SIZE="1.0" ESTIMABLE="YES" MEAN_1="0.9" MEAN_2="-0.1" ORDER="25757" SD_1="1.3" SD_2="2.0" SE="0.7951240294584375" STUDY_ID="STD-Dana-_x0028_both_x0029_-1998" TOTAL_1="9" TOTAL_2="9" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-008.01.03" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="9" TOTAL_2="9" WEIGHT="0.0" Z="0.0">
<NAME>Rey Auditory Verbal Learning - Recall after Interference</NAME>
<CONT_DATA CI_END="1.681802485242922" CI_START="-3.681802485242922" EFFECT_SIZE="-1.0" ESTIMABLE="YES" MEAN_1="-0.6" MEAN_2="0.4" ORDER="25758" SD_1="3.4" SD_2="2.3" SE="1.3682917167849193" STUDY_ID="STD-Dana-_x0028_both_x0029_-1998" TOTAL_1="9" TOTAL_2="9" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-008.01.04" NO="4" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="9" TOTAL_2="9" WEIGHT="0.0" Z="0.0">
<NAME>Rey Auditory Verbal Learning - Delayed Recall</NAME>
<CONT_DATA CI_END="1.5681570853172557" CI_START="-1.3681570853172556" EFFECT_SIZE="0.1" ESTIMABLE="YES" MEAN_1="0.1" MEAN_2="0.0" ORDER="25759" SD_1="1.9" SD_2="1.2" SE="0.749073501808141" STUDY_ID="STD-Dana-_x0028_both_x0029_-1998" TOTAL_1="9" TOTAL_2="9" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-008.01.05" NO="5" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="9" TOTAL_2="9" WEIGHT="0.0" Z="0.0">
<NAME>Rey Auditory Verbal Learning - Correct Recognition</NAME>
<CONT_DATA CI_END="1.5656491005181337" CI_START="-1.7656491005181338" EFFECT_SIZE="-0.1" ESTIMABLE="YES" MEAN_1="-0.1" MEAN_2="0.0" ORDER="25760" SD_1="1.7" SD_2="1.9" SE="0.8498365855987974" STUDY_ID="STD-Dana-_x0028_both_x0029_-1998" TOTAL_1="9" TOTAL_2="9" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-008.01.06" NO="6" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="9" TOTAL_2="9" WEIGHT="0.0" Z="0.0">
<NAME>Mean Reaction Time - Choice</NAME>
<CONT_DATA CI_END="50.10943019245194" CI_START="-58.70943019245193" EFFECT_SIZE="-4.300000000000001" ESTIMABLE="YES" MEAN_1="-12.9" MEAN_2="-8.6" ORDER="25761" SD_1="49.6" SD_2="66.9" SE="27.76042346779154" STUDY_ID="STD-Dana-_x0028_both_x0029_-1998" TOTAL_1="9" TOTAL_2="9" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-008.01.07" NO="7" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="9" TOTAL_2="9" WEIGHT="0.0" Z="0.0">
<NAME>Mean Reaction Time - Sequential</NAME>
<CONT_DATA CI_END="39.173409544150125" CI_START="-49.57340954415013" EFFECT_SIZE="-5.200000000000001" ESTIMABLE="YES" MEAN_1="-12.3" MEAN_2="-7.1" ORDER="25762" SD_1="19.7" SD_2="65.0" SE="22.639910679054267" STUDY_ID="STD-Dana-_x0028_both_x0029_-1998" TOTAL_1="9" TOTAL_2="9" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-008.01.08" NO="8" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="9" TOTAL_2="9" WEIGHT="0.0" Z="0.0">
<NAME>Grooved Pegboard - Dominant Hand</NAME>
<CONT_DATA CI_END="5.247917859551524" CI_START="-26.847917859551526" EFFECT_SIZE="-10.8" ESTIMABLE="YES" MEAN_1="-6.1" MEAN_2="4.7" ORDER="25763" SD_1="19.9" SD_2="14.4" SE="8.187863647564676" STUDY_ID="STD-Dana-_x0028_both_x0029_-1998" TOTAL_1="9" TOTAL_2="9" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-008.01.09" NO="9" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="9" TOTAL_2="9" WEIGHT="0.0" Z="0.0">
<NAME>Grooved Pegboard - Nondominant Hand</NAME>
<CONT_DATA CI_END="21.93196154104568" CI_START="-12.531961541045682" EFFECT_SIZE="4.7" ESTIMABLE="YES" MEAN_1="-5.8" MEAN_2="-10.5" ORDER="25764" SD_1="18.8" SD_2="18.5" SE="8.791978667449603" STUDY_ID="STD-Dana-_x0028_both_x0029_-1998" TOTAL_1="9" TOTAL_2="9" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-008.01.10" NO="10" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="9" TOTAL_2="9" WEIGHT="0.0" Z="0.0">
<NAME>Digit Symbol</NAME>
<CONT_DATA CI_END="5.978703673507708" CI_START="-4.778703673507708" EFFECT_SIZE="0.6000000000000001" ESTIMABLE="YES" MEAN_1="2.9" MEAN_2="2.3" ORDER="25765" SD_1="6.3" SD_2="5.3" SE="2.7442869950337028" STUDY_ID="STD-Dana-_x0028_both_x0029_-1998" TOTAL_1="9" TOTAL_2="9" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-008.01.11" NO="11" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="9" TOTAL_2="9" WEIGHT="0.0" Z="0.0">
<NAME>Composite neuropsychological Z score</NAME>
<CONT_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" MEAN_1="0.0" MEAN_2="0.0" ORDER="25766" SD_1="0.0" SD_2="0.0" SE="0.0" STUDY_ID="STD-Dana-_x0028_both_x0029_-1998" TOTAL_1="9" TOTAL_2="9" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="9" EVENTS_2="6" I2="0.0" I2_Q="0.0" ID="CMP-008.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="5.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="9" TOTAL_2="9" WEIGHT="0.0" Z="0.0">
<NAME>Tolerability</NAME>
<GROUP_LABEL_1>Thioctic+deprenyl</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Thioctic+deprenyl</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.3537364305505157" CI_START="0.9075335058040468" EFFECT_SIZE="1.4615384615384615" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="6" LOG_CI_END="0.3717578292949196" LOG_CI_START="-0.042137332002935235" LOG_EFFECT_SIZE="0.16481024864599214" ORDER="25767" O_E="0.0" SE="0.24312406656045116" STUDY_ID="STD-Dana-_x0028_both_x0029_-1998" TOTAL_1="9" TOTAL_2="9" VAR="0.05910931174089068" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-008.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="9" TOTAL_2="9" WEIGHT="0.0" Z="0.0">
<NAME>All cause mortality</NAME>
<GROUP_LABEL_1>Thioctic+deprenyl</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="25768" O_E="0.0" SE="0.0" STUDY_ID="STD-Dana-_x0028_both_x0029_-1998" TOTAL_1="9" TOTAL_2="9" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="12" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-008.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="4" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="45" TOTAL_2="45" WEIGHT="0.0" Z="0.0">
<NAME>Adverse effects</NAME>
<GROUP_LABEL_1>Thioctic+deprenyl</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Thioctic+deprenyl</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="6" EVENTS_2="1" I2="0.0" ID="CMP-008.04.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="9" TOTAL_2="9" WEIGHT="0.0" Z="0.0">
<NAME>Number of patient experiencing any adverse effects</NAME>
<DICH_DATA CI_END="40.306070383600584" CI_START="0.893165710707621" EFFECT_SIZE="6.0" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="1" LOG_CI_END="1.605370458934295" LOG_CI_START="-0.049067958167007694" LOG_EFFECT_SIZE="0.7781512503836436" ORDER="25769" O_E="0.0" SE="0.97182531580755" STUDY_ID="STD-Dana-_x0028_both_x0029_-1998" TOTAL_1="9" TOTAL_2="9" VAR="0.9444444444444444" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="2" EVENTS_2="1" I2="0.0" ID="CMP-008.04.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="9" TOTAL_2="9" WEIGHT="0.0" Z="0.0">
<NAME>Headache</NAME>
<DICH_DATA CI_END="18.332356199323183" CI_START="0.21819344750390995" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.2632182870354172" LOG_CI_START="-0.6611582957074547" LOG_EFFECT_SIZE="0.3010299956639812" ORDER="25770" O_E="0.0" SE="1.130388330520878" STUDY_ID="STD-Dana-_x0028_both_x0029_-1998" TOTAL_1="9" TOTAL_2="9" VAR="1.2777777777777777" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="2" EVENTS_2="0" I2="0.0" ID="CMP-008.04.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="9" TOTAL_2="9" WEIGHT="0.0" Z="0.0">
<NAME>Nausea</NAME>
<DICH_DATA CI_END="91.51787421498676" CI_START="0.2731706807488985" EFFECT_SIZE="5.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.9615059237367205" LOG_CI_START="-0.5635659150646828" LOG_EFFECT_SIZE="0.6989700043360189" ORDER="25771" O_E="0.0" SE="1.4832396974191324" STUDY_ID="STD-Dana-_x0028_both_x0029_-1998" TOTAL_1="9" TOTAL_2="9" VAR="2.1999999999999997" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="1" EVENTS_2="0" I2="0.0" ID="CMP-008.04.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="4" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="9" TOTAL_2="9" WEIGHT="0.0" Z="0.0">
<NAME>Acute lymphocytic leukemia</NAME>
<DICH_DATA CI_END="65.16081469815073" CI_START="0.13811982004355478" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8139865056042341" LOG_CI_START="-0.8597439961649094" LOG_EFFECT_SIZE="0.47712125471966244" ORDER="25772" O_E="0.0" SE="1.5705625319186327" STUDY_ID="STD-Dana-_x0028_both_x0029_-1998" TOTAL_1="9" TOTAL_2="9" VAR="2.4666666666666663" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="1" EVENTS_2="0" I2="0.0" ID="CMP-008.04.05" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="5" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="9" TOTAL_2="9" WEIGHT="0.0" Z="0.0">
<NAME>Neutropenia</NAME>
<DICH_DATA CI_END="65.16081469815073" CI_START="0.13811982004355478" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8139865056042341" LOG_CI_START="-0.8597439961649094" LOG_EFFECT_SIZE="0.47712125471966244" ORDER="25773" O_E="0.0" SE="1.5705625319186327" STUDY_ID="STD-Dana-_x0028_both_x0029_-1998" TOTAL_1="9" TOTAL_2="9" VAR="2.4666666666666663" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-009" NO="9">
<NAME>Low dose Transdermal selegiline (deprenyl) vs placebo</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-009.01" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="NO" TOTAL_1="228" TOTAL_2="181" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Neuropsychological test scores</NAME>
<GROUP_LABEL_1>Transdermal deprenyl</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Transdermal deprenyl</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-009.01.01" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="9" TOTAL_2="5" WEIGHT="0.0" Z="0.0">
<NAME>Rey Auditory Verbal Learning - Total Number Correct</NAME>
<CONT_DATA CI_END="8.530394149033167" CI_START="-3.130394149033166" EFFECT_SIZE="2.7" ESTIMABLE="YES" MEAN_1="9.0" MEAN_2="6.3" ORDER="25774" SD_1="4.6" SD_2="5.7" SE="2.9747455540114873" STUDY_ID="STD-Sacktor-2000" TOTAL_1="9" TOTAL_2="5" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-009.01.02" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="9" TOTAL_2="5" WEIGHT="0.0" Z="0.0">
<NAME>Rey Auditory Verbal Learning - Number Correct &#8211; Trial 5</NAME>
<CONT_DATA CI_END="0.5694581753320787" CI_START="-3.1694581753320787" EFFECT_SIZE="-1.3" ESTIMABLE="YES" MEAN_1="1.2" MEAN_2="2.5" ORDER="25775" SD_1="1.3" SD_2="1.9" SE="0.9538227182122356" STUDY_ID="STD-Sacktor-2000" TOTAL_1="9" TOTAL_2="5" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-009.01.03" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="9" TOTAL_2="5" WEIGHT="0.0" Z="0.0">
<NAME>Rey Auditory Verbal Learning - Recall after Interference</NAME>
<CONT_DATA CI_END="3.293871292591585" CI_START="-2.0938712925915857" EFFECT_SIZE="0.5999999999999999" ESTIMABLE="YES" MEAN_1="1.9" MEAN_2="1.3" ORDER="25776" SD_1="1.7" SD_2="2.8" SE="1.3744493847032386" STUDY_ID="STD-Sacktor-2000" TOTAL_1="9" TOTAL_2="5" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-009.01.04" NO="4" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="9" TOTAL_2="5" WEIGHT="0.0" Z="0.0">
<NAME>Rey Auditory Verbal Learning - Delayed Recall</NAME>
<CONT_DATA CI_END="5.673962661357969" CI_START="0.1260373386420306" EFFECT_SIZE="2.9" ESTIMABLE="YES" MEAN_1="2.6" MEAN_2="-0.3" ORDER="25777" SD_1="1.7" SD_2="2.9" SE="1.4153130788313626" STUDY_ID="STD-Sacktor-2000" TOTAL_1="9" TOTAL_2="5" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-009.01.05" NO="5" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="9" TOTAL_2="5" WEIGHT="0.0" Z="0.0">
<NAME>Rey Auditory Verbal Learning - correct recognition</NAME>
<CONT_DATA CI_END="2.917995104440135" CI_START="-1.917995104440135" EFFECT_SIZE="0.5" ESTIMABLE="YES" MEAN_1="1.8" MEAN_2="1.3" ORDER="25778" SD_1="2.4" SD_2="2.1" SE="1.2336936410632908" STUDY_ID="STD-Sacktor-2000" TOTAL_1="9" TOTAL_2="5" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-009.01.06" NO="6" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="9" TOTAL_2="5" WEIGHT="0.0" Z="0.0">
<NAME>Digit Symbol</NAME>
<CONT_DATA CI_END="11.339329738203073" CI_START="-6.139329738203074" EFFECT_SIZE="2.6" ESTIMABLE="YES" MEAN_1="3.6" MEAN_2="1.0" ORDER="25779" SD_1="7.8" SD_2="8.1" SE="4.4589236369330205" STUDY_ID="STD-Sacktor-2000" TOTAL_1="9" TOTAL_2="5" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-009.01.07" NO="7" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="9" TOTAL_2="5" WEIGHT="0.0" Z="0.0">
<NAME>Grooved Pegboard - Dominant Hand</NAME>
<CONT_DATA CI_END="51.452895013216626" CI_START="-14.05289501321662" EFFECT_SIZE="18.700000000000003" ESTIMABLE="YES" MEAN_1="9.4" MEAN_2="-9.3" ORDER="25780" SD_1="20.5" SD_2="34.1" SE="16.71096778898351" STUDY_ID="STD-Sacktor-2000" TOTAL_1="9" TOTAL_2="5" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-009.01.08" NO="8" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="9" TOTAL_2="5" WEIGHT="0.0" Z="0.0">
<NAME>Grooved Pegboard - Nondominant Hand</NAME>
<CONT_DATA CI_END="42.88700631697309" CI_START="4.112993683026907" EFFECT_SIZE="23.5" ESTIMABLE="YES" MEAN_1="13.2" MEAN_2="-10.3" ORDER="25781" SD_1="26.4" SD_2="10.1" SE="9.891511512402944" STUDY_ID="STD-Sacktor-2000" TOTAL_1="9" TOTAL_2="5" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-009.01.09" NO="9" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="9" TOTAL_2="5" WEIGHT="0.0" Z="0.0">
<NAME>Mean Reaction Time - Choice</NAME>
<CONT_DATA CI_END="-43.0246398124327" CI_START="-153.9753601875673" EFFECT_SIZE="-98.5" ESTIMABLE="YES" MEAN_1="-11.7" MEAN_2="86.8" ORDER="25782" SD_1="50.1" SD_2="51.1" SE="28.304275295439027" STUDY_ID="STD-Sacktor-2000" TOTAL_1="9" TOTAL_2="5" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-009.01.10" NO="10" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="9" TOTAL_2="5" WEIGHT="0.0" Z="0.0">
<NAME>Mean Reaction Time - Sequential</NAME>
<CONT_DATA CI_END="78.10927861329746" CI_START="-141.90927861329746" EFFECT_SIZE="-31.900000000000002" ESTIMABLE="YES" MEAN_1="-25.6" MEAN_2="6.3" ORDER="25783" SD_1="133.9" SD_2="76.1" SE="56.1282143350779" STUDY_ID="STD-Sacktor-2000" TOTAL_1="9" TOTAL_2="5" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-009.01.11" NO="11" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="9" TOTAL_2="5" WEIGHT="0.0" Z="0.0">
<NAME>Timed Gait</NAME>
<CONT_DATA CI_END="1.9134846170585775" CI_START="-0.7134846170585774" EFFECT_SIZE="0.6000000000000001" ESTIMABLE="YES" MEAN_1="0.8" MEAN_2="0.2" ORDER="25784" SD_1="1.0" SD_2="1.3" SE="0.670157527086812" STUDY_ID="STD-Sacktor-2000" TOTAL_1="9" TOTAL_2="5" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-009.01.12" NO="12" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="43" TOTAL_2="42" WEIGHT="0.0" Z="0.0">
<NAME>NPZ-6</NAME>
<CONT_DATA CI_END="0.24340598444619319" CI_START="-0.30340598444619316" EFFECT_SIZE="-0.03" ESTIMABLE="YES" MEAN_1="0.16" MEAN_2="0.19" ORDER="25785" SD_1="0.71" SD_2="0.57" SE="0.13949541246818037" STUDY_ID="STD-Schiffito-2007b" TOTAL_1="43" TOTAL_2="42" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-009.01.13" NO="13" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="43" TOTAL_2="42" WEIGHT="0.0" Z="0.0">
<NAME>NPZ-8</NAME>
<CONT_DATA CI_END="0.1967225403271064" CI_START="-0.2167225403271063" EFFECT_SIZE="-0.009999999999999953" ESTIMABLE="YES" MEAN_1="0.34" MEAN_2="0.35" ORDER="25786" SD_1="0.6" SD_2="0.34" SE="0.1054726219245391" STUDY_ID="STD-Schiffito-2007b" TOTAL_1="43" TOTAL_2="42" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-009.01.14" NO="14" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="43" TOTAL_2="42" WEIGHT="0.0" Z="0.0">
<NAME>NPZ-total score</NAME>
<CONT_DATA CI_END="0.28764923080053256" CI_START="-0.16764923080053257" EFFECT_SIZE="0.06" ESTIMABLE="YES" MEAN_1="0.24" MEAN_2="0.18" ORDER="25787" SD_1="0.52" SD_2="0.55" SE="0.11614970101297811" STUDY_ID="STD-Schiffito-2007b" TOTAL_1="43" TOTAL_2="42" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.26111158541782664" CI_END="1.1689489725188689" CI_START="0.8317806714523992" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.986057382333978" ESTIMABLE="YES" EVENTS_1="43" EVENTS_2="41" I2="0.0" I2_Q="0.0" ID="CMP-009.02" LOG_CI_END="0.06779555355947608" LOG_CI_START="-0.07999117579495721" LOG_EFFECT_SIZE="-0.006097811117740571" METHOD="MH" NO="2" P_CHI2="0.6093575499072389" P_Q="0.0" P_Z="0.8715108449990889" Q="0.0" RANDOM="NO" SCALE="5.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="51" TOTAL_2="48" WEIGHT="100.0" Z="0.16173969378044065">
<NAME>Tolerability</NAME>
<GROUP_LABEL_1>Transdermal deprenyl</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Transdermal deprenyl</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.823514971077363" CI_START="0.677026468559874" EFFECT_SIZE="1.1111111111111112" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="4" LOG_CI_END="0.2609093332267657" LOG_CI_START="-0.1693943521054154" LOG_EFFECT_SIZE="0.04575749056067514" ORDER="25788" O_E="0.0" SE="0.25276251480171835" STUDY_ID="STD-Sacktor-2000" TOTAL_1="9" TOTAL_2="5" VAR="0.06388888888888888" WEIGHT="12.330754352030949"/>
<DICH_DATA CI_END="1.160687007389919" CI_START="0.8080827720530985" EFFECT_SIZE="0.9684684684684685" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="37" LOG_CI_END="0.06471512302069109" LOG_CI_START="-0.09254415209075766" LOG_EFFECT_SIZE="-0.013914514535033303" ORDER="25789" O_E="0.0" SE="0.09237487664643139" STUDY_ID="STD-Schiffito-2007b" TOTAL_1="42" TOTAL_2="43" VAR="0.008533117835443416" WEIGHT="87.66924564796905"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="15.839866608788066" CI_START="0.06617391212508966" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0238095238095237" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-009.03" LOG_CI_END="1.1997515199737272" LOG_CI_START="-1.179313189610355" LOG_EFFECT_SIZE="0.010219165181686028" METHOD="MH" NO="3" P_CHI2="1.0" P_Q="0.0" P_Z="0.9865659552249026" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="51" TOTAL_2="48" WEIGHT="100.0" Z="0.016837873831243473">
<NAME>All cause mortality</NAME>
<GROUP_LABEL_1>Transdermal deprenyl</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Transdermal deprenyl</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="25790" O_E="0.0" SE="0.0" STUDY_ID="STD-Sacktor-2000" TOTAL_1="9" TOTAL_2="5" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="15.839866608788066" CI_START="0.06617391212508966" EFFECT_SIZE="1.0238095238095237" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1997515199737272" LOG_CI_START="-1.179313189610355" LOG_EFFECT_SIZE="0.010219165181686028" ORDER="25791" O_E="0.0" SE="1.3974743869699322" STUDY_ID="STD-Schiffito-2007b" TOTAL_1="42" TOTAL_2="43" VAR="1.9529346622369879" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="11" EVENTS_2="11" I2="0.0" I2_Q="0.0" ID="CMP-009.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="4" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="342" TOTAL_2="308" WEIGHT="0.0" Z="0.0">
<NAME>Adverse effects</NAME>
<GROUP_LABEL_1>Transdermal deprenyl</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-009.04.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Number of patient experiencing any adverse effects</NAME>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="1" I2="0.0" ID="CMP-009.04.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="9" TOTAL_2="5" WEIGHT="0.0" Z="0.0">
<NAME>Itching</NAME>
<DICH_DATA CI_END="4.165870411266324" CI_START="0.009601834923098575" EFFECT_SIZE="0.2" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.6197057561188571" LOG_CI_START="-2.0176457647908945" LOG_EFFECT_SIZE="-0.6989700043360187" ORDER="25792" O_E="0.0" SE="1.5491933384829668" STUDY_ID="STD-Sacktor-2000" TOTAL_1="9" TOTAL_2="5" VAR="2.4" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="1" EVENTS_2="2" I2="0.0" ID="CMP-009.04.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="9" TOTAL_2="5" WEIGHT="0.0" Z="0.0">
<NAME>Erythema</NAME>
<DICH_DATA CI_END="2.354047161372142" CI_START="0.03277780288062909" EFFECT_SIZE="0.2777777777777778" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.37181515932241577" LOG_CI_START="-1.48442016085699" LOG_EFFECT_SIZE="-0.5563025007672873" ORDER="25793" O_E="0.0" SE="1.0903618155864083" STUDY_ID="STD-Sacktor-2000" TOTAL_1="9" TOTAL_2="5" VAR="1.1888888888888889" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="1" EVENTS_2="1" I2="0.0" ID="CMP-009.04.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="4" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="9" TOTAL_2="5" WEIGHT="0.0" Z="0.0">
<NAME>Herpes zoster</NAME>
<DICH_DATA CI_END="7.094563495150206" CI_START="0.04350401198320763" EFFECT_SIZE="0.5555555555555556" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="0.8509256799232566" LOG_CI_START="-1.3614706901298688" LOG_EFFECT_SIZE="-0.255272505103306" ORDER="25794" O_E="0.0" SE="1.2995725793078619" STUDY_ID="STD-Sacktor-2000" TOTAL_1="9" TOTAL_2="5" VAR="1.6888888888888889" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="1" I2="0.0" ID="CMP-009.04.05" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="5" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="9" TOTAL_2="5" WEIGHT="0.0" Z="0.0">
<NAME>Bell's palsy</NAME>
<DICH_DATA CI_END="4.165870411266324" CI_START="0.009601834923098575" EFFECT_SIZE="0.2" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.6197057561188571" LOG_CI_START="-2.0176457647908945" LOG_EFFECT_SIZE="-0.6989700043360187" ORDER="25795" O_E="0.0" SE="1.5491933384829668" STUDY_ID="STD-Sacktor-2000" TOTAL_1="9" TOTAL_2="5" VAR="2.4" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="1.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="3" I2="0.0" ID="CMP-009.04.06" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="6" P_CHI2="0.0" P_Z="0.0" STUDIES="2" TAU2="0.0" TOTAL_1="51" TOTAL_2="48" WEIGHT="0.0" Z="0.0">
<NAME>Headache</NAME>
<DICH_DATA CI_END="4.165870411266324" CI_START="0.009601834923098575" EFFECT_SIZE="0.2" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.6197057561188571" LOG_CI_START="-2.0176457647908945" LOG_EFFECT_SIZE="-0.6989700043360187" ORDER="25796" O_E="0.0" SE="1.5491933384829668" STUDY_ID="STD-Sacktor-2000" TOTAL_1="9" TOTAL_2="5" VAR="2.4" WEIGHT="0.0"/>
<DICH_DATA CI_END="4.139960697559786" CI_START="0.010116544936349557" EFFECT_SIZE="0.20465116279069767" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.6169962181948287" LOG_CI_START="-1.9949677850536645" LOG_EFFECT_SIZE="-0.688985783429418" ORDER="25797" O_E="0.0" SE="1.5342805849385042" STUDY_ID="STD-Schiffito-2007b" TOTAL_1="42" TOTAL_2="43" VAR="2.3540169133192386" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="2" EVENTS_2="0" I2="0.0" ID="CMP-009.04.07" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="7" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="9" TOTAL_2="5" WEIGHT="0.0" Z="0.0">
<NAME>Nausea</NAME>
<DICH_DATA CI_END="52.52676864550985" CI_START="0.17134120815119563" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.7203806845916225" LOG_CI_START="-0.7661381751522977" LOG_EFFECT_SIZE="0.47712125471966244" ORDER="25798" O_E="0.0" SE="1.4605934866804429" STUDY_ID="STD-Sacktor-2000" TOTAL_1="9" TOTAL_2="5" VAR="2.1333333333333333" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="2" EVENTS_2="0" I2="0.0" ID="CMP-009.04.08" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="8" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="9" TOTAL_2="5" WEIGHT="0.0" Z="0.0">
<NAME>Stomach ache</NAME>
<DICH_DATA CI_END="52.52676864550985" CI_START="0.17134120815119563" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.7203806845916225" LOG_CI_START="-0.7661381751522977" LOG_EFFECT_SIZE="0.47712125471966244" ORDER="25799" O_E="0.0" SE="1.4605934866804429" STUDY_ID="STD-Sacktor-2000" TOTAL_1="9" TOTAL_2="5" VAR="2.1333333333333333" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="1" EVENTS_2="0" I2="0.0" ID="CMP-009.04.09" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="9" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="9" TOTAL_2="5" WEIGHT="0.0" Z="0.0">
<NAME>Facial flush</NAME>
<DICH_DATA CI_END="37.49283370139692" CI_START="0.08641651430788716" EFFECT_SIZE="1.8" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.573948265558182" LOG_CI_START="-1.0634032553515698" LOG_EFFECT_SIZE="0.25527250510330607" ORDER="25800" O_E="0.0" SE="1.5491933384829668" STUDY_ID="STD-Sacktor-2000" TOTAL_1="9" TOTAL_2="5" VAR="2.4" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="1" EVENTS_2="0" I2="0.0" ID="CMP-009.04.10" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="10" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="9" TOTAL_2="5" WEIGHT="0.0" Z="0.0">
<NAME>Vertigo</NAME>
<DICH_DATA CI_END="37.49283370139692" CI_START="0.08641651430788716" EFFECT_SIZE="1.8" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.573948265558182" LOG_CI_START="-1.0634032553515698" LOG_EFFECT_SIZE="0.25527250510330607" ORDER="25801" O_E="0.0" SE="1.5491933384829668" STUDY_ID="STD-Sacktor-2000" TOTAL_1="9" TOTAL_2="5" VAR="2.4" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="1" EVENTS_2="0" I2="0.0" ID="CMP-009.04.11" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="11" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="9" TOTAL_2="5" WEIGHT="0.0" Z="0.0">
<NAME>Chest pain</NAME>
<DICH_DATA CI_END="37.49283370139692" CI_START="0.08641651430788716" EFFECT_SIZE="1.8" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.573948265558182" LOG_CI_START="-1.0634032553515698" LOG_EFFECT_SIZE="0.25527250510330607" ORDER="25802" O_E="0.0" SE="1.5491933384829668" STUDY_ID="STD-Sacktor-2000" TOTAL_1="9" TOTAL_2="5" VAR="2.4" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="1" EVENTS_2="0" I2="0.0" ID="CMP-009.04.12" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="12" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="42" TOTAL_2="43" WEIGHT="0.0" Z="0.0">
<NAME>Calf infection</NAME>
<DICH_DATA CI_END="73.29515452401557" CI_START="0.12856882843488493" EFFECT_SIZE="3.0697674418604652" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.865075264777015" LOG_CI_START="-0.8908643135244886" LOG_EFFECT_SIZE="0.4871054756262634" ORDER="25803" O_E="0.0" SE="1.6188525504152331" STUDY_ID="STD-Schiffito-2007b" TOTAL_1="42" TOTAL_2="43" VAR="2.620683579985905" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="1" EVENTS_2="0" I2="0.0" ID="CMP-009.04.13" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="13" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="42" TOTAL_2="43" WEIGHT="0.0" Z="0.0">
<NAME>Fatigue</NAME>
<DICH_DATA CI_END="73.29515452401557" CI_START="0.12856882843488493" EFFECT_SIZE="3.0697674418604652" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.865075264777015" LOG_CI_START="-0.8908643135244886" LOG_EFFECT_SIZE="0.4871054756262634" ORDER="25804" O_E="0.0" SE="1.6188525504152331" STUDY_ID="STD-Schiffito-2007b" TOTAL_1="42" TOTAL_2="43" VAR="2.620683579985905" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="1" I2="0.0" ID="CMP-009.04.14" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="14" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="42" TOTAL_2="43" WEIGHT="0.0" Z="0.0">
<NAME>Back pain</NAME>
<DICH_DATA CI_END="8.143906058223955" CI_START="0.014285425381653886" EFFECT_SIZE="0.34108527131782945" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9108327553376903" LOG_CI_START="-1.8451068229638132" LOG_EFFECT_SIZE="-0.46713703381306154" ORDER="25805" O_E="0.0" SE="1.6188525504152331" STUDY_ID="STD-Schiffito-2007b" TOTAL_1="42" TOTAL_2="43" VAR="2.620683579985905" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="1" I2="0.0" ID="CMP-009.04.15" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="15" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="42" TOTAL_2="43" WEIGHT="0.0" Z="0.0">
<NAME>Parasthesia</NAME>
<DICH_DATA CI_END="8.143906058223955" CI_START="0.014285425381653886" EFFECT_SIZE="0.34108527131782945" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9108327553376903" LOG_CI_START="-1.8451068229638132" LOG_EFFECT_SIZE="-0.46713703381306154" ORDER="25806" O_E="0.0" SE="1.6188525504152331" STUDY_ID="STD-Schiffito-2007b" TOTAL_1="42" TOTAL_2="43" VAR="2.620683579985905" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="1" I2="0.0" ID="CMP-009.04.16" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="16" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="42" TOTAL_2="43" WEIGHT="0.0" Z="0.0">
<NAME>Shortness of breath</NAME>
<DICH_DATA CI_END="8.143906058223955" CI_START="0.014285425381653886" EFFECT_SIZE="0.34108527131782945" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9108327553376903" LOG_CI_START="-1.8451068229638132" LOG_EFFECT_SIZE="-0.46713703381306154" ORDER="25807" O_E="0.0" SE="1.6188525504152331" STUDY_ID="STD-Schiffito-2007b" TOTAL_1="42" TOTAL_2="43" VAR="2.620683579985905" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-010" NO="10">
<NAME>High dose Transdermal selegiline (deprenyl) vs placebo</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-010.01" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="NO" TOTAL_1="85" TOTAL_2="103" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Neuropsychological test scores</NAME>
<GROUP_LABEL_1>Selegiline</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-010.01.01" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="28" TOTAL_2="34" WEIGHT="0.0" Z="0.0">
<NAME>Neurozological Z-score 6</NAME>
<CONT_DATA CI_END="0.3362410713964027" CI_START="-0.2562410713964026" EFFECT_SIZE="0.04000000000000001" ESTIMABLE="YES" MEAN_1="0.23" MEAN_2="0.19" ORDER="25808" SD_1="0.61" SD_2="0.57" SE="0.1511461811202218" STUDY_ID="STD-Schifitto-_x0028_high_x0029_2007" TOTAL_1="28" TOTAL_2="34" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-010.01.02" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="24" TOTAL_2="28" WEIGHT="0.0" Z="0.0">
<NAME>NPZ - 8</NAME>
<CONT_DATA CI_END="0.012999101045134326" CI_START="-0.4329991010451343" EFFECT_SIZE="-0.20999999999999996" ESTIMABLE="YES" MEAN_1="0.14" MEAN_2="0.35" ORDER="25809" SD_1="0.46" SD_2="0.34" SE="0.11377714223532817" STUDY_ID="STD-Schifitto-_x0028_high_x0029_2007" TOTAL_1="24" TOTAL_2="28" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-010.01.03" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="33" TOTAL_2="41" WEIGHT="0.0" Z="0.0">
<NAME>NPZ total score</NAME>
<CONT_DATA CI_END="0.30115783289903003" CI_START="-0.26115783289903" EFFECT_SIZE="0.020000000000000018" ESTIMABLE="YES" MEAN_1="0.2" MEAN_2="0.18" ORDER="25810" SD_1="0.66" SD_2="0.55" SE="0.1434505098648583" STUDY_ID="STD-Schifitto-_x0028_high_x0029_2007" TOTAL_1="33" TOTAL_2="41" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="36" EVENTS_2="37" I2="0.0" I2_Q="0.0" ID="CMP-010.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="2.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="43" TOTAL_2="43" WEIGHT="0.0" Z="0.0">
<NAME>Tolerability</NAME>
<GROUP_LABEL_1>Selegiline</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours selegiline</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.163099975905237" CI_START="0.813925222033532" EFFECT_SIZE="0.972972972972973" ESTIMABLE="YES" EVENTS_1="36" EVENTS_2="37" LOG_CI_END="0.06561704673003405" LOG_CI_START="-0.08941549332944945" LOG_EFFECT_SIZE="-0.011899223299707707" ORDER="25811" O_E="0.0" SE="0.09106688145439076" STUDY_ID="STD-Schifitto-_x0028_high_x0029_2007" TOTAL_1="43" TOTAL_2="43" VAR="0.008293176897828061" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="1" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-010.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="2.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="43" TOTAL_2="43" WEIGHT="0.0" Z="0.0">
<NAME>All cause mortality</NAME>
<GROUP_LABEL_1>Selegiline</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours selegiline</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="15.477505790203258" CI_START="0.06460989345149956" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1897009751564562" LOG_CI_START="-1.1897009751564562" LOG_EFFECT_SIZE="0.0" ORDER="25812" O_E="0.0" SE="1.3976724838434158" STUDY_ID="STD-Schifitto-_x0028_high_x0029_2007" TOTAL_1="43" TOTAL_2="43" VAR="1.9534883720930232" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="2" EVENTS_2="4" I2="0.0" I2_Q="0.0" ID="CMP-010.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="4" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="215" TOTAL_2="215" WEIGHT="0.0" Z="0.0">
<NAME>Adverse effects</NAME>
<GROUP_LABEL_1>Selegiline</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="1" EVENTS_2="0" I2="0.0" ID="CMP-010.04.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="43" TOTAL_2="43" WEIGHT="0.0" Z="0.0">
<NAME>Rash</NAME>
<DICH_DATA CI_END="71.65227627955493" CI_START="0.12560661666750186" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8552299918017103" LOG_CI_START="-0.9009874823623858" LOG_EFFECT_SIZE="0.47712125471966244" ORDER="25813" O_E="0.0" SE="1.6190157878205267" STUDY_ID="STD-Schifitto-_x0028_high_x0029_2007" TOTAL_1="43" TOTAL_2="43" VAR="2.6212121212121207" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="1" I2="0.0" ID="CMP-010.04.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="43" TOTAL_2="43" WEIGHT="0.0" Z="0.0">
<NAME>Backpain</NAME>
<DICH_DATA CI_END="7.961364031061661" CI_START="0.013956290740833538" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9009874823623856" LOG_CI_START="-1.8552299918017108" LOG_EFFECT_SIZE="-0.4771212547196625" ORDER="25814" O_E="0.0" SE="1.6190157878205267" STUDY_ID="STD-Schifitto-_x0028_high_x0029_2007" TOTAL_1="43" TOTAL_2="43" VAR="2.6212121212121207" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="1" EVENTS_2="0" I2="0.0" ID="CMP-010.04.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="43" TOTAL_2="43" WEIGHT="0.0" Z="0.0">
<NAME>Parasthesia</NAME>
<DICH_DATA CI_END="71.65227627955493" CI_START="0.12560661666750186" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8552299918017103" LOG_CI_START="-0.9009874823623858" LOG_EFFECT_SIZE="0.47712125471966244" ORDER="25815" O_E="0.0" SE="1.6190157878205267" STUDY_ID="STD-Schifitto-_x0028_high_x0029_2007" TOTAL_1="43" TOTAL_2="43" VAR="2.6212121212121207" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="2" I2="0.0" ID="CMP-010.04.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="4" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="43" TOTAL_2="43" WEIGHT="0.0" Z="0.0">
<NAME>Headache</NAME>
<DICH_DATA CI_END="4.047236689258822" CI_START="0.009883286565907583" EFFECT_SIZE="0.2" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.6071586034113897" LOG_CI_START="-2.0050986120834273" LOG_EFFECT_SIZE="-0.6989700043360187" ORDER="25816" O_E="0.0" SE="1.5344528192634188" STUDY_ID="STD-Schifitto-_x0028_high_x0029_2007" TOTAL_1="43" TOTAL_2="43" VAR="2.354545454545454" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="1" I2="0.0" ID="CMP-010.04.05" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="5" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="43" TOTAL_2="43" WEIGHT="0.0" Z="0.0">
<NAME>Shortness of breath</NAME>
<DICH_DATA CI_END="7.961364031061661" CI_START="0.013956290740833538" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9009874823623856" LOG_CI_START="-1.8552299918017108" LOG_EFFECT_SIZE="-0.4771212547196625" ORDER="25817" O_E="0.0" SE="1.6190157878205267" STUDY_ID="STD-Schifitto-_x0028_high_x0029_2007" TOTAL_1="43" TOTAL_2="43" VAR="2.6212121212121207" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-011" NO="11">
<NAME>Low dose (50mg) CPI-1189 vs Placebo</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-011.01" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="NO" TOTAL_1="315" TOTAL_2="315" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Neuropsychological test scores</NAME>
<GROUP_LABEL_1>CPI-1189</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours CPI-1189</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-011.01.01" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="21" TOTAL_2="21" WEIGHT="0.0" Z="0.0">
<NAME>Rey Auditory Verbal Learning - Total Number Correct</NAME>
<CONT_DATA CI_END="2.791724857791713" CI_START="-7.991724857791713" EFFECT_SIZE="-2.6" ESTIMABLE="YES" MEAN_1="-1.8" MEAN_2="0.8" ORDER="25818" SD_1="8.4" SD_2="9.4" SE="2.750930578480498" STUDY_ID="STD-Clifford-2002" TOTAL_1="21" TOTAL_2="21" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-011.01.02" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="21" TOTAL_2="21" WEIGHT="0.0" Z="0.0">
<NAME>Rey Auditory Verbal Learning - Number Correct &#8211; Trial 5</NAME>
<CONT_DATA CI_END="-0.0075122724425942256" CI_START="-2.792487727557406" EFFECT_SIZE="-1.4" ESTIMABLE="YES" MEAN_1="-0.8" MEAN_2="0.6" ORDER="25819" SD_1="2.2" SD_2="2.4" SE="0.7104659772022196" STUDY_ID="STD-Clifford-2002" TOTAL_1="21" TOTAL_2="21" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-011.01.03" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="21" TOTAL_2="21" WEIGHT="0.0" Z="0.0">
<NAME>Rey Auditory Verbal Learning - Recall after Interference</NAME>
<CONT_DATA CI_END="0.3044649254182097" CI_START="-3.30446492541821" EFFECT_SIZE="-1.5" ESTIMABLE="YES" MEAN_1="-0.8" MEAN_2="0.7" ORDER="25820" SD_1="2.2" SD_2="3.6" SE="0.9206622874969126" STUDY_ID="STD-Clifford-2002" TOTAL_1="21" TOTAL_2="21" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-011.01.04" NO="4" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="21" TOTAL_2="21" WEIGHT="0.0" Z="0.0">
<NAME>Rey Auditory Verbal Learning - Delayed Recall</NAME>
<CONT_DATA CI_END="1.317866966947326" CI_START="-2.917866966947326" EFFECT_SIZE="-0.8" ESTIMABLE="YES" MEAN_1="-0.6" MEAN_2="0.2" ORDER="25821" SD_1="3.4" SD_2="3.6" SE="1.0805642265127269" STUDY_ID="STD-Clifford-2002" TOTAL_1="21" TOTAL_2="21" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-011.01.05" NO="5" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="21" TOTAL_2="21" WEIGHT="0.0" Z="0.0">
<NAME>Mean Reaction Time - Choice</NAME>
<CONT_DATA CI_END="68.21689197822104" CI_START="-24.216891978221035" EFFECT_SIZE="22.0" ESTIMABLE="YES" MEAN_1="11.6" MEAN_2="-10.4" ORDER="25822" SD_1="83.9" SD_2="68.1" SE="23.58048022452146" STUDY_ID="STD-Clifford-2002" TOTAL_1="21" TOTAL_2="21" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-011.01.06" NO="6" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="21" TOTAL_2="21" WEIGHT="0.0" Z="0.0">
<NAME>Mean Reaction Time - Sequential</NAME>
<CONT_DATA CI_END="47.67190611682273" CI_START="-52.47190611682273" EFFECT_SIZE="-2.3999999999999986" ESTIMABLE="YES" MEAN_1="48.9" MEAN_2="51.3" ORDER="25823" SD_1="88.1" SD_2="77.1" SE="25.547360314670847" STUDY_ID="STD-Clifford-2002" TOTAL_1="21" TOTAL_2="21" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-011.01.07" NO="7" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="21" TOTAL_2="21" WEIGHT="0.0" Z="0.0">
<NAME>Trail Making - Part A</NAME>
<CONT_DATA CI_END="0.09563644977445684" CI_START="-0.09563644977445684" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="0.1" MEAN_2="0.1" ORDER="25824" SD_1="0.1" SD_2="0.2" SE="0.048795003647426664" STUDY_ID="STD-Clifford-2002" TOTAL_1="21" TOTAL_2="21" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-011.01.08" NO="8" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="21" TOTAL_2="21" WEIGHT="0.0" Z="0.0">
<NAME>Trail Making - Part B</NAME>
<CONT_DATA CI_END="0.09563644977445684" CI_START="-0.09563644977445684" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="0.1" MEAN_2="0.1" ORDER="25825" SD_1="0.2" SD_2="0.1" SE="0.048795003647426664" STUDY_ID="STD-Clifford-2002" TOTAL_1="21" TOTAL_2="21" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-011.01.09" NO="9" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="21" TOTAL_2="21" WEIGHT="0.0" Z="0.0">
<NAME>Digit Symbol</NAME>
<CONT_DATA CI_END="3.274600781216882" CI_START="-8.474600781216882" EFFECT_SIZE="-2.5999999999999996" ESTIMABLE="YES" MEAN_1="5.0" MEAN_2="7.6" ORDER="25826" SD_1="6.5" SD_2="12.1" SE="2.9973003726369374" STUDY_ID="STD-Clifford-2002" TOTAL_1="21" TOTAL_2="21" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-011.01.10" NO="10" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="21" TOTAL_2="21" WEIGHT="0.0" Z="0.0">
<NAME>Grooved Pegboard - Dominant Hand</NAME>
<CONT_DATA CI_END="9.055474317858756" CI_START="-13.855474317858757" EFFECT_SIZE="-2.4000000000000004" ESTIMABLE="YES" MEAN_1="3.3" MEAN_2="5.7" ORDER="25827" SD_1="21.7" SD_2="15.7" SE="5.844737152426307" STUDY_ID="STD-Clifford-2002" TOTAL_1="21" TOTAL_2="21" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-011.01.11" NO="11" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="21" TOTAL_2="21" WEIGHT="0.0" Z="0.0">
<NAME>Grooved Pegboard - Nondominant Hand</NAME>
<CONT_DATA CI_END="15.368695057987622" CI_START="-4.568695057987624" EFFECT_SIZE="5.3999999999999995" ESTIMABLE="YES" MEAN_1="6.1" MEAN_2="0.7" ORDER="25828" SD_1="11.8" SD_2="20.1" SE="5.0861623665635785" STUDY_ID="STD-Clifford-2002" TOTAL_1="21" TOTAL_2="21" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-011.01.12" NO="12" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="21" TOTAL_2="21" WEIGHT="0.0" Z="0.0">
<NAME>Finger Tapping - Dominant Hand</NAME>
<CONT_DATA CI_END="2.695930433322058" CI_START="-6.295930433322058" EFFECT_SIZE="-1.7999999999999998" ESTIMABLE="YES" MEAN_1="0.5" MEAN_2="2.3" ORDER="25829" SD_1="5.9" SD_2="8.7" SE="2.2938842084780044" STUDY_ID="STD-Clifford-2002" TOTAL_1="21" TOTAL_2="21" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-011.01.13" NO="13" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="21" TOTAL_2="21" WEIGHT="0.0" Z="0.0">
<NAME>Finger Tapping - Nondominant Hand</NAME>
<CONT_DATA CI_END="2.255228541069398" CI_START="-5.455228541069398" EFFECT_SIZE="-1.6" ESTIMABLE="YES" MEAN_1="1.5" MEAN_2="3.1" ORDER="25830" SD_1="5.0" SD_2="7.5" SE="1.9669894811736077" STUDY_ID="STD-Clifford-2002" TOTAL_1="21" TOTAL_2="21" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-011.01.14" NO="14" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="21" TOTAL_2="21" WEIGHT="0.0" Z="0.0">
<NAME>Timed Gait</NAME>
<CONT_DATA CI_END="1.3419097944972405" CI_START="-0.5419097944972404" EFFECT_SIZE="0.39999999999999997" ESTIMABLE="YES" MEAN_1="0.6" MEAN_2="0.2" ORDER="25831" SD_1="1.4" SD_2="1.7" SE="0.4805750523616274" STUDY_ID="STD-Clifford-2002" TOTAL_1="21" TOTAL_2="21" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-011.01.15" NO="15" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="21" TOTAL_2="21" WEIGHT="0.0" Z="0.0">
<NAME>Composite neuropsychological Z score</NAME>
<CONT_DATA CI_END="0.7626274249283278" CI_START="-0.16262742492832782" EFFECT_SIZE="0.3" ESTIMABLE="YES" MEAN_1="0.6" MEAN_2="0.3" ORDER="25832" SD_1="0.9" SD_2="0.6" SE="0.23603873774083295" STUDY_ID="STD-Clifford-2002" TOTAL_1="21" TOTAL_2="21" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="19" EVENTS_2="16" I2="0.0" I2_Q="0.0" ID="CMP-011.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="5.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="21" TOTAL_2="21" WEIGHT="0.0" Z="0.0">
<NAME>Tolerability</NAME>
<GROUP_LABEL_1>CPI-1189</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours CPI-1189</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.5656356845684818" CI_START="0.9006924560413716" EFFECT_SIZE="1.1875" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="16" LOG_CI_END="0.19469071136900812" LOG_CI_START="-0.04542347477519978" LOG_EFFECT_SIZE="0.07463361829690418" ORDER="25833" O_E="0.0" SE="0.1410442615254984" STUDY_ID="STD-Clifford-2002" TOTAL_1="21" TOTAL_2="21" VAR="0.019893483709273185" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-011.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="21" TOTAL_2="21" WEIGHT="0.0" Z="0.0">
<NAME>All cause mortality</NAME>
<GROUP_LABEL_1>CPI-1189</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours CPI-1189</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="7.7443737981982546" CI_START="0.014347333174563614" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8889863069264973" LOG_CI_START="-1.8432288163658224" LOG_EFFECT_SIZE="-0.4771212547196625" ORDER="25834" O_E="0.0" SE="1.6049166881048922" STUDY_ID="STD-Clifford-2002" TOTAL_1="21" TOTAL_2="21" VAR="2.5757575757575757" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="24" EVENTS_2="40" I2="0.0" I2_Q="0.0" ID="CMP-011.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="4" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="210" TOTAL_2="210" WEIGHT="0.0" Z="0.0">
<NAME>Adverse effects</NAME>
<GROUP_LABEL_1>CPI-1189</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours CPI-1189</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="12" EVENTS_2="20" I2="0.0" ID="CMP-011.04.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="21" TOTAL_2="21" WEIGHT="0.0" Z="0.0">
<NAME>Number of patient experiencing any adverse effects</NAME>
<DICH_DATA CI_END="0.8796072089086509" CI_START="0.40927358979545014" EFFECT_SIZE="0.6" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="20" LOG_CI_END="-0.05571121999289999" LOG_CI_START="-0.38798627923981277" LOG_EFFECT_SIZE="-0.22184874961635637" ORDER="25835" O_E="0.0" SE="0.19518001458970666" STUDY_ID="STD-Clifford-2002" TOTAL_1="21" TOTAL_2="21" VAR="0.0380952380952381" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="1" EVENTS_2="2" I2="0.0" ID="CMP-011.04.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="21" TOTAL_2="21" WEIGHT="0.0" Z="0.0">
<NAME>Abdominal pain</NAME>
<DICH_DATA CI_END="5.103130184031393" CI_START="0.04898953994595213" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.707836647596448" LOG_CI_START="-1.3098966389244104" LOG_EFFECT_SIZE="-0.3010299956639812" ORDER="25836" O_E="0.0" SE="1.185226520443204" STUDY_ID="STD-Clifford-2002" TOTAL_1="21" TOTAL_2="21" VAR="1.4047619047619047" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="2" EVENTS_2="3" I2="0.0" ID="CMP-011.04.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="21" TOTAL_2="21" WEIGHT="0.0" Z="0.0">
<NAME>Diarhea</NAME>
<DICH_DATA CI_END="3.590847863778261" CI_START="0.12377144933586896" EFFECT_SIZE="0.6666666666666666" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.5551970054264799" LOG_CI_START="-0.9073795235378426" LOG_EFFECT_SIZE="-0.17609125905568127" ORDER="25837" O_E="0.0" SE="0.8591246929842244" STUDY_ID="STD-Clifford-2002" TOTAL_1="21" TOTAL_2="21" VAR="0.7380952380952379" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="1" I2="0.0" ID="CMP-011.04.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="4" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="21" TOTAL_2="21" WEIGHT="0.0" Z="0.0">
<NAME>Fatigue</NAME>
<DICH_DATA CI_END="7.7443737981982546" CI_START="0.014347333174563614" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8889863069264973" LOG_CI_START="-1.8432288163658224" LOG_EFFECT_SIZE="-0.4771212547196625" ORDER="25838" O_E="0.0" SE="1.6049166881048922" STUDY_ID="STD-Clifford-2002" TOTAL_1="21" TOTAL_2="21" VAR="2.5757575757575757" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="1" EVENTS_2="1" I2="0.0" ID="CMP-011.04.05" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="5" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="21" TOTAL_2="21" WEIGHT="0.0" Z="0.0">
<NAME>Fever</NAME>
<DICH_DATA CI_END="14.954425656523698" CI_START="0.06686983659340748" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1747697380632693" LOG_CI_START="-1.1747697380632693" LOG_EFFECT_SIZE="0.0" ORDER="25839" O_E="0.0" SE="1.3801311186847085" STUDY_ID="STD-Clifford-2002" TOTAL_1="21" TOTAL_2="21" VAR="1.9047619047619047" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="2" EVENTS_2="2" I2="0.0" ID="CMP-011.04.06" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="6" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="21" TOTAL_2="21" WEIGHT="0.0" Z="0.0">
<NAME>Headache</NAME>
<DICH_DATA CI_END="6.451402929711635" CI_START="0.15500504477786478" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.8096541670972182" LOG_CI_START="-0.8096541670972182" LOG_EFFECT_SIZE="0.0" ORDER="25840" O_E="0.0" SE="0.9511897312113418" STUDY_ID="STD-Clifford-2002" TOTAL_1="21" TOTAL_2="21" VAR="0.9047619047619047" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="3" EVENTS_2="5" I2="0.0" ID="CMP-011.04.07" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="7" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="21" TOTAL_2="21" WEIGHT="0.0" Z="0.0">
<NAME>Rash</NAME>
<DICH_DATA CI_END="2.195588890534318" CI_START="0.16396512186413478" EFFECT_SIZE="0.6" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="5" LOG_CI_END="0.34155102462740894" LOG_CI_START="-0.7852485238601217" LOG_EFFECT_SIZE="-0.22184874961635637" ORDER="25841" O_E="0.0" SE="0.6618876325292973" STUDY_ID="STD-Clifford-2002" TOTAL_1="21" TOTAL_2="21" VAR="0.4380952380952381" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="1" EVENTS_2="2" I2="0.0" ID="CMP-011.04.08" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="8" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="21" TOTAL_2="21" WEIGHT="0.0" Z="0.0">
<NAME>Upper respiratory tract infection</NAME>
<DICH_DATA CI_END="5.103130184031393" CI_START="0.04898953994595213" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.707836647596448" LOG_CI_START="-1.3098966389244104" LOG_EFFECT_SIZE="-0.3010299956639812" ORDER="25842" O_E="0.0" SE="1.185226520443204" STUDY_ID="STD-Clifford-2002" TOTAL_1="21" TOTAL_2="21" VAR="1.4047619047619047" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="2" I2="0.0" ID="CMP-011.04.09" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="9" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="21" TOTAL_2="21" WEIGHT="0.0" Z="0.0">
<NAME>Weight decrease</NAME>
<DICH_DATA CI_END="3.930879612644028" CI_START="0.010175839491836992" EFFECT_SIZE="0.2" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.5944897432947773" LOG_CI_START="-1.9924297519668148" LOG_EFFECT_SIZE="-0.6989700043360187" ORDER="25843" O_E="0.0" SE="1.5195693169746844" STUDY_ID="STD-Clifford-2002" TOTAL_1="21" TOTAL_2="21" VAR="2.309090909090909" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="2" EVENTS_2="2" I2="0.0" ID="CMP-011.04.10" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="10" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="21" TOTAL_2="21" WEIGHT="0.0" Z="0.0">
<NAME>Nausea</NAME>
<DICH_DATA CI_END="6.451402929711635" CI_START="0.15500504477786478" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.8096541670972182" LOG_CI_START="-0.8096541670972182" LOG_EFFECT_SIZE="0.0" ORDER="25844" O_E="0.0" SE="0.9511897312113418" STUDY_ID="STD-Clifford-2002" TOTAL_1="21" TOTAL_2="21" VAR="0.9047619047619047" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-012" NO="12">
<NAME>High dose (100mg) CPI-1189 vs Placebo</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-012.01" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="NO" TOTAL_1="330" TOTAL_2="315" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Neuropsychological test scores</NAME>
<GROUP_LABEL_1>CPI-1189</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours CPI-1189</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-012.01.01" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="22" TOTAL_2="21" WEIGHT="0.0" Z="0.0">
<NAME>Rey Auditory Verbal Learning - Total Number Correct</NAME>
<CONT_DATA CI_END="6.020309932598908" CI_START="-4.820309932598908" EFFECT_SIZE="0.5999999999999999" ESTIMABLE="YES" MEAN_1="1.4" MEAN_2="0.8" ORDER="25845" SD_1="8.7" SD_2="9.4" SE="2.7655150683143264" STUDY_ID="STD-Clifford-_x0028_high_x0029_-2002" TOTAL_1="22" TOTAL_2="21" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-012.01.02" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="22" TOTAL_2="21" WEIGHT="0.0" Z="0.0">
<NAME>Rey Auditory Verbal Learning - Number Correct &#8211; Trial 5</NAME>
<CONT_DATA CI_END="1.0795410162946704" CI_START="-1.0795410162946704" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="0.6" MEAN_2="0.6" ORDER="25846" SD_1="0.8" SD_2="2.4" SE="0.550796353815658" STUDY_ID="STD-Clifford-_x0028_high_x0029_-2002" TOTAL_1="22" TOTAL_2="21" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-012.01.03" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="22" TOTAL_2="21" WEIGHT="0.0" Z="0.0">
<NAME>Rey Auditory Verbal Learning - Recall after Interference</NAME>
<CONT_DATA CI_END="2.0855061705753664" CI_START="-1.8855061705753662" EFFECT_SIZE="0.10000000000000009" ESTIMABLE="YES" MEAN_1="0.8" MEAN_2="0.7" ORDER="25847" SD_1="3.0" SD_2="3.6" SE="1.0130319670344892" STUDY_ID="STD-Clifford-_x0028_high_x0029_-2002" TOTAL_1="22" TOTAL_2="21" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-012.01.04" NO="4" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="22" TOTAL_2="21" WEIGHT="0.0" Z="0.0">
<NAME>Rey Auditory Verbal Learning - Delayed Recall</NAME>
<CONT_DATA CI_END="2.433826545087105" CI_START="-1.433826545087105" EFFECT_SIZE="0.49999999999999994" ESTIMABLE="YES" MEAN_1="0.7" MEAN_2="0.2" ORDER="25848" SD_1="2.8" SD_2="3.6" SE="0.9866643266615519" STUDY_ID="STD-Clifford-_x0028_high_x0029_-2002" TOTAL_1="22" TOTAL_2="21" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-012.01.05" NO="5" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="22" TOTAL_2="21" WEIGHT="0.0" Z="0.0">
<NAME>Mean Reaction Time - Choice</NAME>
<CONT_DATA CI_END="69.77928430210243" CI_START="-21.37928430210242" EFFECT_SIZE="24.200000000000003" ESTIMABLE="YES" MEAN_1="13.8" MEAN_2="-10.4" ORDER="25849" SD_1="83.9" SD_2="68.1" SE="23.255164207927287" STUDY_ID="STD-Clifford-_x0028_high_x0029_-2002" TOTAL_1="22" TOTAL_2="21" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-012.01.06" NO="6" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="22" TOTAL_2="21" WEIGHT="0.0" Z="0.0">
<NAME>Mean Reaction Time - Sequential</NAME>
<CONT_DATA CI_END="31.844362771233104" CI_START="-82.0443627712331" EFFECT_SIZE="-25.099999999999998" ESTIMABLE="YES" MEAN_1="26.2" MEAN_2="51.3" ORDER="25850" SD_1="111.1" SD_2="77.1" SE="29.053780181882406" STUDY_ID="STD-Clifford-_x0028_high_x0029_-2002" TOTAL_1="22" TOTAL_2="21" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-012.01.07" NO="7" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="22" TOTAL_2="21" WEIGHT="0.0" Z="0.0">
<NAME>Trail Making - Part A</NAME>
<CONT_DATA CI_END="0.09520074614276836" CI_START="-0.09520074614276836" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="0.1" MEAN_2="0.1" ORDER="25851" SD_1="0.1" SD_2="0.2" SE="0.04857270179130825" STUDY_ID="STD-Clifford-_x0028_high_x0029_-2002" TOTAL_1="22" TOTAL_2="21" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-012.01.08" NO="8" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="22" TOTAL_2="21" WEIGHT="0.0" Z="0.0">
<NAME>Trail Making - Part B</NAME>
<CONT_DATA CI_END="0.09388150344009555" CI_START="-0.09388150344009555" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="0.1" MEAN_2="0.1" ORDER="25852" SD_1="0.2" SD_2="0.1" SE="0.04789960641145494" STUDY_ID="STD-Clifford-_x0028_high_x0029_-2002" TOTAL_1="22" TOTAL_2="21" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-012.01.09" NO="9" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="22" TOTAL_2="21" WEIGHT="0.0" Z="0.0">
<NAME>Digit Symbol</NAME>
<CONT_DATA CI_END="4.750505070811662" CI_START="-6.750505070811662" EFFECT_SIZE="-1.0" ESTIMABLE="YES" MEAN_1="6.6" MEAN_2="7.6" ORDER="25853" SD_1="6.0" SD_2="12.1" SE="2.93398507124157" STUDY_ID="STD-Clifford-_x0028_high_x0029_-2002" TOTAL_1="22" TOTAL_2="21" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-012.01.10" NO="10" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="22" TOTAL_2="21" WEIGHT="0.0" Z="0.0">
<NAME>Grooved Pegboard - Dominant Hand</NAME>
<CONT_DATA CI_END="12.284371701215559" CI_START="-7.084371701215557" EFFECT_SIZE="2.6000000000000005" ESTIMABLE="YES" MEAN_1="8.3" MEAN_2="5.7" ORDER="25854" SD_1="16.7" SD_2="15.7" SE="4.941096763820481" STUDY_ID="STD-Clifford-_x0028_high_x0029_-2002" TOTAL_1="22" TOTAL_2="21" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-012.01.11" NO="11" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="22" TOTAL_2="21" WEIGHT="0.0" Z="0.0">
<NAME>Grooved Pegboard - Nondominant Hand</NAME>
<CONT_DATA CI_END="22.017428555219908" CI_START="0.9825714447800902" EFFECT_SIZE="11.5" ESTIMABLE="YES" MEAN_1="12.2" MEAN_2="0.7" ORDER="25855" SD_1="14.5" SD_2="20.1" SE="5.366133581116818" STUDY_ID="STD-Clifford-_x0028_high_x0029_-2002" TOTAL_1="22" TOTAL_2="21" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-012.01.12" NO="12" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="22" TOTAL_2="21" WEIGHT="0.0" Z="0.0">
<NAME>Finger Tapping - Dominant Hand</NAME>
<CONT_DATA CI_END="1.9851425292374172" CI_START="-7.585142529237417" EFFECT_SIZE="-2.8" ESTIMABLE="YES" MEAN_1="-0.5" MEAN_2="2.3" ORDER="25856" SD_1="7.2" SD_2="8.7" SE="2.441444111719404" STUDY_ID="STD-Clifford-_x0028_high_x0029_-2002" TOTAL_1="22" TOTAL_2="21" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-012.01.13" NO="13" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="22" TOTAL_2="21" WEIGHT="0.0" Z="0.0">
<NAME>Finger Tapping - Nondominant Hand</NAME>
<CONT_DATA CI_END="1.7980079923100556" CI_START="-5.998007992310056" EFFECT_SIZE="-2.1" ESTIMABLE="YES" MEAN_1="1.0" MEAN_2="3.1" ORDER="25857" SD_1="5.3" SD_2="7.5" SE="1.9888161328764433" STUDY_ID="STD-Clifford-_x0028_high_x0029_-2002" TOTAL_1="22" TOTAL_2="21" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-012.01.14" NO="14" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="22" TOTAL_2="21" WEIGHT="0.0" Z="0.0">
<NAME>Timed Gait</NAME>
<CONT_DATA CI_END="1.8051365644540356" CI_START="-0.6051365644540354" EFFECT_SIZE="0.6000000000000001" ESTIMABLE="YES" MEAN_1="0.8" MEAN_2="0.2" ORDER="25858" SD_1="2.3" SD_2="1.7" SE="0.6148768926163944" STUDY_ID="STD-Clifford-_x0028_high_x0029_-2002" TOTAL_1="22" TOTAL_2="21" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-012.01.15" NO="15" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="22" TOTAL_2="21" WEIGHT="0.0" Z="0.0">
<NAME>Composite neuropsychological Z score</NAME>
<CONT_DATA CI_END="0.9214322117643733" CI_START="0.07856778823562671" EFFECT_SIZE="0.5" ESTIMABLE="YES" MEAN_1="0.8" MEAN_2="0.3" ORDER="25859" SD_1="0.8" SD_2="0.6" SE="0.21502038562370368" STUDY_ID="STD-Clifford-_x0028_high_x0029_-2002" TOTAL_1="22" TOTAL_2="21" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="20" EVENTS_2="16" I2="0.0" I2_Q="0.0" ID="CMP-012.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="5.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="22" TOTAL_2="21" WEIGHT="0.0" Z="0.0">
<NAME>Tolerability</NAME>
<GROUP_LABEL_1>CPI-1189</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours CPI-1189</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.5679995921370442" CI_START="0.9079612382419795" EFFECT_SIZE="1.1931818181818181" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="16" LOG_CI_END="0.19534594538116573" LOG_CI_START="-0.04193269154162683" LOG_EFFECT_SIZE="0.07670662691976943" ORDER="25860" O_E="0.0" SE="0.139378645876644" STUDY_ID="STD-Clifford-_x0028_high_x0029_-2002" TOTAL_1="22" TOTAL_2="21" VAR="0.01942640692640693" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-012.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="22" TOTAL_2="21" WEIGHT="0.0" Z="0.0">
<NAME>All cause mortality</NAME>
<GROUP_LABEL_1>CPI-1189</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours CPI-1189</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="7.416604723905314" CI_START="0.01370698844745378" EFFECT_SIZE="0.3188405797101449" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8702051334271592" LOG_CI_START="-1.8630579532572575" LOG_EFFECT_SIZE="-0.49642640991504916" ORDER="25861" O_E="0.0" SE="1.6055322669889123" STUDY_ID="STD-Clifford-_x0028_high_x0029_-2002" TOTAL_1="22" TOTAL_2="21" VAR="2.5777338603425557" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="40" EVENTS_2="40" I2="0.0" I2_Q="0.0" ID="CMP-012.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="4" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="220" TOTAL_2="210" WEIGHT="0.0" Z="0.0">
<NAME>Adverse effects</NAME>
<GROUP_LABEL_1>CPI-1189</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours CPI-1189</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="20" EVENTS_2="20" I2="0.0" ID="CMP-012.04.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="22" TOTAL_2="21" WEIGHT="0.0" Z="0.0">
<NAME>Number of patient experiencing any adverse effects</NAME>
<DICH_DATA CI_END="1.1236676932425589" CI_START="0.8108776556208268" EFFECT_SIZE="0.9545454545454546" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="20" LOG_CI_END="0.050637894570257795" LOG_CI_START="-0.09104466674683169" LOG_EFFECT_SIZE="-0.02020338608828695" ORDER="25862" O_E="0.0" SE="0.08322503785764794" STUDY_ID="STD-Clifford-_x0028_high_x0029_-2002" TOTAL_1="22" TOTAL_2="21" VAR="0.006926406926406933" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="2" I2="0.0" ID="CMP-012.04.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="22" TOTAL_2="21" WEIGHT="0.0" Z="0.0">
<NAME>Abdominal pain</NAME>
<DICH_DATA CI_END="3.7647659960801065" CI_START="0.009721016800319015" EFFECT_SIZE="0.19130434782608696" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.5757379872380594" LOG_CI_START="-2.0122883063008703" LOG_EFFECT_SIZE="-0.7182751595314054" ORDER="25863" O_E="0.0" SE="1.5202194557615323" STUDY_ID="STD-Clifford-_x0028_high_x0029_-2002" TOTAL_1="22" TOTAL_2="21" VAR="2.311067193675889" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="3" EVENTS_2="3" I2="0.0" ID="CMP-012.04.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="22" TOTAL_2="21" WEIGHT="0.0" Z="0.0">
<NAME>Diarhea</NAME>
<DICH_DATA CI_END="4.211744319360134" CI_START="0.216337212257893" EFFECT_SIZE="0.9545454545454546" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.624461998776173" LOG_CI_START="-0.664868770952747" LOG_EFFECT_SIZE="-0.02020338608828695" ORDER="25864" O_E="0.0" SE="0.75735927642901" STUDY_ID="STD-Clifford-_x0028_high_x0029_-2002" TOTAL_1="22" TOTAL_2="21" VAR="0.5735930735930737" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="2" EVENTS_2="1" I2="0.0" ID="CMP-012.04.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="4" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="22" TOTAL_2="21" WEIGHT="0.0" Z="0.0">
<NAME>Fatigue</NAME>
<DICH_DATA CI_END="19.51956795075902" CI_START="0.18671663780508174" EFFECT_SIZE="1.9090909090909092" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.2904702006934885" LOG_CI_START="-0.7288169815421001" LOG_EFFECT_SIZE="0.2808266095756942" ORDER="25865" O_E="0.0" SE="1.1861392864779443" STUDY_ID="STD-Clifford-_x0028_high_x0029_-2002" TOTAL_1="22" TOTAL_2="21" VAR="1.406926406926407" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="1" EVENTS_2="1" I2="0.0" ID="CMP-012.04.05" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="5" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="22" TOTAL_2="21" WEIGHT="0.0" Z="0.0">
<NAME>Fever</NAME>
<DICH_DATA CI_END="14.296628932753293" CI_START="0.06373229864740675" EFFECT_SIZE="0.9545454545454546" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1552336452625687" LOG_CI_START="-1.1956404174391424" LOG_EFFECT_SIZE="-0.02020338608828695" ORDER="25866" O_E="0.0" SE="1.3809150614452748" STUDY_ID="STD-Clifford-_x0028_high_x0029_-2002" TOTAL_1="22" TOTAL_2="21" VAR="1.906926406926407" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="4" EVENTS_2="2" I2="0.0" ID="CMP-012.04.06" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="6" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="22" TOTAL_2="21" WEIGHT="0.0" Z="0.0">
<NAME>Headache</NAME>
<DICH_DATA CI_END="9.34832805573884" CI_START="0.38986951222108157" EFFECT_SIZE="1.9090909090909092" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="2" LOG_CI_END="0.9707339444451835" LOG_CI_START="-0.4090807252937951" LOG_EFFECT_SIZE="0.2808266095756942" ORDER="25867" O_E="0.0" SE="0.8105099671974472" STUDY_ID="STD-Clifford-_x0028_high_x0029_-2002" TOTAL_1="22" TOTAL_2="21" VAR="0.6569264069264069" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="3" EVENTS_2="5" I2="0.0" ID="CMP-012.04.07" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="7" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="22" TOTAL_2="21" WEIGHT="0.0" Z="0.0">
<NAME>Rash</NAME>
<DICH_DATA CI_END="2.1025083125554893" CI_START="0.1560120009832127" EFFECT_SIZE="0.5727272727272728" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="5" LOG_CI_END="0.32273772151624847" LOG_CI_START="-0.8068419929255352" LOG_EFFECT_SIZE="-0.24205213570464335" ORDER="25868" O_E="0.0" SE="0.6635207157728689" STUDY_ID="STD-Clifford-_x0028_high_x0029_-2002" TOTAL_1="22" TOTAL_2="21" VAR="0.44025974025974024" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="3" EVENTS_2="2" I2="0.0" ID="CMP-012.04.08" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="8" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="22" TOTAL_2="21" WEIGHT="0.0" Z="0.0">
<NAME>Upper respiratory tract infection</NAME>
<DICH_DATA CI_END="7.731212717431891" CI_START="0.26517228030250284" EFFECT_SIZE="1.4318181818181819" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.8882476226608089" LOG_CI_START="-0.5764718767260204" LOG_EFFECT_SIZE="0.1558878729673943" ORDER="25869" O_E="0.0" SE="0.8603834844182797" STUDY_ID="STD-Clifford-_x0028_high_x0029_-2002" TOTAL_1="22" TOTAL_2="21" VAR="0.7402597402597402" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="1" EVENTS_2="2" I2="0.0" ID="CMP-012.04.09" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="9" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="22" TOTAL_2="21" WEIGHT="0.0" Z="0.0">
<NAME>Weight decrease</NAME>
<DICH_DATA CI_END="4.879891987689756" CI_START="0.04667915945127044" EFFECT_SIZE="0.4772727272727273" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.6884102093655262" LOG_CI_START="-1.3308769728700625" LOG_EFFECT_SIZE="-0.3212333817522681" ORDER="25870" O_E="0.0" SE="1.1861392864779443" STUDY_ID="STD-Clifford-_x0028_high_x0029_-2002" TOTAL_1="22" TOTAL_2="21" VAR="1.406926406926407" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="3" EVENTS_2="2" I2="0.0" ID="CMP-012.04.10" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="10" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="22" TOTAL_2="21" WEIGHT="0.0" Z="0.0">
<NAME>Nausea</NAME>
<DICH_DATA CI_END="7.731212717431891" CI_START="0.26517228030250284" EFFECT_SIZE="1.4318181818181819" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.8882476226608089" LOG_CI_START="-0.5764718767260204" LOG_EFFECT_SIZE="0.1558878729673943" ORDER="25871" O_E="0.0" SE="0.8603834844182797" STUDY_ID="STD-Clifford-_x0028_high_x0029_-2002" TOTAL_1="22" TOTAL_2="21" VAR="0.7402597402597402" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-013" NO="13">
<NAME>Low dose nimodipine vs Placebo</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-013.01" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="0" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="0" TOTAL_2="0" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Neuropsychological test scores</NAME>
<GROUP_LABEL_1>Nimodipine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours nimodipine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-013.01.01" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Rey Auditory Verbal Learning - Total Number Correct</NAME>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-013.01.02" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Rey Auditory Verbal Learning - Number Correct &#8211; Trial 5</NAME>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-013.01.03" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Rey Auditory Verbal Learning - Recall after Interference</NAME>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-013.01.04" NO="4" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Rey Auditory Verbal Learning - Delayed Recall</NAME>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-013.01.05" NO="5" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Mean Reaction Time - Choice</NAME>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-013.01.06" NO="6" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Mean Reaction Time - Sequential</NAME>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-013.01.07" NO="7" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Trail Making - Part A</NAME>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-013.01.08" NO="8" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Trail Making - Part B</NAME>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-013.01.09" NO="9" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Digit Symbol</NAME>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-013.01.10" NO="10" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Grooved Pegboard - Dominant Hand</NAME>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-013.01.11" NO="11" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Grooved Pegboard - Nondominant Hand</NAME>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-013.01.12" NO="12" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Finger Tapping - Dominant Hand</NAME>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-013.01.13" NO="13" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Finger Tapping - Nondominant Hand</NAME>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-013.01.14" NO="14" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Timed Gait</NAME>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-013.01.15" NO="15" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Composite neuropsychological Z score</NAME>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="12" EVENTS_2="6" I2="0.0" I2_Q="0.0" ID="CMP-013.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="5.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="14" TOTAL_2="11" WEIGHT="0.0" Z="0.0">
<NAME>Tolerability</NAME>
<GROUP_LABEL_1>Nimodipine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours nimodipine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.8074816044002495" CI_START="0.8795739752067104" EFFECT_SIZE="1.5714285714285714" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="6" LOG_CI_END="0.4483169192937317" LOG_CI_START="-0.055727629005795296" LOG_EFFECT_SIZE="0.1962946451439682" ORDER="25872" O_E="0.0" SE="0.296078262731896" STUDY_ID="STD-Navia-1998" TOTAL_1="14" TOTAL_2="11" VAR="0.08766233766233766" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="1" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-013.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="14" TOTAL_2="11" WEIGHT="0.0" Z="0.0">
<NAME>All cause mortality</NAME>
<GROUP_LABEL_1>Nimodipine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours nimodipine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="11.19842402691616" CI_START="0.05512801955808027" EFFECT_SIZE="0.7857142857142857" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.049156907976197" LOG_CI_START="-1.2586276090162232" LOG_EFFECT_SIZE="-0.104735350520013" ORDER="25873" O_E="0.0" SE="1.3556040489989463" STUDY_ID="STD-Navia-1998" TOTAL_1="14" TOTAL_2="11" VAR="1.8376623376623378" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="8" EVENTS_2="12" I2="0.0" I2_Q="0.0" ID="CMP-013.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="4" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="70" TOTAL_2="55" WEIGHT="0.0" Z="0.0">
<NAME>Adverse effects</NAME>
<GROUP_LABEL_1>Nimodipine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours nimodipine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="4" EVENTS_2="6" I2="0.0" ID="CMP-013.04.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="14" TOTAL_2="11" WEIGHT="0.0" Z="0.0">
<NAME>Number of patient experiencing any adverse effects</NAME>
<DICH_DATA CI_END="1.4074831427924708" CI_START="0.1949411747050786" EFFECT_SIZE="0.5238095238095238" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="6" LOG_CI_END="0.148443202076811" LOG_CI_START="-0.7100964212281994" LOG_EFFECT_SIZE="-0.28082660957569416" ORDER="25874" O_E="0.0" SE="0.504310424569039" STUDY_ID="STD-Navia-1998" TOTAL_1="14" TOTAL_2="11" VAR="0.2543290043290043" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="2" EVENTS_2="3" I2="0.0" ID="CMP-013.04.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="14" TOTAL_2="11" WEIGHT="0.0" Z="0.0">
<NAME>Haematological toxicity</NAME>
<DICH_DATA CI_END="2.6087315619143467" CI_START="0.10517617881397368" EFFECT_SIZE="0.5238095238095238" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.41642939256238287" LOG_CI_START="-0.9780826117137712" LOG_EFFECT_SIZE="-0.28082660957569416" ORDER="25875" O_E="0.0" SE="0.8191432542575633" STUDY_ID="STD-Navia-1998" TOTAL_1="14" TOTAL_2="11" VAR="0.6709956709956709" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="1" EVENTS_2="1" I2="0.0" ID="CMP-013.04.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="14" TOTAL_2="11" WEIGHT="0.0" Z="0.0">
<NAME>Cardiac toxicity</NAME>
<DICH_DATA CI_END="11.19842402691616" CI_START="0.05512801955808027" EFFECT_SIZE="0.7857142857142857" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.049156907976197" LOG_CI_START="-1.2586276090162232" LOG_EFFECT_SIZE="-0.104735350520013" ORDER="25876" O_E="0.0" SE="1.3556040489989463" STUDY_ID="STD-Navia-1998" TOTAL_1="14" TOTAL_2="11" VAR="1.8376623376623378" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="1" EVENTS_2="1" I2="0.0" ID="CMP-013.04.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="4" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="14" TOTAL_2="11" WEIGHT="0.0" Z="0.0">
<NAME>Psychiatrics toxicity</NAME>
<DICH_DATA CI_END="11.19842402691616" CI_START="0.05512801955808027" EFFECT_SIZE="0.7857142857142857" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.049156907976197" LOG_CI_START="-1.2586276090162232" LOG_EFFECT_SIZE="-0.104735350520013" ORDER="25877" O_E="0.0" SE="1.3556040489989463" STUDY_ID="STD-Navia-1998" TOTAL_1="14" TOTAL_2="11" VAR="1.8376623376623378" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="1" I2="0.0" ID="CMP-013.04.05" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="5" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="14" TOTAL_2="11" WEIGHT="0.0" Z="0.0">
<NAME>Hypotension</NAME>
<DICH_DATA CI_END="5.974689197843464" CI_START="0.011902060300773187" EFFECT_SIZE="0.26666666666666666" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.7763153182942684" LOG_CI_START="-1.9243778537497063" LOG_EFFECT_SIZE="-0.5740312677277188" ORDER="25878" O_E="0.0" SE="1.586400537905439" STUDY_ID="STD-Navia-1998" TOTAL_1="14" TOTAL_2="11" VAR="2.516666666666666" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-014" NO="14">
<NAME>High dose nimodipine vs Placebo</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-014.01" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="0" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="NO" TOTAL_1="0" TOTAL_2="0" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Neuropsychological test scores</NAME>
<GROUP_LABEL_1>Nimodipine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours nimodipine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-014.01.01" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Rey Auditory Verbal Learning - Total Number Correct</NAME>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-014.01.02" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Rey Auditory Verbal Learning - Number Correct &#8211; Trial 5</NAME>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-014.01.03" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Rey Auditory Verbal Learning - Recall after Interference</NAME>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-014.01.04" NO="4" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Rey Auditory Verbal Learning - Delayed Recall</NAME>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-014.01.05" NO="5" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Mean Reaction Time - Choice</NAME>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-014.01.06" NO="6" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Mean Reaction Time - Sequential</NAME>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-014.01.07" NO="7" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Trail Making - Part A</NAME>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-014.01.08" NO="8" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Trail Making - Part B</NAME>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-014.01.09" NO="9" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Digit Symbol</NAME>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-014.01.10" NO="10" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Grooved Pegboard - Dominant Hand</NAME>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-014.01.11" NO="11" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Grooved Pegboard - Nondominant Hand</NAME>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-014.01.12" NO="12" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Finger Tapping - Dominant Hand</NAME>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-014.01.13" NO="13" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Finger Tapping - Nondominant Hand</NAME>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-014.01.14" NO="14" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Timed Gait</NAME>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-014.01.15" NO="15" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Composite neuropsychological Z score</NAME>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="9" EVENTS_2="6" I2="0.0" I2_Q="0.0" ID="CMP-014.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="13" TOTAL_2="11" WEIGHT="0.0" Z="0.0">
<NAME>Tolerability</NAME>
<GROUP_LABEL_1>Nimopidine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours nimopidine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="9.980686044579771" CI_START="0.3522428202126683" EFFECT_SIZE="1.875" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="6" LOG_CI_END="0.9991603945073242" LOG_CI_START="-0.4531578503798489" LOG_EFFECT_SIZE="0.27300127206373764" ORDER="25879" O_E="0.0" SE="0.8530989261379819" STUDY_ID="STD-Navia-_x0028_high_x0029_-1998" TOTAL_1="13" TOTAL_2="11" VAR="0.7277777777777779" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="1" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-014.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="13" TOTAL_2="11" WEIGHT="0.0" Z="0.0">
<NAME>All cause mortality</NAME>
<GROUP_LABEL_1>Nimodipine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours nimopidine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="12.011998353083218" CI_START="0.05960509736310207" EFFECT_SIZE="0.8461538461538461" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.0796152639825778" LOG_CI_START="-1.2247165982798012" LOG_EFFECT_SIZE="-0.07255066714861173" ORDER="25880" O_E="0.0" SE="1.3535759425196032" STUDY_ID="STD-Navia-_x0028_high_x0029_-1998" TOTAL_1="13" TOTAL_2="11" VAR="1.8321678321678323" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="10" EVENTS_2="12" I2="0.0" I2_Q="0.0" ID="CMP-014.09" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="9" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="65" TOTAL_2="55" WEIGHT="0.0" Z="0.0">
<NAME>Adverse effects</NAME>
<GROUP_LABEL_1>Nimodipine (high)</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours nimodipine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="5" EVENTS_2="6" I2="0.0" ID="CMP-014.09.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="13" TOTAL_2="11" WEIGHT="0.0" Z="0.0">
<NAME>Number of patient experiencing any adverse effects</NAME>
<DICH_DATA CI_END="1.6897645459619395" CI_START="0.2942456017647581" EFFECT_SIZE="0.7051282051282052" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="6" LOG_CI_END="0.22782619365899232" LOG_CI_START="-0.5312900200514654" LOG_EFFECT_SIZE="-0.15173191319623652" ORDER="25881" O_E="0.0" SE="0.4459086216193839" STUDY_ID="STD-Navia-_x0028_high_x0029_-1998" TOTAL_1="13" TOTAL_2="11" VAR="0.19883449883449886" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="4" EVENTS_2="3" I2="0.0" ID="CMP-014.09.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="13" TOTAL_2="11" WEIGHT="0.0" Z="0.0">
<NAME>Haematological toxicity</NAME>
<DICH_DATA CI_END="3.990867469485659" CI_START="0.31893988488482516" EFFECT_SIZE="1.1282051282051282" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.601067305777823" LOG_CI_START="-0.4962911668584466" LOG_EFFECT_SIZE="0.05238806945968822" ORDER="25882" O_E="0.0" SE="0.6445937988385906" STUDY_ID="STD-Navia-_x0028_high_x0029_-1998" TOTAL_1="13" TOTAL_2="11" VAR="0.41550116550116545" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="1" I2="0.0" ID="CMP-014.09.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="13" TOTAL_2="11" WEIGHT="0.0" Z="0.0">
<NAME>Cardiac toxicity</NAME>
<DICH_DATA CI_END="6.382640876683116" CI_START="0.012789792601279291" EFFECT_SIZE="0.2857142857142857" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8050004092641299" LOG_CI_START="-1.8931364979646812" LOG_EFFECT_SIZE="-0.5440680443502757" ORDER="25883" O_E="0.0" SE="1.584898975299297" STUDY_ID="STD-Navia-_x0028_high_x0029_-1998" TOTAL_1="13" TOTAL_2="11" VAR="2.5119047619047614" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="1" EVENTS_2="1" I2="0.0" ID="CMP-014.09.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="4" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="13" TOTAL_2="11" WEIGHT="0.0" Z="0.0">
<NAME>Psychiatrics toxicity</NAME>
<DICH_DATA CI_END="12.011998353083218" CI_START="0.05960509736310207" EFFECT_SIZE="0.8461538461538461" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.0796152639825778" LOG_CI_START="-1.2247165982798012" LOG_EFFECT_SIZE="-0.07255066714861173" ORDER="25884" O_E="0.0" SE="1.3535759425196032" STUDY_ID="STD-Navia-_x0028_high_x0029_-1998" TOTAL_1="13" TOTAL_2="11" VAR="1.8321678321678323" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="1" I2="0.0" ID="CMP-014.09.05" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="5" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="13" TOTAL_2="11" WEIGHT="0.0" Z="0.0">
<NAME>Hypotension</NAME>
<DICH_DATA CI_END="6.382640876683116" CI_START="0.012789792601279291" EFFECT_SIZE="0.2857142857142857" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8050004092641299" LOG_CI_START="-1.8931364979646812" LOG_EFFECT_SIZE="-0.5440680443502757" ORDER="25885" O_E="0.0" SE="1.584898975299297" STUDY_ID="STD-Navia-_x0028_high_x0029_-1998" TOTAL_1="13" TOTAL_2="11" VAR="2.5119047619047614" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-015" NO="15">
<NAME>Any adjunctive therapy vs placebo</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="313" EVENTS_2="300" I2="0.0" I2_Q="0.0" ID="CMP-015.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="5.0" SORT_BY="STUDY" STUDIES="15" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="407" TOTAL_2="396" WEIGHT="0.0" Z="0.0">
<NAME>Tolerability</NAME>
<GROUP_LABEL_1>Adjunctive therapy</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Adjunctive therapy</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.5679995921370442" CI_START="0.9079612382419795" EFFECT_SIZE="1.1931818181818181" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="16" LOG_CI_END="0.19534594538116573" LOG_CI_START="-0.04193269154162683" LOG_EFFECT_SIZE="0.07670662691976943" ORDER="25886" O_E="0.0" SE="0.139378645876644" STUDY_ID="STD-Clifford-_x0028_high_x0029_-2002" TOTAL_1="22" TOTAL_2="21" VAR="0.01942640692640693" WEIGHT="0.0"/>
<DICH_DATA CI_END="1.5656356845684818" CI_START="0.9006924560413716" EFFECT_SIZE="1.1875" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="16" LOG_CI_END="0.19469071136900812" LOG_CI_START="-0.04542347477519978" LOG_EFFECT_SIZE="0.07463361829690418" ORDER="25887" O_E="0.0" SE="0.1410442615254984" STUDY_ID="STD-Clifford-2002" TOTAL_1="21" TOTAL_2="21" VAR="0.019893483709273185" WEIGHT="0.0"/>
<DICH_DATA CI_END="2.3537364305505157" CI_START="0.9075335058040468" EFFECT_SIZE="1.4615384615384615" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="6" LOG_CI_END="0.3717578292949196" LOG_CI_START="-0.042137332002935235" LOG_EFFECT_SIZE="0.16481024864599214" ORDER="25888" O_E="0.0" SE="0.24312406656045116" STUDY_ID="STD-Dana-_x0028_both_x0029_-1998" TOTAL_1="9" TOTAL_2="9" VAR="0.05910931174089068" WEIGHT="0.0"/>
<DICH_DATA CI_END="2.2348585393474605" CI_START="0.7954766471692912" EFFECT_SIZE="1.3333333333333333" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="6" LOG_CI_END="0.3492500386423989" LOG_CI_START="-0.09937256542579911" LOG_EFFECT_SIZE="0.12493873660829992" ORDER="25889" O_E="0.0" SE="0.2635231383473649" STUDY_ID="STD-Dana-_x0028_thioctic_x0029_-1998" TOTAL_1="9" TOTAL_2="9" VAR="0.06944444444444442" WEIGHT="0.0"/>
<DICH_DATA CI_END="1.5363827814901816" CI_START="0.3937418974574756" EFFECT_SIZE="0.7777777777777778" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="9" LOG_CI_END="0.18649943130640095" LOG_CI_START="-0.40478837015653707" LOG_EFFECT_SIZE="-0.10914446942506803" ORDER="25890" O_E="0.0" SE="0.3473253815011518" STUDY_ID="STD-Dana-1997" TOTAL_1="15" TOTAL_2="15" VAR="0.12063492063492064" WEIGHT="0.0"/>
<DICH_DATA CI_END="2.2348585393474605" CI_START="0.7954766471692912" EFFECT_SIZE="1.3333333333333333" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="6" LOG_CI_END="0.3492500386423989" LOG_CI_START="-0.09937256542579911" LOG_EFFECT_SIZE="0.12493873660829992" ORDER="25891" O_E="0.0" SE="0.2635231383473649" STUDY_ID="STD-Dana-1998" TOTAL_1="9" TOTAL_2="9" VAR="0.06944444444444442" WEIGHT="0.0"/>
<DICH_DATA CI_END="1.067261167795642" CI_START="0.7279088140128578" EFFECT_SIZE="0.8814016172506739" ESTIMABLE="YES" EVENTS_1="66" EVENTS_2="77" LOG_CI_END="0.028270707946957963" LOG_CI_START="-0.13792302185647753" LOG_EFFECT_SIZE="-0.05482615695475978" ORDER="25892" O_E="0.0" SE="0.09762301955876847" STUDY_ID="STD-Heseltine-1998" TOTAL_1="106" TOTAL_2="109" VAR="0.00953025394777169" WEIGHT="0.0"/>
<DICH_DATA CI_END="2.430985688224023" CI_START="0.6626722458160668" EFFECT_SIZE="1.2692307692307692" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="6" LOG_CI_END="0.3857824020586261" LOG_CI_START="-0.17870121824448712" LOG_EFFECT_SIZE="0.10354059190706949" ORDER="25893" O_E="0.0" SE="0.3315804728050341" STUDY_ID="STD-Navia-_x0028_high_x0029_-1998" TOTAL_1="13" TOTAL_2="11" VAR="0.10994560994560995" WEIGHT="0.0"/>
<DICH_DATA CI_END="2.8074816044002495" CI_START="0.8795739752067104" EFFECT_SIZE="1.5714285714285714" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="6" LOG_CI_END="0.4483169192937317" LOG_CI_START="-0.055727629005795296" LOG_EFFECT_SIZE="0.1962946451439682" ORDER="25894" O_E="0.0" SE="0.296078262731896" STUDY_ID="STD-Navia-1998" TOTAL_1="14" TOTAL_2="11" VAR="0.08766233766233766" WEIGHT="0.0"/>
<DICH_DATA CI_END="1.823514971077363" CI_START="0.677026468559874" EFFECT_SIZE="1.1111111111111112" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="4" LOG_CI_END="0.2609093332267657" LOG_CI_START="-0.1693943521054154" LOG_EFFECT_SIZE="0.04575749056067514" ORDER="25895" O_E="0.0" SE="0.25276251480171835" STUDY_ID="STD-Sacktor-2000" TOTAL_1="9" TOTAL_2="5" VAR="0.06388888888888888" WEIGHT="0.0"/>
<DICH_DATA CI_END="1.192391125577024" CI_START="0.7446749375567123" EFFECT_SIZE="0.9423076923076923" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="13" LOG_CI_END="0.07641873511699145" LOG_CI_START="-0.12803326232956255" LOG_EFFECT_SIZE="-0.025807263606285505" ORDER="25896" O_E="0.0" SE="0.12009611535381537" STUDY_ID="STD-Schiffito-1999" TOTAL_1="16" TOTAL_2="14" VAR="0.014423076923076927" WEIGHT="0.0"/>
<DICH_DATA CI_END="1.6330540606304904" CI_START="0.6967177665499352" EFFECT_SIZE="1.0666666666666667" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="5" LOG_CI_END="0.2130005618615268" LOG_CI_START="-0.1569431146610397" LOG_EFFECT_SIZE="0.028028723600243534" ORDER="25897" O_E="0.0" SE="0.21730674684008836" STUDY_ID="STD-Schiffito-2006a" TOTAL_1="9" TOTAL_2="6" VAR="0.04722222222222225" WEIGHT="0.0"/>
<DICH_DATA CI_END="1.1465743254061285" CI_START="0.81097833622443" EFFECT_SIZE="0.9642857142857143" ESTIMABLE="YES" EVENTS_1="54" EVENTS_2="56" LOG_CI_END="0.05940221263551315" LOG_CI_START="-0.0909907470019769" LOG_EFFECT_SIZE="-0.015794267183231903" ORDER="25900" O_E="0.0" SE="0.08834156894821828" STUDY_ID="STD-Schiffito-2007a" TOTAL_1="70" TOTAL_2="70" VAR="0.007804232804232805" WEIGHT="0.0"/>
<DICH_DATA CI_END="1.160687007389919" CI_START="0.8080827720530985" EFFECT_SIZE="0.9684684684684685" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="37" LOG_CI_END="0.06471512302069109" LOG_CI_START="-0.09254415209075766" LOG_EFFECT_SIZE="-0.013914514535033303" ORDER="25899" O_E="0.0" SE="0.09237487664643139" STUDY_ID="STD-Schiffito-2007b" TOTAL_1="42" TOTAL_2="43" VAR="0.008533117835443416" WEIGHT="0.0"/>
<DICH_DATA CI_END="1.163099975905237" CI_START="0.813925222033532" EFFECT_SIZE="0.972972972972973" ESTIMABLE="YES" EVENTS_1="36" EVENTS_2="37" LOG_CI_END="0.06561704673003405" LOG_CI_START="-0.08941549332944945" LOG_EFFECT_SIZE="-0.011899223299707707" ORDER="25898" O_E="0.0" SE="0.09106688145439076" STUDY_ID="STD-Schifitto-_x0028_high_x0029_2007" TOTAL_1="43" TOTAL_2="43" VAR="0.008293176897828061" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="11" EVENTS_2="11" I2="0.0" I2_Q="0.0" ID="CMP-015.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="15" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="407" TOTAL_2="395" WEIGHT="0.0" Z="0.0">
<NAME>All cause mortality</NAME>
<GROUP_LABEL_1>Adjunctive therapy</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Adjunctive therapy</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="7.416604723905314" CI_START="0.01370698844745378" EFFECT_SIZE="0.3188405797101449" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8702051334271592" LOG_CI_START="-1.8630579532572575" LOG_EFFECT_SIZE="-0.49642640991504916" ORDER="25901" O_E="0.0" SE="1.6055322669889123" STUDY_ID="STD-Clifford-_x0028_high_x0029_-2002" TOTAL_1="22" TOTAL_2="21" VAR="2.5777338603425557" WEIGHT="0.0"/>
<DICH_DATA CI_END="7.7443737981982546" CI_START="0.014347333174563614" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8889863069264973" LOG_CI_START="-1.8432288163658224" LOG_EFFECT_SIZE="-0.4771212547196625" ORDER="25902" O_E="0.0" SE="1.6049166881048922" STUDY_ID="STD-Clifford-2002" TOTAL_1="21" TOTAL_2="21" VAR="2.5757575757575757" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="25903" O_E="0.0" SE="0.0" STUDY_ID="STD-Dana-_x0028_both_x0029_-1998" TOTAL_1="9" TOTAL_2="9" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="25904" O_E="0.0" SE="0.0" STUDY_ID="STD-Dana-_x0028_thioctic_x0029_-1998" TOTAL_1="9" TOTAL_2="9" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="25905" O_E="0.0" SE="0.0" STUDY_ID="STD-Dana-1997" TOTAL_1="15" TOTAL_2="15" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="25906" O_E="0.0" SE="0.0" STUDY_ID="STD-Dana-1998" TOTAL_1="9" TOTAL_2="9" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="10.058568052413063" CI_START="0.7475540029570854" EFFECT_SIZE="2.742138364779874" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="3" LOG_CI_END="1.0025361585330799" LOG_CI_START="-0.12635742863681093" LOG_EFFECT_SIZE="0.43808936494813455" ORDER="25907" O_E="0.0" SE="0.6631176812169743" STUDY_ID="STD-Heseltine-1998" TOTAL_1="106" TOTAL_2="109" VAR="0.43972505914257687" WEIGHT="0.0"/>
<DICH_DATA CI_END="12.011998353083218" CI_START="0.05960509736310207" EFFECT_SIZE="0.8461538461538461" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.0796152639825778" LOG_CI_START="-1.2247165982798012" LOG_EFFECT_SIZE="-0.07255066714861173" ORDER="25908" O_E="0.0" SE="1.3535759425196032" STUDY_ID="STD-Navia-_x0028_high_x0029_-1998" TOTAL_1="13" TOTAL_2="11" VAR="1.8321678321678323" WEIGHT="0.0"/>
<DICH_DATA CI_END="11.19842402691616" CI_START="0.05512801955808027" EFFECT_SIZE="0.7857142857142857" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.049156907976197" LOG_CI_START="-1.2586276090162232" LOG_EFFECT_SIZE="-0.104735350520013" ORDER="25909" O_E="0.0" SE="1.3556040489989463" STUDY_ID="STD-Navia-1998" TOTAL_1="14" TOTAL_2="11" VAR="1.8376623376623378" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="25910" O_E="0.0" SE="0.0" STUDY_ID="STD-Sacktor-2000" TOTAL_1="9" TOTAL_2="5" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="25911" O_E="0.0" SE="0.0" STUDY_ID="STD-Schiffito-1999" TOTAL_1="16" TOTAL_2="14" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="25912" O_E="0.0" SE="0.0" STUDY_ID="STD-Schiffito-2006a" TOTAL_1="9" TOTAL_2="6" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="4.092080860459946" CI_START="0.009774977905862802" EFFECT_SIZE="0.2" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.611944206883865" LOG_CI_START="-2.0098842155559025" LOG_EFFECT_SIZE="-0.6989700043360187" ORDER="25915" O_E="0.0" SE="1.540074993601121" STUDY_ID="STD-Schiffito-2007a" TOTAL_1="70" TOTAL_2="70" VAR="2.371830985915493" WEIGHT="0.0"/>
<DICH_DATA CI_END="15.465490926561218" CI_START="0.06466008772360077" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1893637105217114" LOG_CI_START="-1.1893637105217114" LOG_EFFECT_SIZE="0.0" ORDER="25913" O_E="0.0" SE="1.3972762620115438" STUDY_ID="STD-Schiffito-2007b" TOTAL_1="42" TOTAL_2="42" VAR="1.9523809523809526" WEIGHT="0.0"/>
<DICH_DATA CI_END="7.961364031061661" CI_START="0.013956290740833538" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9009874823623856" LOG_CI_START="-1.8552299918017108" LOG_EFFECT_SIZE="-0.4771212547196625" ORDER="25914" O_E="0.0" SE="1.6190157878205267" STUDY_ID="STD-Schifitto-_x0028_high_x0029_2007" TOTAL_1="43" TOTAL_2="43" VAR="2.6212121212121207" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="188" EVENTS_2="189" I2="0.0" I2_Q="0.0" ID="CMP-015.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="14" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="398" TOTAL_2="391" WEIGHT="0.0" Z="0.0">
<NAME>Number of patient experiencing any adverse effects</NAME>
<GROUP_LABEL_1>Adjunctive therapy</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Adjunctive therapy</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.1236676932425589" CI_START="0.8108776556208268" EFFECT_SIZE="0.9545454545454546" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="20" LOG_CI_END="0.050637894570257795" LOG_CI_START="-0.09104466674683169" LOG_EFFECT_SIZE="-0.02020338608828695" ORDER="25916" O_E="0.0" SE="0.08322503785764794" STUDY_ID="STD-Clifford-_x0028_high_x0029_-2002" TOTAL_1="22" TOTAL_2="21" VAR="0.006926406926406933" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.8796072089086509" CI_START="0.40927358979545014" EFFECT_SIZE="0.6" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="20" LOG_CI_END="-0.05571121999289999" LOG_CI_START="-0.38798627923981277" LOG_EFFECT_SIZE="-0.22184874961635637" ORDER="25917" O_E="0.0" SE="0.19518001458970666" STUDY_ID="STD-Clifford-2002" TOTAL_1="21" TOTAL_2="21" VAR="0.0380952380952381" WEIGHT="0.0"/>
<DICH_DATA CI_END="40.306070383600584" CI_START="0.893165710707621" EFFECT_SIZE="6.0" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="1" LOG_CI_END="1.605370458934295" LOG_CI_START="-0.049067958167007694" LOG_EFFECT_SIZE="0.7781512503836436" ORDER="25918" O_E="0.0" SE="0.97182531580755" STUDY_ID="STD-Dana-_x0028_both_x0029_-1998" TOTAL_1="9" TOTAL_2="9" VAR="0.9444444444444444" WEIGHT="0.0"/>
<DICH_DATA CI_END="13.643801456189747" CI_START="0.0732933561962918" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1349353909531412" LOG_CI_START="-1.1349353909531412" LOG_EFFECT_SIZE="0.0" ORDER="25919" O_E="0.0" SE="1.3333333333333333" STUDY_ID="STD-Dana-_x0028_thioctic_x0029_-1998" TOTAL_1="9" TOTAL_2="9" VAR="1.7777777777777777" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.958128371409792" CI_START="0.3026116719367649" EFFECT_SIZE="0.5384615384615384" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="13" LOG_CI_END="-0.018576299627153937" LOG_CI_START="-0.519114324958006" LOG_EFFECT_SIZE="-0.26884531229257996" ORDER="25920" O_E="0.0" SE="0.29401851378252775" STUDY_ID="STD-Dana-1997" TOTAL_1="15" TOTAL_2="15" VAR="0.08644688644688646" WEIGHT="0.0"/>
<DICH_DATA CI_END="51.50577047184636" CI_START="1.2425792180894195" EFFECT_SIZE="8.0" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="1" LOG_CI_END="1.7118558881419772" LOG_CI_START="0.09432408584190972" LOG_EFFECT_SIZE="0.9030899869919435" ORDER="25921" O_E="0.0" SE="0.9501461875826149" STUDY_ID="STD-Dana-1998" TOTAL_1="9" TOTAL_2="9" VAR="0.9027777777777777" WEIGHT="0.0"/>
<DICH_DATA CI_END="1.2073606265143444" CI_START="0.8757986198652603" EFFECT_SIZE="1.028301886792453" ESTIMABLE="YES" EVENTS_1="79" EVENTS_2="79" LOG_CI_END="0.08183700888173175" LOG_CI_START="-0.057595743530024814" LOG_EFFECT_SIZE="0.012120632675853438" ORDER="25922" O_E="0.0" SE="0.08190348896992168" STUDY_ID="STD-Heseltine-1998" TOTAL_1="106" TOTAL_2="109" VAR="0.006708181505446081" WEIGHT="0.0"/>
<DICH_DATA CI_END="1.6897645459619395" CI_START="0.2942456017647581" EFFECT_SIZE="0.7051282051282052" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="6" LOG_CI_END="0.22782619365899232" LOG_CI_START="-0.5312900200514654" LOG_EFFECT_SIZE="-0.15173191319623652" ORDER="25923" O_E="0.0" SE="0.4459086216193839" STUDY_ID="STD-Navia-_x0028_high_x0029_-1998" TOTAL_1="13" TOTAL_2="11" VAR="0.19883449883449886" WEIGHT="0.0"/>
<DICH_DATA CI_END="1.4074831427924708" CI_START="0.1949411747050786" EFFECT_SIZE="0.5238095238095238" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="6" LOG_CI_END="0.148443202076811" LOG_CI_START="-0.7100964212281994" LOG_EFFECT_SIZE="-0.28082660957569416" ORDER="25924" O_E="0.0" SE="0.504310424569039" STUDY_ID="STD-Navia-1998" TOTAL_1="14" TOTAL_2="11" VAR="0.2543290043290043" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.9956370517563475" CI_START="0.3417688977901263" EFFECT_SIZE="0.5833333333333334" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="12" LOG_CI_END="-0.0018989498759095357" LOG_CI_START="-0.4662674621908264" LOG_EFFECT_SIZE="-0.23408320603336794" ORDER="25925" O_E="0.0" SE="0.27277236279499045" STUDY_ID="STD-Schiffito-1999" TOTAL_1="16" TOTAL_2="14" VAR="0.07440476190476189" WEIGHT="0.0"/>
<DICH_DATA CI_END="62.265295761701466" CI_START="0.19673880690910994" EFFECT_SIZE="3.5" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.7942460553486765" LOG_CI_START="-0.7061099666481251" LOG_EFFECT_SIZE="0.5440680443502757" ORDER="25926" O_E="0.0" SE="1.468721504282843" STUDY_ID="STD-Schiffito-2006a" TOTAL_1="9" TOTAL_2="6" VAR="2.157142857142857" WEIGHT="0.0"/>
<DICH_DATA CI_END="2.5768324357029693" CI_START="1.0565296999054934" EFFECT_SIZE="1.65" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="20" LOG_CI_END="0.4110861784982845" LOG_CI_START="0.023881709929528025" LOG_EFFECT_SIZE="0.21748394421390624" ORDER="25929" O_E="0.0" SE="0.22744582153031903" STUDY_ID="STD-Schiffito-2007a" TOTAL_1="70" TOTAL_2="70" VAR="0.05173160173160173" WEIGHT="0.0"/>
<DICH_DATA CI_END="1.995663078608756" CI_START="0.08403710644574813" EFFECT_SIZE="0.4095238095238095" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="5" LOG_CI_END="0.3000872225966493" LOG_CI_START="-1.0755289095773524" LOG_EFFECT_SIZE="-0.3877208434903516" ORDER="25927" O_E="0.0" SE="0.8080437254486836" STUDY_ID="STD-Schiffito-2007b" TOTAL_1="42" TOTAL_2="43" VAR="0.6529346622369877" WEIGHT="0.0"/>
<DICH_DATA CI_END="1.6414412977456805" CI_START="0.02436882759982653" EFFECT_SIZE="0.2" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="5" LOG_CI_END="0.2152253558311291" LOG_CI_START="-1.6131653645031665" LOG_EFFECT_SIZE="-0.6989700043360187" ORDER="25928" O_E="0.0" SE="1.0740057598043984" STUDY_ID="STD-Schifitto-_x0028_high_x0029_2007" TOTAL_1="43" TOTAL_2="43" VAR="1.1534883720930231" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES>
<FIGURE FILENAME="Other figure.png" FILE_TYPE="PNG" ID="FIG-01" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>prevalence.</P>
<P>Prevalence of AIDS dementia complex according to country</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAABCMAAAGfCAIAAADqHY82AABI50lEQVR42u3dS7Lktnao4ZqA++54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</FILE>
</FIGURE>
<FIGURE FILENAME="Other figure.jpg" FILE_TYPE="JPG" ID="FIG-02" NO="2" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>HIV-1 Neuroinvasion.</P>
<P>Ghafouri 2006<BR/>1) According to the "Trojan Horse hypothesis" entry of HIV-1 into the brain takes place by the migration of infected monocytes which differentiate into perivascular macrophage.<BR/>2) the passage of infected CD4+ T cells can be another source of infection in the brain. Other probable causes of CNS infection might be: 3) the direct entrance of the virus or 4) entrance of HIV-1 by transcytosis of brain microvascular endothelial cells.</P>
</CAPTION>
<FILE>/9j/4AAQSkZJRgABAgAAAQABAAD/2wBDAAgGBgcGBQgHBwcJCQgKDBQNDAsLDBkSEw8UHRofHh0a
HBwgJC4nICIsIxwcKDcpLDAxNDQ0Hyc5PTgyPC4zNDL/2wBDAQkJCQwLDBgNDRgyIRwhMjIyMjIy
MjIyMjIyMjIyMjIyMjIyMjIyMjIyMjIyMjIyMjIyMjIyMjIyMjIyMjIyMjL/wAARCAG6Al8DASIA
AhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQA
AAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3
ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWm
p6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEA
AwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSEx
BhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElK
U1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3
uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD3+iii
gAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKRv
un6UALRXFa78Q/Dugzy20t611dx8NbWY8x1IOCpOQqHPZmBrn5PjTabv3Wg35Q93ljVvyyR+tUoN
7EuaW56pmlrz3TPi14cvZBHdm70xm4Bu4x5ef99CyqP94iu3hmjuIklhkWSNgGDqdwYeoPSk4tbj
Uk9i3RSUUhhRTWbCk+1clqvxC8P6RL5cl39plGQyWo8wr9ccD86ai3oiXJR3Ovorz+L4teH5XKvF
fxD+88AIx/wFia6fSPEOla1Fv0++inI6oGwy/VeoocJLdCU4vZm1RTe4Ip1IsKKKKACiiigAoooo
AKKKKACiiigAooooAKKKKACikooAWikpaACiiigAooooAKKKKACiiigAooooAKKKKACiiigAoooo
AKKKKACiiigAooooAKKKKACiiigBKWiqV5PJb2kkscTSFFzsU4JHtnvQG5byKM81w58TRy6tDdp9
rXTFtpRNJ5LhVcMmM8cbRvyexyCcCt/S7574yz7AtuH2wNzmQY+9/unse/XvSTTLlCUVdm3QelR7
ievFBPofrVWM7iml7iud1DXo7G8NnPFOrSR5heNS4kb+6Mcgjr0xjnNZ2m67M+m6fZvFK+sNDEJ4
plKFSQA8jf7OQ3sTx1NTzK9maKnK17Ha0lRAnA9c89etSDPemR1sOoprZ7VnX1td3NqYrW8a1ZmG
ZVjDMF7hQeAfQkHHoaANOiuX8EXM934J0S5uZXlnls43kkcks5Kj5iTyc/Sun5oAWik5ooAWg9KQ
+1B6GgBp6HvXifjvx9dandz6Lo1y8VnExjubqJgGuGB5RT/CgPG7q3Tpy3efEfXZtC8HXMtrL5V3
dMtrbvn7rPnLD3Chm/CvC7G3RVRETagAAXOcD/Hr+db0Kak+Z7GFabSsgtbFUjSONQEAAwP8881b
GnkjkHH8q1rS0G0E4yB37Vr6DokGu64LeC8QQiIyTiNwWwDhQvXueT6V31OWlDmOTDU3Wk03p39D
intsxiUDIYBu/cA9vrWn4V8Wah4KvQYg9xpTH9/ZHgHP8UfZXH90ZDd8HBrpPF3ha38PzWvlXLi0
lUjEjDIZcY5x93H4++OBxd5CjAmMqe2VINYR5a0dVY6KtN4ed07p7H0Vp2oW+p2UF7aOJ7SdQ0cq
nIYdvof88Hirs80dvE8srqkaKWZmOAoHJJryv4Paw2/U9AlcMif6Zag9lYkSD6btp+rmtf4r61JZ
aLDpkL7ZL5jvI4PlrjP5kqPpmuNwfPyG3OuTmOO8Y+O7zX7qWxsJHg01GK91af13eg/2fz56ctFZ
mTnFSWcG8iugs7IEdMcda9SjRVlY8yvUknqc+2ntjofyqFBcWNws9tJJBNH9x0PzLXYPYDb/APWr
IvbMAHitJUzKNU9I8A+Of7eU6dqJC6jGvDjgTKO/s3qO/UcdPQAa+X4bm40rU4Ly2O2eGTzEI7n+
6frX0jpV9Fqem2l9CR5dxEsq49CP/r15VenyPQ9ShU5lZmjRRRWJ0BRRRQAUUUUAFFFFABRRRQAh
prHCk8fiac33TziuO8deLB4V0QzRhZNQuG8u0ibOC/XJ9lHJ9elQ3y6gS+JPGukeFo1W9laS6kUm
O0hAMjjPXBIAHuSB6Zrzu/8Ai74gumH9nWVlaQkfL5geaQ/jlVH0+b61xH+kX11Ld3kz3N3O2+aa
T7znA9OMAYAHQDgAYFXorAt2rysRmHK7QJcjbj+KXjCMlmmsJh/dktTj/wAdYH+ddRoXxctJZ1g1
+zNgcc3UTmSEf7wIDJ/48B6iuAbTuOlUZ7NkYdvcdR9KwpZlK9mxcx9M288dxEs0LrJG6hldf4ge
hzVuvn34f+L5fC+pRaZdSZ0a4faFJ/49pGOAy/7JOcjpnkYORXvynOP8ivap1FUjzIpO5JRRRWow
ooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACjtRQelADD90/TtWFr
NnNdWzsurXFkqo2RF5W0j1JdCR+dbx6c1UurOC8iEdxGHRXDlWGRkdKGrocZcskzltM1u2g8OQ24
tbjz44FjEEcBJkIGAU4ClTjhuAO+Km8PafOllaSrrEzRxKEa1iEZiQjgpnYW4PHJzx26VsvYv/bE
F0r4hjtpImjHQlmjIOPYKfzqxDaQW80skUao8py5XjcfcUoxfU0nUVnb1LZGRkVHKpaF1DMhIIDK
MkfSpeM9KUjANVcxscJMz6L4igmnvLzUN9s6kGOMvCNynOI1XCcYznrjtkiS4uE1XWrVoLiezURM
i3QjCGRiQQieYpzkLuPB6cZOcdGLC3je4liiVZZ+ZH7udvGaisdLjj0SxsLzbcNbwxozsPvOoHzD
PuM1Fnc39rGyfXYs2UE1tAIpLye6bcf3s4Td/wCOBR+lLe6tp+m7DfX1ta7/ALvnShM/nVsDaAOn
HYk1RvNJ07Umj+3WFrdeXwnnRq+zPpkewqtNmZN3ZB/wlnh7/oOad/4FJ/jQfFXh4jC67puT0/0p
P8aX/hFPDv8A0A9N/wDAVP8ACj/hFPDv/QD03/wFT/Cr9zzJ1MjRdX8N6Jollplvr9m8FpCkKNLd
RlyoGBnGOcDPTp2rX/4Szw7/ANB7Tf8AwKT/ABo/4RPw7/0AtN/8BU/wo/4RPw7/ANALTf8AwFT/
AApe55i1G/8ACWeHjwNc00n/AK+k/wAay7vx5oFneQQPfRPFMCRcxOHjBGMhiCcdR1rVPhTw8o40
PTv/AAFT/CuN8SfDcaze2a6cLXTrOJD5vlRhcsSDwigD8eKuhGlKdqjaj3B8yWh39rdw3kKzW8qT
Rv0dGyMVbP3SK5bwx4Rs/CyMLWa5leTG8ySEKfoo4/T8a6k/his6igptQd15ji21qeVfGZ3/ALP0
ZP8Almbt2P8AveWwH6E15YzNGyMDgDmvZvizpr33gwXSqfM064S5YAZ+TBR/wAcn/gNeL/fiVv5d
6U7+zbXQ7crUHioxqbSTWvmdzprrIiyIQwOMGtK3+1x36XUM7WphBWNo8FpBxncDwV4HHPPPFcDp
urS6e+MGSNv4CcflXTWnie0uF8ss0TsMEOOPzrtw+MoYinGM3aS7ix+TYrB1pTpRcoPa2uha1O7v
NVWDULi48+VoxhXGFRDgkKF6HOOe/Q8AVzupAfMMcc8fjW1dXQKcH5fUYxXOX84JPc+ldihCCtA+
fqVak9J7628vI3Phc7J8Q7fbxvtJ1bHp8h/mBWr8XHdvFNkh/wBWtmCPqXYH9AKb8HdMefxDqOrP
kxWsAtUbbwzuQzfiFRM/71avxd0xmj0/VY0OI2aCTA6ZOV/9m/OvP5l7U6qcWqZ5nYzeTqKbmwpJ
Bru7FR5YPH1HNecyHJB7NW1pXiF7OIRXAaRR0Zeo/wDrVjhcbGhVlTqvS9z6TMcleMwkK2HV2kro
7mRV2VhX6rg/SpotatryMmGUHHVTwaz7y5DAnOT6Zr3XWhUjzRd0fEVMNWoVOSrFxfmc/f4zjt3r
3T4dO0ngTS2frtcfgJGA/kK8InLTzLGiF2Y4VR/Eewr6J8OWH9k+H9PsCcvDCoc4wSxGSfxOa8vF
SVrHo4RM26Wkpa4ztCiiigAoopKAFoppNAPvQA6ikpaAGtwK8B+JmpPqXj2e3JPk6dEkCLngMwDu
fx3IP+AV7+elfNni9Gj8fa8j9ftefwKIR+hFcmMk40tBMjsYAxFdFaWanGeB61i6djArpbR1A69q
+OxUpK9jKRha9qK6dsggQPcyLux/zzHT9a56S51JV8yTYy/3cD+nNX/EAMPil2lBCOqbCemAoH8w
aknuIPspr6fL8HR9hGTV2y0tNTEd47q3Y7M5BV1HWvofwBqsms+CtMupm8ydUMMr92eNihb8cZ/G
vnS3+ZZWP3GavdvhCjjwMjt0e7nZf++yD+oNbYb3KkoLYpaHf0UUV3jCiiigAooooAKKKKACiiig
AoopG+6fpQAtFYeuWmp3losej6oNNuA+fPNss2VwcrtPvg1xeg2/jjXLCa8XxjFBGbiaGBf7JjY4
jdky3I2nKnC847kmgD1CiuY8Gahfah4VtbrUp1uL0STRyyogVXKSumVC5G35eCOowe9dPQAUUUUA
FFFFABRRRQAUUUUAFFFFABTcgmnUYoAbSHpStgKfpXL3+pajFqsdnZrBOLiPI3MV8jGAWJAIIORg
dc+3ITdtSoxcnZG/DIssauhBRlBUjnggYqzXDWJ1ayi0zQJgluY4kBuY5Mh4owFKrlRhyccYxg5B
zwO0THAyDg+uaadwlDl63JTQCKYzAdTik3gtg/kadiOpJ/KlrPtb+K5nuo4yd1vKIpMjoxVW/k61
dDZ6HNIpprckoph6Hms7UlvZrIxafcLb3DMAJXj37BnkhfXGcZ49aBGpRXHeFdSvb/UdWga9fUNN
tZUitr6REVpX581QUVVZVO1cgDncOcV2GaAA9DScYpc0YpPyATrgU49KSg5xQBUnhiuIJIZkV45F
KujDIYEYII9K+evFnhe48H6oIWVn0u4JFncN+Zjc9mAzjP3seu7H0bWffadZ6nZyWd7bx3FvIuGj
lUEMPp6+9XCfKS11W6PmYIj/AHTtI7HkU8W5x95P1r0jWPg9hzJoGoiNeotb3LKpJ5CyDLAezBj7
1zc/w88T217FaONLMs2fKUX2PMwBkgFdxwPb8KXsaM3dq3oetTz3G04KCkpW7rUxluBBb+VuL4qG
zs7/AF7Vo9O02ET3kuTjICoueXY8YX14HPAyTXc2Hwe1eeXOr6pa2sWQWSzDSuw/3mCqp/4C3416
PoPh3S/C9qYNNtNm4jzJWO6SU+rMev8AnArplWUYqMNkeE6cqlWVWdrvVj/DXh628M6Fb6ZbZcxk
vJK3DSyE/M5x6n9MCruq6Zb6vptxYXKboZVKn19iPcGtSkI4Ncqbvc6HFWsfNXiDw/eeG9RazvI8
xHJhmCnbIvqPQ9sdR9OuUIg/KuPo1fS2qaTY6taNbX9tHPEw+645B9QRyD9K861P4SeZLv0i+Eak
/wCquQSF+hH9RmtHCjV/iLXudWEzLE4V2hLR9Oh5nFFscOZQMHsaknvCwwGPPeu2T4Q63yJdQsEX
PVN7n8ttdboXw00fSpVnvC1/cKflMvCKfZe/4k/hWtJ0qMXGFzmx1erjainVtdbaHNfDnwZLcXkW
uajEUt0+e2jYYMjf3voO3qefr7EMZA9B0qNFCgAAADoAOB2qWsJzc3dkQgoKw6ikoqSxaRvumkzV
eeWOCGSWV1SNFLMzHAUDkkntSuBi+IPEWn+HdLe+1CYom4KijlpGPRVB7459B1ryXW/iZ4k1qRks
ZRpVpyFSEBpiPVnPT/gI/E1ieIfEE3i3Xn1KXcLdMpZwtwYosjBx2Zup/AdqbbWZfr0615OLxvI+
WJLfQpyz6lckPPqeoTOP45LyRjn6sTn8BV6x8R+I9JkEllrd+m3/AJZzSmePH+7JkAfTH1FXksBt
HH5VDPYALnFcMcfNy3IuzvfCXxRj1S8g03XI0sr2RgkM8ZzFMegHJJUk+5B6ZzXqCZz/AFr5ZvLV
Qrow+Vgcjrj3r2L4WeKZdZ0+bSb+RnvtPA2yM2TLCeFJ9wQQfXAPevXwuK9qrPctM9Gboa8O+Lej
tYeJ4dZjTFvqKBJGGf8AXxjAz7lAAP8AcNe4noc5x7Vg+IdBtfEejXGm3qv5Ui8OnDRsDwyn1HXn
rXRWgpwce5R4FZ3W3GTW9a3m3AznvWHr+gan4T1E2epIWjZj9nu1GI7gevHRscFD07EjBNeO+xjn
p6GvmsTg2nZoiSN/VIrXVLdEn6oPlcNhhXOS6Sked127qOg2/pmp21AkYy1U57zcVy33jtUA8knt
WmGdemuWDdidRkucrBbRM8jMI4Y1+87HhQPcnFfSPhXRV8PeGtO0sbd9vCBIV4DSH5nI9ixY/jXn
/wAO/Alxa3MWv61E0c4ybWyZcNFn+OQdmI4Cjhe/OQvrg4x/KvcwtF00292aJC0tFFdYwooooAKK
KKACiiigAooooAKKKKAEbJU4614/faT/AMJDqWo6jonhFriweeSOeZdaks/t7qSjkRplSNwb5m+9
Xr7/AHD/AIZryDUNX/4RrUr7TNF8X+VZJM7zxHR5Lz7C7MXcCSP5fvE/K33c0Ad94YubO88PWMun
2hs7YK0Ytdu3ySjFGQj1VlYHHfmujrm/CNnaWPhyyisLw3tuymYXRYMZ2cl2kyP7zMx56dK6SgAo
oooAKKKKACiiigAooooAKKKKACg9KKRvunHpQBDIiyRsjqGVgQVPQ+1cY1klnrv2jQNNt4/JQpdH
yhFHICQcKyjJcdc4IxkEg9OqvL62sLVri9uYbaBMF5Z3CIufVm4ot7m3vrVLi0mjngkXckkT7lb6
HkUpK6LhPlOSmVtUntL7VLKKfS5ECwoq+cF37SJHBA44xwCB1Oc5HW2dla2MQhs7eKCLJISKMIo/
IUtjZxafY29nCP3NvGsSA8/KqgD+QqwKUV1Cc+bySHMo69647xDqcUd9bQ6bqVqmreYsAhaXIw3H
zJnPGcjHOfYmuyYkCue1qxm1QpZRKsdu2HkuQ+HTB48sDndnvxg+vSm7vYKbipXZl32mT6DbyXkG
rT/v5lN2ZQnzA4UuuFwGAAxxj26Y29I1HS7mFbfTb6C6MQG8R3AlZc92IJ5+vWsL+zrzUpLiP+0H
mfTrlUSO4jAjeQIkmX24J+9x0APIB4rX1G90610gLrpitYLoG2kV2O0lgcruHQYDcnH4dKUbylsV
Vacd7s32cYPOD61heJtMuNa0SfT7PVRp7z4Bm8vedmcsoAZSMjjIOeax7PwL4Hv4vNs7WG4jH8UV
27D8w1Wx8NvCfbSeP+u8n/xVbuNNaNv7v+CYJtl3Q7K90m1FreX+nSW8SrHbxWlmbZYlGeMGR89g
MYxjvW39oh/57J/30K5n/hW/hIf8wkf9/wCT/wCKpf8AhXXhX/oEr/3+k/xo5aXd/cv8x6nSfaYQ
MmaP/voUn222/wCfiL/vsVzv/CuvCoP/ACCU/wC/r/40v/Cu/Cv/AECI/wDv4/8A8VQlS7v7l/mG
p0H261/5+ov++xSfbrP/AJ+4f+/o/wAawR8PfCuf+QRH/wB9P/jTv+FfeFv+gRF/303+NFqXd/cv
8w1Nr+0bP/n7g/7+ik/tOxH/AC+W/wD38H+NY/8Awr/wt/0B4Pzb/Gl/4QHwv/0B4Pzb/Glal3f3
L/MXvGudUsMH/Tbf8ZBXI69f2bePfCki3UJRPtRZhIPlzGOta/8AwgXhf/oDW/6/41y+teE9CtfG
Xhq0h02FLe5a4E0YBw+1ARnmqhGk3q39y/zB3sd7/a2mjn+0Lb/v8P8AGk/trS/+gha/9/l/xrLP
gbwyBn+xrYfgaUeCPDPA/sa0x/u0JUu7+5f5h7xp/wBuaX/0EbX/AL/L/jSf27pP/QTs/wDv+v8A
jVD/AIQjw1/0BbT/AL4pf+EK8Nf9AWz/AO/YpWpd39y/zC7Lv9v6R/0FLL/v+v8AjTT4h0bH/IWs
v+/6/wCNVf8AhC/Df/QGsv8Av0KX/hDPDf8A0BLL/vyKi1Pux6lg+ItFx/yF7D/wIX/Gk/4STQ/+
gxYf+BC/41APB3hsH/kB2H/fhf8ACnf8Ih4d/wCgJYf9+F/wp+55hqSf8JNoY/5jOn/+BC/40h8U
aDj/AJDVh/4Er/jUf/CH+G/+gFp//gOv+FL/AMIh4c/6AWn/APgOv+FL935hqOPinQCv/IasB35u
U/xrLu/HWg2d9BbvfRtHMCVuY2DxhgcFWYHg81pN4S8Ogf8AID04f9uyf4VyPib4dJrOo2n2D7Np
1jGreYIowu5if7oAHbvV0o0pTtNtIT5raHoMM8U0CywuskbDIZTkEVyXxRvWsvAGopG217kpbZ/2
ZHAf/wAd3VqeHPDVp4ZsmtbSSeQE5JlkJyfYdBWH8W4DL4Dnk5It7iCVsenmAE/rWFVRXNyu6HfT
U8WtUJKhELF2ACou4seg4HXr0rrn0DV9IgM99YOsUjADDiTaSAAGx0ySefz6iuY0i9/s+/tbxE3v
C6vtGfmIPTnv1r0vXvGtnquiNZWltOGk2rK0oAEaggnvlj2GPz9fAnTpyhJzdmdtOnHlTte+9+hg
Tv8AYNKkuphudFyfr0C1xPl3eru080jEFvlTPAFdnfWSXmiXEEDSO8iAqHkY7sHKjk+o6VyGnagl
rH5UnyunBDdDjrTyuFKXM38SOOaSnJLYquJrCdUYkxseh7V0vw+vG0/4haUVYBbgyWknupQkf+PI
lc1fXAvp1RMFRyxHpW74Jga7+IWhxjJK3LSvj+ELG5z+Yx+NejKMY1Y8ujEz6Q/iApzfdNJjkU6u
1DKF9Y2uo2klre28dxA4+aORAykZzyDXD3/we8PXLlrKe/044wI4pRJH+ThiPwIr0alpOKktQPKo
/gpYZPn67fsh4xHHGp/Mg11Ph/wN4e8PSLPY2WbocfaZ2MknTHU/d+gxXV4opRpwi7pBZCY+bOBT
qKK0AKKKKACiiigAooooAKKKKACiiigApD0paRvumgBpPB5H4153plz4g8KWdzpUXhefVIxczTW9
3bXMSLKHdpP3gcgqwzg8HpWv47/scaAn9t2VxfQfaESC1tmYPJM3yqo2kep6mvPG03w3c3L2OlfD
/VbrU7dd17Z3GoSW5tkwNvzGQq5bkqAecHpQB6h4N0u60fw3bWd6IlufMlmkjh+5GZJGk2L7Lux+
FdHXKeCptLm8K6fLo0MsGnujNFFKWZozvbepLZPDbup/lXV0AFFFFABRRRQAUUHpTRmgB1FJmjNA
C0UmaM0ALTWztOOuOKXNBPFAHO6ubLzLOK6kijuppilhLPH5ix3GxipHTnG7qQT0BrI+H6GHS9Ut
JJRPPa6pcJNcxnCXEjFZC6qBhQN+3aMgFTXV3thaalava3trDcwP96KaMOrfVTRZ2Frp9oltZWsN
vAg+SKFAip9AAKAZj+HNWuNXk1YTpEos9RltYxGCMxqBgnk/Nzz0+ldL3rkPA4Am8RL6axP/AOy1
1+acopOy6CTutRT0NRFRycnP8qlzRkUAQJGiMxVQpc7mxjn60k9vDcxtHNCkiH7yyLuBqx+FNY/K
cdccUmw9Ti9T8H+HUeGUxppc7uIYprebyCXPQKBgFienfNO/sHxRpYH9leIftUa9IdRi3/8Aj45r
l/F2pXkniC0uL3RdUKWOr28dlthUxOob5pAd3LueBxwo9zXqS7mXoQe4PGPbuKaqTtbf1DlRyv8A
wkviLTcDV/DcsqDrNp0gkB/4CcEfnVm08eeHrx/KN8LWfOGiulMJB9PmwM/jXUnpVG90yw1GIx3t
nBcL6SIG/LPSq5oS+JW9GFmtiWKWOdQ8UiOh5DKQQfxBq1muOl8A6YjGXSri+0uU8lrScgfipyP5
Uw2fjbTOLbULLVIV/guo/Kkx6ZXgn3NHs4t+7L79Au1udnmgCuRtPEl/HHcnV9Hnsfs0DTGbzA8T
BQOjDuc5waq+DfHFv4mhMM4SDUU+9EM4Yccr/UdaPYVFFytdLe2ocyvY7qikz6GlzWaGFcZ4k48c
eEWH9+4H5xiuyJ4rjvFA2+LvCkh7XMq/mhqoK7sKQnxBtjc+Ctac3N1GkOn3MuyJ9gkIiYgMcZwD
/DnnoQRXV2I/0G3/AOuS8/hVe/sbfUdOurG6i8yC5ieGVNxG5GBBGRyMgnpT40EUaRRjCIAo5zgD
jGef1pDLtLSZozSAWikzRmmAtFITxSA0AOopPpRmgAPSkApc0ZoATFZ+rafBq+k3en3IzDcwtE/Y
gMCMj35rRzTWPy9KLAfLk9pdaJqdxpt6u25tpCj5/iA6Pn/aBDD2I9K0LK6CEjPp+gA/pXq/jXwN
B4rgSe3lW21OEYinKnDjvG+OSp6jH3eo6141qdhqfhy5Ntq9nJaSZ2ozcpIeuUcfKfp19q8bGYJ3
cog5SV7M6OO+2pgEKPSs+/isrtjJPCjSHqR1NZC3r4HIxjI561DLfAFUdsMwG0dST6Adz7V51HDT
jO8dGZtO9yaQwwZSFQgHPGc16R8HfD7vNc+JJ1IjKG1swehXOXce24bR9G9aw/C/w01TX5kudYhm
sNN3bjG52S3I7gAcxqe+efQd69ss7eGztore2hSKCNAiRom1UUdAB6CvawuHlD3plIv4FLSZozXo
FC0UmaM0ALRSZozQAtFJmjNAC0UmaM0ALRSZozQAtFJmk+lADqKTNGaAFopM0ZoAWkbpRmjNAHG+
OLDVr200efSLFb25sNSivGt3mEW5VVsjcQccsPWsGxl8dWfifVdZXwXbO1/DBD5X9roPL8rfzu2c
539MDpXqGaTigDlfAWm32keD7Wy1G3WC6WW4d4lcOF3zO4GR14Ydq6ymLyafQAUUUUAFFFB6UANP
Sq8sscETySMqKilmZjgADvVg9K5H4hFh4J1jYeTasoI9DjIpN2RUIc8lEtnxn4YB/wCRg0oYODm7
QY9R1qT/AITTwt/0Muk/+Bkf+NfKdvp8t3cLDbQPLK5+VI1yTXW2fwo8R3SK0kdtbZGQJpece+0H
B+uKwjVctkejWwNKlb2k7Hv3/CaeF/8AoZNJ/wDAyP8Axp3/AAmvhX/oZdJ/8DI/8a8AuvhP4itU
3xx2117QTHP/AI8B+ma5K4sJrSZ4LiF4pU4Kuu1h+HanKrKKvJF0cupVtIVE/Q+rP+E18K/9DJpP
/gZH/jR/wmvhX/oZNJ/8DI/8a+TPs9J9nqfrKOn+w3/N+B9Zf8Jn4YIOPEek5/6/I/8AGp7HxBo2
qSmLT9XsbuQc7ILhJDjv9018jfZz6Zrf8KGW18YaJJGxVvt0KkrxkM6gg/hRHEXexnUyiUYOV9vI
+gvBZC3nif21WU/otaEnjDwzFMY5PEOloynBVrxAQfQ5PFc/oblIfGe04K3kxB99gr5yjtHkdVVG
kkY8BQSWJ7CurE1OSdvT8kcWEwTxCbvax9Xf8Jp4W/6GLSf/AAMj/wAaP+E18Lf9DHpP/gZH/jXz
9YfDDxFfxrIbeC1RsFftEgUn8Bk/pU1x8JfEMCF4/sVwR/DDNg/+Pqv86wVSTV1E0lhKEZcvtFc9
+/4TXwt/0Mmk/wDgZH/jUbeNPC//AEMek/8AgZH/AI18tX2j3mmXjW19avbzL1VwQfwz1/DNVPIr
N4izs0dcMnU480ZXXofVE3ijwfc7PP1zRJfLcSJ5l1EdrA5DDJ4IPcVaPjTwtj/kZdJ/8DY/8a+T
PIo8il9ZK/sN/wA34H1zaeKdA1C4W3s9a0+5mb7scNyjsfwBpbzxJommzCC/1fT7WbGTHPcojdPQ
mvkmES286TxOUljYOjA8hgcg10PjqNp/GupO7Fj5g5JycBRj8ulUq65bmLymSny8x9GDxr4W/wCh
i0n/AMDI/wDGnHxp4WIx/wAJHpP/AIGR/wCNfOOkeAdd1uETW1l5cDdJZ2Ean6A8mtd/hB4gWPck
+nu390TNn9VA/WqU5y1UTGeDo05csppHsWua74U1zSJ9Om8U6dDHMAHaK9jDYznHXvWJpNl8ONGu
ormHXtPkuIWykr6kmR+RArxPV/C2q6E4XULKSFW+7JwyN9GHFZX2fkYq1ip0oOCbSe+u50U8njVX
PGV0fWI8a+FuMeJNJ/8AAyP/ABpf+E08L/8AQy6T/wCBkf8AjXygloz5KgZ9PWp59JmiWLfBJGXH
O9SO55+mMVj9aXYr+x30l+B9Tjxn4ZZtq+IdKLHgAXkeSfzrK8YOovvDN0p+X+1I03LjGHVvz6V8
ym2Ck5BIHXHevatIkkPwn8L3cz7ms9SjcseeFmZR/St6FVTkcePy6WFipNnqd5qdjplv5+oXcFrF
kAyTShFB9MtiqX/CaeFf+hj0n/wMj/xrx743yTTeK7G2ZybeOzWRE7bi7hj+QWuC0jwrquuuRp9k
8yKcNIMKin3Y4X9azlValypajpYBSoqrOVkfTn/Ca+Fv+hi0n/wMj/xpf+E18Lf9DHpP/gZH/jXg
6fCHX2Tc0unIcZ2vMxP6Lj9ax9X8Ba7osTS3FiJYF6ywkOo/LkU3UkldxCng6NSXLGorn0l/wmnh
b/oZNJ/8DI/8aP8AhNfC3/QyaT/4GR/418mm3IHrn26Uz7Oay+snb/Yb/m/A+tP+E18Lf9DHpP8A
4GR/40h8a+Fv+hj0n/wMj/xr5M8ilEJz0o+sh/YfeX4H16NX0/7F9u+3Wv2LGfP81fLxnA+fOKpD
xp4W7eJNJ983sf8AjXy19puzpf8AZolkNn5vn+Tk434xn8ql0zQL/WbjyNPtJJ5AMkqflH1Pan9Y
vokRLJ+SLdSdkfUP/CaeFv8AoYtJ/wDAyP8Axpf+E08Lf9DJpP8A4GR/414ND8IvEMiBnexiOM7X
mbI/75U1n6p8OPEOlQtK9ok8KgkvbPvx74wDWkpzUb2OSOEoSlyxqK59Ff8ACa+FT/zMmk/+Bkf+
NH/CaeFv+hk0n/wMj/xr5ONvgYI6HGB2+tM+z1l9ZO5ZI2rqR9af8Jp4V/6GPSf/AAMj/wAar3Hi
3whc27w3GvaNJE4wySXcRUj3BODXyn5FKIMHOOlH1kP7Cf8AN+B9NW3hj4f65vl0/T9Gutpyfsmz
APvso8Inw5D4ag1+HSdN0cSbg7hEQjDFOXwDzjvXjnwsea2+IFhHE5CTJIki9AyiNiP1Aqx4ulm/
4Vx4StlkdYpHundQepWTAz9NxFdEXB0pVLappfmcE8A4V1Rvue4Dxr4Xz/yMek/+BkfH60v/AAmv
hbH/ACMWk/8AgZH/AI18v6XoOoa1cNBp9nJcSDk7D8q/U9q6qH4Q+IZE3tLYxEjOxpmyPrtBqFUl
Je6i6uBo0nac7PzPeB408Ld/Eek/+Bkf+NIPGnhbP/Ix6T/4GR/41876l8N/EOlxtM9mtxEoJL2z
b8e+ODXMtb4b7vI4xnp9RUyrOO6NaOWU6yvTnf0PrH/hNfC3/QyaT/4GR/40f8Jr4W/6GTSf/AyP
/Gvkw2/cDmm+Qaj6ydH9hv8Am/A+tG8a+FwM/wDCRaT/AOBkf+NWrLW9L1NHfT9RtbtUOHaCVXC/
Ug18hCHBBHWrdndXmnrObOd4fPiaGTacbkPUGmsSJ5HK2ktT6kfxj4ZSRkfxBpasDgg3aAgjsQTT
/wDhNvC3/QyaT/4GR/418qQafNdTpb20Dyyv8qovJP8AkV1tn8KPEdyoeSO2tc8hZphnH0XP9KuN
Vy2RzVcupUf4k7Hvx8aeFv8AoYdJ/wDAyP8Axpn/AAmvhf8A6GPSf/AyP/GvBLv4U+I7WPekdtc+
0EvP5MB+ma5K40yW1neG4t3hlQ4McikFfwNEqsofEgoZdSr/AMKabPqv/hNPDH/QyaT/AOBkf/xV
H/Ca+F/+hk0n/wADI/8A4qvk37MfSk8is/rJ1f2HL+b8D6zPjXwsBz4k0n/wMj/xqS08T6FqFx9m
sdZsLubnEcNyjsccngGvkjyKmt2ntLmK5t2aOaFxIjDswOQaf1ldhPJH/N+B9Z3nifQ9OmMF/rFh
azDlo57lFYfgTUI8a+Fs8eJNJ/8AAyP/ABr5Un828upLiZmlnmcu7NyXY10WmfDbxDqkSzJaC3iY
ZV7l9ufovWnGs5PRGFXK4UY3qzsfRD+NPC3/AEMOk/8AgZH/AI0g8a+Gf+hh0n/wMj/xrwmX4R+I
EXckljKQMlVnIP8A48oH61y2q+H9Q0acwahZy28vbeOGHsehqnUlHVozpYGlVfLTmmz6i/4TXwt/
0Mmk/wDgZH/jS/8ACa+Fv+hk0n/wMj/xr5L+znFJ5FZ/Wl2Oz+w3/N+B9af8Jr4W/wChk0n/AMDI
/wDGmr4x8NSMsaeItKZ2OFVbuMkn0HzV8neR7Uv2fPGOtH1nyD+w3/N+B9ko4kUMOhOf8kVYrhvh
fczXXw/0ySdy7qsibieyyMB+gFdqOtdSd0meDUg4TlB9CWiiimSFHaig9KAG1ynxDOPA2pn/AKYH
+YrqjXM+NLWa+8G6paWw3XMts3lpnlm64Huamb901oSUKsZPujxr4a6rpml6zcressUtwgWCd+in
nK57ZGPyr2NSJFV0wwYZDLgg/jmvnCTw74hjDO+g6oqp94m0kxgd+mMfjV2207xnYKVttO163BP/
ACxhmQE9c8YrlpV/ZqzR6mOpYfFS541EmfQTMqKS5AUDJ3Yrx34latpmq6vbrYyJNLboyzzxnIc8
cA9+/wCfWudutO8Z3q7brT9fnX0lgmb+YqoPDfiPoPD+q/8AgFJ/8TRWxPtI2SKy6lh8JU55VE/Q
p/LSfLV3/hGvEv8A0L+q/wDgFJ/hSf8ACNeJP+hf1X/wCk/wrj5T6L+1MN/Min8ta/hvH/CUaL/1
/wAH/oxaqjw14jyM+H9Vx/15Sf8AxNb/AIN8Ka/L4q02WfS7y1gtrmOeSS5haNQFIOPmA547Grpr
3jmxOZUPZSSktU+p6zo/+q8aj/p6k/8ARYryLwJqen6X4niuNQKrE0bKkrDiJzjkn6ZFewaPGJr7
xfbggPLclVBPBzHXg7eGfE0bsj6DqZwx5S0kYH6cYNd2JmnPmXS35HgZdXouE6c5W5j6LhlinhE0
EivG/IdCCD+tP9/TjNfO1tpPi+yJNppWuwHv5VvMv8hUs9n43u023Vh4hmT0linYfyoWLSWxg8BR
59Kqt5nZfE/V9LvIrSxt3imvInLPIhB2Kc5BPucflXmh2jNXD4a8Rg8aBquD1/0OT/4mgeG/EWCP
+Ef1X/wCk/8Aia4qkvaS5mfRYHF4bDUVT507dblL5aPlq6fDfiMgEeH9V/8AAKT/AOJpP+Ea8Sf9
C/qv4WUn/wATWfKdf9qYb+ZfeU/lrpvE0sMHjy4luYzJDHcI0iYzuUYJH4iqVl4P8S6hdw2w0a9g
EjAeZPA8aKM8kkgDj8TW1428Na6fF2oy22kXt1byuHjlt4DIrAqP7o7Hj1rWLSicNTHYeVbWStY9
e07U7DU7VZtPuY5oiAPkYHZj+Ej+H6H8KukcY6V85QaD4ptpfNh0XWY3HAZLWVSP/HautD49dNkl
r4kZP7rR3BH8q7IYtRSTR4VXBUZSvGotX1PVPHmsaVa+Hr2zu5Y5LmeMrFbghmDdA+O2Dzk/hXhw
2g89Kunw34lLFm0DVS2Oc2kpJ/8AHaT/AIRvxIf+Zf1X/wAApP8ACuWtP2kkz3Mur4bCU3H2l2zZ
8GXOn2fiWzm1AIsCv95xlQ2ODjt9a9O+IWseHrnwrLEZoJ53A8hY2BbOeo9gO9eNDw74kAwNA1Ue
/wBik/wpx0DxIDGV8P6vnbz/AKFJz/47ShPli4rqGIq4WrXjVdS1uzRRYJuwOn1Ga9m0i1N38B2V
eqpLKD7LOzf0ryVfDXiN5QB4f1Tk9Ws5AM+5K8V7/wCDdHfTvh9aaNqJVJjDIJkJ+7vZmwT9GxWu
FahUTZyZzjKNalGMWtzy34pXQvvEOm3S9JtLhkB+rPXa+BNY0u78PWVpbNFFcwJtlhyA5bAyce5y
fxrhPEOg61qOn6dd2dpJdtYRNplxFCpZozE7EfL16MOn92uYHh7xKrB10HVgQeCLWQY/8drSrNQq
u3cx9rhq+EjSc7OJ9H9OOmKp6nqVhpVq9xqFxHDFjq7AFvYDvXhSQ+PIkEcdt4kRB0VY5wP5VTm0
LxVcyGS40TWJXP8AE9rMx/UU5Yq60Ry0sHRUryqK3kQ6hLDPe3MtvH5UEkrtHHjGxSxIH5YqsceW
Kt/8I14jHP8Awj+q/wDgFJ/8TSf8I34j/wChf1b/AMApP8K4Gru7PqIZjh4x5VJbW3Kfy0fLVz/h
GvEa8/8ACP6r/wCAcn/xNL/wjfiQjP8AYGq/+Acn+FLluV/aeH/mX3lRdoNeufDTWdMXRF0xZI4b
5JGaQHgyZJIYHvgYH4Vw3/CvfEZ8P/2n9gk3mTb9lx+92f3tnB68Yxn2rH/4RzxGDn+wNV9j9kk/
wrWjP2crnBj8XhcVT9nzpfM+kOCOoIxnORUN3eW1jA091cRwxoPmd2A//XXgkVv46t0EcVp4jjQD
hUinUD8hVa40fxbdyeZdaPrcz/3pbaVj+orseLXY8KGBoqV3VViXxNfWeoeI9QvLFAttNJlBjAPA
yce5yfxrH4NXf+Eb8Rn/AJgGq/8AgHJ/8TSf8I14j/6F/Vf/AACk/wDia4GrtyZ9RRx2HpU1DnTS
80U/lo+Wrn/CNeI/+gBqv/gFJ/8AE05fDfiIHJ8P6rx/05S/4VPKaf2phv5l95vfDPH/AAsLSsf9
Nf8A0U9S+J2x4M8JHti8/wDRorS+GvhTW4fFtvqd9YXFja2iuS1xG0ZclWXCg8/xZ9Kdq/h7UtY+
G/h6606Brh7NrkSQxDLFXlOCAOuNuK76cl7CUVvdHg18bReOjUTVrGz8M9Y0tdDTTBLHDfqzM6k7
TLzww/vYGB+Fd/j3BGM5BFfOH/CN+IwePD2rZHf7HJj+VXYrbx3AgjitPEca44VIp1A/IUqeJ5Y2
aMMbhqGIqOpGok2e93d5bWNu091cRwxoDuZmAH556+1eA+Jb2z1DxHf3digS1lkygAwDwMnHucn8
aiuNG8WXj77rSNanb1ktpmP6iof+Ea8R/wDQvar/AOAUn/xNZ163tNEjsyv6vg3KXtE3+BT+Wk+W
rv8AwjXiT/oX9V/8A5P8KT/hGvEn/QA1X/wEk/wrl5T2VmmH/mRT+Wj5avL4b8RbudA1Ue/2KX/C
tbSPh/4j1ZLljp89mIoyyi7Rot7f3ADzn9KaiTLM8NFXcl95sfDfWNM03Wbpb5kiknRVhnc/KpBO
5c+/FewoQ0alGUoeVKnINfOL+GfEa7o28P6qW6HFpIQce+MGrNtYeNLJNtrp+v26+kcM6fyFddGv
7Nctjwcwhh8VNzjVSbPoUlVBdmAUdWJwMV418SdW03U9WtksXSV7eMrNKn3WPGFz7cn8a56507xn
fDF3p2v3C+ksMzfzFVT4b8Rjp4f1X/wDk/wor4hVFypBltPD4Spzyqp+hTO3NJxV/wD4RvxJ/wBC
/qv/AIBSf4U0eGvEf/Qv6r/4BSf4VxqJ9D/amHv8SKXy0fLV7/hGvEnfw/quP+vOT/4mrel+DPEm
pX8VqdHvbZHYb5biBo0Rc8k7gOgo5SHmuGW8kM8NXdnp3iOxur9A9tFJ84K529QD+Bwa+gbS8tr+
AT2lwk8LdJEfcPpx/wDrFeCan4O8SaZfzWv9kXlwEY7ZreBpEZexyOOeuDzVa20XxbavvttG1qFz
1MdtKp/QV1UK3suh5GZPDYy0o1LNfcfReOh68/5615/8StY0o6IdNaSOa/aRSqIcmHBySf7vHHrz
Xn01t46uIyk1n4ilTGNrxTsPyxVD/hG/En/Qv6tz3NnL/wDE1pVxKnGyRy4LDUKFVVJVE7dim2O4
4pvy1d/4RvxL/wBC/qv/AIBSf4Un/CNeJP8AoX9V/wDAKT/4muHlPonmmHb+JFP5aPlq5/wjXiT/
AKF/Vf8AwCk/wqRPDHiVpAo8P6puPA3WjqM/UjA+pp8of2phv5ke/wDwnwfh7p31l/8ARr12vWuW
8B6VcaF4OsNPusefGrNIFIO0s5bHHpux+FdSO9epBe6j4vEyUq0pLZtj6KKKsxCg9KKQ9DQAw56V
karocWqSI8kjqU6bcf1rYXpSkcVE4RmrS2M5QjNcstUef+KvDFtY+ENcvFuJy0GnzyKpxglY2OOn
tWw3hOzJ4nnHPTIPH5dKveJ7GbVfCms6fb4M91YzwRg92aNlH6mtMAcHjrzjkZrP6vTtblVheyja
ySOf/wCEPtf+e0/6f4Uf8Ida/wDPef8AT/CunxRil9Xp/wAqF7GHY5f/AIQ21/5+Lj8x/hR/whtr
/wA/Fx+Y/wAK6fFBHBxS+rw/lQexh2Oa/wCENtP+fq4/T/Cm/wDCHWmP+Pq4x74x/KukzkkdcdqU
8DpVfV6f8qG6EeyPP9J0mO/1fWrSSSULYTIiEYy4K55qzJpGnxRs8k0yoByzlQBirHhrP/CVeK0x
0ni/9Aqn4msp77R54LZz5qsHwBy4HUVz4mjBVIxSSuZwoxlVjB2Sk7NixaVp88fmxXMroTjKMpH6
VL/Yln/DJcfmP8K830vV7nR7ppIxuBOHifOGA/ka6Q+O/wB1/wAg8+Yf+muB+opV8uqRf7uzR6OK
yGtTf7lqUX16nR/2JaD+O4/Mf4VDPpVhb20s0ssyxopZyWHygDJPSp7LUBNpMeoXWy2R1LPvbAQZ
65wKqabZS+I4L9ZNUZtLV2t4xDtZpAQN25gDnGcDHXGa4I0nKfIkrnl0sM3KSlZJb9SwdDtNxXfO
OTg7hjv7VYtPDdlcEr586t6ZB/pWfcpHpetfZ9W1RWgjjEts00ix5JLA7hwGYcYPpyBkE1vWGHuI
mjkDISCGBzkY7EVUKfLWUJpCnR9lUUdGmN/4RC1/5+Jh+X+FJ/wh1r/z9z/p/hXRhSPenY9q9X6t
Tf2Ub+xjvZHN/wDCG2v/AD8T/mP8KP8AhDbX/nvP+n+FdN+VLSWHgvsofsY9jmf+EPtP+e8/6f4U
f8Ifa/8APeb9P8K6bAo20fV6f8qF7GPY5c+DrYKSLifIHH3f8Kw/Dmkx6x/aomkkjFnqM1onl8bk
Tbtzn+ld3K6RRPJIQqqCSScAD8a43wVcRwya4k0saNPrE7xBjgup24Iyec9OK1hhYSi3yrSxLoxT
Whpjwfa9ftE36Up8H2ne4m4+n+FdH24HFH1FR9Xhf4UV7CNtked32nx6f4ptLC5lkSwvoysFwMZE
2c7W4xhu3fNb48HWZ/5bz/Xj/CtHWdGtNc02SzuwQpwyyKcMjDoR7iuag1PxB4cPkavYTanZqcJe
2a75AO2+PrnHU+nc1UsNCok0kmvxBUIp6pGp/wAIfaf8/Nx+n+FL/wAIfZ/8/M/6f4VFD8QvDUp2
vqHkSD7yTxPGR+Yx+tWW8c+GFUn+2bX8GzS+pwX2Q9kvIj/4Q20/5+bj8x/hQfB1pji4uP0/wqCT
4i+G0fy4rx55OoSGB2J/IVkan8To9OvLYtpl4tlKCGE8RilBGOQD1HNXDAKo+WMdQdGK3SNS58N2
dsRumuCfwqkdO0pJ/JN6/nEcRl13Vfg13Ttft47mwuFlVT86FdrIf9pT0rzXXbC70/U5jPIz+Y29
J+m4eorjp4SFStKlL3bdzXBYGGKqSpyai1t5noB0WzJGXn/NaBoloDnfP+n+FcnY+Nbi3hSO6txM
UGNwYocf1rZ0fxO+raoLdbPZDgszl87RjjtXPXwNWndtKy6kYrJ6+H5pStZdTSOjWo5Ek/0yOf0o
/sWzO4K8p2naRuHH6fT86bqlxfWixSWgjmLMsQt5DtLEnAYH9T7CkvLXVdCt7nUBPb3XnzK8ytGU
CsVWMOOT8owMj9eOeanSlNOUUtDmpYSU482iuSJodocBpJlBPqP8K0U8JWjoCLmfB+n+FV7a3eGG
JJJmlk2/O7H7zdz9Pb/CulsT/o0eeuK3wcFUk1NIVGl7zhNLQxP+ENtv+fif8x/hSf8ACHW3/PxP
+n+FdRRXf9Wp/wAqOj2EOxy58I2qjd9pn457f4Vh+E9MTXvDdnqVxM8Us28FY/u/K5Hf2Fd+w+U1
yfw0/wCRA03H/TX/ANGvWsaFP2T91br9RfV4X2Ra/wCEQtT/AMvU/wCn+FL/AMIhaf8APzP+n+FW
9WivJrdVtdQ+wIHLz3GxWZYwOdu4FQc45YHjPBrO8H6jeapp01xdTG4g+1OlnctHsa4gAG2QgADJ
O7kAAqFOOan6vT/lRXsYroiT/hDbX/n4uPzH+FH/AAhtr/z8XH5j/Cuo20hHFL6vT/lQvYx7HLHw
jaLGz/aLg4Ht/hWfLpOnQIXkuJUQdWkZcCuykGUYHpivPfFun3Woab/orMxhbzGRf4h61zVMPD2s
YaJMdPDxnWhTlZJ7svR6Vp0yb4LiWVP7yupH6U7+xLLHMk35ivO9L1e50W58yDDqeGjYHBH9DXRD
x3+6ydP+f183j8gM0V8uqQlenZxOzGZFWhL901KP3HRf2JaY4eb8xR/Ytr/z0m/76H+FS2N013Y2
9w8PktIuSmScfpV0/drzZ3i2pJaHg1IypzcJJXRmf2Jbd3m/76H+FWrXw1ZXGR9ouAR9P8KskLjn
pVrTc/al+nNXh1z1EpJNDpPmmk0it/wiFof+Xm4/T/Ck/wCEOs/+fmf8h/hXS7aMewr2Fh6f8qPR
9iuyOd/4RCz/AOfm4/T/AApP+EPsjx9ouP0/wro8ewpcewp/V6f8qD2MeyOb/wCENtB/y8XH5j/C
k/4Q21/5+J/0/wAK6fFGBU/V4fyoPZR7HL/8Iba/8/Fx+Y/wo/4Q21/5+Lj8x/hXT4oxR9Xp9kHs
Y9jmP+ENtf8An4uPzH+FH/CG2v8Az8XH5j/CunxRij6vT7IPYx7HM/8ACHWuP9fP+n+FJ/wh9tgH
z5uD7V1GPpSGj6vT7IXsYdjP0zTotOt1gicso55wP5VogYFNpT92t4pRVlsaRioqyVkPoooqigoo
ooAKinOLeQkZG0/yqU9KjZQylSAQwwcjNAHjvhO1bQYvB2oTWWlWdvdWQQzWAYT3DG2Lhphgblwp
JxuO4LV638TeIXa4hS+lLXWlfbLaW/jtoMt5qJmMAnarB/lEuecZOK7rT/DugaXOZtO0XT7SXGPM
gtY0cg+4GTmnQ+G9Dt96waPp8YkVo3EdsgDq2NynjkHauR/sj0oA4qTxHrcptNIt31h7xrueK4Y2
9ql3FsjRxH8zeQxIcNuH8I4GeajuvEniSXTbu9j1GK2k0/RkvniSOKVJ5hJMrbmUsArCL7qtkHgN
kHPeP4c0M6eun/2NYGzEnmi2+zJ5e/8AvbcYB96hsYNH1HTIrm0t7aayu7VEXMAUSW+DtQggfJ8x
wpGBuPHNAHJajr/iDTrw6Ml3c3dxLqEMAuY4bdZkV4HkZVDlY8gxnG7PDdWOMuttS8R6nNZ2J1Jr
CVbS9kmkEcEsrmKZETdtLxq3zfOBnlSPlzx2tzpWm3sc0d1YWs6XG3zhLCreZt+7uBHOO3p2pkWm
2Nq8SwWVvEscbRRrHCo8tDglRjopIBx3NAHK+Dbu91PW7nULq7kIudNsJhbDb5cbPGzEr8u7GQcc
9znPb0CsmDSrCC5jmgsreKaOFbdJEiUMsQ6RhscL32jitc9KAOM8Nf8AI5eLRz/rYDx/uGtifT5D
O0iFcHn3BrJ8N4Hjvxavo9t/6LNdeQPaoxFKNR2fkZSpqa1OQuvDlpcSGSfTo3c9WCgE/jVJfDel
QzI409BIhyMluPwzXdYprwxyfeRT9RXNKhNK0JtF89dR5Yza+ZzLZC8DHY4yP5Vixz6ppNvqWqwG
OOF905tZUyflT7+QwAZtvuPoc13hs7fn9yv0xVafTLO4gkhlgDRyKVdckAgjBFc0cFUpvmUjKhCd
K+qd+5ylut+NWe5uik5uowPMRCoh2nITGTwck+oPB7V02n2xR/NcYzwoNWY7KCMjbGoxjGecDpjm
rROxSccAZwBW1HB2n7Sbuy5x55870H4xS965aDx34dllMJ1WOGRTtKz5jwfcsMfrW9a3cF5CJ7aZ
Jo2PDxsGU8+orvlTlFXkmi01si7RSZpaBhSHoaWmOSB3/CgCvcW8d1bSwTIHikQoynuCMEV414V8
HS2vxKktJlLW+mt5wbHDj/ln/j/wE17K8yK2wuoYDJG7Bx6/pWXZ6pZXFzqMoKI1s4ieUsPmUIHz
n+6PMI+ua2o15UoygvtL+mDg5am4MZA/SlPWqdpdRXVvHNAxeJgCp9R/WrnpWCWgNNOzFpCMjpTq
KLAVZrS3uOJreOQf7aA1ANG0xTuGnWoPqIVz/KtCg9KLy6MNCukEcSbY40jHoqgYrC1fwlpeuahb
3d/C0zW6bFjZsLj3ArozSYFVGpODvF2fcVk9GZx0q3is1trOGO3jT7scaBVH4Vm3OjfaYDFcW8cy
ZztKg/zroSyqOSBUEc8LtsSWNnXG5VYEjj0rmqUFUlz637mbprnU07M42TwvpQB3aao+mRz+FW7e
zgsbYQWsaQxjkgZH6mutaNZBhhkVE1nbt1hU/UVz1MLVlpzu3YKrrzi4Sm2vNnC6jaWpuENnZINT
kcSLNHANy4IO5ye3bB5PY06/1HUNRtZbU2SpDBKgvRFN5jPhVfCcDK4K8nkjIA9O3Nlb4/1KflVe
HSLS3nuJUi+aeQSPnJGQqr/JBUxwtWCcYy3NaU5Qgo6Oxg6Pp9oUV9Pto4IJfmIjjCc984Gcjp/n
jrIkEaqoGcDrTljVcBVCj2pWGO9dGHwyoruzOFPlbk9Wx9DdKWmSHCE+nNdRoYviC1vLzQ7uDT7h
4LsoTE69dw5xz2NeafDO61u+1wwPcyJYWSM0lugCJuZiApAHBzuP4Yrp9X+KHhzTLhoIrmXUpVba
yWKCRQeuN5KrnHYMfpXNab8TtI0y8vp7bw7fIL2XzpXMkeSeh4z68nnqxq6eLp0qU6ckm3t5EOPv
Jnd+K/D934isoLS31CO1hWUSXEctuZUuVXojgOh255Izg9DWnpVrqFva+XqF5bXEgb921vamBVTG
ANpd+evOe/Sua0f4n+HdWuFhmuJdOlc4VL5AgJ9PMUlB7Ddk12YkD4ZTlTyDkYx6j1rGMk1dFlqi
kpe1WBG4yprHuNNfzi8RByc4NbR5FJj2FY1aMaqtIznTUjj7vwzZzOZJtOiZj1ZVwTVaHw/pdrcp
PDYosidASTtP0zXcYGKja2hc5Mak+pFYzw0+W0JtFOdfl5Yza+ZzmTnH8h0pTnFdAbO3xzEv5VG2
n27fwD9RXHLLp781zheEm3e5hbdxAArW021aMeY4G49PpVmOzhi5WMA1ZGBgcV0YbB+zfM2a0cNy
O7HUtJSnpXoHWQzSxwxNJJIqIvVmOAKSKRZFV0YMjdGByDWF42DHwjfhDgkIM+29c1R+H14JfD4s
yu17RypGexJI/UkfhXO66VRU2O2lzsaWkoY4Ga3uIKDXK+LfEEmiWkS2qq91MSE3LlVA6t+oFcNo
uraxN4lspHv7hxNcIJEMp2lSwzhRxjFcdXF04T9n1KUWz2Olpin5qVuh4z7etda2JBjhc+leGWVx
8PZ7vUh4vuZ7jWkvZxLM73Ox08xtnl7OAoXaMdq9hv4Lyf7L9jvfspjuFeY+UH82MZynPTPHI6V5
nq3iwWOqXcMvxTtrYxyt+4XSEl8oZxtLDOcZHOcmqA9C8Kf2L/wjln/wjxzpPz+Ty5/jOfv/ADfe
3da3q5zwffNqXhqyvDqjaoJd5+1ta/Z/N+dgD5f8OMY98Z710dABRRRQAUUUUANb7px1xXLeMLF9
Q0e2tUhmlD6haeYsOc+WJk3529F25yfSurooA8lfw3dWEcr6HYzwXyapdRWkgQjyrdreXYqnB2xe
YQR/Dnkc1Us9DvW0DUobaC6j8+xhjlih0qazLTeYMsWeRi8gG7LgHsd3avZaKAPLW8NR6fq99caf
pk8Zg1mxNn5cZ2xwsIRP5fYIcybyOM9elY2m6NOvhZYdO0jUbe9Hh+8i1IS2sqGeZowI1ywBds7t
u3JVfl4ziva8UYoA8f8AFugeXaS2Gm6S/wC50zdazfY5rmR5yZCfLKkLDLu2kuxJOeny1rPoUj39
1q/2G4OpDXbTyZyjb1tysAkC/wCxzJu7fez049KooA8s8FaVqdr4gt57wSLe4nXUH/syWIynPG+d
pSsvOCpVScAj5RxXqD/cbAzx09aeelRFs5BJA9aAPItK8dQ2vjLVJF026e61OaGH7MAMxsilcZzz
kn0H4160jEhSQQTzj0z2rkrfwfaQePZ9dJUmSIPFAcZWTo7Y+mOf9o12IPHTFbV5U24+zXTX1Jim
tySim8k06sSgpKWigBKa3Q0+g9KAPJPHXgKfUfEttdaZEQl8+24wOI26lz9R+q+9a2l6nd+CYYtM
1y2Qaap2Q6jbKfLXk8yg/dJ7npn15NehEDBqCaGOeFo5Y1dGBBVlyCPpW08RKcFCesURyJO6Egni
uokmglEkTAFXUggirIriJ/DWo6BK194WmCxs26XTJ3PlP7oT9w/pV/QvFdpq8zWkiyWeoRf62zuR
tcH1Hqvv+grKVO/vQ1X4r5FX7nVVG2SCcc0ufyPpQQdpx1pDOH15RqOt6dZ3NlcwxCcqbjKbJhtJ
2cMSVYjkEdRU3iLSNLtrSCeG0hjlS5i2hEUeb8wHln1B7A9CM9q09V0satcQRzv/AKJF+88pWILP
2ORyMDkY789qx7fQ2vW1EvJdfaLS622UssrOFxGjhsE85JKk4yRxUtO5spJKLva3Y6bT7qW5i/e2
FxZlSAFmMZ3D22M3H1xWiOlVoN/lxmQjftG7GcZ/pVruKpKysYtp3sOooooAKD0ozTWPBpXQCHp1
rH1zxBYaDaCa7dtznbFFGMvK3oorL1rxUlpd/wBmaVC2o6uw4gi6R+8h7AfnRoXh6eC6Oqa1cLea
qw+XC4jtweqxg9OOtWoKK5p/JdWK76Hn3jLQtf1K1m8RzWoto8j/AEJWJdIx/Ew6bs9QOn5iu7+H
vhv/AIR7QUE6bb24PmT5GCv91fwH9a7AgEdAR6UoA7YH0q6mKnOCp6WX3i5LO4+loorIoSjApaKA
CiikbpQBWmlWKJ5HZVVQWZmOAAO59q8G8aeObvxbPJZWUkkOhoSm0EK12R1dz2TkYXv1PPC9z8Xt
bex8NwaZC5STVJTHIB18lRucfj8qn2avJbSEMAuOMflXn43EOmuVdRWb0Q2GzyqhQMY4x2qwdPbG
cH8q1bSFGgSY4Cvg5Pv2/Wr1xHBa2rzzsqRjqzV4U8RJzstyZKUXytanKT2PBDKCpGCD6V0ngvx1
d+FbxLK+lafRXOGD8tak/wAan+56r0AGR3Fc/PrUUrkQ2sjIM8lhk/XrVVnhuVLp2+8p7V6NH29K
0pqyDVH1FDIk6pIhDRuAyMvRh1BqyOlecfCPWGvfDU+lTyb5tLl8pM9fJYZj/D7yj2UV6OK9mElJ
KSLTuhaKKKsAooooAKSlooArzlxA5ix5gU7d3TPbNedWHxDvft/lanZxCIOUbyVYOhB64JPH5V6U
3KnHWvPvF/hJmkbVNOjy3WaJf/QlrixftVDmp9BxtfU7mzu4L63juLeRZI3GQy96s15n4S1k6ZKY
pji1fr/sNXo8UqSxK8bBlIyCKWGxcasbvRroVKNjM8TJ5vh67j/vAf8AoQrmfBn+hanLCThZk+7/
ALQ6fpXUa2wayMPXzGH6c/0rBtIDb3UMoAG1hnp0zXjY7Gxp4qFnsXCN4M7MHimSOqIWYgKBkk9h
TBIpTzMjbjk1h6vevcxtDF8sY4Ynqf8A61eniMwpUqSnfV7eZnGLbscz4kmGsamGSMmKPCIB/Ecn
p+daPhvwpJZ3cGo3b7JEBKxAZ6jGWNW9BsY5tQedkGIRlR7nOP0rqlwB6Z9sVy4Ci669vV3b0Lk7
LlQ4dR0/Cn0UV7qVjIa/3a8pstM1Wxsbe703TodTGk6reEfZrpGa8gmMm/r0dWKgq3UpXpN7fWun
2kl3e3EVvbxjdJLK4VVHbJPAryeS7g8OW32qx+Jtra6VqFxNPbQRaYlwqkuS+PmLbQSSegByeOlM
D0HwfZ3mm+GLS3v7cWs++V/syOGECNI7JECOoVSFGPSumrD8OtM+iWb3GrLqzum8XyRLGswJJUhV
4HBA/D3rcoAKKKKACiiigAooooAKKKTvQAtFJketB6UALQelNPUf0px6UAMPQ46+9Yet3U1lp0tz
BLEjxDftlyQ4HJXjkE9OAx9j0rcPTmub8Uafp95pkjXVktxchSkDrAskoYnA25HHP4etJ7FQ+JXM
+RtfN5Drf2K3xHbSJ9lM+JNrFGxnBXcNn05PPetXQZpry2F7NO0r3KiQIAQka9lAPf1J5z6DAGYL
zX/IGntbWQ1B4mYP5zFCBwW243dSvGerfeI5q14e0zTooYbm3sPKvEHlyTTQhZsgchiOueO+DwRx
ilG6+ZrUsotNK/l2OpHQU6kxS1RgFFFFABRRRQAU1iNp+lOppHymkwOJ1fxNdnxVB4f0WWxF7HGZ
p/tjEK3TbCu3o7A7s4O1ecHOKcLHTvHWi29+0MkFwCypPG4EsEiMyNtcfeAYHHY9eM1oXWg6QmmX
sVzpcd3bSySXc8TRecZJDySFOcscYA7cAVz+l3mvaZqMdklstxLLbm6k0oGOCHTYSQsSLIAdxwjL
gZUkMcqBzSbi7x0Yb6MsLrOs+FtkOvxm+0wYCalAhLIP+mqf1/rXY2t7b39vHcWs6SxOMo8bZBFU
NMv4NZ0W11CJD9nvIFmVZAM7WGcHtnn8f1rCufC11pdy2o+FLhbaRz5ktjISYJj7Acqf0qrqe+j/
AAFtsdrjP1FKPeuY0Txbb6hcnT76GTT9UQfPazfxe6How+ldMpyM9RUOMouzQJ3HYA5xTqbSk8Ur
jsFIelJng+tc7rviaz0NUidZJ72bi3tIeZZT9Owz3ojFydoq7B6G3c3UFlA89zKsUKDLO5wAK4l9
V1bxe7QaIZLDSM7ZNRdDvlXPSFf/AGY//Wqe18O3/iC5S/8AFDjyVYNDpkRPlr6GT+8fbp/IddHG
kSLFGioigAKAOB9Kv3Ybay/BC1Zn6HoNjoVt5FlDt3HLyNy8jdyzdzWzgelLRUNuT5m7sa0AUtFF
CVgCiiimAUUUUAFNP3TTqRvumgDxX4yyu3iLR0I+RLSVl+pdc/8AoK1m+A9Fsta1zyb4F4oYjIIw
du88D6lf0+nSuk+Mums+n6VrMeSLaVreXA6LIAQx+jKB/wADrznTbmW2uY54ZZIpYzuVo22kHp19
K8nFPkqqc1odFCcYt3dtPuPRPFGhWGiahZNYxPtlDlrYOCAVx84DHHfntn3rjfGMsjW1ipRo0kkc
tu74xjoSOhq5Fe3F40d1NcPJcFQDJM24kf3R9Pap9Uhg1ax8iRipHzq2DlT/AIV5Uq9NYiM+XS4q
9VOyvdrqYdtBEbXnGMVhyhU1JlQ8Ec4q29nqlt+7XY6gY3BhjH+NQ/Z/ILGV98jdcdq9ytiaUqdk
73Oe6sz0L4LO48R6vGP9W1pEzfUO+P8A0Jq9qryj4M6W62eqaxICFuZlgi44Kx5JI/4G5H/AK9Xr
ooJqmrgthaKKK3GFFJRQAtFJSN92lcB1McDac9KZ5qF9gdd/oDzT+op2A4jX9CFtcC/tkCxSECUI
OFPZh7VSTVU0u1ilmmeKAuquyE7F3cDd6c4/OvQJ4kmieN13KwwR7V5V4hg1htL1Cxt7G3niMTxy
H7SyyOuDvRVCHkgED5hXz2MwSjiIyg7KW+tjaMtLGpa+KrC7124sX1K3aMQReSxkwGl3Sh1V+jcK
vA962rG7i1CL7Vb+Y0BJCybMCTHG5fVT2PT86yNa1nwrceBJbO2u7Se0ls/Ks7SJwXLAYRVU8qyk
L94DaQScYJGjp8usbYo7+0sQgjwZobt3LHHXaYlGCf8Aa7nGa4syy+nG04yu3ZatI0pyb0OV8RfE
my0S7k0+1t5L+aL5ZQsgVEP93ODk8ehx6nkU/QPHlj4kmazML2d8VysTsGVvUqw6/l+NeR3ME2n6
td2l8pFzHKRIXH3jk/Nj3/r71b8MW8174w0/7MjHy5lkdh2QcsSfccV0VMFQdGzWyve57ssDQjhl
VjL3j6O8PKPs8z9zKRn2/wAmtzvXN+H7jE09sx5++MnuOD/SujHevTy2UZUI8rvY+bmtWPpG5Wil
r0yDz/4mzwW+m6G16pewGsW7XYWFpR5ah2OVAORlRxg/SuZ0XxZ4O0/xx4g1XMkdteW9skUiadPh
2AcSjAQ46Ic9/U17NiigDh/hgwPw/wBPKhghluNm5SuU+0SbflPI4x2ruKKKACiiigAooooASk+t
KelZGsavYaFYte6lcrBbrgFmz19scn6UBZvRGoSAD14HavJviB8QrnSp59C0gFLoKqy3J5MeQCAo
9cd+g+tdEfih4VlG2PVASeBmCQD8yuK8V1G0m/tG4NzMJpHcyNJuDK4OMNnvng5ropUm9z1MBgXV
k+daH0R4buJ7jwzps93JvuJLWN5WPdioJz+dcB43+KP2C4bT9BMck6ZEt04LIh9FA6n6/L9e1WXx
3HF4KttPs0l/tD7MsDFlwI8Lgtn37Y/TpXm/2Qexz1PUnv8AzqoUHdtm+GyqU5SnUVknp5n0D4E1
y81/wnaX98B9pcsrlQAGIYjIA+ldMzYPPSuL0y+0/wAGeC7KG6cK0UQHlqRueQjLbfxzXmniPxhq
/iGeQfapLazOQsETbRj/AGiOWz78e1RGi5tpHLDLquIqPkVop7n0BuDc0oJA+Yfl1rzb4UxX66bd
z3M80lrIyi3SUk7QM7iM8c5A/wCA16Q0iAdRWcouL5Wcdei6VRwvexVNjG2pxXzZ86OJ4hg8YYqT
/wCgiroA44pqsrfdIP607vUWMm29GPopKTmgB1FMGf1p1AC0UlLQAUUUUAIehrnNU8O2esTebcG5
SQxGGRred4jJGSTsYqQDzn6ZOOtdJQelAHkeo6OLWSUX1hc2QhmnuLrVYyApsQWVLeAq2V3IY02A
DGCR820nr7XXLKztbO01ZrTSZxbCZrYuBHbR52ohfgA4OMdDtbGQDW3f6fBqNjLaXUYlgkXYyEkZ
HqCOQfpXKP4QbT9Zg1bS4BqEgMzSJqd2+7e+1UYSFXJ2KrIMg/K5wTk5ANvWND03xDZIl1Gsgxvh
njbDJ6MrA8evpWGt/rXg9gmpLLqmjjhbuMZmhH+2vcD1/l0rKg1B7PUTNp15JFpSLcWljaqN4RkJ
M10wBGY0IKhWz227d4rvrS5ivLWGdFKLNEsvlyABgrDPzD19eaqM2lyy1Qmuo/T9Ss9UtUurK4jn
gfo0ZyPp7GrjsqqSTtGOa5K/8JTWl4+qeGbhbG8Y5kgYEwT/AO8vr7iuf+33viXWxo2vznR4VVT9
jViGuz0Pz9MH0BP4nmmqSlrF6de6BuxsXniW+1i7k03wvGk0inbNfSL+5g9f99vbp/OtXQvC1po0
j3Usj3mpTf627mO5yfQei+1bFjY2unWsVraQpDDGMIiDgVbpTqWXLDT82CV9WAIP4U+m4pe1R0KY
tFFFMQUUUUAFFFFABRRRQAUHpRTW6UAZer6ba6xpVzp16m+3uIyjgHkA9wexHY+tfO+t6Lf+FNYb
Tb8A5ybadVwk8YOMjsCO69ifpn6Ml1C3j1K3sJGxPcxySIMHDKm0N/6EKr6xomna9p7WWpWiXMLc
gMMEN6gjBB9xWFejGrGzBq6Pnu3vinP4cVZ/tHI611mrfB+7iffoeqxyR5G2G/yGAx08xAcjv93t
yT1rH/4Vd4x8wobWxx/f+1/L9fu5/SvGqZbO+mpDiYNxfFzxk49KdoOh6h4s1pdO08bQCHubgfdt
4zxuz3J/hXqevQZrttN+Dl5JIG1rVIo48/NBYKST/wBtGAx+Cfl1r0nTdN0fwrpq2tmkFlar1JYD
cfViep9ya7cNgORpyGoom0nTLbSNMtbCzi8u2tkEaDuRjqfUk9fU81q1zV5478N2bbG1SKWTONlu
DKxPp8uapnxtc3Z/4lXhrVbo/wALSqIEb8Wr1FRm1e2n3Id0dnSGuN8/x3fnKWmlaZGf+e0jSuPp
t4/Okbwprl6P+Jn4rvWB6x2kawge2RyRT9ml8UkvxC51Vxd29qu+eeOJPWR8CsK78d+G7RijapDL
J02QZlOf+A5qC3+Hvh6JvMntZL2UdXu5WkJP0JxXQWelWGnLts7K3t1/6ZRhadqce7/ANTm/+E1u
rokaV4Z1W59GmQQI3/AmpDP45vlJS20rS0P/AD2dpnH02/LXX4HpTyOKn2i+zH7ws+p4x418Pa5N
qujssjXmpXCPE0kC+UPlbcM7eQAHAz2xXoHhPRLzRdNWK+1C5vbl+XaWVmVP9lQTx/np0rpSoLAk
An1xSsOKutiZTpRg0rR8hKCvcjlZY4mdzhVBJPoK4S9trbWZpY5dz2ss2WRWx5gySAcc49u9X/Ee
tq8v9m20h+U/vmB6f7NSaFpbzxxzTDEZxgdzxXyuYTqYqtGnR3R0QXKrsqmwCapBcxwxCE2kscxK
gbmLRBNwAyQFD/nVzTbSGwtvs1urxwhiVjc58vOPlHoP8eOMV0vkoECbQQBjFc/qsf2CUYI2SZIH
pz/9euTM8FXhQUua6W5UJpuxm6x4Z0XXmVtQsI7hwAFcAo4Hb5l5plr4f07QoHi0+wW3VvvkLy//
AAInJre0QCfzJSM7SAPr3rYkiSRNrqCvpRg8vrV8MnKb8kXOvJe7fQ89luZrSdJ4HZJB39vSt7QP
FUWouLW5CxXQ4BHAk+g7H2NU/EeitAn2mEMYB1Xun/1q4K6ZlkDodrqw2kHnPb6VeFlXwNT2ctiG
lJXPcQQfelxmuQ8F+IP7Ys2gunU3tv8Ae7F17Nj+fvz3FdhX1NKpGpFSiYNNMWiiitRBRRRQAUUU
UAFHaiigBuK5Lxz4aPivw3JYI6pcK6yws4yA4Hf0yCR+NdaemazdRv7bTbGa7vJligiQs7sRgY56
etON7lQbUk4ny7Jaz2V5Na3MTJPC5SSPGSGB5H9f5cV2OneBtduYIZTDFCsmCN74IB9hzWR4u162
8S+JJ9RtLUwwkLGMnmTGeSOx/oOtet+GvE1nr9irIyxToNskLEAg+oH92uTNMTiaFKMsPG/c+klV
r0qMZxj6mVZfDizSH/TLmWSbqfLG0D/H8fyqC9+HMYRns7t2OCRHIB8x9M8V0WoeJ9K051Se5y7Z
wqfMeD6jgVoWOoWWo26TWkgeNuh9K+YWPzOnJVJX5W+2hh9YxUPfbdvTQ8XuEmEpS4ZmkiJTDEkj
1A/GprOCwN2Pt8kyWygk+Wu4vzwPbIrQ8RmN9evCmOWH3enQZ/XNYcwBGe/Sv0XDydWhCdrXV/mf
TQj7SgntddDc1jx1cSWcen6CslhaRIBuBAkYY46ZK/gc+prgr64muXLzzSysTyzuWJ/M1rJaz313
Fa2y755n2IoO3JPA5rvdD+DzzgTa7dFc8i3tsZ/4E3P6fnWU+SG54eKWGw0bdX33Z0nwkguIvA0B
uC5V5naIPwQnQY+pBP4135ztOOuOKo2dtDY2MNtAAkUMaxxgnOFAAGfwFTNMMHDAkD1ril7zuj5q
S55uSOS8Z+P7DwrA8KEXGolf3duD09Cx7D9a39Evm1XQbDUJECNc26SlQSQNwB/KvnTXbm61jWrv
ULsYmkkJZRg7eoC/gFA59K9hHii00XwDZTiWJ7gWqRRRKwOZAoBGPYjn/GtZUmkjvqYCUacOVXcm
aPi3x3pnhWNY5d1zeuMx2sbDcfdv7o960fDWvReJNDttUhjaNZcgox5UhiD6Z5FfOdz9pvrqS5un
eS4lbc7PknJPT3r3nwbbx6B4DshcSLGBEZ3eQ4CliWP5A4/CipS5I6jxeAVCjH+Zs7Olrx/xD8Ur
zz5LbRIYxEvy/aZgSWPqo4A/H8q3/h14j1bxDa3Z1RUP2d0WOZBtLkg7s9vTp/eqZUZRjdnNUwVa
nT9pNWR6FRTO3WgHnvWRx3H0UlLQMKQ/dP0paKAOa1bwxaalY6nHFttrm/tWtXuFj3FY2LEjafXc
c+p561xmtaTqGmeIT9lurx/Nt0Kyq7pNfTszA5lQYGwBCsTAR4djwASPWKQjigDN077V/Ztp/aG0
3ghT7Rs+75m0bse2c9Kh1fRbDW7M22o26yr1BzgofUN2Na4x6UEDFJNp3WgPVWZwYk17we2JvN1f
RR0kAzcW6+4H3wPz/lXS6drFjq9iLuyuI5YccsG+6e4YdQa1WwVIx2rzXxxpUmn281zoGl3X2zUE
Mdy1op27OMkqMDcemcZxnvWtPlqyUXo31Jd4q6PQoJo7iKOWJw6OAysCCCDyKtV5v8Mb6/gs5NE1
K0uYTb5eB5omUFSeVyR1B5/H2rt7uR7a2klijaVkG7y8jJHfGe9TVp+ym4t37eZUXzI0R1oHWuH/
AOEnifVoLtBdjTFt5RNJ5D7VfcmM8cbQHBPY5BOBXQaVfPfmabywtvu2wsckyAdW/wB08Y9eveoT
T2LlTlFXaNqmuMqR1pqsSeeBSt900yDlbvxbJA2pi20TUbuLTXKXMsbwqqkRiQ43OGPyuv8ADVyX
xPo8Jt/NvQhuUjdAUbCh/u7jjCZ7bsc1haj4Mg1fW9clvI5hBdpbyQSRztgSqrIxMedpICx5yDuH
GDiqF54QvZXlvNT1DTUe7gjju2leTyldOBIsW4ISV2/K2QrdCRwRK4GvqHix20jWH0q0uJbizguD
HNJH+5aWIlWXrkYYHrtzjiq174tuHkITTpUjtHs5LmYXG1dszJ0A+ZgoZic4HA9eM27ufCMHiVdV
n1i0nmDyMiWtshkfehQo8sYyygFjg45xkkio7GW3FrNbaZ4d1zUY57WK0P2vbErxxlzHh8dR5hGT
2VT25pUptXtp9yFdFzVtZ1jU/DGq3drc2lnGwu0tAHcT+ZAzYGQcMWET5UY2jnnpVW+1LVpdfzBe
TeXutpdPZGZvtMLBfMHlIojclvMDMWG1cHA4Y3IdK8Sz6nJf2+i6JpU8uWd5XaZ1YjDEBflDEHk9
+9XIfBmqNAsN34luo4B0gsIUtkUdcDbVezS+KSX4hfsZFpZT2PiLTby6sJ0vba/uzfahNKojlgcS
eXhiRn/llhQPkAxgcV1F3468N2jbDqsMr9lgzJk/8BzzUdv8PvD8cglubWS8m/v3UzSE/gTit+y0
uw08Ys7OCAdP3UYWi1KPd/h/mGrOZ/4TW5u2K6X4Z1W5z0aZBAh/4E3rSGbxzqByltpWmxt2mkaV
x9NvH512eBS4pe0ivhivnqFm9zjP+EV1y951PxXenvss0WAD2yOSKmg+HugRuJbm2kvph1kupmkJ
+oJxXW0tJ1JvZ29NAsihZaVYaeALSzt4B0/dRhavYHpQKWpbbd2x2sHAopaKAE60tFFABQelFHag
Bp6VheKNVfSdDmuIsea2EQnsT3/Ct09KztX0qDWLI2txvVdwYFGwQR6VjVTlBqO4Hn3hrT5dT1EF
1ZolYNMxI4zlhmvT0VUUKoAAGBxVHTNPt9MtEtbZSsa9Mjk/jgVoGubC4RUFd6yZUpXFPQ1yHjW4
8hrL3EnX/gNdc3euH+IsEn9mW14g4hkKPjsGH+IxSx1N1KMooIbmt4Nl87S5n9Zz/wCgrXR1y/gW
B4vDiSv/AMt5GkA9un67c/jXUVrgo8lGMRS1lcjkQSRsrAEHgg9DXnXifwhc24kudOUyQklmj6sn
rj1FelUYFPEYanXVpIE7bHkvgTS9R/4SSG9WCSO0jRg7sCAwII2g98HFesijApaeHoqjDlvcbdxa
KKK6SQooooAKKKKACg9KKD0oAYfunHXHevDfjTf3q61Y2PmSrYNb+ZsGQrSbmBz68BeO1e5HO09c
4rK1bQdK1yJY9Ss4rlY2yu8ZKn2PWqg+V3Zth6ipVFNq9j5x8N+GdW8RzMmm2xlVCFeVmARfqc/p
g1sa14bu/DN3Da3csUhlTeDGSR16cgele9WWm2em2ywWVrFbwrwEiQKo/D/Jryf4t3Pl+I7OPuLb
cPxYj+ldMJqcrPY9rCZjOrXUPs9jk43CgAGrEOoT2+Rb3E0QPLbHI/lXY/D/AMJ22o6c+q6jbrMJ
GxbpKuVK4+8QeufeuD1qWOPXb+CNAqpdSrGEAwAHIAGOla2pT/dtaHsQzClVqSpWuok7SgsWLEse
SSSSaikIYda7bSvh+ZPD1zeakHju3hYwxhj+6wMgn3Pf2rh9DRdR17T7RxvSa4RHX2LYNbRqwStH
oaxzOjOM+X7K+RSklkhkSWJ2SRCGR16qRyCPevTvB/xP+23NvpOsRMLqV1iS4j5DE8Dcv8J9xkeu
K6HxJ4B0vXrQLGgtrlBtjmRfx5HcV4lr+g6l4c1oWcqOJkYGCSMEeZzwV6c57c1yzlCqtTwsRicP
jIXatJbHtXxN0zUNU8GzxWDSmRJFkeKPgyoOCvv/AHv+A18/27ujAjckinIHQg57V9YjHlDcOMZO
c186eMxpj+Lbx9JdHgfa0hixs8z+IKe4z36EkjrWdN7o5sumuZwauRQQahqs3m+TcXMjnG8IW3eh
zx9OTXSWfgLVrm38x1it89Ekbn8hkf1r0fRbmyudLt5dPdGtinybccDpVt7qONsyOie7MBXymLz/
ABXtHSows07a6nbPH1b2hFKx5PeeB9YsomcwLKigkmJ88fTqar6pr+rarbJbXd0TbqP9WmApwepx
24x6V7IxEqghgyN3yCDXjniaOPTdYvBFGWRZMsE6qCNxI9hmvSyXNamKqSp1170db2OrAYqOJm1i
Erx1WhU07R31C9+zpJFGMF3aVgoUA8n36iuuuPGOm+DtIj03QRHe3KjMlwSdhfAyxxncfx6DrxXB
yQ3pgj1GPT74aaImkN19mfy8fLhsgcLjofrWY0rygvsCqx+QE/MwwOT2/rX0c1GpLcrEexxM7c14
rovzZ0l58UfFrylo9RSBSfuJBGR+oJr1H4ba3qeveFRd6pJ5lwJ3j8zABdQcA4UDvkfhXk+ifDzX
/EREkUH2S26+dc5TI/2Rgk/yr3nw9o0OgaJaabCqhYUCkqMbm/iP4nJ/GuWtyLSJ4mYewj7lNK/k
bNLSYornPKFopKKAFopKKAFopKKADtSEDBpaSkwGcAE459qw9WsZbiF2TVrizVUbIi8raR6kuhPH
1rf4xVS7tLa9iCXMYkjDB9rdMjpRZsqL5XdHJaXrdtb+HoLZbW48+O3WMQRW5JkIUAFOApU44PAH
fFXPDVlNDa20v9pyyRJGIzaoE8qIgY2g7Q/HTk9Rz6DXaxZtXgulfbBHbSQtGOASzIQfTgKfzqxB
a28E0skUSo8rZcr/ABEdyKFG25U6qasupZkyq5GOPU4rkTN45vWxFa6XpqE4/euZXH028ep5rsgA
B0oqlLl6XMrHFnwtrd4P+Jp4pvSDzts0WHHtkZJH4VYh+Hvh+JxLPaPezd5LqVpCfwJxXWd6Wn7W
fR29NAsihZ6VYacNtnZwW49IowtXto9KOlLmo5m3dsdhMAUtFLQAnWlpKWgApD0NLSMflNMDO1HU
7HSbU3OoXtvZwDgyzyrGoJ9zTtO1Ox1S3W60+9gu4G4EkEgdfzBNZutaVpNxJbatqkQddKEs8ZfJ
SP5eWKdCQM4z07Vh+ALB5LnVfExtVsYNbeKa3shjKRKpCyv6O+cnHtnJyaAO+ooooAKKKKACiiig
AooooAKTFLRQAlKelRyHCEkgAdSTioLaeG5hWaCVZIm+6yHcp7cUgLJ6HFUNQsLbU7CW0u4xLBKM
MmcbucirrH5TkZFcxpviVb/xfqmhFADZKjI+c7wQC3HsWWjkck9L2BtI6C1t47WBIIU2RxjaqjPA
+pq1SdBQ3SkkkrB1ClFYOj66mranqdvDETBZSLEJ92RI5GWAHseK3hVOLjuAtFFFABRRRQAUUUUA
FFFFABRRRQAUlLR2oAYcgHHWud1vwpoviBkbUrJJ2jXarFiGx6ZUg4ro6Q/dOKE2thxk4u6KCwpa
2Yit02rHHtVAM4A6DHWvLPBPw6vn1GPW/EICP5nnJak5YuSTuc/06+uORXf6n4m0vRtRsLC9uALq
9lVIo1GTk8A+y9v8mugyCCR0x1FXdxNoValKLS+11EaMFCpxg8Y7VwGh/DSx0PxH/ay3UkypkwwF
QBGT3LZ+bAPoPXk10WqeJtI0W4hg1G/igkmIVIydzHJxyBkge/ArcBDYYfoePWldpaEKdSCsna5N
gHimsoKk4UkDvT+KQ9DU3Mzx74teLr7TZY9Bsz5Udxb+ZPKPvMpZl2j0+6cnuK8otIpZ5FiiR3kb
ACxjcSSfbmvoTxj4B0/xgYJpppLe6iGFmQA5QnOCO9TeGfBmleF4mWzjaSRzuaeXBcj9MD6AfjXR
TqqCPUw2Np0KXur3jyC1ude8MyGIGeyaUGQRyLwRk87SMA/rS3WoXV/IGvLh5mAIBY8deeBXTfFa
RRr1ohI3fZ8n8WIrP8I+FJfE6S3MkrRWcbbQUAy7EAkA9gOKqFDD/wARxXM+tj3MNiaMKCr1Uk2J
p/ivUtNgEEUqvGOgkXdj8ua57WZpdQS6uZZ8NICzr8u1uc4JI6H3p2qrFp+pXtojkpBPJEpYjOFb
b7fpWvpnhTUdY0O41YqEtolMkSsDmQqMnHtxwfX17aRw+HpOUqcUnLr1OmtPCwg52S51+Z3n/Czv
DC6Qbgy3AnMefsAgbzs9dnTHtnO33rxrTruawurS/gKl4ZBKkQC+WD12jjoOnXpV2wia/wBVtLVX
2mV/I6Z5ZkH9K7nxF8L0jsvO0L5nXO63kc/N7hj0Oeo//VUqEabs3uePClh8LUcZyb5jrvC/jrS/
EaLEkvkXnRraRgGJ9V9R/nFbuq69pmiW4m1C7igU52gn5m/3V6n8K+ZmkvNE1iOV4jHdWcySFJEA
IZTkZ9uO/XtX0/eWFpqdoba9to54m6rIoI/Xp+FY1IRjJN7Hl46hCnP929GcXB8W9Hm1VYDFLDZB
TuupAc57AIoJ/PFa/wDwszwn/wBBX/yXl/8AiaqaT4AsdD8SJqunzSJHsZTbuCwGe4bqPofzqceM
FZnnfSNSi09LtrP7e/k+UHEvlElRJ5gG8EZ2/l1p1nR5l7NO1u/X7jgipdSX/hZnhL/oK/8AkvL/
APE0f8LM8Jf9BX/yXl/+JrVfXtGjFyz6rYKlrgXBM6ARZzjcc/L0PX0qLUdf0zSrBbya9thHIhaH
96gM2F3YjyQGJ+tZ3p9n9/8AwB6mf/wszwl/0Ff/ACXl/wDiaP8AhZnhL/oK/wDkvL/8TWpbaxp9
zbJMtxEqN5e7cwBRpApRTzwSHXA754qvqPiXRdMhvpbm/td1hEZriJZFaRFHYrnIJPT1ovT7P7/+
AGpT/wCFmeE/+gr/AOS8v/xNB+JfhPB/4mhH/bvJ/wDE1pWesWV/cGKGeEnICFZUbzgY0fcuDkjE
i/mD0wS9tZ0qKW2jk1CySS4YpCjToGkI4IXn5iDxgetO9Ps/v/4AWZzt58SvD4tJX0+6+1XKxtJH
CYpE3hRk/Nt9M1PoHxD0XXnjhWU21052rDPgFj6Kc8/z9q29d0pdY0S704SCL7Qmzfs3YBPXHesz
w94M0jw3FutofNuSMG4lwzn6dgPYD86q9D2T0fNfTUm0r6HUMfkJ56dq5bUfE0S2l5b2iynVUSQR
WxhLMHAypIGcLkr83Q+tdBdLO1vILeRI5cfK0ib1B7cZH8xXLW8w0/xHK2r3NsLie3QRTrGY0IBY
lOScdc43c/gawk7G9OKd7l+28QW9xLBDEsj3Uj4khKlWiAxlmB6DkHn+8MV0QX2rjoppdS8R3dxo
9xaoI4khlmkj8xXYFjtG1lPG7rnHOOoNdVGZAi+YRuGASoIBPsD/APXoTbCrCMWrK3UuUjZ2nHXt
SZ59KUnjrTsZ3MXWPEulaDLAupXaweeGMeVJ3Yxnp9RVePxz4amXKa1aL/vvt/nit1olkG11Vwex
qnLoumTH97p9q/8Avwg04unazTuJ36EMfibQ5SAms2DZ9Lhf8auRajZz/wCpu4JB/sSKf61nSeEP
Dkpy2iWAJ7iBR/Sqkvw+8LzA7tJiH+4zL/I00qb3b+4NTpA6nkMD9DT81yP/AArjw8n+ohuYf+ud
1IP60w+ALZf9RreuW57eXesAPzzTcafST+7/AIIXZ2VFcf8A8Ibfwj9z4s1gf9dHWT+YpP8AhHfF
Mf8AqPGMh9pbKNv1oVOH8y/H/ILnYUmOa5H+zvHEQ+TW9On/AOutqV/9BpD/AMLAiPI0CZfYyqaT
pLpJP+vMV/I6DUbaS90y6topUilmheNZHiDqhIIBKnhgM9Dwabp9vJa2NpbyyCV4olRpFjEYcqOo
Ufdz1wOB0rB/tLxvFw+hWE//AFyutv8AMUg8R+KIzmfwdJ9Yr2N6r2MujX3oOY7LNJXHHxpfRD/S
PCesD18qNZP5Gj/hPrUf67Rtbg/37JuPyNT7Kpta/o0x3R2VFcf/AMLJ8OpxcXFxbn0ltpB/SrMX
j/wxMPl1aIf76sv8xSdKa6MOZHT0VhReLvD0vC63YZ97hQf1NXYtZ02b/U6hayf7syn+tHJJdAuj
RpKiWVJBlXVh/skGnkjHLcVLVtxjqKoteW63a2jTILlhvERYbivPNXCaVmAyb7prhfhlNssdX00t
k2d/Iqrn7qngfqGrvG+6fpXkOg65Z+FfH/iG11OVYIru4LrIfuj5iyg/8Bat6NJ1ISjHdakt21PX
uxrzXRozH8a9ZUHj7Ln81iP9a6l/F/h9I2f+2rAgDOBOpOPoDn9K8cufGoi+IE2v2zZRmx5LNt8y
LAXH5AH64rfC4arNSVradSZyR9CngVz3irWhoPh+5vCVEoQJCD/z0PTPsOtYtr8T/Ds1rHLcXUtv
MRloWhdmU/guD+ded+K/Fc3jLV7fTrVSlkJlWJSPmdj8oY9xkGihga0qnvxajHcJVEkep/D2y+xe
DbAsv7y4U3Dt3becjPvgiuszVWzgjtrSGCLiONAij2HSreK5KsuaTfmaLZDqKKKQBRRRQAUUUUAF
FFFABRRRQAUHpRTTypzQA2sXxHq66FodzqLIzrCvyonViSAB+Zrgvij4t8Q+HdTsYdNnW1t5oi3m
bFcyMCdw+YHgDb6feriT451+/gkt9Tu1vbWVdkkMkSrkE5B4UHPp2raFJyd0ehhcDUq2krWKWhtL
eeM9Nu7t2lnlvo3kdiTk7x/9b8q9o8ceKP8AhG9CMsOHvJj5cKH1/vY9v514nCSkyyxExOjblIJy
h6g59q2dQtdf1ci7vYLy4KjALRngY6ADp69Pxp1Z0oyXPJL1PXxGXwlUg20oo5mVL3WtWDzNJNd3
M23exJJJ4A9q+nEeO0sgZJAiRJ8zscAADv8ASvAtHZdH1y1vbm2LCCQMYz8p4zg8+hx1rY8T+Lr7
xCPKANvZDny1YEv/ALxFa+zVS3Lt3JxWWyxFSMKS92251ep/FfSrO58mztLi9VWAaRAEX3xnlvy/
Gu10DWYNd0iDUbcMkUoICuMEEEg/qDXg2l6Fc6vfpbW8bHJCyOV+WMZPLH+nevSLzxjofgmzh0qF
ZbmS3jC+VCV+TH945wCT1/lUVaSjotzhxuXwpONOldy7HouM9etLgCvHZfjhsbA0Jivr9qwcfTZj
9a9W0+8j1DT7a8jBCTxrKueuGAI/Q1g4OO55lWhOl8ascd4y8AR+K7+G9GoNaSRp5ZxH5gYc47jn
JPrXQ6VplvoOiRWVsB5UEfUDGT3J61u4wKjYAqQVByOh6Uc7tZjdacoqMn7q6Hz94W8Lah40159S
ngaLTXuWmmlkHEuTkqo75zjPQfpXvBtoxaGBFCptKhQAOOlTwxRRRKkShUUBVAHAA6U7HydacpuR
dbFTqNX6bI8d8L/DfWNP8XRXF/5X2K1cukiybjL1K4HUc88+lewlRt2kD8e9S4HoKKJTctyK1edV
pyexzWq+C/D+t3q3l/p8c064+csVLemdpGfxroFAXAx78dPSpcD0oFRdmbk2rNiNyCPauG0PwbEu
661UXbzjU7m6jgN7IbdSbh3jcRB9g4KsAQTk889O7o4pLQR5zBoF7pyaTeDSTcSWup3l1c20bR+Y
wkeXZICzBSVDjgnOG46YrPPhbVrXTroLoS3ov9PurdLRJYsWTSTvKiMXK/LtdAducGMYyMGvV6KY
HmB0TW4IbnT/AOypZlur3TbnzxLFsjWEW4kBBcMWHkseAevU0smg6rLoGp6I2hq1y0GohdRllj2z
PNv2lcNuy25d25VA29elenUUAecXuk65INS1XTdOMOorfxXVhBcPGMg2qQyKxViowPMGOmVByeKz
9S8EaklxNa2p1CS0msLe1jNrJbIqmPcCJGlRnX5m3hkBPLZAOCfV6KAKy7sjOeo5Pp/j/n2qf/PN
OxSUmuwDWxtPTp36Vy+o+H0fRNVigUve3cMgE0p+cuVIXLdgDjAHTqOa6qkIGOlFhqTWxhjTLaO6
tbkIY54gFDx/LuXptbsR6A/hzWvMTHGXClsDOB1NPI+Xgc+1Zeox6hJGosbi3hYE7jLEZAR26MvP
509th3c5amJc+KI5ru1+xLLcW4kYXbRwu3lrsY4IA4bdt+X7w74PFalhqq6jcE2yM9soyLg/cYns
v97Hcjj+dY3hzVNPtNLniubq1huI5pTMS3lq7bjluTznuc8HI7Gjw9/aU8Ej2dxa29qbiRvImtWa
RQWJ5/eDaTndjBxu6dhCk+rNKlOKTstvxO1HJ7U6sq81rTtMnt4L67ht5LjPl+Y23djAOPzFXlcS
KrKwZSc5U8H8arW2xiWKSgmkouFhaMVG+fKbGc47df1rkdSu/F9xrF3b6VDp1lYWsalLm+RpPtLk
ZIUK42qOmSDQB2WKK5nwfr0nifwzp+ryQrC1wrbkDFhuVypKk9QduRx0PWunosAlJkU6imA3iinU
1zhCfQUrALTHKhCSdoA5PpXM6B4s0fxPE50+7DXEPyzWk2Y54WHBV0PI5yCen5Vh/EHU7iR7Hw3Z
yL5mpMBOGySyF0QIVHIVtzM2OdkUn1DFc6rStVsdctF1DT7iO4tmZ0EiZ2sVYq2CRyAQeRwevpWh
Lp1lKP3tpBJ/vRg/0rhdH1q20nVdJ8D+GbT7dFp8e3ULlcIluoBGSVGDIz8kfXvyO/IZgQCenb/P
9KLtDM6TwzoM3MmjWDn1Nun+FUZvA3hubO7RrYf7i7f5UzR/Ekepa9q+jyw+ReabOFK793mRsius
g44znG3JIrqMU1Umtm0JxTOQb4b+F925NPeJvVLiRf5NTH8Aaag/cX+qwHt5V4w/xNdlikwPSj2k
u7DlR4z4q8J63c+JLOz0r7dci1gG27uJeQS7Ny/GcAj3r0Lwzaa3Yacset38d3Pn5Si4IHoW43f9
8g/WukwKTHHNaVMROdNU2lZdbakqCTuB6c14Z8WNKNn4ojv1U+XeRDc2OrqNv8tte6HpWRrGiWGu
WL219bpImDgkcofVT2NaYDEfVq6qNXXUdSPNGx8xy7hGVVlXcdu5ui57n6V9A2fgPw1Boo0k6Tbz
xFNrzSxgyyEjl2kAB3HrkYwcYxxjyfxh4JufDj7mP2nT5DtSXaAR/ssP8/h0Fiw+Jfimw0hNP820
uWRdqXk6M023sWAIDEf3jjPGcnNe7jqc8YoVcM7oxhJQ0kczqVgulaxqGmpI0sVndSQRu5BcqpIG
7sTjGcenQDgavgyzN94x0qH0uFkP0TLf+y1jWVpc3lylvAk1zcTNk5JZ5Hbksx7k85PPc17j4K8E
W3huNL24xLqLp87g/LHnsv8AUmujG4qOGwipSd5tEQjzTujuRjPFPFFHevkF5nWLRRRTAKKKKACi
iigAooooAKKKKACkPQ0vamNwp78dMZoAwPEnh6z8R6PNZXijay5jfqY27MP8K8G8O6PDP4ug0i+k
BjWd4pGRuGKg8A++B0rsPiP8Q5pZp9B0iSSNY3KXM44LY4Kr7Z6n+nXzO0d42R0cq6jcHHUHPWt/
YzlSlGLs2fQZbRqRpyu7XWh9A2fh3R7B0kttOt0dD8rbdxH0JzWuo3chQK8vsPiPfR2KQy2cc06r
tEpcrn0yMH+dQS+MtanvPPW52JuyIto2jHbHXmvjqmSY6vN3le3Vv9C45fiar1+9s77XtJi1LTJo
mQb9u6NsD5TXkLSoHEfmBZCueenrXfP4/gk054zayi4ZCoPBQnH5/hiuN0e3s73xZpdvqqQf2e07
g+c2BI+07FJxjlgMjPJ+U9cH3ckoYrCUpRxCdr6HXhXXwlKcqkXZFGHW7i3guYLa+eCJZMt5bHn5
Fz79+1Y0j+cqsobJxjOST7+terfEfw/4esvCktxFYWNnfLJGLUwqsTSOCo24XGRtzkc4xnjGa4rw
nLoya8o8Q20b2rrhTIWKI2cAtwBjgjn8q9yNVyTbRnRxjq05VeXVdupleH/C994m1G3ggtZmtXlA
muQhKovfLdM47da+mraBIII4V+7GoUHvxxUNmlultGLREWHA2CMALj2x2q6AOK5Kk3JngYvFSrz1
Vkh/TFLRRWZyBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAAelVLu3W7tZIHLIr
jBKHBx6Zq3SHpQBzt1oyrd6R9khijgtJmZ1UYAXy3AH03MD9ee1XYrCGPUpL2MFZJECPg4DYzjI9
un/6q0jjpilAHoKVle43NtWuUb3TrHU7YwX1pFcRf3JFDD8PSubfwZc6axk8Oavcaec5FtIfOgPt
tP3fwrssUuKcZyjs/wDImyZxJ8T65o/y+IdEdoh1vdPPmxgepT7wrf0rX9L1qIPYXsUxAyUVsMv1
XqK1jyDXPar4N0XVZTO9qILrqtxbHypM/UVV4S3Vn3X+QWaOgblT9PXFcd44RbzTNP0ubUPscGoX
8VrORvDTqTkxKVHylwMZOBjNN+w+LtD5sb2LWbVf+WV3hJgPQOOD+NTWvjvT/tCWurwXGj3R4CXi
7VJ/2X6H0odN7xd/QL9zoba3itYYYLeNIoI1CRxou1VUDgAeg9P8Kv1XjmjmiWWJw8bDKspyD+VP
VwXZQckH1qHcd0SHpWBreuWmgnTvtYl/4mF7HYwFADiVwdueRx8v51vngetcN8SrEX2jadukCJHf
pmRTho3eOSGN191lljb2xmmtQZ1A1Kz/ALSGm/aoftvkef8AZw/7zy843467c8Zqvrmq2+haTdan
diU21snmSCKMyEAHk4H/AOodTXnmm6lB4g+IfhnW4Fj8yfT7Z8o27y90V/vi3egcDI9U9uPWnAZC
GAKkYIIyDQLc8l8SS+D9Xb+2YL6bTL1RvW8n065jjkwPvMSqHdjoyMG92Hy1Sn0ltT8Px6rd3WsH
ULr7PbQ2tzIUIdZGEak7N5Xc7NvPz7csCNtegXPgjw1cLK39gabFNJk/aIbVEmRj/ErgblbuCOQa
5zRbiWfxNpNpqzs81jLd2wcgfPcqo8tyBwC1vvf0O88DApomSfQ6jw14ds/C+kR2FjEAwOZptgBl
fuSB29AM4HHFYnjLU9f0HWNP1Oznd9IOIJ7MqmwyEnGWxuG4fKpzgOEBGGNd/j2rK1uayttDv59S
jV7KOBnuEdQ4ZACWBU8HjPHelfUvoed3GqwxeMLfxLozm6huLV5bu2UHzlWMxxzqydVcboG29cxO
P4qnl8V634m1Maf4daa0TyVnRkEe8xt92SUyIywqeSqAM7Ag/IBS+H47qCOG0stJiudaFtEL+4kk
CLHx8qSTAOzOB0GG9TjPNqT4dHUrie81HWLiKa5YPNDYApCzbVUZWRpASAoXcAOnQVRCbua3hrw1
qWk6pLf6r4p1DVrp4zG0THy7dQSCCIucPx1B6HGO9dnXIeGfAmieF7qa8sYGe/uPklumChmXOQNq
BUUcDO1RkjnNdfUssKKKKACkbpS0h6UAUL+xttRs5bS7iSWGRcMrDIPvXz94m8J3nh3WkstrTxXD
ZtpAuTJyBj/eBIz/APqr6N4HXpXnnxBKjxN4QQ9TqA/9Djrty/G1MPNqOzW3yM6kVJalzwR4QtfD
1jDPLbj+0poh5srHLLnnYOw/D0+ldwBigAYHFOrlrVZ1ajnN6stJJWQUtFFZpDCiiimAUUUUAFFF
FABRRRQAUUUUAHamMPlOOuKfSEcGgDxDxN8KtZvfFN3d6a8BtryRpyZZCvlsxyQQAepzzg11/hv4
caRodur3Ful7eYy0sy5UH/ZUnA+v6132AMcCmtjaePyq/aStY6Xi6rhyXsj528RpFbeJ9RjgjRES
4ICqBgdewq1Y+HtSvdGm1OOOOO1iiZwXOC4AydvHt7Vr6p8Ptf1DxlcuY0On3Fy0jXKyD5I2bJG3
OcjGOld34ra30H4fahEiBYo7TyEHT7wCDP4mux4iySjue281cIQpwd3p8jxT7Qd3GOTjnpmpLrTr
prCG9ubeX7DIcR7hhXOMgn+9xz/njR+H/htvE2rmS5iZtOtxmRm4Ejdk9+OT7fhXp/xD0p7vwRcw
2luZJINjxxxjJwpHT8M1U66bSbv3N8Vm8VONJap7nkGh+HX8RaqbG3YxOj8S4JMSBV6f8C7U3xL4
b1Hw9c/Z72P5D8sdwv3JB6+x/wA/XtPhDpdyb281WWJ0hEYhjZgV35bJxn02j869YvrCDULSS3uY
lkikGGRxkGsZVeWVuhwVcwVGtywScDxH4UeILm38VppMs87WtzG4ihLfLG4+Y8HpwpHFe9CvNtB+
FlvoHiiHV4dRkeGAt5cBi5GVK4LbuRg+lek+lc82m7o8zF1IVKnNAdRRRUHMFFFFABRRRQAUUUUA
FFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFJ1paKVgGEDHFVruztb6Bobq3jmi
PVJFz/OrlIaNVqgOMbwlY6FN/aWnX91plvAfOngjk3Qug5YFT04B6V594a8dXkfi+4uboSyWV/J+
8QAkxfwo34AYOO1e3SRpKjI6hlPVT3oSGOMAIiqvoBW1KvGMZKUb301Jcb7GHrniPSfDOnm+1a+S
1tg4QM+SWY5+VQOSe+Ow9q4+/wDiRa69pk1jpOhXl+l0hTzGtftEAQ8FpEhZpAMdtoyeMr1r09sF
RwCR69q4HxLr+vy6rJoGh6RqUcgKq+ovBiIqQCRFI2VB55ZumCArHFY+hTMLTbSw0ewsNZtpRPeW
N7Cuo3L25hkk4MMhkU4ZSqTFuR2XrnJ9aX72e568159beBtRs9Ikii1dZLuUvJLaXKCW1mZiSyu7
KZjkHBcuTznbj5apaZrmseFL+PSNQs7qS1Yl4rd3M88UeBnyZP8Al5jU9VIWRQc4YACrdmRFNbnq
J6dcV5trh/s34k292IyYlmsZ3Veu6UXFoSPYeZCTXY6Zqdnq9mt3YTLNGSVI6FG7qwPKsOcgjOa5
nxrYLPq2nSTKyWt9DLp00qnDwyNiSJwcEAhkYDn7zLSW5Tsd52IHAPeuB8faqrKmjqjuh8ue8RCN
zr5gWOFc/wAUsgC/7oatrw9rEl74bW91CRI7iBXS8wMKkkZIf/gPykj2x+PK+E7Z9R13Sby63zXc
lidUv2b+C4kCJEPZQnnqoHTb+ZbUT2Oy8OaXLpmmKt2ySX07me8kQkq0r8sFJ52Lwq55Cqo7Vv8A
FNGOn9KdSGlZC0UUUDCiiigAoPSig9KAGnkV5t8Qw3/CY+D2/hN2P/RkVek9q84+IX/I3eDf+v7/
ANnirbD/AMT5P8iJfCejD+lO70g6UorG9ylsLRRRQMKKKKACiiigAooooAKKKKACiiigAooooAKQ
nilpD0oAYcdhWXrmi2mv6c9jfRl7d3VmVWxnawIBrWwBzS0wTa1M+xsLbTraO1tII4YYgAqIuAv0
FXuDS4FLSu+o223djdqg8CnUtFAhMAnNLRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFF
FFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFJxS0UANIAHSsXVtEsdajWG9g3qjCR
GUlGjccBkYYZWxxkHpW5RQB5dqXhm80q/N0Yb26ZQRFq+mkJeRLwdsyLjzhkLjhge6dzI1xrXi3w
7fafay6HqJP7s3QupbaSCQYZC8PlvtdWUHlgTjoOlelsOP8A6+K87i1kxeKdUutLt45hfXVtp0aF
iqzzR7vPkyAQNseRnBz5GOwp7k2SOM0nxdpfjjxtNodiLuxs76RXnV8Sx3yxEOSy8eUzrHtY/Nle
COmO+D3nhvV764fSbm9S7nURmzkjJSBI1AyrFOd5Y7QCPn4rA09tP0fVLjUtK8F2sfiW4v57F4xe
kRs6xvKzRuU4DBMD5FyTg4HJfC2l6hrr3movcXFjqD4trx5nhlspydrWrFSpiU7UwDj5gwOSyijU
G0dXD420aSaOOeS5smkO0G9tJYE3f3S7qEz6YY57V0qsCAQcg8gj0/DrXKz+DIfLZLLVtVt45Fw0
Mk4ukkPTnzxI2MHopArn/wCxPFfhhQ+mXIewGC8dkm4D1K20uSB7RygnspNGgXfU9OfheuP61z8/
ibSbbXYNGnvANQm2hYwjkcqzAMQCqkhGIDEEha5+y8ReI9QhmS0udGleNvLklktriF4W/wBu3Y7g
fbd7965vw1r2i6WjeItT1KO8v7lDNHBC6yTKHwTLNghYnYBRgsFRVCAnmiwcyvY9kU5PXPPan1yP
hfxJqfiGaSV/D9xYaaqgw3N1MA8zZ6CMA8Y53bsE9MjmuupFBR2oooAbXnPxD/5G3wZ/1/f+zxV6
K/3TzivIPidrS2/iXRzFGZJdLk8+QY+QFirKpPrhK3w0HKrZdn+RE/hPYB0o7Vi6Hr1hr9mLmxnW
UDG9Acsh9GHrW0KwlFxbUlZopNNaDqKKKBhRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUU
AFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQA
UUUUAFFFFABRRRQAUUjcCmgndyeKAH0UUUAFFFFABSMMqRQeBVK/1Gy0y1e4v7yG1hXlpJpAgH4m
gDF8U6w+iaK725U39wRBZxuc7pn4HHUheWPoqmsnwTpKFLXUY1YWFnaCz0xXwDImfnnOP7+1Nvfa
Cf48DES1m8c+LJJrwTQ2Yg3CPcUeO0LsqKo+8jzFGZyNrBFCdea9JiQRQCJFVY0+VAowFAGB0/8A
rY/CntoStWedXu6PxJd2sDbbg+IrSaEMMHY0MRcjnoVEw6HOMdTmtnxJ4b8+WbUrC1WaWSJo72zD
7VvYSuCDzjzBxhjzj5SQMGqkj/b/AIuwiNSsdqsaOW7tFBOWXH0vYj+FehkDHQUXBLc47wTr39pW
I0+4d5bu1jX9864NxFkorkfwtlCrqcEMp4wRXZMPlrzLX9Pu9B8XRalpoCfbJC8HZTcbR5kDnssq
qGB7OpY81uQePPD72iSPqSQ3BHzWLkm6R+hUwgFyR04U8jv1oBPox3i21GnSweJbdQr2u2G7C8eZ
blgCT6lM7h7bx/FXI+GtY0afxQzXqs1ozJJpzPaNDDbGTiP5CPvPhtspPXcoCZw3Spr+keOLbW9A
tJLn7SbR45UltXTYkilVJ3ADJ3ZAOGx2GDXGJpd3r3w7u1FneRa3o0tzatAu4PJHJtkmh2jIcFHA
U/3lQqeaEw5Ve57UpJYHt6jpUlYfhvUv7W8OaXqOQTdWsUx2kYBZAT098jnuK3KRQUdqKKAGN0rm
NV8PRajYtFsieV7tLp5JV3bgsgJBwPm+T5QPTFdTRQm07oPIx7bR7O21STUIYRFPJGIpdvRwMYz6
4AxmtiilpNuW4kktgooopjCiiigAooooAKKKKACiiigAooooAKKKKACikPQ461matey6fps13Dbm
dogWMYbbkA8mpcrbgaR5BqtHNFJLJEkimSM/OoIJXPPNVtK1SDVrBLqBjtbqpIJU+hrOsgYPF2pt
0W6EZz/tKgGPyrCWIppRd9JOw0mzpO1MB4HNc/4gkmkszYWksq3U20IyMVKgNySfQjip/D2jxaLp
qWkbb2Ls7vjBYk8/yH5U41lOpyR1S3C2lzdopKWugQUUUUAFFFFABRRTWOFJzjigBc0VwupfEzw/
ptybdXnu2Q4Y2qKVB78kgHHtWvonivSfEYb7BcEyx/6yGRdrr+B/oayjWpydk9QujpKKSlrUAooo
oAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiig9KAGv9w+lYtnq+m6hNLBaX0Es0UksUkay
DcrxsqyDaf7pZfpuX1FWNRupbawmuIbKa9kjG4QwFdz89txA469e3GTxXhfhjxZDo/xIu73U0XRb
O5uJA9pPcLN5ctxjzZfMAHHmW0aspztLH7uDQBb8QfEXVPEfhq50SxFpfm6l2Pdaa4i820LiNl8q
RvMhkZnjQBgwYM2Oma67U/GGqeBvBNgNat7Yay8TusaLstQEcMbcMv3ZPJJC9QWU8ngFPiXBDp8m
h+Kd3lxWeoWy386rnFqZlfccDcdrLhQM8SOO9O8YtceLPE+neE7C6MBs3/tG9u1PzR7Cq+XGcHEm
2UE8rgOp6EigC7oXxP0DxL4hTSdKW9l3hil20axwMQgLAF2V2IyBgLngn7vNd+DzXOad4R0DTJ47
m10ezW6j5F28IknLHO5jIw3EnPJJrox6f/WoAVunFZGu2t/e6XNbaVqn9mXr7fKu/IWby/mBPyNw
cgEe2c1rN909fwrC17w1pfiexFhrNu1xaq4fylndBkDjJQgn8aAPLNZW+0mG4jtvF95qV9bBfMWG
O+ZFY95pRcmKIcbj0wM/KeBWhY3GlDyZLLQ573XWnEKi+U/aJT5ZkLq853hSkblScAkY4B47Sw8A
eGtMSFINOZ44WDxRXFzLPHGwOQypI7KCPUDNYPj+M2Wu+G9ZhzHcJObdHU4LOSpAP94bBOv/AG0O
OtNOxEo33LngDVrfUn1TKTQaqbyR7q3nGJEjDGOLuQQFTBwThww9a7mR0jjLswVVGSzHAA96888T
2kHhjxVY+LhdQ21mzOt7AxIkuJWj2RpEMYO4hSwJAHlKx+6axtX8S6nrhsZNTsvsfhy5nKMpfYsy
rE0pLseXTEZ4VQpzjewJFD1G7RWho6ddLceM7bW4yyWV/qkggmI/1ifY1jGfRXaHIP8Asr616YWG
M8n2HNeO6vqMOo6n/Z2ry6hpWn3FqjJa3NlC6RkNkPMMMWQ/ISyOuwrhip5HS6LpvjHRfEFnBLND
f6HL5izs05d4PlJQqHG8c4XBeThv4QM0MIO+5q+NG3HQrftLqiZPf5I5JcgfWMVxGrakg164a7tr
3X9MTan2bS5Jd1idvzh1jHlyAsFYmSQYzwMddPxBZx+NfiFHoN1EJNL02Mm6iPG9mRXznscvBj/t
pU3wyuJZra58yRmeSC0uJsrlnlMCxuxfOOTH068Fs4YUXsieX3rljw58RPB73Fvolm8elzOwSG0c
RqCxPTKMyhieME5JrvVOSvP6j/PWpsUYGelI0FooooAKKKKACiiigAooooAKKKKACiiigAooooAK
KKKAEP3T9K43SvEst34gvY7hIU09klexlTO6QQv5cxbkg4baVwOQxP16W7jmms5kt5RDO6MscjLu
CMRwSMjOD2zXLQeANL0+PSpNKVLG/sWXdepApkmXYUcNnqWDE85+bBIOKACXxs0mjR6nZ6NqTrJN
aLEsgjUSxzyKgZGDlSefukhgSu7aDmpT4ytGefy9P1GQpdtZQhIlzczKWDLHlucBGbccKADznIFG
HwHNDFetHeWUE8z20o+y2BjiMkEwlDyRiTDsxUAkFePSrx8LTR2tu1tfql9a6lcahDO0G5MytJuR
k3jI2yleoORn2oAl/wCE1sXt4GtbLULi5cTF7SGEGWARMEk3gnA2sQMAknPyhqn/AOEps2RzFBdS
Ti7FotuEHmPIYxIMBmAAMZD8kcdcHis2HwffWNwt/ZavHHqUq3H2uaS03JJ5rhyVTeNhUgBcs3GQ
c9aLLRZ38eTak6XP2a2s44g02B59xgjzVweoj+Unj72McGgBll49jbRbC+udMvVkmsEv7lIQki2s
Lf8ALRju5U4YjGWwCSByB2m5SpPb3ye1edr8OEa3s0lutMuXt7BNPMt3pSzARxlvLeMM/wAj7WwT
8ysQDjtXeLGIEWNAAqABVAxjt9MewFTIZi3ViNK1L7RaHy45wQyAYXI5qn4gv7nStEu9Rtbdrm5h
TcqAZLHgZ47AVom4Os6i0MGfs1sdskhBBL5IIA/DrU96i2rwIpGJW2DPqeK+Ux2HrOt7SGsItaHR
Smo7nG+BPFF94mmae+gWMxSBVlQFUkyCcDJPI+p6jpXpXb3rC1TSmmtGa3crMg3KOuSPT0qj4Y8Q
SXtzLpd4f9IhB2sQTuAOGz7g8V6uClKFRwqR5b6p3vcmvKM5c0FbyDXb3xFYajpsVheaXHb392tq
qT2Mkjx/unfcWEyg/wCrxjaOvtzdvdWbSbG0a7D3d5NIsCRWkQUzylSxCqz4UYVm5bgDOfWbVdMb
UrnSpRMI/sF4LoALu3ny3Qr1GP8AWZ/Co9b0ufUfsM9tdx291Y3AuIJJIjIhJR0YMoZcgo7DqMde
a9gwM+fxnbQRgix1FykJuLlVhANrEGZd0oLAjlH+7uJ2kjIoi8S3jeJhpgWBrc6kLQPg7in2IXGc
5xu3H06du9UNS8AnU7xb26u9Pu72S38iea+0tLjGHdg0QLfuyPMIx8wIVc5xzpw+GEh1uPUUuwFW
++1rCIQMf6KLbbwemBuyBj270AdbRRRQAh6GuJ+Jmpy6b4RZYXKPdzLbsy9gQS35hcfjXbHocda5
3xZoC+INBnsAwSU4eFz/AAuOmfbt+NZVb8jsB45ZWUSafLcOMrEhcgdTgZrH07WLjStcstShMaur
hgIyfu91OeORxWjcf2t4emez1CzljYZGWBKuPUHuPpn3xWl4O8EXet6xBe3Nk9tpsTiRmdSBLzkK
gPOD3/n2ryMHTlCpJTjdvYzitdT2LXNUTR9DvdTeNpFtYWlManBYgHC/ieKyTqWu6RdWD6vJp01t
eXC25W2hdGt3f7nJYhxngnC9j7Vuanp9vqml3Wn3amS3uonilUEglWGCAR3rGTRNRlu7E6trCXtv
YyedHGlr5TyOAQrStvIYjOcKqjdg46CvaimlqaFbSPGcNzoEN3fRMlz9ltZ5I4lwHM/CCPJ5y4Ze
ucj8aePHWnC+SGSG8jtZHmSK9kjUQt5KuZTndnC7COQM9RkcijbeFZIdX8M2n72S20ayEdzclQsd
yUC+UuM5yrAuOw981mr4Z1PUNUttKuFuE0O2lvdyvCi4WaORBtkDt5n+tO3CrtGQ3OKoDox4108Q
yyT2uoW7JDHNDFNGu+4SRwiFACeS7KuGwQSMgdaq2XjYyT36z6Zd+el+LO1skjX7Q7eQkjbsvsGM
ud27G3HPq2XwbeXyLLf6yk13BDDHZTQ2uzyjHIkoZlLneS0cecFQQOg61DdeA5NRllutRu9Pvbxr
77btudO32xzCsJQxmQ8YRSDnIPryKALlx45s44kki0/U52Nu9zIkMS7oURism7LABlZSCuT7Zpus
eM47Rkj022muMXVpbyXHlgwR+c8fyn5g27y5AwIBAJXJ5xUlj4OWyhaNbmJN+nyWRW3tFhRd7s5Z
UQjHLdOTxyxOSYJPBl2hFtBqqQ2L3NpdXCG03O8kHlcq+7ChhAmQQcHJyc4oAsp4ztJd/kafqUrG
5e1gRY0BuZEL7wmWxhTG2WbaPc0p8a2TJBJb22oXUjRySywQQgyW6xsUfepI5DBhtXLEqcBgKYPC
9xBBYmy1BIr2xuri4jkmty8TCZpCyFNyngPwQw5Xnjiorfwfe2MgmsdYFvdzQyx3c0lruMhklaUv
GA42MHkbGd4AIHOKAL0/iy2itJZIre5mmW4ltRbqFDGSNGcnk4ClVyCexXjJxVK38cR/YLO4udOv
t5tIru9MSoyWaODhn+focE8biACSBTbXQ5LnxnqWpSw3EcH2byEEu3EszALJKoz02RxKDgH7wPFU
ZPhuriFpp9Lu5fscNpLJdaQs7bY8hGj3udjFTg53AkZ46UAehqOmetSVTB2gZz19fp9P8+1XKACi
iigAooooAKKKKAGuMoR7ViR+GtGg0250+DR7GKzuQfOt4oFjSUkYO4KOTjjNbjfdNcZe/ELwvZa9
Lok19M2pxZBtYbKeVj8u7ACoQcDmgDzrxT4cvfCENro2l63INFv5hts5YXuXgKyI8bquWBBmKqdq
j/WcpIareHdXubXXYH8N6hBrM1xZQxyTXUBLtNsCusAZoF2bYI/vkMfK43FXI6zw9CfGuvf8JvrC
R/2dZO8WjwHBjQKx3TnORvyoGeOV4ztUnD8LeHvtfwe0HWrSa3sdX0Yz3cN3MmBhJpS0ch4Plkde
eOuKBHQv8T7nRYZIvE3hXU7C8jid0ES+ZFNtXcQJOBnALEAsAByxOQNXwB42fxZYRiaNZbqNGa7u
LONhaRy7uIlZzln2kE7dy+/Izysvja28faRf+G00O7j19bOSZF3xFILhYy0ZRi+7dux0UEFucYJr
rPh1peuaH4bOma2ZMwT/AOhK0iOY7YohVGZcZKsXXnuDjKgGgZ3VFFFADX+6cfjWLqej6fqiW326
2Sc286XEBOQySIQQwI5ByOe3rW5RQBga5Y6XNbi91XT0vFsFa4RXg850IX+FcEk+mOc1xWk6Lrni
/Vv7c8QWosrKVh5dnMgMot1ZikeOse47WkJOXxt2gAV6pRQBz3iDQrTX9P8Ask+RIvzRSqBvhbGM
rkEd+QRgg4PBqr4RtNY07QF03VvLeWzdreGdXz58K8I7KSdpIwMEnpnviurxSYHpQBk2mmWVpqeo
X9vbBLq+ZGuZcktJsQKuc8DAGMfj3rJ8EeHh4Y8NWGnsxe6EaNdSbtweUIqnBx90BQq9PlUe9dbi
igAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACkwPSlooAKY3Q0+
mMQFOegGaTAz9P0630y1FtbRhIwenXJx1/lVTWbG5u7jTXt9n7m6R5c8fIOTisXxn4t/4Ra0hkit
/tNxcErHHztGOSxIBzyRxxUepeNfs+s6bpNnFHc3c8yi5YNhYkIyxB65xkj2FTLD88eW2htGhVkl
JLf9Dt8DFQx2dslw0628SzN1kCAMfx61jQeJdKm1kaVHexyXnP7tSTyMkqSOAR6V0IJPtVOmuqMn
GUdGOwPSlxSYpaYgxRRRQAUUUUAFB6UjfdP0qje3kFhZTXV1II4IVLOx7KBnp3oAuY9qUAV5Pf8A
xT1CScnSdOgFsDgPcksz++AwA+mTWv4V+IMet6gum6lbizviSE2sSkpHpnG0+3OfXtVuhKK5rGMa
0G7JnoeKKQetLUGwUUUUAFGKKKACiiigAxRiiigAxRRRQAUUUUAFFFFABRRRQAUUUdqAGv8AdNcL
4h+HOg+IUuGvY55L2SKZILi4u5phA8ikFkjZ9owcEKABwMdK7puBTFbJ/wAKAPA9R8HeJdBv9J8M
6CXey1GG1l1KFUZrQSxgJKzNtGEYKCVB3PznHyg7WjeDfEtjZ+INCg1SdfMgEQlmzJbXKytzPESS
0cuxZQ0ecFmQ52kEeye+TSDj1oFoea/D7wTaWOkPc6to9q1419Lc2bXlpG13bx78p5knUvxuznjO
O2B6Wo24/wAKRc7uelSUDCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAo
oooAKKKKACiiigAooooAgmOIJDgn5TwDjt6142mvaz/wqV9POp3h1j7F9rW+80+cYTb/AGrfuzux
uBhz7V7Q4DRsD0IIrnk8IaF5JgFipX+zv7JP7x8/ZQMeXnP69aAMO217VLjVW0rTRbrcvc3b+fdm
SVBHF5YwBuByTIowDhRk4NJP4r1yObUH+zacIbae0s403Oxaa4WHBL5A2K0pzxkjHTvv3HhXSLja
Xtpo3WR5VkhuJY3DP9/5lYHBwMjODTf+Ea0w2NzYrZKttdFDLGrMOURUXGD8pUJHjBHK560AYv8A
wkuuHVDoIFh/aouvKN35L/Z9nkCUHy9+7fzt2b/9rPasabxFqV1Db3058uQ2d4slvBcusZaO8iiV
gQwOcZ+bIPOOhxXR6h4Tt5LBINPQLKLkXMks887SSNsK585XEgOMAHOMfLjHR2l+DNOsdFtdPuYx
cPFFJEzruVT5kglYBc9N4GM5IxyTk5AKkPim9Hi21sVa1lsri+lsyIrabMRSORgTOcRs2YyDGBle
mTiu1kdY4nd2CqASWJ4ArCi8LaPFqEd2Lebzop2uIgbiUxpK5bcyoWKgksxOB35rVv7OK/0+5spt
3lXETRPtODtYEHH50rXGt9Tw7StK8PN4k1Oyk1hhYRybrdlcKsvsSeDjpx16jiugv7Tw3Jp882lv
DDeWysUeOQ5I6kDnBznrWjf/AA5sdO8Ky22i2jT3qurpLKw8xvmGfm4AAXPAGD71z8nhG5/4SCz0
mETMPs6S3c4GViLFsqDjGcCpdBzqKpztWasuh7mGr0J2cpNW2+X+ZgWV1eWsyppYjW7nYJHL0dd3
GAScDJPoCOmRXqfgTRte02ynfXtQkuZJijRxvM0hiAGMZPfPoT0681y2kfD+61M6lHfC4szBII7a
QqPnAyCcZ5Xp0P4123g7TdZ0vRRaazcxXUySMI5EdnzGQCMlsHu3HPau7ETjL4TLMsRRq/wreen5
GbqGqXGmfEszTXsqaSLC3gmiLnyomka4YS4PGcwqmevz1naBrniCS7utOjlU39/fSXERv2eVLSL7
Nby+VtBBODMFxkfxGuyv9A0rVhdjULITi8jhinBZhvWNmdOAeMMzHjnnmo7nwxpd3LJO8Mizyzi4
M0NxJE4fy1jyHUggFEUYGBxXIeOc3/wl+uXtuJLCCwhaLT5bqf7RvYF4pGjZFKleGKEgnoOcHoJZ
PFmpOtxqNtBbHTbK5tre4iYM1xKZREzMhBCjaJhgEEnB+7xXSw+HdKt4lihtPLjW1+xqquwAiPJX
GepPc8+9Vm8J6ObuKf7K+U8s7BPII3MYAjZow21iu1QCwJ4HpQBlJr+vz6Td61aQadJa4uDbWvz+
a3lMwHOcMXCOcALtyM7uajufEGoajruly6ZdQppX9qfZwwhZ2ukFpJK+CGHy9hxwyg84wdlfDdnZ
zz3lhDsvW814xPNI8MbyEM+IyxVcnk7QMkn1qLSvCVnp+h6TpkitI2nSCeOSNmiPnYbcw2kcEu42
nI2sQeDQBl+FPFmpa3e2zz2LraXtsbhHSwuI1t+QVRpZBsk3BiQyYGV7gg0/4qPKnhBRFny3uoxN
/u/Mf/QttbeneHNK0i6We0hZXVGSPdPI6xKxBIjVmIQEgcKOcD0qxrOmwaxpc+n3SFoZlIIHUY6E
cHnPtTTtJMT1PGfD0trc2x80p5wzlT6VQ1Q/Z9Yt3sf+PhZVaPb/AHgRj9a2NT+F2v2d0wsFjvIs
nbIkojYDsCGI5+hP1ro/CXw8ubPUYdU1lo5JY2DQwIS209mZiByPbP8ASuuGKk6bjNK/RmdbC0ud
TpN67p9Pmdd4ynmtPBGvXMDvHPFp87xyRsVdGEbYII6Edc1y7X+oaD9q1q30zXbbTLSxlaSDVL83
P2iYlfLCDzJWXHzZPHB6Gu91Gyt9S0y6sruMyW1zC8MqAkbkYEEZHPQnpT7izt76xmsrqNJreZDH
IjdHUjBB9fSuPrc0W1jh08T6+yeVHbwtdPdwQQ3FxYXNrCyyh9wCSYZihXJIJBBX7pzh8Xiq40iS
6k1JFe1Sa8jeSEuS08Sq6ooZjgMgkwo6FcDk1vW/hrSbdxIIZXkWVJjLPcSSvvQHZ8zsTgbmIGcc
njmrNx4b0q5hMU1mJIzdi9Ks7Y84EEN19unSgZydz4u1fTb61gm+xFo5bSC9ghgmkKPMYwzGb/Vx
Y8zhWyWwDn5qV/G+pWM2q/bobeKS2inlhsXglilba4VCJDlJVbPzMuNnoe3TXfhTSL68kuZ4JTJJ
Kk7qLiRUMibdrlA23cNq84/hFRf8Iho3mTbrNpUlSWJo5ppHjVZeXCoTtXceu3FAFWLVdastU02x
1L+z5Wu7lo2e1DrhPJdxhSSVO5MZJO4c/L0GL/wlN811Pfm4gjAtHjRJHfyAwvGhDbVJLNgDgct0
GK6H/hE9HFuqeXdF45RKs5vZvODhdgPmht/3SVwDjkjFNTwpoccIt1sSsSrtXbNJlR5vmgg5yD5h
3Ag5BGB0oAw7Txdr18Y9Pt1sxfNqRsjPcWc0CFBbeeH8l2Dqf4cE+9bOv6rrFtq1hp+kiy8y4trm
dpbqN2VfKMWAAGH3t+OvvzjBt2fhjSbO7S4ht3M4uDc+Y88kjGQxmPcSxOfkJXng5z1q7PYW1zfQ
3kibpoo5IY2DEYSTaWHHXOxee1AHJW3jPVP7NF1eR6dAbvToL+2B8zEIkdU2ORkyN8642gEk7cdC
UsfF2sX7jTIxarqL35tVuZrOaGPYIFmLmFmD7sMF27h/ezit+TwrpE1tb2z2YEUFvHbRBJXUxohV
kCkHIZSqkMDnimnwfoqRsqW1wHecXJmF3N5vm7dm8S7twO3g88jg8UAY174r1uxnv2ltdNMOm2MM
9zGsjEyyyGVQqtnCruQEkgkAng0XviTxBYXzaRKmmvqDT2ojm2OsXlTtIuSu7O5WiJ6jd2xW/B4b
0iK3ubcWKeRc262ssbMWDxLuwDk9fnYk9TnJ5rLvvBGm3NusEPnqDeRXE8stxK80gjztHmF964z8
uCMc460AZi6z4iv/ABHY2VpNZx3lv9ut7guJGtpCn2dkk2Bs5w4GCx27m5Pdsfji9eXQZES3MWoR
2bXNuI5JJYzOSOXACIAeQGyX+bAUCuts/D+n6dNbTW1sVlg80JIZGd281laQszH5ixRSScnjis8e
DdBSS0ZLEr9lEPlKJ5Ao8k7ozjdhip6EjpweDQBgP421aytLbVriC0fTruyur2KGLeJY0hj3KrMS
Qxbu2Fxit3wrrepaldXMGo2zqUjjkSZbC4tky2Q0eJhklcKcjAO7oCDWfa+BETWftl4YZYFSdBDH
5mxxLgN8jMyoMZyEAyec9AOj0rQrDRpHNnHMHdVQvLcSTNsXO1QXZiAMk4GBzQBuUUUUAIen+NVb
rctq5RgDjqf89Kt01hlcUnsB55J4j160uzBPpbzqzYR7ckjHucGt2O9uCgLM4yM7WIzW9JbRSLhk
BNQDTrcH7n/jxrhrUJytyu33kYm9VJQSjbtfUi0uR5I23g9epNafao44liACKAtSZrqpQlGKjJ3C
nFxik3cfRRRWpYUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRR
QAUUUUAFFI3Cn6VmJqNm0EFwLuAxXATyJDKCsm77m09DnPHc0AalFZdrqNldsI7e8t5n2bwsUwcl
ckZGDkjIIz6g1JbXENw0qwzRSGJvKcIwOxwAdpx0OCDjtQBoYoxVCK5gkuJIY5UeWLb5iAjcmRkZ
HUcVbdgqMxOAASSTjFAElNzxWeL61Fit4LiIW7qrLMXGwg42nPocjH1q2G3c+pyOQePX6UAS55oP
4Up6Uxvuk5A44JoQC7eaX8KhikWRVZG3Kw3KeowelTH7p5xRuGwvFLWaLyM6g1oJ4zcrGJDAHG8I
SQGI64JBAPTINS211DdIJIJo5IydoaNgy5BOQCPpQBdooooAMUUUUANbhTiqd7exWMKSyAlXmjiG
31dwg/U1dPSsHxNZT3nh67itGdbpFWaAoAT5kZDp1BH3lFEUpOwPYtXt99lv9OttuftkrR7s9MRs
3/stF9d/ZpLSBCvnXM6xoGPGACzf+Oq2PfFeHXvjPXNavGW71i00afR7aa7hZ4SGnmQAeWQx64LA
gc4P3TyK6P4ealrHirxOmpau0kyWVuwjcxhFjdiBtG0DkjPX0rpeEnGLlJr3d/0sRzX2PYADkZp+
Ko3FzDaW0txcSpDDEheSR2CqigZJJPQAd6hl1KyitYJ5L23jguCiQyNKqiRm+6FJOCW7DvXNe5Zq
UVRguYrlEmgljlib7rxsGU844I6/0q9QAUUUUAFFFIeh7UALRVUXUP2kW3mx+ft3+VuG7bnrirVA
CYA5paKQ8g0ALRVOW6ggEXnTRp5rhI9zAbmPQDPU1JJKkETySOqIoLMzHAAHUk0AWKKz47iKSWSN
Jkd4mCSKpyUYqDg88HDA89iKkuLmG1hM080cUYxl5GCqM8Dk0AXKKz7eaO5BeCRZVV2jYowIVlba
VOO4IIPpgipYrmGad4UlRpYseYgbJXIyMigC3SHpQfums+e8gtpEE88UZdiqb3C7mALEDJ5OATjs
AaAL9GcGqUM8VxaxzQSLJDIgdJFOQwwCDn3GK5jxx48tPBQs2uLO4uWui+1YmxtCYyf/AB4Unpqx
xi5vljudp2oHSvHv+F+6d1Oh3ePaVaT/AIX3p7Zzod7j/rovSl7SJ0LB13tE9h/ClFeZeGPi3p/i
bXbbSI9Nu7eW437HcqV+VS2D+C16Z1NOMlLYxqU5U3aasPooopkBRRRQAUUUUAFFFFABRRRQAUUU
UAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAjfdP0ryPSrHU4vBngmefWPOs2l08rbC
1VNoO3aNwOeP16167RQB5VZ3C6D4V0LxOyuYrI3NtdCMZLRSSPjH0kWPH1NdPoltrOk2On2n9n20
vn7p9RuGuijRzyMXk2qEO4ZY4O4dhXXUUAcd4asbbTvEviOC1iEURkt2Pfcxj5JOck56k1RurrU1
8VzaF9puVj806oJFY8W/lkeVn/rtzj+7Xf4oxQB49bXGoXHh+71J9Vvt9tp2neXGLhggMkaF2I/i
J468dcck1eTVbmTWoymr3LawdVuoLnTTMdkVqvnbD5YGF+VYnEmMknqc4r1Om4HOOtAHnfg5ryK/
0QzahfXX9o6H9rnFzcNIDKDDyoJIUfvGBx7fjreMZbyHSovshlAM6CQwyBZtuedgPBPse1daBTWV
WUhlyMcg0mrqxdOfLJS3OF8EmVblok8xrNYU+ytczZk8nauNqgYK5/i69M9q7vr1qC1t4bOCK3hV
VijRUQAfwgYFWe9NKyCrPnlzLQ861izuR481HVdNQvqOnabZPFFnBuIzJciSI+pYKMHsypXIwa1f
NplsbfUVsLU2Ml1YvLfS2u6VrifcQiRv57DEf7s9c9Du491pCB1IzQQeaahr72d3qtlcakYL9tV0
77PAsxD+S32YPsVv4M+bk+7A+lUxPPDbWNzqmt38Fhf6peRXlw960ccSxvMIo1fOYlOAMg5JABPS
vV8D0oIBGKAPJYJNT1S0lWXWdTWK30y7mtpY7honlCTuIJnIxuzGEPPDA5OeK9K0md7rSrGeX/WS
wJI2cdSAT+tXxjsMYp1AB2ppxindqbSYHmnxE8IWOp3WmXwiWK4lvYbaZ0AyyuQoP1Hau40jSrTR
tPisbKMRwxjjHc9yaq+J4laxs2I+5qNmVx/13Qf1rcHPFazqzlBQb0RPKr3Oe8ff8k88Sf8AYMuP
/RbVwmoI7+RojIwh8N6rZ7Nw4/e3kP2fH+7Czqfc9ulevYorJaFHk1nqzSxwjV9cvrFY9PE1l5U5
V55zNKrYX/lqy7YhsIb7/IyanFxcxQrd6hrd9DY3eu3Vrezm6ZEt4Eefy1U5/dAusalgc8gZAxXq
GBkZA4pxAIwelMDyoatrVlpkU9te3N1Fey3Ok2Ekjlizs/8Ao0xJ6gAPl+cjafrFqWsTWniy3ht9
RuQ8GqWtmyXGqPveNhGp/wBHC7WQ7s+Y5zuYc4Ir1nA9BntQAM5AwT3oA8hk1vUbK51tLTUrm+vv
s13IkkF08xi2uP8AW2rj9yyA4XbgNznPFa8es6Zpt9pctl4iubnRxe7bi5uLwyQrutpCAZmODlgj
YJIBI6EgV6TSADpigDx6LW5Gt59UkuLrdNaPGJkmEbKjag6LmRgdigEZYj5VBPUCpNJurvVb2LST
q10tsdaeMtaanLOfK+xeYEExCuyiQE54/HrXrpGRQMDgUAeb+ONQvrfWrC2e7SzsmtZnEkmovZK0
wK4HmIjFmCkkJjDdwcYFHUbnVJrLVL+fVr2K607Q7O8jS3leKMzESlmZCAWB2D5WX/gOa9WIGaWg
DyS+vRceJrT7Rqk/9rR+IDGuntOdggCt5bCLphl2nzMdW79Kzru/k1Lwvcxx6veX15d+H7uXWLY3
DN9nnWNSBtH+q+fcmwABh1BxXtYABzRgZoA8oVEiudW1jTtVumji1TTUg8m7Z4pUdLVXLDOJNyP9
5s+vHOc46rqt9a6ut9dQu5eQXNv9rkleJku41iHlbAsICFsc5kBDc7ePacUYoA8g1TV5mh+zSahc
QyfadTaN5NTazj+S5ZFwyqWkcdoxxg88YroPAN3LqEl5fTuWmubSwldjxuZrcEnoO5PWu+IBPTmj
pQB5Adaux4bu7uz1m9m8QeRIb60MpZLbEqK52EEQFFJ28DIy209aks7qe4bT42vLe6tE1b9w0Ooy
3wUmyuCy+dIi7h0IAJxuwSOletbQOcdaAAOgoAwvCI/4ofQen/INt+v/AFzWvN/jTKkV/wCHZpYl
lSJ5mKv91gDHwfY17KRWfqGk6fqsKxahZW93GpyFnjDgfgamceZWNqFVUqim1c8avPiZoE+jtaro
spfZtEEip5ak+hznjqOK8v8A3W3ACj29PSvqX/hC/Cx/5l7Sf/ANP8Kb/wAIb4ZOAPDulf8AgHH/
AIVhOi57s9XD5pToX5Yavuzwb4ZBT8QtKK8n96x/79PX0wOuKyrHw7oulzm4sNJsrSYjBeC3RCR9
QK11rSlBwjZnnY7E/WaimlYfRRRWpyhRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFF
FABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUh6U
tFAHM+JrbUrvTootLWFrhbqCU+cSFASRWzx7jn23d8VrwPKyRtOqLIygsiNvCnuAcAnB74/AVfoN
J6oANFFFMAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAoo
ooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAP//Z
</FILE>
</FIGURE>
<FIGURE FILENAME="Other figure.jpg" FILE_TYPE="JPG" ID="FIG-03" NO="3" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Neuropathogenesis.</P>
<P>Ghafouri 2006<BR/>Two components of this mechanism are: A) the direct effect of the HIV-1 infection and B) the indirect effect - secretion of cytokines and neurotoxins. <BR/>The infected macrophages and microglia participate actively in the neurodegeneration by: <BR/>1) shedding viral proteins and 2) releasing of cytokines and neurotoxins into the CNS. <BR/>3) Tat and TNF-alpha contribute to the disruption of the blood brain barrier, which in turn become more permeable and the secreted pro-inflammatory cytokines activates 4) microglia and 5) astrocytes which in turn secrete neurotoxin. 6) Multifactorial neuronal injury.</P>
</CAPTION>
<FILE>/9j/4AAQSkZJRgABAgAAAQABAAD/2wBDAAgGBgcGBQgHBwcJCQgKDBQNDAsLDBkSEw8UHRofHh0a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</FILE>
</FIGURE>
<FIGURE FILENAME="Other figure.png" FILE_TYPE="PNG" ID="FIG-04" NO="4" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Inclusion form.</P>
<P>ELIGIBILITY FORM</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAABPsAAAZyCAIAAADJpnZZAACAAElEQVR42uzd25ajOBIF0Pr/n2ae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=
</FILE>
</FIGURE>
<FIGURE FILENAME="Other figure.jpg" FILE_TYPE="JPG" ID="FIG-05" NO="5" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Trial flow.</P>
<P>Quorom statement flow diagram of the process of identifying and including references for the systematic review - Ajunctive therapies for AIDS dementia complex</P>
</CAPTION>
<FILE>/9j/4AAQSkZJRgABAgAAAQABAAD/2wBDAAgGBgcGBQgHBwcJCQgKDBQNDAsLDBkSEw8UHRofHh0a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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK/>
<APPENDICES/>
<EXTENSIONS/>
</COCHRANE_REVIEW>